{"17db7db279c02280b3c2aae2b374c0905b95da0a": [["IntroductionThe coronavirus disease 2019 (COVID-19) pandemic continues to pose a significant threat to public health, with more than three million cases reported globally, including over 228,000 deaths (as of 30 April 2020).", [["coronavirus disease", "DISEASE", 16, 35], ["COVID-19", "CHEMICAL", 42, 50], ["deaths", "DISEASE", 195, 201], ["COVID-19", "ORGANISM", 42, 50], ["coronavirus disease 2019 (COVID-19", "SPECIES", 16, 50], ["The coronavirus disease", "PROBLEM", 12, 35], ["COVID", "TEST", 42, 47], ["pandemic", "PROBLEM", 52, 60], ["coronavirus disease", "OBSERVATION", 16, 35]]], ["The causal agent is severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and extensive public health measures are being deployed around the world to mitigate the spread of this virus [1] [2] [3] [4] [5] [6] [7] [8] [9] .", [["acute respiratory syndrome coronavirus", "DISEASE", 27, 65], ["[1] [2] [3] [4] [5] [6] [7] [8]", "CHEMICAL", 192, 223], ["SARS-CoV-2", "ORGANISM", 69, 79], ["[1] [2] [3] [4] [5] [6] [7] [8] [9]", "SIMPLE_CHEMICAL", 192, 227], ["severe acute respiratory syndrome coronavirus", "SPECIES", 20, 65], ["SARS-CoV-2", "SPECIES", 69, 79], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 20, 65], ["SARS", "TEST", 69, 73], ["CoV", "TEST", 74, 77], ["this virus", "PROBLEM", 181, 191], ["severe", "OBSERVATION_MODIFIER", 20, 26], ["acute", "OBSERVATION_MODIFIER", 27, 32], ["respiratory syndrome", "OBSERVATION", 33, 53]]], ["In the United Kingdom, initial interventions focused on preventing transmission from the individuals that were most likely to be infected [10] .", [["initial interventions", "TREATMENT", 23, 44], ["most likely", "UNCERTAINTY", 111, 122], ["infected", "OBSERVATION", 129, 137]]], ["For example, symptomatic individuals and their contacts, as well as anyone who had visited severely affected areas, were asked to self-isolate.", [["individuals", "ORGANISM", 25, 36], ["symptomatic individuals", "PROBLEM", 13, 36], ["symptomatic", "OBSERVATION_MODIFIER", 13, 24]]], ["Since these measures were not sufficient to prevent sustained transmission, interventions have now intensified, with all members of the public being asked to stay at home.", [["interventions", "TREATMENT", 76, 89]]], ["Interventions are therefore no longer targeted specifically at individuals with a higher risk of having contracted the virus.IntroductionThe routine public health measures that were implemented early in the COVID-19 pandemic have been successful in the past.", [["Interventions", "TREATMENT", 0, 13], ["contracted the virus", "PROBLEM", 104, 124], ["The routine public health measures", "TREATMENT", 137, 171], ["no longer", "UNCERTAINTY", 28, 37], ["virus", "OBSERVATION", 119, 124]]], ["For example, the 2003 SARS pandemic was eventually brought under control following a policy based on detection and isolation of symptomatic hosts and their contacts [11] .", [["SARS", "DISEASE", 22, 26], ["detection", "TEST", 101, 110], ["isolation of symptomatic hosts", "TREATMENT", 115, 145]]], ["One of the key factors determining the success of such measures during any infectious disease outbreak is the level of symptoms exhibited by individuals who are transmitting the pathogen [12, 13] .", [["such measures", "TREATMENT", 50, 63], ["any infectious disease outbreak", "PROBLEM", 71, 102], ["symptoms", "PROBLEM", 119, 127]]], ["The proportion of transmissions occurring prior to symptoms has been noted as particularly important [14] .", [["transmissions", "PROBLEM", 18, 31], ["symptoms", "PROBLEM", 51, 59]]], ["This is because individuals displaying few symptoms are harder to detect and isolate or treat effectively than those with clear, disease-specific symptoms.", [["few symptoms", "PROBLEM", 39, 51], ["specific symptoms", "PROBLEM", 137, 154]]], ["After infection by SARS-CoV-2, hosts develop mild symptoms initially, such as a dry cough and fever, followed by more serious symptoms, such as breathing difficulties ( Figure 1A , see also [15, 16] ).", [["infection", "DISEASE", 6, 15], ["dry cough", "DISEASE", 80, 89], ["fever", "DISEASE", 94, 99], ["breathing difficulties", "DISEASE", 144, 166], ["SARS-CoV-2", "ORGANISM", 19, 29], ["hosts", "ORGANISM", 31, 36], ["SARS-CoV", "SPECIES", 19, 27], ["infection", "PROBLEM", 6, 15], ["mild symptoms", "PROBLEM", 45, 58], ["a dry cough", "PROBLEM", 78, 89], ["fever", "PROBLEM", 94, 99], ["more serious symptoms", "PROBLEM", 113, 134], ["breathing difficulties", "PROBLEM", 144, 166], ["infection", "OBSERVATION", 6, 15], ["mild", "OBSERVATION_MODIFIER", 45, 49], ["symptoms", "OBSERVATION", 50, 58]]], ["Initial symptoms tend not to be specific to COVID-19, although, for a limited number of patients, gastrointestinal symptoms might be an early and distinct indicator of infection by SARS-CoV-2 [17] .", [["gastrointestinal", "ANATOMY", 98, 114], ["gastrointestinal symptoms", "DISEASE", 98, 123], ["infection", "DISEASE", 168, 177], ["SARS", "DISEASE", 181, 185], ["COVID-19", "CHEMICAL", 44, 52], ["patients", "ORGANISM", 88, 96], ["gastrointestinal", "ORGAN", 98, 114], ["patients", "SPECIES", 88, 96], ["SARS-CoV", "SPECIES", 181, 189], ["Initial symptoms", "PROBLEM", 0, 16], ["COVID", "TEST", 44, 49], ["gastrointestinal symptoms", "PROBLEM", 98, 123], ["infection", "PROBLEM", 168, 177], ["CoV", "TEST", 186, 189], ["gastrointestinal", "ANATOMY", 98, 114], ["infection", "OBSERVATION", 168, 177]]], ["A.B.Date of symptom onset in 2020 (t) Jan 6 th Jan 13 th Jan 20 th Evidence is slowly accumulating about the relationship between COVID-19 symptoms and the transmissibility of SARS-CoV-2 [14, [18] [19] [20] [21] .", [["SARS", "DISEASE", 176, 180], ["[18] [19] [20", "SIMPLE_CHEMICAL", 192, 205], ["SARS-CoV", "SPECIES", 176, 184], ["COVID", "TEST", 130, 135], ["symptoms", "PROBLEM", 139, 147], ["the transmissibility of SARS", "TEST", 152, 180], ["CoV", "TEST", 181, 184]]], ["It has become increasingly apparent that individuals can transmit the virus when they are not displaying clear symptoms [22] [23] [24] [25] [26] [27] .", [["individuals", "ORGANISM", 41, 52], ["[22] [23] [24] [25] [26] [27]", "SIMPLE_CHEMICAL", 120, 149], ["clear symptoms", "PROBLEM", 105, 119]]], ["A recent study by Ferretti et al. [14] distinguished between: (i) Symptomatic transmissions (direct transmissions from individuals displaying clear symptoms); (ii) Presymptomatic transmissions (direct transmissions before the source individual develops clear symptoms) and (iii) Asymptomatic transmissions (direct transmissions from individuals who never develop clear symptoms).", [["A recent study", "TEST", 0, 14], ["Symptomatic transmissions (direct transmissions from individuals", "PROBLEM", 66, 130], ["clear symptoms", "PROBLEM", 142, 156], ["Presymptomatic transmissions (direct transmissions", "PROBLEM", 164, 214], ["clear symptoms", "PROBLEM", 253, 267], ["Asymptomatic transmissions", "PROBLEM", 279, 305], ["clear symptoms", "PROBLEM", 363, 377]]], ["In that study, one of the key findings was that SARS-CoV-2 spreads too fast for containment by routine public health measures such as standard contact tracing and isolation of known infected hosts.", [["SARS", "DISEASE", 48, 52], ["that study", "TEST", 3, 13], ["SARS", "PROBLEM", 48, 52], ["routine public health measures", "TREATMENT", 95, 125], ["standard contact tracing", "TEST", 134, 158], ["known infected hosts", "PROBLEM", 176, 196], ["infected hosts", "OBSERVATION", 182, 196]]], ["This is partly because of the significant proportion of transmissions occurring prior to clear symptoms developing.B.Here, we consider the earliest stages of the COVID-19 pandemic and show that the proportion of infections arising from individuals with few symptoms (including infected individuals with no symptoms at all) is a quantity that changes during an outbreak.", [["infections", "DISEASE", 212, 222], ["clear symptoms", "PROBLEM", 89, 103], ["the COVID", "TEST", 158, 167], ["infections", "PROBLEM", 212, 222], ["few symptoms", "PROBLEM", 253, 265], ["infected individuals", "PROBLEM", 277, 297], ["symptoms", "PROBLEM", 306, 314], ["significant", "OBSERVATION_MODIFIER", 30, 41], ["infections", "OBSERVATION", 212, 222]]], ["In our initial analysis, we consider the control of symptomatic hosts and estimate changes in the time period between symptom onset and hospitalisation using data for 212 patients who reported symptoms between 2 January 2020 and 22 January 2020.", [["patients", "ORGANISM", 171, 179], ["patients", "SPECIES", 171, 179], ["our initial analysis", "TEST", 3, 23], ["symptomatic hosts", "PROBLEM", 52, 69], ["symptoms", "PROBLEM", 193, 201]]], ["The period between symptom onset and hospitalisation reflects the time in which symptomatic hosts were potentially transmitting the virus in the community and is a proxy for the time period between individuals developing clear symptoms and being isolated.B.Then, we turn our attention to infected individuals with few symptoms.", [["symptom onset", "PROBLEM", 19, 32], ["clear symptoms", "PROBLEM", 221, 235], ["few symptoms", "PROBLEM", 314, 326]]], ["The proportion of transmissions occurring from hosts with few symptoms at the start of any outbreak is an important factor affecting the controllability and severity of the outbreak.", [["transmissions", "PROBLEM", 18, 31], ["few symptoms", "PROBLEM", 58, 70], ["the outbreak", "PROBLEM", 169, 181]]], ["For a fixed value of the basic reproduction number, there is a threshold value of the initial proportion of transmissions occurring from hosts with few symptoms.", [["few symptoms", "PROBLEM", 148, 160]]], ["If the initial proportion of transmissions occurring from hosts with few symptoms is above this threshold, then the outbreak cannot be controlled by interventions targeting hosts exhibiting clear symptoms alone.B.However, as public health measures and public awareness have changed during the COVID-19 pandemic, the proportion of transmissions from hosts with few symptoms will have varied.", [["B", "GENE_OR_GENE_PRODUCT", 211, 212], ["few symptoms", "PROBLEM", 69, 81], ["clear symptoms", "PROBLEM", 190, 204], ["few symptoms", "PROBLEM", 360, 372]]], ["As we show, changes in the period between symptom onset and hospitalisation lead to temporal variations in the proportion of transmissions occurring from hosts prior to clear symptom development.", [["symptom onset", "PROBLEM", 42, 55], ["temporal variations", "PROBLEM", 84, 103], ["clear symptom development", "PROBLEM", 169, 194]]], ["Consequently, after the start of the pandemic, a high proportion of transmissions from individuals with few symptoms is not always indicative of an uncontrollable outbreak.", [["few symptoms", "PROBLEM", 104, 116], ["an uncontrollable outbreak", "PROBLEM", 145, 171], ["not always indicative of", "UNCERTAINTY", 120, 144], ["uncontrollable", "OBSERVATION_MODIFIER", 148, 162], ["outbreak", "OBSERVATION", 163, 171]]], ["Instead, it can show that some transmissions from infected individuals with clear symptoms are being prevented effectively.Time from Symptom Onset to HospitalisationWe considered temporal changes in the time period from symptom onset to hospitalisation during the initial stages of the COVID-19 pandemic.", [["infected individuals", "PROBLEM", 50, 70], ["clear symptoms", "PROBLEM", 76, 90], ["temporal changes", "PROBLEM", 179, 195], ["the COVID", "TEST", 282, 291], ["pandemic", "PROBLEM", 295, 303], ["infected", "OBSERVATION_MODIFIER", 50, 58]]], ["We denote the expected time from symptom onset to hospitalisation for an individual developing clear symptoms on day t by 1/\u03b3 t days, where \u03b3 t is the rate of hospitalisation.", [["clear symptoms", "PROBLEM", 95, 109]]], ["In our analysis, the value t = 0 days corresponds to 2 January 2020.Time from Symptom Onset to HospitalisationWe estimated 1/\u03b3 t using a publicly available line list dataset describing this period for 231 patients from around the world [28] .", [["patients", "ORGANISM", 205, 213], ["patients", "SPECIES", 205, 213], ["our analysis", "TEST", 3, 15]]], ["Implausible time periods (negative values and periods longer than 30 days) were assumed to be reported incorrectly and were excluded from the analysis.", [["the analysis", "TEST", 138, 150]]], ["There were 19 such patients, so that our analysis was performed with data from 212 patients (Supplementary Material: Table S1 ).", [["patients", "ORGANISM", 19, 27], ["patients", "ORGANISM", 83, 91], ["patients", "SPECIES", 19, 27], ["patients", "SPECIES", 83, 91], ["our analysis", "TEST", 37, 49]]], ["Of these, 190 patients were from China and 22 were from other countries.Time from Symptom Onset to HospitalisationWe used data for patients with dates of symptom onset up to 22 January 2020 (i.e., t = 20 days).", [["patients", "ORGANISM", 14, 22], ["patients", "ORGANISM", 131, 139], ["patients", "SPECIES", 14, 22], ["patients", "SPECIES", 131, 139], ["symptom onset", "PROBLEM", 154, 167]]], ["This is because, when the analysis was performed (on 9 February 2020, i.e., 18 days later), it is unlikely that individuals symptomatic on 22 January 2020 would not yet have been hospitalised.", [["the analysis", "TEST", 22, 34], ["individuals symptomatic", "PROBLEM", 112, 135], ["unlikely", "UNCERTAINTY", 98, 106]]], ["In the data used in our analysis, only one patient was recorded as having a period between symptom onset and hospitalisation longer than 18 days.", [["patient", "ORGANISM", 43, 50], ["patient", "SPECIES", 43, 50], ["our analysis", "TEST", 20, 32]]], ["If we had considered data from patients with later symptom onset dates than 22 January 2020, then \"right censoring\" may have occurred [29] [30] [31] .", [["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39], ["right", "ANATOMY_MODIFIER", 99, 104]]], ["Specifically, we could have been preferentially including patients with short periods between symptom onset and hospitalisation in the analysis, leading to underestimation of the symptomatic infectious period (i.e., the part of the infectious period during which individuals display clear symptoms).Time from Symptom Onset to HospitalisationThe symptomatic infectious period was assumed to be the difference between the symptom onset and hospitalisation dates.", [["patients", "ORGANISM", 58, 66], ["patients", "SPECIES", 58, 66], ["short periods between symptom onset", "PROBLEM", 72, 107], ["the analysis", "TEST", 131, 143], ["the symptomatic infectious period", "PROBLEM", 175, 208], ["clear symptoms", "PROBLEM", 283, 297], ["symptomatic", "OBSERVATION_MODIFIER", 179, 190], ["infectious", "OBSERVATION", 191, 201], ["infectious", "OBSERVATION", 232, 242], ["symptomatic", "OBSERVATION_MODIFIER", 345, 356], ["infectious", "OBSERVATION", 357, 367]]], ["Locally estimated scatterplot smoothing (LOESS) with a span parameter of 0.75 and tricubic distance weighting (the default settings in the R software package STATS) was used to estimate 1/\u03b3 t .", [["Locally estimated scatterplot smoothing", "PROBLEM", 0, 39], ["a span parameter", "TEST", 53, 69], ["the R software package STATS", "TREATMENT", 135, 163], ["scatterplot smoothing", "OBSERVATION", 18, 39]]], ["All analyses in this manuscript were performed using R software version 3.6.1.Time-Varying Reproduction NumberWe define the time-varying reproduction number, R t , as the expected number of secondary infections over their entire course of infection generated by an individual who first shows clear symptoms on day t (where t = 0 corresponds to 2 January 2020) [32] [33] [34] [35] [36] .", [["infections", "DISEASE", 200, 210], ["infection", "DISEASE", 239, 248], ["R software version", "TEST", 53, 71], ["secondary infections", "PROBLEM", 190, 210], ["infection", "PROBLEM", 239, 248], ["clear symptoms", "PROBLEM", 292, 306], ["secondary", "OBSERVATION_MODIFIER", 190, 199], ["infections", "OBSERVATION", 200, 210], ["infection", "OBSERVATION", 239, 248]]], ["Over the course of a coronavirus infection, infected hosts tend to have few symptoms initially, before potentially developing more clear symptoms ( Figure 1A ).", [["coronavirus infection", "DISEASE", 21, 42], ["coronavirus", "ORGANISM", 21, 32], ["coronavirus", "SPECIES", 21, 32], ["a coronavirus infection", "PROBLEM", 19, 42], ["infected hosts", "PROBLEM", 44, 58], ["few symptoms", "PROBLEM", 72, 84], ["clear symptoms", "PROBLEM", 131, 145], ["coronavirus", "OBSERVATION_MODIFIER", 21, 32], ["infection", "OBSERVATION", 33, 42]]], ["The time-varying reproduction number (which we refer to as \"the reproduction number\" hereafter) is the sum of the expected number of secondary infections when the individual has few symptoms and the expected number of secondary infections when that individual has clear symptoms.", [["infections", "DISEASE", 143, 153], ["infections", "DISEASE", 228, 238], ["secondary infections", "PROBLEM", 133, 153], ["few symptoms", "PROBLEM", 178, 190], ["secondary infections", "PROBLEM", 218, 238], ["clear symptoms", "PROBLEM", 264, 278], ["secondary", "OBSERVATION_MODIFIER", 133, 142], ["infections", "OBSERVATION", 143, 153], ["secondary", "OBSERVATION_MODIFIER", 218, 227], ["infections", "OBSERVATION", 228, 238]]], ["The basic reproduction number, R 0 , corresponds to the reproduction number at time t = 0.Time-Varying Reproduction NumberIn our analysis, we considered changes in the reproduction number due to temporal variations in the time between symptom onset and hospitalisation alone.", [["our analysis", "TEST", 125, 137], ["temporal variations", "PROBLEM", 195, 214], ["basic", "OBSERVATION_MODIFIER", 4, 9], ["reproduction", "OBSERVATION_MODIFIER", 10, 22], ["number", "OBSERVATION_MODIFIER", 23, 29]]], ["The expected number of infections arising from the infectious period with few symptoms was assumed unchanged during the outbreak, and is given by \u03b1 0 R 0 , where \u03b1 0 represents the expected proportion of infections generated by infectious hosts in the period before clear symptoms near the beginning of the outbreak (i.e., t = 0).", [["infections", "DISEASE", 23, 33], ["infections", "DISEASE", 204, 214], ["\u03b1 0", "GENE_OR_GENE_PRODUCT", 162, 165], ["infections", "PROBLEM", 23, 33], ["few symptoms", "PROBLEM", 74, 86], ["infections", "PROBLEM", 204, 214], ["clear symptoms", "PROBLEM", 266, 280], ["number", "OBSERVATION_MODIFIER", 13, 19], ["infections", "OBSERVATION", 23, 33], ["infectious", "OBSERVATION_MODIFIER", 51, 61], ["few", "OBSERVATION_MODIFIER", 74, 77], ["symptoms", "OBSERVATION", 78, 86], ["unchanged", "OBSERVATION_MODIFIER", 99, 108], ["infections", "OBSERVATION", 204, 214], ["infectious", "OBSERVATION_MODIFIER", 228, 238]]], ["The expected number of infections arising from the symptomatic infectious period is then given by (1 \u2212 \u03b1 0 )R 0Time-Varying Reproduction Numberwhere the factor 1/\u03b3 t 1/\u03b3 0 reflects the change in the symptomatic infectious period between the beginning of the period considered and time t.", [["infections", "DISEASE", 23, 33], ["\u03b3 0", "PROTEIN", 168, 171], ["infections", "PROBLEM", 23, 33], ["the factor", "TEST", 149, 159], ["number", "OBSERVATION_MODIFIER", 13, 19], ["infections", "OBSERVATION", 23, 33], ["symptomatic", "OBSERVATION_MODIFIER", 51, 62], ["infectious", "OBSERVATION", 63, 73], ["change", "OBSERVATION_MODIFIER", 185, 191], ["symptomatic", "OBSERVATION_MODIFIER", 199, 210], ["infectious", "OBSERVATION", 211, 221]]], ["Consequently, the reproduction number is given byProportion of Transmissions from Individuals with Few SymptomsThe proportion of transmissions occurring from infectious hosts with few symptoms (i.e., the expected proportion of secondary infections generated by an infected host that arise before that host develops clear symptoms) is a dynamic quantity that changes throughout the outbreak.", [["infections", "DISEASE", 237, 247], ["Few Symptoms", "PROBLEM", 99, 111], ["few symptoms", "PROBLEM", 180, 192], ["secondary infections", "PROBLEM", 227, 247], ["an infected host", "PROBLEM", 261, 277], ["clear symptoms", "PROBLEM", 315, 329], ["infectious", "OBSERVATION_MODIFIER", 158, 168], ["secondary", "OBSERVATION_MODIFIER", 227, 236], ["infections", "OBSERVATION", 237, 247]]], ["We denote this quantity by \u03b1 t .", [["\u03b1 t", "DNA", 27, 30]]], ["An expression for \u03b1 t is derived by considering the ratio between the expected number of transmissions in the infectious period when there are few symptoms and the reproduction number:Proportion of Transmissions from Individuals with Few SymptomsWe note that this final expression for \u03b1 t does not depend on the value of the basic reproduction number, R 0 .Time from Symptom Onset to HospitalisationAs described in the Methods, we considered how the time from symptom onset to hospitalisation changed in the initial stages of the COVID-19 pandemic ( Figure 1B) .", [["\u03b1 t", "DNA", 18, 21], ["\u03b1 t", "DNA", 285, 288], ["few symptoms", "PROBLEM", 143, 155], ["Symptom", "PROBLEM", 367, 374], ["the COVID", "TEST", 526, 535], ["infectious", "OBSERVATION", 110, 120], ["few", "OBSERVATION_MODIFIER", 143, 146]]], ["The estimated mean value of this quantity changed from around 6.5 days in the period between 2 January and 14 January to a lower value of around 2 days by 22 January.", [["The estimated mean value", "TEST", 0, 24], ["mean", "OBSERVATION_MODIFIER", 14, 18], ["value", "OBSERVATION_MODIFIER", 19, 24], ["quantity", "OBSERVATION_MODIFIER", 33, 41], ["lower value", "OBSERVATION_MODIFIER", 123, 134]]], ["Towards the end of the time period considered, the mean time from symptom onset to hospitalisation appeared to be reducing more slowly than earlier in the time period considered.", [["symptom", "PROBLEM", 66, 73]]], ["This potentially indicates a limit to the ability of isolation measures to decrease the symptomatic infectious period.Reproduction Number and Proportion of Transmissions from Individuals with Few SymptomsIf the period from symptom onset to hospitalisation tends to decrease during an outbreak, the expected number (and proportion) of transmissions from hosts displaying clear symptoms decreases.", [["isolation measures", "TREATMENT", 53, 71], ["the symptomatic infectious period", "PROBLEM", 84, 117], ["Few Symptoms", "PROBLEM", 192, 204], ["symptom", "PROBLEM", 223, 230], ["clear symptoms", "PROBLEM", 370, 384], ["symptomatic", "OBSERVATION_MODIFIER", 88, 99], ["infectious", "OBSERVATION", 100, 110], ["decrease", "OBSERVATION_MODIFIER", 265, 273]]], ["In that case, the reproduction number can be expected to decrease, and the relative proportion of transmissions from individuals with few symptoms will increase.Reproduction Number and Proportion of Transmissions from Individuals with Few SymptomsOf particular interest is the threshold for outbreak control, i.e., R t = 1 [32, 35] .", [["few symptoms", "PROBLEM", 134, 146], ["outbreak control", "TREATMENT", 291, 307], ["decrease", "OBSERVATION_MODIFIER", 57, 65]]], ["For a single value of R 0 , there is a corresponding threshold value of \u03b1 0 that determines whether or not the outbreak can ever be brought under control via the isolation of symptomatic hosts alone.", [["symptomatic hosts", "TREATMENT", 175, 192]]], ["In particular, in the impossible case in which symptomatic hosts are isolated perfectly and immediately, so that 1/\u03b3 t approaches zero days, then Equation (1) indicates that the threshold for outbreak control is achieved exactly if \u03b1 0 = 1 R 0 .", [["outbreak control", "TREATMENT", 192, 208]]], ["Consequently, if \u03b1 0 > 1 R 0 , then in the absence of other effects (e.g., acquired immunity as the pathogen infects individuals in the population), any intervention that only involves control of hosts with clear symptoms will fail to bring R t < 1 and therefore will not bring the outbreak under control.Reproduction Number and Proportion of Transmissions from Individuals with Few SymptomsSince perfect control of symptomatic infectious hosts is impossible to achieve in reality, some values of \u03b1 0 that are less than 1 R 0 are also likely to correspond to scenarios in which isolation of symptomatic hosts alone will fail to control the outbreak.", [["any intervention", "TREATMENT", 149, 165], ["clear symptoms", "PROBLEM", 207, 221], ["Few Symptoms", "PROBLEM", 379, 391], ["symptomatic infectious hosts", "PROBLEM", 416, 444], ["some values", "TEST", 482, 493], ["symptomatic hosts", "PROBLEM", 591, 608], ["symptomatic", "OBSERVATION_MODIFIER", 416, 427], ["infectious", "OBSERVATION", 428, 438]]], ["We explored this in the specific context of the range of symptomatic infectious periods shown in Figure 1B .", [["symptomatic infectious periods", "PROBLEM", 57, 87], ["symptomatic", "OBSERVATION_MODIFIER", 57, 68], ["infectious", "OBSERVATION", 69, 79]]], ["For example, when R 0 = 2 (Figure 2A) , then any value for the proportion of transmissions from hosts with few symptoms on 2 January below \u03b1 0 = 0.27 will have seen R t reduce below 1 by 22 January 2020.", [["few symptoms", "PROBLEM", 107, 119]]], ["If, instead, R 0 = 3 ( Figure 2B ), then isolation of hosts with clear symptoms was only able to reduce R t below 1 by 22 January 2020 if the proportion of transmissions from hosts with few symptoms was very low (specifically \u03b1 0 < 0.03).", [["clear symptoms", "PROBLEM", 65, 79], ["few symptoms", "PROBLEM", 186, 198], ["very low", "PROBLEM", 203, 211]]], ["For values of R 0 > 3.2, even if no transmissions occur from hosts with few symptoms, then R t would not have been reduced below 1 by 22 January 2020 given the reduction in the symptomatic infectious period shown in Figure 1B .Reproduction Number and Proportion of Transmissions from Individuals with Few SymptomsIf transmissions from hosts with clear symptoms could be eliminated completely, then it might or might not have been possible to reduce R t below 1 without resorting to the current \"lockdowns\" in place in countries worldwide, depending on the precise values of R 0 and \u03b1 0 .", [["values", "TEST", 4, 10], ["transmissions", "PROBLEM", 36, 49], ["few symptoms", "PROBLEM", 72, 84], ["the reduction", "TREATMENT", 156, 169], ["the symptomatic infectious period", "PROBLEM", 173, 206], ["Few Symptoms", "PROBLEM", 301, 313], ["clear symptoms", "PROBLEM", 346, 360], ["symptomatic", "OBSERVATION_MODIFIER", 177, 188], ["infectious", "OBSERVATION", 189, 199]]], ["The calculation of the target period from symptom onset to hospitalisation for each pair of values simply involved rearranging Equation (1) to find the critical value of 1/\u03b3 t days corresponding to R t = 1.", [["symptom", "PROBLEM", 42, 49]]], ["If R 0 < 1, then the outbreak was already under control when t = 0 days and so there was no target period from symptom onset to hospitalisation (bottom of Figure 2D ).", [["no", "UNCERTAINTY", 89, 91]]], ["If \u03b1 0 and R 0 were both large, then it would be impossible to bring R t < 1 by reducing the symptomatic infectious period alone (top right of Figure 2D ).", [["\u03b1 0", "GENE_OR_GENE_PRODUCT", 3, 6], ["R 0", "GENE_OR_GENE_PRODUCT", 11, 14], ["large", "OBSERVATION", 25, 30], ["symptomatic", "OBSERVATION_MODIFIER", 93, 104], ["infectious", "OBSERVATION", 105, 115]]], ["In general, if \u03b1 0 and R 0 were larger, then the target period from symptom onset to hospitalisation for outbreak control would be shorter.", [["\u03b1 0", "GENE_OR_GENE_PRODUCT", 15, 18], ["R 0", "GENE_OR_GENE_PRODUCT", 23, 26], ["symptom", "PROBLEM", 68, 75]]], ["(D) Required time within which symptomatic infectious hosts must be isolated on average (1/ days) so that is less than one (i.e., the outbreak is controlled), calculated using Equation (1) for different pairs of values of and .", [["symptomatic infectious hosts", "PROBLEM", 31, 59], ["symptomatic", "OBSERVATION_MODIFIER", 31, 42], ["infectious", "OBSERVATION", 43, 53]]], ["In panels A-C, the horizontal black line shows the threshold value of for outbreak control ( = 1).", [["the horizontal black line", "TREATMENT", 15, 40]]], ["The value of 1/ used in all panels is 6.7 days (as estimated in Figure 1B ).DiscussionIn this article, we used data from early in the COVID-19 pandemic to demonstrate that the proportion of transmissions arising from infectors with few symptoms changes during an outbreak.", [["The value", "TEST", 0, 9], ["infectors", "PROBLEM", 217, 226], ["few symptoms changes", "PROBLEM", 232, 252]]], ["We found that, in the initial stage of the pandemic, symptomatic hosts were hospitalised/isolated increasingly effectively ( Figure 1B) .", [["symptomatic hosts", "PROBLEM", 53, 70], ["symptomatic", "OBSERVATION_MODIFIER", 53, 64]]], ["This is likely to be due to changes in public awareness about the outbreak, as well as the introduction of containment measures (e.g., contact tracing followed by isolation of secondary infected hosts).", [["changes in public awareness", "PROBLEM", 28, 55], ["containment measures", "TREATMENT", 107, 127], ["contact tracing", "TEST", 135, 150], ["secondary infected hosts", "PROBLEM", 176, 200], ["likely to be due to", "UNCERTAINTY", 8, 27]]], ["The consequences of improved isolation of symptomatic hosts, in the absence of changes to other factors, are that the proportion of infections due to hosts with few symptoms is likely to have increased and the reproduction number is likely to have decreased (Figure 2A-C) .DiscussionWe considered the impact of transmissions from infectors with few symptoms on the controllability of infectious disease outbreaks, using COVID-19 as a case study.", [["infections", "DISEASE", 132, 142], ["infectious disease", "DISEASE", 384, 402], ["symptomatic hosts", "PROBLEM", 42, 59], ["infections", "PROBLEM", 132, 142], ["few symptoms", "PROBLEM", 161, 173], ["infectors", "PROBLEM", 330, 339], ["few symptoms", "PROBLEM", 345, 357], ["infectious disease outbreaks", "PROBLEM", 384, 412], ["a case study", "TEST", 432, 444], ["improved", "OBSERVATION_MODIFIER", 20, 28], ["isolation", "OBSERVATION_MODIFIER", 29, 38], ["symptomatic", "OBSERVATION_MODIFIER", 42, 53], ["hosts", "OBSERVATION_MODIFIER", 54, 59], ["infections", "OBSERVATION", 132, 142], ["increased", "OBSERVATION_MODIFIER", 192, 201], ["decreased", "OBSERVATION_MODIFIER", 248, 257], ["infectious", "OBSERVATION_MODIFIER", 384, 394]]], ["The reproduction number (R t ) and the proportion of transmissions from hosts with few symptoms (\u03b1 t ) vary in response to changes in the period between symptom onset and hospitalisation.", [["few symptoms", "PROBLEM", 83, 95], ["symptom onset", "PROBLEM", 153, 166]]], ["Values of R t and \u03b1 t were calculated using Equations (1) and (2), respectively.", [["Values", "TEST", 0, 6], ["Equations", "TEST", 44, 53]]], ["Lines represent different values of the initial proportion of transmissions from hosts with few symptoms (\u03b1 0 ).", [["few symptoms", "PROBLEM", 92, 104], ["different", "OBSERVATION_MODIFIER", 16, 25], ["values", "OBSERVATION_MODIFIER", 26, 32]]], ["Values of \u03b1 0 between 0 and 0.4 were considered in steps of 0.05 (i.e., nine values in total).", [["Values", "TEST", 0, 6]]], ["In the period from 2 January to 22 January 2020, transmissions from hosts with clear symptoms were typically prevented increasingly effectively, leading to a temporal trend from the tops to the bottoms of the lines shown.", [["clear symptoms", "PROBLEM", 79, 93], ["a temporal trend", "PROBLEM", 156, 172], ["bottoms", "ANATOMY_MODIFIER", 194, 201], ["lines", "OBSERVATION", 209, 214]]], ["(D) Required time within which symptomatic infectious hosts must be isolated on average (1/\u03b3 t days) so that R t is less than one (i.e., the outbreak is controlled), calculated using Equation (1) for different pairs of values of \u03b1 0 and R 0 .", [["symptomatic infectious hosts", "PROBLEM", 31, 59], ["symptomatic", "OBSERVATION_MODIFIER", 31, 42], ["infectious", "OBSERVATION", 43, 53]]], ["In panels A-C, the horizontal black line shows the threshold value of R t for outbreak control (R t = 1).", [["the horizontal black line", "TREATMENT", 15, 40]]], ["The value of 1/\u03b3 0 used in all panels is 6.7 days (as estimated in Figure 1B ).DiscussionIn this article, we used data from early in the COVID-19 pandemic to demonstrate that the proportion of transmissions arising from infectors with few symptoms changes during an outbreak.", [["The value", "TEST", 0, 9], ["infectors", "PROBLEM", 220, 229], ["few symptoms changes", "PROBLEM", 235, 255]]], ["We found that, in the initial stage of the pandemic, symptomatic hosts were hospitalised/isolated increasingly effectively ( Figure 1B) .", [["symptomatic hosts", "PROBLEM", 53, 70], ["symptomatic", "OBSERVATION_MODIFIER", 53, 64]]], ["This is likely to be due to changes in public awareness about the outbreak, as well as the introduction of containment measures (e.g., contact tracing followed by isolation of secondary infected hosts).", [["changes in public awareness", "PROBLEM", 28, 55], ["containment measures", "TREATMENT", 107, 127], ["contact tracing", "TEST", 135, 150], ["secondary infected hosts", "PROBLEM", 176, 200], ["likely to be due to", "UNCERTAINTY", 8, 27]]], ["The consequences of improved isolation of symptomatic hosts, in the absence of changes to other factors, are that the proportion of infections due to hosts with few symptoms is likely to have increased and the reproduction number is likely to have decreased (Figure 2A-C) .DiscussionWe considered the impact of transmissions from infectors with few symptoms on the controllability of infectious disease outbreaks, using COVID-19 as a case study.", [["infections", "DISEASE", 132, 142], ["infectious disease", "DISEASE", 384, 402], ["symptomatic hosts", "PROBLEM", 42, 59], ["infections", "PROBLEM", 132, 142], ["few symptoms", "PROBLEM", 161, 173], ["infectors", "PROBLEM", 330, 339], ["few symptoms", "PROBLEM", 345, 357], ["infectious disease outbreaks", "PROBLEM", 384, 412], ["a case study", "TEST", 432, 444], ["improved", "OBSERVATION_MODIFIER", 20, 28], ["isolation", "OBSERVATION_MODIFIER", 29, 38], ["symptomatic", "OBSERVATION_MODIFIER", 42, 53], ["hosts", "OBSERVATION_MODIFIER", 54, 59], ["infections", "OBSERVATION", 132, 142], ["increased", "OBSERVATION_MODIFIER", 192, 201], ["decreased", "OBSERVATION_MODIFIER", 248, 257], ["infectious", "OBSERVATION_MODIFIER", 384, 394]]], ["If symptomatic hosts can be isolated effectively, then it may be possible to bring an outbreak under control (Figure 2A) .", [["symptomatic hosts", "PROBLEM", 3, 20]]], ["However, this depends on the value of the basic reproduction number (R 0 ) and the initial proportion of infections arising from hosts with few symptoms (\u03b1 0 ).", [["infections", "DISEASE", 105, 115], ["infections", "PROBLEM", 105, 115], ["few symptoms", "PROBLEM", 140, 152], ["infections", "OBSERVATION", 105, 115]]], ["If the values of R 0 and \u03b1 0 are both high, then control of any outbreak by targeting symptomatic hosts alone is impossible (top right region of Figure 2D ).", [["R 0", "GENE_OR_GENE_PRODUCT", 17, 20], ["the values", "TEST", 3, 13], ["high", "OBSERVATION", 38, 42], ["right", "ANATOMY_MODIFIER", 129, 134]]], ["Under this scenario, other public health measures are necessary [13] , for example, strategies involving finding and isolating hosts with few symptoms (e.g., tracing and testing of known contacts, whether or not they are showing clear symptoms [2] ) or reducing transmission via large-scale interventions that are not focused on infectious hosts alone (e.g., school closures, workplace closures, prevention of large-scale gatherings and/or transport bans, most of which are now in place for COVID-19 in a number of countries worldwide [37] ).DiscussionWe also found that temporal variations in the proportion of transmissions occurring from hosts with few symptoms are independent of the value of R 0 .", [["few symptoms", "PROBLEM", 138, 150], ["tracing and testing", "TEST", 158, 177], ["clear symptoms", "PROBLEM", 229, 243], ["large-scale interventions", "TREATMENT", 279, 304], ["large-scale gatherings", "TREATMENT", 410, 432], ["COVID", "TEST", 491, 496], ["temporal variations", "PROBLEM", 571, 590], ["few symptoms", "PROBLEM", 652, 664], ["temporal", "OBSERVATION_MODIFIER", 571, 579], ["variations", "OBSERVATION", 580, 590]]], ["As an example, if the initial percentage of transmissions from individuals with few symptoms is 10%, then Equation (2) indicates that a 50% reduction in the time from symptom onset to hospitalisation would correspond to the proportion of transmissions from hosts with few symptoms increasing to 18%, regardless of the value of R 0 .DiscussionIn this study, we developed a simple model that includes both transmissions from infected individuals with few symptoms and transmissions from infected individuals with clear symptoms.", [["few symptoms", "PROBLEM", 80, 92], ["a 50% reduction", "TREATMENT", 134, 149], ["symptom", "PROBLEM", 167, 174], ["few symptoms", "PROBLEM", 268, 280], ["this study", "TEST", 345, 355], ["infected individuals", "PROBLEM", 423, 443], ["few symptoms", "PROBLEM", 449, 461], ["infected individuals", "PROBLEM", 485, 505], ["clear symptoms", "PROBLEM", 511, 525], ["infected", "OBSERVATION", 423, 431], ["infected", "OBSERVATION_MODIFIER", 485, 493]]], ["Our main goal was not to estimate temporal changes in R t and \u03b1 t during the COVID-19 pandemic accounting for the wide range of factors affecting these quantities.", [["R t and \u03b1 t", "DNA", 54, 65], ["temporal changes", "PROBLEM", 34, 50], ["the COVID", "TEST", 73, 82], ["pandemic", "PROBLEM", 86, 94]]], ["Instead, we considered the specific effect that increasingly efficient isolation of symptomatic hosts alone has on the values of R t and \u03b1 t .", [["R t", "GENE_OR_GENE_PRODUCT", 129, 132], ["\u03b1", "GENE_OR_GENE_PRODUCT", 137, 138], ["R t and \u03b1 t", "DNA", 129, 140], ["symptomatic hosts", "PROBLEM", 84, 101]]], ["We therefore focused on changes in the symptomatic infectious period.", [["symptomatic", "OBSERVATION_MODIFIER", 39, 50], ["infectious", "OBSERVATION", 51, 61]]], ["However, the model could be extended to account for additional features of emerging outbreaks.", [["emerging outbreaks", "PROBLEM", 75, 93], ["outbreaks", "OBSERVATION", 84, 93]]], ["As an example, precisely what constitutes \"few symptoms\" and \"clear symptoms\" might change as an outbreak is ongoing.", [["few symptoms", "PROBLEM", 43, 55], ["clear symptoms", "PROBLEM", 62, 76]]], ["For COVID-19, initial symptoms are nonspecific.", [["COVID", "TEST", 4, 9], ["initial symptoms", "PROBLEM", 14, 30], ["nonspecific", "OBSERVATION_MODIFIER", 35, 46]]], ["Consequently, when case numbers were very low early in the pandemic, an individual developing such symptoms may not have considered them to be indicative of infection by SARS-CoV-2.", [["infection", "DISEASE", 157, 166], ["SARS", "DISEASE", 170, 174], ["SARS-CoV-2", "ORGANISM", 170, 180], ["SARS-CoV", "SPECIES", 170, 178], ["very low", "PROBLEM", 37, 45], ["such symptoms", "PROBLEM", 94, 107], ["infection", "PROBLEM", 157, 166], ["CoV", "TEST", 175, 178], ["indicative of", "UNCERTAINTY", 143, 156], ["infection", "OBSERVATION", 157, 166]]], ["Now that the number of cases has increased, an individual might assume that nonspecific symptoms are an indicator of infection by SARS-CoV-2 and might self-isolate despite not having developed more obvious symptoms.", [["infection", "DISEASE", 117, 126], ["SARS", "DISEASE", 130, 134], ["SARS-CoV-2", "ORGANISM", 130, 140], ["SARS-CoV", "SPECIES", 130, 138], ["nonspecific symptoms", "PROBLEM", 76, 96], ["infection", "PROBLEM", 117, 126], ["SARS", "PROBLEM", 130, 134], ["CoV", "TEST", 135, 138], ["obvious symptoms", "PROBLEM", 198, 214], ["increased", "OBSERVATION_MODIFIER", 33, 42], ["infection", "OBSERVATION", 117, 126]]], ["Our assumption that the expected number of infections in the infectious period with few symptoms is unchanged during an outbreak could be amended to reflect this.DiscussionAs in previous studies, we assumed that the period between symptom onset and hospitalisation is a proxy for the period between symptom onset and isolation [1, 4] .", [["infections", "DISEASE", 43, 53], ["infections", "PROBLEM", 43, 53], ["few symptoms", "PROBLEM", 84, 96], ["previous studies", "TEST", 178, 194], ["number", "OBSERVATION_MODIFIER", 33, 39], ["infections", "OBSERVATION", 43, 53], ["infectious", "OBSERVATION_MODIFIER", 61, 71], ["few", "OBSERVATION_MODIFIER", 84, 87], ["unchanged", "OBSERVATION_MODIFIER", 100, 109]]], ["We could have made other assumptions about the symptomatic infectious period-for example, assuming that an infected host is isolated at the point that the SARS-CoV-2 infection is laboratory confirmed rather than at the time of the first medical visit.", [["SARS", "DISEASE", 155, 159], ["infection", "DISEASE", 166, 175], ["SARS-CoV-2", "ORGANISM", 155, 165], ["SARS-CoV", "SPECIES", 155, 163], ["the symptomatic infectious period", "PROBLEM", 43, 76], ["an infected host", "PROBLEM", 104, 120], ["the SARS-CoV-2 infection", "PROBLEM", 151, 175], ["symptomatic", "OBSERVATION_MODIFIER", 47, 58], ["infectious", "OBSERVATION", 59, 69], ["infected", "OBSERVATION", 107, 115], ["SARS", "OBSERVATION", 155, 159]]], ["Whereas this would lead to a longer symptomatic infectious period than the value estimated here, the opposite effect would be seen if individuals that self-isolated at home early in their infection were included in the analysis.", [["infection", "DISEASE", 188, 197], ["a longer symptomatic infectious period", "PROBLEM", 27, 65], ["their infection", "PROBLEM", 182, 197], ["the analysis", "TEST", 215, 227], ["symptomatic", "OBSERVATION_MODIFIER", 36, 47], ["infectious", "OBSERVATION", 48, 58]]], ["We also used a simple method to estimate the mean length of the period between symptom onset and hospitalisation, namely LOESS.", [["a simple method", "TREATMENT", 13, 28]]], ["One advantage of this approach is that it did not require a specific distribution for the time from symptom onset to hospitalisation to be chosen.", [["symptom", "PROBLEM", 100, 107]]], ["However, we did assume that the period between symptom onset and hospitalisation was 0.5 days for individuals that developed symptoms and were hospitalised on the same day.", [["individuals", "PROBLEM", 98, 109], ["symptoms", "PROBLEM", 125, 133]]], ["In theory, other methods of parameter estimation could be used.", [["parameter estimation", "TEST", 28, 48]]], ["For example, the period between symptom onset and hospitalisation could be estimated using Markov chain Monte Carlo in shifting time windows throughout the outbreak.", [["symptom onset", "PROBLEM", 32, 45], ["Markov chain Monte Carlo in shifting time windows", "TREATMENT", 91, 140]]], ["This would have the advantage that interval-censored data could be specified for possible periods between symptom onset and hospitalisation for each host in the dataset, rather than assuming a precise value (see, e.g., [1, 32, 40] ).", [["symptom onset", "PROBLEM", 106, 119]]], ["However, this would involve assuming a parametric distribution (or range of distributions) characterising the symptomatic infectious period, which was not necessary in our analysis.DiscussionDespite these simplifications, our analysis has allowed us to demonstrate the principle that the proportion of transmissions from individuals with few symptoms is not a fixed quantity and has instead varied temporally during the COVID-19 pandemic so far.", [["our analysis", "TEST", 168, 180], ["our analysis", "TEST", 222, 234], ["few symptoms", "PROBLEM", 338, 350], ["the COVID", "TEST", 416, 425], ["parametric distribution", "OBSERVATION", 39, 62], ["symptomatic", "OBSERVATION_MODIFIER", 110, 121], ["infectious", "OBSERVATION", 122, 132]]], ["Such changes are particularly likely early in an outbreak and whenever intervention strategies are altered.", [["intervention strategies", "TREATMENT", 71, 94], ["particularly likely", "UNCERTAINTY", 17, 36], ["early", "OBSERVATION_MODIFIER", 37, 42]]], ["The proportion of transmissions from individuals with few symptoms at the beginning of any outbreak can, in theory, be used, along with the value of the basic reproduction number, to predict whether or not an outbreak can be brought under control via isolation of symptomatic hosts alone.", [["few symptoms", "PROBLEM", 54, 66], ["symptomatic hosts", "TREATMENT", 264, 281]]], ["If these quantities are known simultaneously at another point in time, a similar assessment can be performed.", [["a similar assessment", "TEST", 71, 91]]], ["Nonetheless, whenever control of symptomatic hosts is enhanced, the proportion of transmissions from individuals with few symptoms is expected to increase.DiscussionSince we began our analysis, a range of values have been estimated for the proportion of transmissions occurring from individuals with few symptoms for COVID-19 [14, 41, 42] .", [["COVID-19", "CHEMICAL", 317, 325], ["symptomatic hosts", "PROBLEM", 33, 50], ["few symptoms", "PROBLEM", 118, 130], ["our analysis", "TEST", 180, 192], ["few symptoms", "PROBLEM", 300, 312], ["COVID", "TEST", 317, 322]]], ["For example, Ferretti et al. [14] estimated a range of between one-third and one-half of transmissions occurring from presymptomatic infected individuals using data from 40 source-recipient pairs.", [["presymptomatic infected", "DISEASE", 118, 141], ["presymptomatic infected individuals", "PROBLEM", 118, 153]]], ["As our results show, estimates of the proportion of transmissions occurring from individuals with few symptoms alone should not be used to assess whether or not an outbreak is controllable.", [["few symptoms", "PROBLEM", 98, 110]]], ["Instead, a thorough investigation, like the one conducted by Ferretti et al. [14] , is required to make that assessment.", [["a thorough investigation", "TEST", 9, 33], ["that assessment", "TEST", 104, 119]]], ["The proportion of transmissions occurring from individuals with few symptoms might take a high value as a result of measures that have reduced transmission from hosts with clear symptoms.", [["transmissions", "PROBLEM", 18, 31], ["few symptoms", "PROBLEM", 64, 76], ["clear symptoms", "PROBLEM", 172, 186]]], ["This should be considered when interpreting estimates of the proportion of infections arising from individuals with few symptoms during the COVID-19 pandemic.DiscussionSupplementary Materials: The supplementary material is available online at http://www.mdpi.com/2077-0383/9/ 5/1297/s1.", [["infections", "DISEASE", 75, 85], ["infections", "PROBLEM", 75, 85], ["few symptoms", "PROBLEM", 116, 128], ["the COVID", "TEST", 136, 145], ["pandemic", "PROBLEM", 149, 157], ["infections", "OBSERVATION", 75, 85]]]], "PMC7502301": [["INTRODUCTIONThe ongoing novel coronavirus disease (COVID-19) pandemic has forced several countries to impose lockdown to contain the further spread of infection.", [["coronavirus disease", "DISEASE", 30, 49], ["infection", "DISEASE", 151, 160], ["coronavirus", "ORGANISM", 30, 41], ["ongoing novel coronavirus disease", "PROBLEM", 16, 49], ["COVID", "TEST", 51, 56], ["pandemic", "PROBLEM", 61, 69], ["infection", "PROBLEM", 151, 160], ["coronavirus disease", "OBSERVATION", 30, 49], ["infection", "OBSERVATION", 151, 160]]], ["In India, the first confirmed case of COVID-19 was reported on 30th January 2020, and nationwide lockdown was imposed on 22nd March 2020, with subsequent extensions in three phases until 31st May 2020.", [["COVID", "TEST", 38, 43]]], ["During this period, barring a few exceptions, all modes of transport were restricted, nonessential establishments were shut down, a nationwide curfew was imposed to prevent public gatherings, and social distancing and the use of face masks were advised.", [["face masks", "TREATMENT", 229, 239]]], ["The lockdown and prioritization of healthcare services for acute care of COVID-19 may have helped to a certain extent in handling COVID-19.", [["COVID-19", "CHEMICAL", 130, 138], ["acute care of COVID", "TREATMENT", 59, 78]]], ["However, it has put patients with chronic illnesses, such as Parkinson\u2019s disease (PD), who need regular follow-up, at a healthcare disadvantage [1-4].", [["Parkinson\u2019s disease", "DISEASE", 61, 80], ["PD", "DISEASE", 82, 84], ["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28], ["chronic illnesses", "PROBLEM", 34, 51], ["Parkinson\u2019s disease", "PROBLEM", 61, 80], ["chronic", "OBSERVATION_MODIFIER", 34, 41], ["illnesses", "OBSERVATION", 42, 51]]], ["A matter of concern is that most health centers are postponing elective procedures to conserve hospital resources for the management of COVID-19.", [["elective procedures", "TREATMENT", 63, 82], ["the management", "TREATMENT", 118, 132], ["COVID", "TEST", 136, 141]]], ["Even though there was no restriction for healthcare emergencies, elective and routine follow-up appointments were deferred to prevent the spread of COVID-19.", [["COVID-19", "CHEMICAL", 148, 156], ["COVID", "TEST", 148, 153]]], ["Furthermore, apart from the lack of public transportation, which was a deterrent for patients\u2019 to access healthcare, several patients harbored apprehensions about visiting hospitals as they feared the possibility of contracting the infection.", [["infection", "DISEASE", 232, 241], ["patients", "ORGANISM", 85, 93], ["patients", "ORGANISM", 125, 133], ["patients", "SPECIES", 85, 93], ["patients", "SPECIES", 125, 133], ["the infection", "PROBLEM", 228, 241], ["infection", "OBSERVATION", 232, 241]]], ["The pandemic crisis poses challenges for the management of patients with deep brain stimulation (DBS) for various indications.", [["brain", "ANATOMY", 78, 83], ["patients", "ORGANISM", 59, 67], ["brain", "ORGAN", 78, 83], ["patients", "SPECIES", 59, 67], ["The pandemic crisis", "PROBLEM", 0, 19], ["the management", "TREATMENT", 41, 55], ["deep brain stimulation", "TREATMENT", 73, 95], ["various indications", "TREATMENT", 106, 125], ["pandemic", "OBSERVATION_MODIFIER", 4, 12], ["crisis", "OBSERVATION", 13, 19], ["deep", "ANATOMY_MODIFIER", 73, 77], ["brain", "ANATOMY", 78, 83]]], ["These patients may face difficulty visiting their doctors for programming and for battery replacement in the case of battery exhaustion, as it may not be considered a healthcare emergency.", [["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14], ["battery replacement", "TREATMENT", 82, 101], ["battery exhaustion", "PROBLEM", 117, 135]]], ["We report our experience with the management of acute worsening of symptoms due to battery exhaustion in 3 patients with DBS for advanced PD (two) and generalized dystonia (one).METHODSThis study was conducted at the National Institute of Mental Health and Neurosciences, Bengaluru, India.", [["PD", "DISEASE", 138, 140], ["dystonia", "DISEASE", 163, 171], ["patients", "ORGANISM", 107, 115], ["patients", "SPECIES", 107, 115], ["the management", "TREATMENT", 30, 44], ["acute worsening of symptoms", "PROBLEM", 48, 75], ["battery exhaustion", "PROBLEM", 83, 101], ["DBS", "TREATMENT", 121, 124], ["advanced PD", "PROBLEM", 129, 140], ["generalized dystonia", "PROBLEM", 151, 171], ["METHODSThis study", "TEST", 178, 195], ["acute", "OBSERVATION_MODIFIER", 48, 53], ["worsening", "OBSERVATION_MODIFIER", 54, 63], ["generalized", "OBSERVATION_MODIFIER", 151, 162], ["dystonia", "OBSERVATION", 163, 171]]], ["Patients with DBS for movement disorders who visited the emergency room due to DBS battery exhaustion during the nationwide lockdown from April 2020 to May 2020 were included in this study.", [["movement disorders", "DISEASE", 22, 40], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["movement disorders", "PROBLEM", 22, 40], ["DBS battery exhaustion", "PROBLEM", 79, 101], ["this study", "TEST", 178, 188]]], ["A chart review of these cases was performed, and details pertaining to their pre-DBS, pre- and post-DBS battery exhaustion and post battery replacement assessments were analyzed.Case 1 ::: RESULTSA 67-year-old man with advanced PD of 17 years had undergone subthalamic nucleus DBS (STN-DBS) implantation with a nonrechargeable neurostimulator 4 years ago.", [["subthalamic nucleus", "ANATOMY", 257, 276], ["PD", "DISEASE", 228, 230], ["man", "ORGANISM", 210, 213], ["man", "SPECIES", 210, 213], ["A chart review", "TEST", 0, 14], ["DBS battery exhaustion", "TEST", 100, 122], ["post battery replacement assessments", "TEST", 127, 163], ["advanced PD", "PROBLEM", 219, 230], ["subthalamic nucleus DBS", "PROBLEM", 257, 280], ["STN-DBS) implantation", "TREATMENT", 282, 303], ["subthalamic", "OBSERVATION", 257, 268], ["nucleus DBS", "OBSERVATION", 269, 280]]], ["He was independent for activities of daily living (ADL) with a modified Rankin scale (mRS) score of 2.", [["a modified Rankin scale", "TREATMENT", 61, 84]]], ["He presented with an acute-onset akinetic rigid state of 2 days duration with no fever, seizures, loss of consciousness, or incontinence (Figure 1).", [["fever", "DISEASE", 81, 86], ["seizures", "DISEASE", 88, 96], ["loss of consciousness", "DISEASE", 98, 119], ["incontinence", "DISEASE", 124, 136], ["an acute-onset akinetic rigid state", "PROBLEM", 18, 53], ["fever", "PROBLEM", 81, 86], ["seizures", "PROBLEM", 88, 96], ["loss of consciousness", "PROBLEM", 98, 119], ["incontinence", "PROBLEM", 124, 136], ["acute", "OBSERVATION_MODIFIER", 21, 26], ["akinetic", "OBSERVATION_MODIFIER", 33, 41], ["rigid", "OBSERVATION", 42, 47], ["no", "UNCERTAINTY", 78, 80], ["fever", "OBSERVATION", 81, 86]]], ["He was due for a follow-up 2 months prior to presentation but had deferred due to the COVID-19 pandemic.", [["He", "ORGANISM", 0, 2], ["the COVID", "TEST", 82, 91], ["pandemic", "PROBLEM", 95, 103]]], ["The patient was conscious, alert, oriented, afebrile, tachycardic, tachypneic and had normal blood pressure and oxygen saturation.", [["blood", "ANATOMY", 93, 98], ["tachypneic", "DISEASE", 67, 77], ["oxygen", "CHEMICAL", 112, 118], ["oxygen", "CHEMICAL", 112, 118], ["patient", "ORGANISM", 4, 11], ["blood", "ORGANISM_SUBSTANCE", 93, 98], ["oxygen", "SIMPLE_CHEMICAL", 112, 118], ["patient", "SPECIES", 4, 11], ["afebrile", "PROBLEM", 44, 52], ["tachycardic", "PROBLEM", 54, 65], ["tachypneic", "PROBLEM", 67, 77], ["oxygen saturation", "TEST", 112, 129], ["blood pressure", "OBSERVATION", 93, 107], ["oxygen saturation", "OBSERVATION", 112, 129]]], ["He was anarthric with severe asymmetrical parkinsonism and an akinetic rigid state.", [["parkinsonism", "DISEASE", 42, 54], ["akinetic", "DISEASE", 62, 70], ["He", "ORGANISM", 0, 2], ["severe asymmetrical parkinsonism", "PROBLEM", 22, 54], ["an akinetic rigid state", "PROBLEM", 59, 82], ["severe", "OBSERVATION_MODIFIER", 22, 28], ["asymmetrical", "OBSERVATION_MODIFIER", 29, 41], ["parkinsonism", "OBSERVATION", 42, 54], ["akinetic rigid", "OBSERVATION", 62, 76]]], ["The rest of his neurological and systemic examination was normal.", [["neurological", "ANATOMY", 16, 28], ["systemic examination", "TEST", 33, 53], ["normal", "OBSERVATION", 58, 64]]], ["His Unified PD Rating Scale-III (UPDRS-III) OFF-state score was 79 (Table 1).", [["PD", "DISEASE", 12, 14], ["His Unified PD Rating Scale", "TEST", 0, 27], ["state score", "TEST", 48, 59]]], ["On evaluation, his DBS battery was found to have reached end-of-service status.", [["evaluation", "TEST", 3, 13], ["his DBS battery", "TEST", 15, 30]]], ["The results of routine blood investigations, including serum creatine kinase, were normal.", [["blood", "ANATOMY", 23, 28], ["serum", "ANATOMY", 55, 60], ["creatine", "CHEMICAL", 61, 69], ["creatine", "CHEMICAL", 61, 69], ["blood", "ORGANISM_SUBSTANCE", 23, 28], ["serum", "ORGANISM_SUBSTANCE", 55, 60], ["creatine kinase", "GENE_OR_GENE_PRODUCT", 61, 76], ["serum creatine kinase", "PROTEIN", 55, 76], ["routine blood investigations", "TEST", 15, 43], ["serum creatine kinase", "TEST", 55, 76], ["normal", "OBSERVATION", 83, 89]]], ["Dopaminergic medications were optimized with mild improvement (UPDRS-III ON-state score 51).", [["Dopaminergic medications", "TREATMENT", 0, 24], ["UPDRS", "TEST", 63, 68], ["mild", "OBSERVATION_MODIFIER", 45, 49], ["improvement", "OBSERVATION_MODIFIER", 50, 61]]], ["Following screening and testing for COVID-19, the patient was taken up for battery replacement under general anesthesia.", [["patient", "ORGANISM", 50, 57], ["patient", "SPECIES", 50, 57], ["screening", "TEST", 10, 19], ["testing", "TEST", 24, 31], ["COVID", "TEST", 36, 41], ["battery replacement", "TREATMENT", 75, 94], ["general anesthesia", "TREATMENT", 101, 119]]], ["Significant improvement was noted after battery replacement and the restoration of neurostimulation.", [["battery replacement", "TREATMENT", 40, 59], ["the restoration of neurostimulation", "TREATMENT", 64, 99], ["improvement", "OBSERVATION_MODIFIER", 12, 23]]], ["At the time of discharge, he was ambulant and independent for ADL with a UPDRS-III (DBS-ON, Drug-ON) score of 28.Case 2 ::: RESULTSA 60-year-old woman with advanced PD of 17 years had undergone STN-DBS implantation with a nonrechargeable neurostimulator 4 years ago.", [["PD", "DISEASE", 165, 167], ["woman", "ORGANISM", 145, 150], ["woman", "SPECIES", 145, 150], ["a UPDRS", "TEST", 71, 78], ["DBS", "TEST", 84, 87], ["advanced PD", "PROBLEM", 156, 167], ["STN-DBS implantation", "TREATMENT", 194, 214]]], ["Following this, she was independent for ADL with an mRS score of 2.", [["an mRS score", "TEST", 49, 61]]], ["She presented with worsening parkinsonian symptoms for 2 weeks prior to presentation (Figure 1).", [["parkinsonian symptoms", "DISEASE", 29, 50], ["worsening parkinsonian symptoms", "PROBLEM", 19, 50], ["worsening", "OBSERVATION_MODIFIER", 19, 28], ["parkinsonian symptoms", "OBSERVATION", 29, 50]]], ["Owing to the lockdown, she was unable to visit our hospital for evaluation.", [["evaluation", "TEST", 64, 74]]], ["However, she consulted a nearby neurologist and had her dopaminergic medications adjusted, and she noticed mild improvement.", [["her dopaminergic medications", "TREATMENT", 52, 80], ["mild", "OBSERVATION_MODIFIER", 107, 111], ["improvement", "OBSERVATION", 112, 123]]], ["At presentation, the patient was conscious, alert, and oriented.", [["patient", "ORGANISM", 21, 28], ["patient", "SPECIES", 21, 28]]], ["She had asymmetric parkinsonism with a UPDRS-III OFF-state score of 73 (Table 1).", [["parkinsonism", "DISEASE", 19, 31], ["asymmetric parkinsonism", "PROBLEM", 8, 31], ["a UPDRS", "TEST", 37, 44], ["state score", "TEST", 53, 64], ["asymmetric", "OBSERVATION_MODIFIER", 8, 18], ["parkinsonism", "OBSERVATION", 19, 31]]], ["The rest of her neurological and systemic examination was normal.", [["neurological", "ANATOMY", 16, 28], ["systemic examination", "TEST", 33, 53], ["normal", "OBSERVATION", 58, 64]]], ["On evaluation, her DBS battery was found to have reached end-of-service status.", [["evaluation", "TEST", 3, 13], ["her DBS battery", "TEST", 15, 30]]], ["Routine blood investigations, including serum creatine kinase, were normal.", [["blood", "ANATOMY", 8, 13], ["serum", "ANATOMY", 40, 45], ["creatine", "CHEMICAL", 46, 54], ["creatine", "CHEMICAL", 46, 54], ["blood", "ORGANISM_SUBSTANCE", 8, 13], ["serum", "ORGANISM_SUBSTANCE", 40, 45], ["creatine kinase", "GENE_OR_GENE_PRODUCT", 46, 61], ["serum creatine kinase", "PROTEIN", 40, 61], ["Routine blood investigations", "TEST", 0, 28], ["serum creatine kinase", "TEST", 40, 61], ["normal", "OBSERVATION", 68, 74]]], ["Further elevation of the dopaminergic medication dose was attempted; however, there was no significant improvement (UPDRS-III ON-state score 64).", [["the dopaminergic medication dose", "TREATMENT", 21, 53], ["UPDRS", "TEST", 116, 121], ["elevation", "OBSERVATION_MODIFIER", 8, 17], ["no", "UNCERTAINTY", 88, 90], ["significant", "OBSERVATION_MODIFIER", 91, 102], ["improvement", "OBSERVATION_MODIFIER", 103, 114]]], ["Following screening and testing for COVID-19, the patient was taken up for battery replacement under general anesthesia.", [["patient", "ORGANISM", 50, 57], ["patient", "SPECIES", 50, 57], ["screening", "TEST", 10, 19], ["testing", "TEST", 24, 31], ["COVID", "TEST", 36, 41], ["battery replacement", "TREATMENT", 75, 94], ["general anesthesia", "TREATMENT", 101, 119]]], ["Significant improvement was noted after battery replacement and the restoration of neurostimulation.", [["battery replacement", "TREATMENT", 40, 59], ["the restoration of neurostimulation", "TREATMENT", 64, 99], ["improvement", "OBSERVATION_MODIFIER", 12, 23]]], ["At the time of discharge, she was ambulant and independent for ADL with a UPDRS-III (DBS-ON, Drug-ON) score of 26.Case 3 ::: RESULTSA 33-year-old man with idiopathic gradually progressive generalized dystonia of 9 years had undergone bilateral globus pallidus interna DBS implantation 3 years prior to the current presentation.", [["globus pallidus interna", "ANATOMY", 244, 267], ["dystonia", "DISEASE", 200, 208], ["man", "ORGANISM", 146, 149], ["man", "SPECIES", 146, 149], ["a UPDRS", "TEST", 72, 79], ["DBS", "TEST", 85, 88], ["idiopathic gradually progressive generalized dystonia", "PROBLEM", 155, 208], ["bilateral globus pallidus interna DBS implantation", "TREATMENT", 234, 284], ["idiopathic", "OBSERVATION_MODIFIER", 155, 165], ["gradually", "OBSERVATION_MODIFIER", 166, 175], ["progressive", "OBSERVATION_MODIFIER", 176, 187], ["generalized", "OBSERVATION_MODIFIER", 188, 199], ["dystonia", "OBSERVATION", 200, 208], ["bilateral", "ANATOMY_MODIFIER", 234, 243], ["globus pallidus", "ANATOMY", 244, 259], ["interna DBS", "OBSERVATION", 260, 271]]], ["Following DBS, he had significant improvement in dystonia (Table 1) and had maintained the improvement at his last follow-up, which was 6 months prior to the emergency presentation.", [["dystonia", "DISEASE", 49, 57], ["DBS", "TEST", 10, 13], ["dystonia", "PROBLEM", 49, 57], ["significant", "OBSERVATION_MODIFIER", 22, 33], ["improvement", "OBSERVATION_MODIFIER", 34, 45], ["dystonia", "OBSERVATION", 49, 57], ["improvement", "OBSERVATION_MODIFIER", 91, 102]]], ["He presented to our emergency room with acute overnight worsening of dystonia, and evaluation revealed end-of-service status of the battery.", [["dystonia", "DISEASE", 69, 77], ["acute overnight worsening of dystonia", "PROBLEM", 40, 77], ["evaluation", "TEST", 83, 93], ["the battery", "TEST", 128, 139], ["acute", "OBSERVATION_MODIFIER", 40, 45], ["dystonia", "OBSERVATION", 69, 77]]], ["The patient was advised to undergo a battery replacement; however, owing to financial constraints, he deferred the surgery to a later date.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["a battery replacement", "TREATMENT", 35, 56], ["the surgery", "TREATMENT", 111, 122]]], ["His medication was optimized to improve the current worsening, and he was discharged.DISCUSSIONThe lockdown and restrictions placed to prevent the spread of COVID-19 may have significant implications for both patients with DBS and those scheduled to undergo surgery [5].", [["COVID-19", "CHEMICAL", 157, 165], ["patients", "ORGANISM", 209, 217], ["patients", "SPECIES", 209, 217], ["His medication", "TREATMENT", 0, 14], ["The lockdown and restrictions", "TREATMENT", 95, 124], ["COVID", "TEST", 157, 162], ["DBS", "TREATMENT", 223, 226], ["surgery", "TREATMENT", 258, 265], ["worsening", "OBSERVATION_MODIFIER", 52, 61]]], ["Planned DBS surgeries for various indications have been rightly put on hold as they are elective surgeries and hospitals may be burdened with the care of patients with COVID-19.", [["COVID-19", "CHEMICAL", 168, 176], ["patients", "ORGANISM", 154, 162], ["patients", "SPECIES", 154, 162], ["DBS surgeries", "TREATMENT", 8, 21], ["various indications", "TREATMENT", 26, 45], ["elective surgeries", "TREATMENT", 88, 106], ["COVID", "TEST", 168, 173]]], ["However, over time, elective DBS surgeries will have to be resumed as they cannot be put on hold indefinitely, and most patients are considered for DBS surgeries due to inadequate management with medication.", [["patients", "ORGANISM", 120, 128], ["patients", "SPECIES", 120, 128], ["elective DBS surgeries", "TREATMENT", 20, 42], ["DBS surgeries", "TREATMENT", 148, 161], ["inadequate management", "TREATMENT", 169, 190], ["medication", "TREATMENT", 196, 206]]], ["In places where there are no limitations of resources, a proper plan of action in consultation with the DBS team, appropriate health authorities and hospital administration should be formulated to establish a system to prioritize patients and determine extra precautions necessary during hospitalization and surgery to resume elective DBS surgeries.", [["patients", "ORGANISM", 230, 238], ["patients", "SPECIES", 230, 238], ["extra precautions", "TREATMENT", 253, 270], ["surgery", "TREATMENT", 308, 315], ["elective DBS surgeries", "TREATMENT", 326, 348], ["no", "UNCERTAINTY", 26, 28]]], ["However, surgical intervention is an emergency in patients with battery malfunction due to exhaustion or other device-related issues, such as lead fracture or migration, electrical malfunction or infection.", [["fracture", "DISEASE", 147, 155], ["infection", "DISEASE", 196, 205], ["patients", "ORGANISM", 50, 58], ["patients", "SPECIES", 50, 58], ["surgical intervention", "TREATMENT", 9, 30], ["battery malfunction", "TREATMENT", 64, 83], ["exhaustion", "PROBLEM", 91, 101], ["other device-related issues", "PROBLEM", 105, 132], ["lead fracture", "PROBLEM", 142, 155], ["migration", "PROBLEM", 159, 168], ["electrical malfunction", "PROBLEM", 170, 192], ["infection", "PROBLEM", 196, 205], ["fracture", "OBSERVATION", 147, 155], ["migration", "OBSERVATION_MODIFIER", 159, 168], ["infection", "OBSERVATION", 196, 205]]], ["These patients are at risk of developing life-threatening complications of interrupted neurostimulation, such as DBS withdrawal syndrome, acute dystonic crisis, and the return of disabling tremor, which can be refractory to medication.DISCUSSIONAll 3 cases discussed in this report were scheduled for a routine follow-up a few months prior to the acute worsening; however, they deferred the visit as their conditions were well maintained, and in view of the evolving COVID-19 pandemic, they wanted to reduce the risk of infection.", [["withdrawal syndrome", "DISEASE", 117, 136], ["acute dystonic crisis", "DISEASE", 138, 159], ["tremor", "DISEASE", 189, 195], ["infection", "DISEASE", 520, 529], ["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14], ["interrupted neurostimulation", "TREATMENT", 75, 103], ["DBS withdrawal syndrome", "PROBLEM", 113, 136], ["acute dystonic crisis", "PROBLEM", 138, 159], ["disabling tremor", "PROBLEM", 179, 195], ["medication", "TREATMENT", 224, 234], ["the acute worsening", "PROBLEM", 343, 362], ["infection", "PROBLEM", 520, 529], ["acute", "OBSERVATION_MODIFIER", 138, 143], ["dystonic crisis", "OBSERVATION", 144, 159], ["disabling", "OBSERVATION_MODIFIER", 179, 188], ["tremor", "OBSERVATION", 189, 195], ["acute", "OBSERVATION_MODIFIER", 347, 352], ["worsening", "OBSERVATION", 353, 362], ["infection", "OBSERVATION", 520, 529]]], ["As there was no restriction for healthcare emergencies during lockdown, two of our three cases visited the emergency room shortly after the onset of symptom worsening.", [["symptom", "PROBLEM", 149, 156], ["no", "UNCERTAINTY", 13, 15]]], ["Two patients underwent emergency battery replacement as they did not have satisfactory improvement with medication alone.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["emergency battery replacement", "TREATMENT", 23, 52], ["medication alone", "TREATMENT", 104, 120]]], ["Although it is difficult to accurately predict when exactly the battery may run out, patient-controlled programmers can alert patients to impending end of service through the elective replacement indicator, which appears approximately 4\u20136 weeks prior to complete discharge of the battery.", [["patient", "ORGANISM", 85, 92], ["patients", "ORGANISM", 126, 134], ["patient", "SPECIES", 85, 92], ["patients", "SPECIES", 126, 134], ["the battery", "TEST", 60, 71], ["the elective replacement indicator", "TREATMENT", 171, 205]]], ["Patients may notice gradual worsening in symptoms as the battery runs out; however, there can be sudden worsening with complete drainage of the battery.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["gradual worsening in symptoms", "PROBLEM", 20, 49], ["the battery runs", "TEST", 53, 69], ["complete drainage of the battery", "TREATMENT", 119, 151], ["gradual", "OBSERVATION_MODIFIER", 20, 27], ["worsening", "OBSERVATION_MODIFIER", 28, 37], ["worsening", "OBSERVATION_MODIFIER", 104, 113], ["drainage", "OBSERVATION", 128, 136]]], ["Apart from battery exhaustion, acute worsening may also be due to lead fracture or migration, which could occur secondary to falls or a neck injury.DISCUSSIONAll patients with DBS who are due for battery replacement should be counseled about the need to check battery status with the patient-controlled programmer and to contact the treating neurologist if the programmer shows the elective replacement indicator or end-of-service status.", [["neck", "ANATOMY", 136, 140], ["fracture", "DISEASE", 71, 79], ["falls", "DISEASE", 125, 130], ["neck injury", "DISEASE", 136, 147], ["neck", "ORGANISM_SUBDIVISION", 136, 140], ["patients", "ORGANISM", 162, 170], ["patient", "ORGANISM", 284, 291], ["patients", "SPECIES", 162, 170], ["patient", "SPECIES", 284, 291], ["battery exhaustion", "PROBLEM", 11, 29], ["acute worsening", "PROBLEM", 31, 46], ["lead fracture", "PROBLEM", 66, 79], ["migration", "PROBLEM", 83, 92], ["falls", "PROBLEM", 125, 130], ["a neck injury", "PROBLEM", 134, 147], ["DBS", "TREATMENT", 176, 179], ["battery replacement", "TREATMENT", 196, 215], ["the elective replacement indicator", "TREATMENT", 378, 412], ["battery exhaustion", "OBSERVATION", 11, 29], ["acute", "OBSERVATION_MODIFIER", 31, 36], ["worsening", "OBSERVATION", 37, 46], ["may also be due to", "UNCERTAINTY", 47, 65], ["lead", "OBSERVATION_MODIFIER", 66, 70], ["fracture", "OBSERVATION", 71, 79], ["migration", "OBSERVATION", 83, 92], ["neck", "ANATOMY", 136, 140], ["injury", "OBSERVATION", 141, 147]]], ["In PD, long-standing STN-DBS (> 5 years), advanced disease (> 15 years), low-dose dopaminergic medications and older age are risk factors for DBS withdrawal syndrome and should be a high priority for battery replacement in the case of battery exhaustion [6,7].", [["PD", "DISEASE", 3, 5], ["withdrawal syndrome", "DISEASE", 146, 165], ["long-standing STN-DBS", "PROBLEM", 7, 28], ["advanced disease", "PROBLEM", 42, 58], ["low-dose dopaminergic medications", "TREATMENT", 73, 106], ["risk factors", "PROBLEM", 125, 137], ["DBS withdrawal syndrome", "PROBLEM", 142, 165], ["battery replacement", "TREATMENT", 200, 219], ["battery exhaustion", "PROBLEM", 235, 253]]], ["Urgent battery replacement or troubleshooting hardware malfunction is a high priority in most patients but should be decided on an individual basis after discussing the risk of complications, exposure risk to COVID-19 for both patients and healthcare workers and the availability of resources during the pandemic.", [["patients", "ORGANISM", 94, 102], ["patients", "ORGANISM", 227, 235], ["patients", "SPECIES", 94, 102], ["patients", "SPECIES", 227, 235], ["Urgent battery replacement", "TREATMENT", 0, 26], ["troubleshooting hardware malfunction", "PROBLEM", 30, 66], ["complications", "PROBLEM", 177, 190], ["battery replacement", "OBSERVATION", 7, 26], ["hardware", "OBSERVATION", 46, 54]]], ["If the battery cannot be replaced immediately, patients can be temporarily managed with dose escalation until the battery is replaced.", [["patients", "ORGANISM", 47, 55], ["patients", "SPECIES", 47, 55], ["dose escalation", "TREATMENT", 88, 103], ["the battery", "TREATMENT", 110, 121]]], ["The dose of medication can also be pre-emptively escalated prior to the exhaustion of the battery to compensate for decreasing neurostimulation and to avoid sudden worsening of symptoms, DBS withdrawal syndrome or acute dystonic crisis.DISCUSSIONProgramming-related follow-ups can be supplemented with video teleconsultations and the use of the patient-controlled programmer.", [["withdrawal syndrome", "DISEASE", 191, 210], ["patient", "ORGANISM", 345, 352], ["patient", "SPECIES", 345, 352], ["medication", "TREATMENT", 12, 22], ["the battery", "TEST", 86, 97], ["decreasing neurostimulation", "TREATMENT", 116, 143], ["sudden worsening of symptoms", "PROBLEM", 157, 185], ["DBS withdrawal syndrome", "PROBLEM", 187, 210], ["acute dystonic crisis", "PROBLEM", 214, 235], ["video teleconsultations", "TEST", 302, 325], ["acute", "OBSERVATION_MODIFIER", 214, 219], ["dystonic crisis", "OBSERVATION", 220, 235]]], ["First-time programming in PD can be deferred by asking patients to continue on their presurgery medication dose.", [["PD", "DISEASE", 26, 28], ["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 55, 63], ["their presurgery medication dose", "TREATMENT", 79, 111]]], ["For other indications where medications alone would not suffice and for reprogramming in the case of symptom worsening or stimulation-related side effects, video teleconsultation can be offered, and remote programming can be attempted with the help of the patient-controlled programmer.", [["patient", "ORGANISM", 256, 263], ["patient", "SPECIES", 256, 263], ["medications", "TREATMENT", 28, 39], ["symptom", "PROBLEM", 101, 108], ["stimulation", "PROBLEM", 122, 133], ["side effects", "PROBLEM", 142, 154], ["video teleconsultation", "TEST", 156, 178]]], ["If these measures fail, individual decisions can be made about in-person consultation or medication adjustment after discussing the various risks involved.DISCUSSIONDBS surgeries during this pandemic may pose extra challenges and several logistical issues.", [["medication adjustment", "TREATMENT", 89, 110], ["DISCUSSIONDBS surgeries", "TREATMENT", 155, 178], ["extra challenges", "TREATMENT", 209, 225]]], ["Testing for COVID-19 in those undergoing surgeries should be decided based on prevailing guidelines issued by regulatory bodies.", [["COVID-19", "DNA", 12, 20], ["Testing", "TEST", 0, 7], ["COVID", "TEST", 12, 17], ["surgeries", "TREATMENT", 41, 50]]], ["No emergency procedure should be delayed due to the lack of a COVID-19 test report.", [["emergency procedure", "TREATMENT", 3, 22]]], ["There may be an unprecedented increase in the total cost of DBS surgeries during the pandemic due to the inclusion of the cost of testing for COVID-19 and protective equipment to prevent the spread of infection.", [["COVID-19", "CHEMICAL", 142, 150], ["infection", "DISEASE", 201, 210], ["DBS surgeries", "TREATMENT", 60, 73], ["testing", "TEST", 130, 137], ["COVID", "TREATMENT", 142, 147], ["protective equipment", "TREATMENT", 155, 175], ["infection", "PROBLEM", 201, 210], ["may be", "UNCERTAINTY", 6, 12], ["unprecedented", "OBSERVATION_MODIFIER", 16, 29], ["increase", "OBSERVATION_MODIFIER", 30, 38], ["infection", "OBSERVATION", 201, 210]]], ["Difficulty in procuring DBS-related hardware and any additional costs should be discussed with the manufacturer and suppliers, as these devices may need to be imported.", [["Difficulty in procuring DBS", "PROBLEM", 0, 27], ["hardware", "TREATMENT", 36, 44], ["any additional costs", "PROBLEM", 49, 69], ["these devices", "TREATMENT", 130, 143], ["hardware", "OBSERVATION", 36, 44]]], ["These costs may be additional expenses that insurance companies may not be willing to cover.CONCLUSIONSThe COVID-19 pandemic and subsequent restrictions to control it have resulted in many unprecedented challenges for DBS-related patient management.", [["patient", "ORGANISM", 230, 237], ["patient", "SPECIES", 230, 237], ["COVID", "TEST", 107, 112], ["subsequent restrictions", "TREATMENT", 129, 152], ["DBS", "TREATMENT", 218, 221], ["patient management", "TREATMENT", 230, 248], ["may be", "UNCERTAINTY", 12, 18]]], ["Although the control of the pandemic is the first priority and of utmost importance, care should be taken to ensure that patients with other illnesses are not sidelined.", [["patients", "ORGANISM", 121, 129], ["patients", "SPECIES", 121, 129], ["other illnesses", "PROBLEM", 135, 150]]], ["With no clear end of the pandemic in sight, elective surgeries such as DBS implantation cannot be indefinitely put on hold, and a plan of action is necessary to restart these surgeries.", [["elective surgeries", "TREATMENT", 44, 62], ["DBS implantation", "TREATMENT", 71, 87], ["these surgeries", "TREATMENT", 169, 184], ["no", "UNCERTAINTY", 5, 7], ["clear", "OBSERVATION_MODIFIER", 8, 13], ["end", "OBSERVATION_MODIFIER", 14, 17]]], ["Better use of telemedicine and patient-controlled programmers should also be considered.", [["patient", "ORGANISM", 31, 38], ["patient", "SPECIES", 31, 38], ["telemedicine", "TREATMENT", 14, 26]]], ["This pandemic should motivate us to generate better guidelines to address DBS-related issues during such scenarios.", [["DBS", "PROBLEM", 74, 77], ["related issues", "PROBLEM", 78, 92]]]], "7136721ae5362bd4485ddf6362fea675767d3eab": [["KlinikKlinisch f\u00fchrendes Symptom sind h\u00e4ufig eine progrediente Dyspnoe und/oder ein therapieresistenter Husten.", [["KlinikKlinisch f\u00fchrendes Symptom sind h\u00e4ufig eine progrediente Dyspnoe und/oder ein therapieresistenter Husten", "SPECIES", 0, 110], ["Symptom", "PROBLEM", 25, 32]]], ["Lungenfunk tionsanalytisch zeigt sich eine restrikti ve und/oder obstruktive Ventilationsst\u00f6 rung.", [["Lungenfunk tionsanalytisch zeigt sich eine restrikti ve und/oder obstruktive Ventilationsst\u00f6 rung", "SPECIES", 0, 97], ["Lungenfunk", "TEST", 0, 10]]], ["B. Kollagenosen) von be sonderer Bedeutung.KlassifikationHinsichtlich der Einteilung der intersti tiellen Lungenkrankheiten werden ent sprechend einem Konsensus der Ameri can Thoracic Society und der European Respiratory Society Lungenparenchy merkrankungen mit bekannter Ursache, granulomat\u00f6se Lungenerkrankungen und andere Formen von Lungenparenchym erkrankungen von den idiopathischen interstitiellen Pneumonien abgegrenzt (.", [["KlassifikationHinsichtlich der Einteilung der intersti tiellen Lungenkrankheiten werden ent sprechend einem Konsensus der Ameri can Thoracic Society und der European Respiratory Society Lungenparenchy merkrankungen mit bekannter Ursache, granulomat\u00f6se Lungenerkrankungen und andere Formen von Lungenparenchym erkrankungen von den idiopathischen interstitiellen Pneumonien abgegrenzt", "SPECIES", 43, 425], ["Klassifikation", "PROBLEM", 43, 57], ["Ursache", "TEST", 272, 279], ["Thoracic", "ANATOMY", 175, 183]]], ["Abb.", [["Abb", "GENE_OR_GENE_PRODUCT", 0, 3], ["Abb", "PROTEIN", 0, 3]]], ["1, [17] ).Diffuse Lungenparenchymerkrankungen mit bekannter UrsacheSie umfassen insbesondere die exogen allergische Alveolitis (\"hypersensitivity pneumonitis\"), Medikamentennebenwir kungen, Pneumokoniosen und Kollage nosen.", [["Alveolitis", "DISEASE", 116, 126], ["hypersensitivity", "DISEASE", 129, 145], ["pneumonitis", "DISEASE", 146, 157], ["Diffuse Lungenparenchymerkrankungen mit bekannter", "PROBLEM", 10, 59], ["Alveolitis", "PROBLEM", 116, 126], ["hypersensitivity pneumonitis\"", "PROBLEM", 129, 158], ["Medikamentennebenwir kungen", "TREATMENT", 161, 188], ["Alveolitis", "OBSERVATION", 116, 126], ["hypersensitivity pneumonitis", "OBSERVATION", 129, 157]]], ["Drogenmissbrauch zu nennen.Diffuse Lungenparenchymerkrankungen mit bekannter UrsacheMedikamenteninduzierte Lungenpar enchymerkrankungen k\u00f6nnen sich unter dem histologischen Bild einer interstiti ellen oder einer organisierenden Pneumo nie, einer Bronchiolitis obliterans, eines eosinophilen Infiltrats, eines diffusen Al veolarwandschadens (\"diffuse alveolar damage\") oder einer granulomat\u00f6sen Ent z\u00fcndung manifestieren.Diffuse Lungenparenchymerkrankungen mit bekannter UrsacheEine exogenallergische Alveolitis kann sowohl infolge einer beruflichen als auch einer h\u00e4uslichen Exposition gegen\u00fcber or ganischen St\u00e4uben auftreten (z.", [["Bronchiolitis obliterans", "DISEASE", 246, 270], ["alveolar", "TISSUE", 350, 358], ["Drogenmissbrauch zu nennen", "SPECIES", 0, 26], ["Diffuse Lungenparenchymerkrankungen mit bekannter", "PROBLEM", 27, 76], ["sich", "PROBLEM", 143, 147], ["Pneumo nie", "PROBLEM", 228, 238], ["Bronchiolitis obliterans", "PROBLEM", 246, 270], ["Infiltrats", "PROBLEM", 291, 301], ["diffuse alveolar damage\"", "PROBLEM", 342, 366], ["Diffuse Lungenparenchymerkrankungen mit", "PROBLEM", 420, 459], ["Alveolitis", "PROBLEM", 500, 510], ["Bronchiolitis obliterans", "OBSERVATION", 246, 270], ["diffuse", "OBSERVATION_MODIFIER", 342, 349], ["alveolar damage", "OBSERVATION", 350, 365], ["Alveolitis", "OBSERVATION", 500, 510]]], ["B. so ge nannte Farmerlunge -BK 4201 -oder so genannte Taubenz\u00fcchterlunge).Diffuse Lungenparenchymerkrankungen mit bekannter UrsacheLungenparenchymerkrankungen in folge einer Exposition gegen\u00fcber anor ganischen mineralischen oder metal lischen St\u00e4uben (Pneumokoniosen) um fassen insbesondere die Silikose/Silikotu berkulose (Idiopathische interstitielle PneumonienDie erste Klassifikation der sp\u00e4ter als \"idiopathisch\" bezeichneten interstiti ellen Pneumonien geht auf eine Ver\u00f6f fentlichung von Liebow u.", [["Diffuse Lungenparenchymerkrankungen mit bekannter UrsacheLungenparenchymerkrankungen in folge einer Exposition gegen\u00fcber anor ganischen mineralischen oder metal lischen St\u00e4uben (Pneumokoniosen) um fassen insbesondere die Silikose/Silikotu berkulose (Idiopathische interstitielle PneumonienDie erste Klassifikation der sp\u00e4ter als \"idiopathisch\" bezeichneten interstiti ellen Pneumonien geht auf eine Ver\u00f6f fentlichung von Liebow u.", "SPECIES", 75, 505], ["Diffuse Lungenparenchymerkrankungen mit bekannter UrsacheLungenparenchymerkrankungen", "TREATMENT", 75, 159], ["metal lischen St\u00e4uben (Pneumokoniosen)", "TREATMENT", 230, 268], ["Silikose", "TREATMENT", 296, 304], ["Silikotu berkulose", "TREATMENT", 305, 323], ["Idiopathische interstitielle PneumonienDie", "TREATMENT", 325, 367], ["bezeichneten interstiti", "TREATMENT", 419, 442]]], ["Sie beinhaltet die gew\u00f6hnliche interstitielle Pneumo nie (UIP), die desquamative interstitielle Pneumonie (DIP), die Bronchiolitis ob literans mit diffusem Alveolarwandscha den (DAD), die lymphozyt\u00e4re interstitielle Pneumonie (LIP) und die riesenzellige in terstitielle Pneumonie (GIP).", [["desquamative interstitielle Pneumonie (DIP)", "PROBLEM", 68, 111], ["Bronchiolitis", "PROBLEM", 117, 130], ["die lymphozyt\u00e4re interstitielle Pneumonie", "PROBLEM", 184, 225], ["terstitielle Pneumonie", "PROBLEM", 257, 279], ["Pneumo", "OBSERVATION", 46, 52], ["LIP", "ANATOMY", 227, 230]]], ["W\u00e4hrend Letztere heute der Hartmetallpneumo koniose aufgrund einer Kobaltexpositi on zugerechnet wird und damit aus der Gruppe der idiopathischen interstitiellen Pneumonie ausgeschlossen wurde, wur den mit der akuten interstitiellen Pneu monie (AIP), der nichtspezifischen in terstitiellen Pneumonie (NSIP) und der Bronchiolitis obliterans -organisierende Pneumonie (BOOP) von Katzenstein u.", [["NSIP", "DISEASE", 301, 305], ["Bronchiolitis obliterans -organisierende Pneumonie", "DISEASE", 315, 365], ["BOOP", "DISEASE", 367, 371], ["zugerechnet wird", "TREATMENT", 85, 101], ["terstitiellen Pneumonie", "PROBLEM", 276, 299], ["NSIP)", "PROBLEM", 301, 306], ["Bronchiolitis obliterans", "PROBLEM", 315, 339], ["organisierende Pneumonie", "PROBLEM", 341, 365], ["Bronchiolitis obliterans", "OBSERVATION", 315, 339]]], ["Myers [5] Musters die \"gew\u00f6hnliche interstitielle Pneumonie\" (UIP), die \"nichtspezifische interstitielle Pneumonie\" (NSIP), die \"organisierende Pneumonie\" (COP), den \"diffusen Alveolarwandschaden\" (DAD), die \"respiratorische Bronchiolitis\" (RB), die \"desquamative inter-stitielle Pneumonie\" (DIP), die \"lymphozyt\u00e4re interstitielle Pneumonie\" (LIP) sowie \"unklassifizierbare interstitielle Pneumonien\".", [["NSIP", "DISEASE", 117, 121], ["Bronchiolitis", "DISEASE", 225, 238], ["interstitielle Pneumonie", "PROBLEM", 90, 114], ["NSIP", "PROBLEM", 117, 121], ["Bronchiolitis\" (RB)", "PROBLEM", 225, 244], ["desquamative inter-stitielle Pneumonie", "PROBLEM", 251, 289], ["lymphozyt\u00e4re interstitielle Pneumonie", "PROBLEM", 303, 340], ["Bronchiolitis", "OBSERVATION", 225, 238], ["LIP", "ANATOMY", 343, 346]]], ["Entscheidend ist dabei, dass der Pathologe ein histologisches (Fibrosierungs-)Muster angibt, w\u00e4hrend der klinische Kollege daraus in Kenntnis des klinischen und radiologischen Befunds die abschlie\u00dfende Diagnose ableitet, sodass der klinisch-pathologischen Korrelation bei der Diagnostik interstitieller Lungenkrankheiten eine besondere Bedeutung zukommt.Schl\u00fcsselw\u00f6rterInterstitielle Lungenkrankheiten \u00b7 Idiopathische interstitielle Pneumonie \u00b7 ATS/ERS-Klassifikation \u00b7 Gew\u00f6hnliche interstitielle Pneumonie (UIP) \u00b7 Nichtspezifische interstitielle Pneumonie (NSIP)Interstitial lung diseases AbstractInterstitial lung diseases comprise a heterogeneous group of about 200 entities.", [["lung", "ANATOMY", 576, 580], ["lung", "ANATOMY", 611, 615], ["NSIP", "DISEASE", 558, 562], ["Interstitial lung diseases", "DISEASE", 563, 589], ["Interstitial lung diseases", "DISEASE", 598, 624], ["lung", "ORGAN", 576, 580], ["lung", "ORGAN", 611, 615], ["Schl\u00fcsselw\u00f6rterInterstitielle Lungenkrankheiten \u00b7 Idiopathische interstitielle Pneumonie \u00b7 ATS/ERS-Klassifikation \u00b7 Gew\u00f6hnliche interstitielle Pneumonie (UIP) \u00b7 Nichtspezifische interstitielle Pneumonie", "SPECIES", 354, 556], ["dass der Pathologe ein histologisches", "TEST", 24, 61], ["Fibrosierungs", "TEST", 63, 76], ["Schl\u00fcsselw\u00f6rter", "TEST", 354, 369], ["interstitielle Pneumonie", "PROBLEM", 418, 442], ["ERS", "TEST", 449, 452], ["Klassifikation", "TEST", 453, 467], ["Gew\u00f6hnliche interstitielle Pneumonie", "PROBLEM", 470, 506], ["Nichtspezifische interstitielle Pneumonie", "PROBLEM", 515, 556], ["NSIP)", "PROBLEM", 558, 563], ["Interstitial lung diseases", "PROBLEM", 563, 589], ["Interstitial lung diseases", "PROBLEM", 598, 624], ["Interstitial", "ANATOMY_MODIFIER", 563, 575], ["lung", "ANATOMY", 576, 580], ["diseases", "OBSERVATION", 581, 589], ["Interstitial", "ANATOMY_MODIFIER", 598, 610], ["lung", "ANATOMY", 611, 615], ["diseases", "OBSERVATION", 616, 624], ["heterogeneous", "OBSERVATION_MODIFIER", 636, 649]]], ["In the classification of these diseases, diffuse parenchymal lung diseases with known cause, granulomatous diseases, and other specific interstitial lung diseases are separated from the important group of idiopathic interstitial pneumonias, which are classified according to the 2002 ATS/ERS consensus classification.", [["parenchymal lung", "ANATOMY", 49, 65], ["granulomatous", "ANATOMY", 93, 106], ["interstitial lung", "ANATOMY", 136, 153], ["parenchymal lung diseases", "DISEASE", 49, 74], ["granulomatous diseases", "DISEASE", 93, 115], ["interstitial lung diseases", "DISEASE", 136, 162], ["interstitial pneumonias", "DISEASE", 216, 239], ["lung", "ORGAN", 61, 65], ["lung", "ORGAN", 149, 153], ["these diseases", "PROBLEM", 25, 39], ["diffuse parenchymal lung diseases", "PROBLEM", 41, 74], ["granulomatous diseases", "PROBLEM", 93, 115], ["other specific interstitial lung diseases", "PROBLEM", 121, 162], ["idiopathic interstitial pneumonias", "PROBLEM", 205, 239], ["diseases", "OBSERVATION", 31, 39], ["diffuse", "OBSERVATION_MODIFIER", 41, 48], ["parenchymal", "ANATOMY_MODIFIER", 49, 60], ["lung", "ANATOMY", 61, 65], ["diseases", "OBSERVATION", 66, 74], ["granulomatous", "OBSERVATION", 93, 106], ["specific", "OBSERVATION_MODIFIER", 127, 135], ["interstitial", "ANATOMY_MODIFIER", 136, 148], ["lung", "ANATOMY", 149, 153], ["diseases", "OBSERVATION", 154, 162], ["idiopathic", "OBSERVATION_MODIFIER", 205, 215], ["interstitial", "ANATOMY_MODIFIER", 216, 228], ["pneumonias", "OBSERVATION", 229, 239]]], ["Concerning the histological pattern, this classification differentiates between \"usual interstitial pneumonia\" (UIP), \"nonspecific interstitial pneumonia\" (NSIP), \"organising pneumonia\" (COP), \"diffuse alveolar damage\" (DAD), \"respiratory bronchiolitis\" (RB), \"desquamative interstitial pneumonia\" (DIP), \"lymphocytic interstitial pneumonia\" (LIP) and \"unclassifiable interstitial pneumonias\".", [["interstitial", "ANATOMY", 87, 99], ["alveolar", "ANATOMY", 202, 210], ["respiratory", "ANATOMY", 227, 238], ["interstitial", "ANATOMY", 368, 380], ["interstitial pneumonia", "DISEASE", 87, 109], ["UIP", "DISEASE", 112, 115], ["interstitial pneumonia", "DISEASE", 131, 153], ["NSIP", "DISEASE", 156, 160], ["pneumonia", "DISEASE", 175, 184], ["COP", "DISEASE", 187, 190], ["alveolar damage", "DISEASE", 202, 217], ["DAD", "DISEASE", 220, 223], ["respiratory bronchiolitis", "DISEASE", 227, 252], ["RB", "DISEASE", 255, 257], ["interstitial pneumonia", "DISEASE", 274, 296], ["DIP", "DISEASE", 299, 302], ["interstitial pneumonia", "DISEASE", 318, 340], ["interstitial pneumonias", "DISEASE", 368, 391], ["alveolar", "TISSUE", 202, 210], ["the histological pattern", "PROBLEM", 11, 35], ["usual interstitial pneumonia\"", "PROBLEM", 81, 110], ["\"nonspecific interstitial pneumonia\"", "PROBLEM", 118, 154], ["NSIP", "PROBLEM", 156, 160], ["\"organising pneumonia\"", "PROBLEM", 163, 185], ["diffuse alveolar damage\"", "PROBLEM", 194, 218], ["\"respiratory bronchiolitis\"", "PROBLEM", 226, 253], ["\"desquamative interstitial pneumonia\"", "PROBLEM", 260, 297], ["\"lymphocytic interstitial pneumonia\"", "PROBLEM", 305, 341], ["\"unclassifiable interstitial pneumonias\"", "PROBLEM", 352, 392], ["interstitial", "ANATOMY_MODIFIER", 87, 99], ["pneumonia", "OBSERVATION", 100, 109], ["nonspecific", "OBSERVATION_MODIFIER", 119, 130], ["interstitial", "OBSERVATION_MODIFIER", 131, 143], ["pneumonia", "OBSERVATION", 144, 153], ["NSIP", "OBSERVATION", 156, 160], ["pneumonia", "OBSERVATION", 175, 184], ["diffuse", "OBSERVATION_MODIFIER", 194, 201], ["alveolar damage", "OBSERVATION", 202, 217], ["respiratory bronchiolitis", "OBSERVATION", 227, 252], ["desquamative", "OBSERVATION_MODIFIER", 261, 273], ["interstitial", "OBSERVATION_MODIFIER", 274, 286], ["pneumonia", "OBSERVATION", 287, 296], ["lymphocytic", "OBSERVATION_MODIFIER", 306, 317], ["interstitial", "ANATOMY_MODIFIER", 318, 330], ["pneumonia", "OBSERVATION", 331, 340], ["LIP", "ANATOMY", 343, 346], ["unclassifiable", "OBSERVATION_MODIFIER", 353, 367], ["interstitial", "OBSERVATION_MODIFIER", 368, 380], ["pneumonias", "OBSERVATION", 381, 391]]], ["A key message of this classification is that the pathologist will give the diagnosis of a histological pattern, whereas the final clinicopathologic diagnosis can be made only by the clinical pulmonologist after careful correlation with the clinical and radiologic features, which is essential in the diagnosis of interstitial lung diseases.KeywordsInterstitial lung diseases \u00b7 Idiopathic interstitial pneumonias \u00b7 ATS/ERS classification \u00b7 Usual interstitial pneumonia (UIP) \u00b7 Nonspecific interstitial pneumonia (NSIP)KeywordsDie Prognose der Erkrankung ist schlecht.", [["interstitial lung", "ANATOMY", 313, 330], ["lung", "ANATOMY", 361, 365], ["interstitial lung diseases", "DISEASE", 313, 339], ["Interstitial lung diseases", "DISEASE", 348, 374], ["Idiopathic interstitial pneumonias", "DISEASE", 377, 411], ["interstitial pneumonia", "DISEASE", 445, 467], ["UIP", "DISEASE", 469, 472], ["interstitial pneumonia", "DISEASE", 488, 510], ["NSIP", "DISEASE", 512, 516], ["lung", "ORGAN", 326, 330], ["lung", "ORGAN", 361, 365], ["interstitial lung diseases", "PROBLEM", 313, 339], ["Interstitial lung diseases", "PROBLEM", 348, 374], ["Idiopathic interstitial pneumonias", "PROBLEM", 377, 411], ["ATS", "PROBLEM", 414, 417], ["Usual interstitial pneumonia (UIP)", "PROBLEM", 439, 473], ["Nonspecific interstitial pneumonia (NSIP)", "PROBLEM", 476, 517], ["interstitial", "ANATOMY_MODIFIER", 313, 325], ["lung", "ANATOMY", 326, 330], ["diseases", "OBSERVATION", 331, 339], ["lung", "ANATOMY", 361, 365], ["diseases", "OBSERVATION", 366, 374], ["Idiopathic", "OBSERVATION_MODIFIER", 377, 387], ["interstitial", "OBSERVATION_MODIFIER", 388, 400], ["pneumonias", "OBSERVATION", 401, 411], ["interstitial", "ANATOMY_MODIFIER", 445, 457], ["pneumonia", "OBSERVATION", 458, 467], ["interstitial", "ANATOMY_MODIFIER", 488, 500], ["pneumonia", "OBSERVATION", 501, 510]]], ["Ohne eine Lungentransplanta tion versterben die meisten Patienten 5-10 Jahre nach der Diagnosestellung an einer respiratorischen Insuffizienz und einem Cor pulmonale.KeywordsMorphologie.", [["Cor pulmonale", "DISEASE", 152, 165], ["pulmonale", "ORGAN", 156, 165], ["Ohne eine Lungentransplanta tion versterben die meisten Patienten 5-10 Jahre nach der Diagnosestellung an einer respiratorischen Insuffizienz und einem Cor pulmonale", "SPECIES", 0, 165], ["Ohne eine Lungentransplanta", "TREATMENT", 0, 27], ["Cor pulmonale", "PROBLEM", 152, 165], ["pulmonale", "OBSERVATION", 156, 165]]], ["Ein wesentliches histolo gisches Charakteristikum ist die Heteroge nit\u00e4t der Lungenver\u00e4nderungen mit Are alen einer betont subpleural ausgepr\u00e4gten alveolarseptalen Fibrose und einem ho nigwabenf\u00f6rmigen Lungenumbau (\"ho neycomb fibrosis\") neben Abschnitten einer noch weitgehend erhaltenen Lun genarchitektur (\"spatial heterogeneity\") (.", [["fibrosis", "DISEASE", 227, 235], ["Ein wesentliches histolo gisches Charakteristikum ist die Heteroge nit\u00e4t der Lungenver\u00e4nderungen mit Are alen einer betont subpleural ausgepr\u00e4gten alveolarseptalen Fibrose und einem ho nigwabenf\u00f6rmigen Lungenumbau (\"ho neycomb fibrosis\")", "SPECIES", 0, 237], ["fibrosis", "PROBLEM", 227, 235], ["subpleural", "ANATOMY", 123, 133], ["fibrosis", "OBSERVATION", 227, 235]]], ["Abb.", [["Abb", "GENE_OR_GENE_PRODUCT", 0, 3], ["Abb", "PROTEIN", 0, 3]]], ["Neben einer Verbreiterung der Alveolarsepten durch eine Vermeh rung von Kollagenfasern finden sich kleinherdig Areale mit einem lockeren fibroblastenreichen Granulationsgewebe (\"fibroblastic foci\") (.", [["fibroblastic foci", "ANATOMY", 178, 195], ["fibroblastic foci", "CELL", 178, 195], ["sich", "PROBLEM", 94, 98], ["fibroblastic foci", "OBSERVATION", 178, 195]]], ["Abb.", [["Abb", "GENE_OR_GENE_PRODUCT", 0, 3], ["Abb", "PROTEIN", 0, 3]]], ["Die wabenf\u00f6rmig um gebauten Luftr\u00e4ume sind h\u00e4ufig von respi ratorischen Epithelien und Becherzellen ausgekleidet (Bronchiolisation) und wei sen eine Sekretretention auf.", [["Die wabenf\u00f6rmig um gebauten Luftr\u00e4ume sind h\u00e4ufig von respi ratorischen Epithelien und Becherzellen ausgekleidet (Bronchiolisation) und wei sen eine Sekretretention auf", "SPECIES", 0, 168]]], ["Begleitend findet sich ein sehr unterschiedlich aus gepr\u00e4gtes interstitiell akzentuiertes Infil trat aus Lymphozyten, Plasmazellen und Histiozyten.", [["aus Lymphozyten", "TREATMENT", 101, 116], ["Plasmazellen und Histiozyten", "TREATMENT", 118, 146]]], ["Fokal finden sich Hyperpla sien der TypIIPneumozyten und der glatten Muskulatur (muskul\u00e4re Zirrhose Meessen).", [["Fokal finden sich Hyperpla sien der TypIIPneumozyten und der glatten Muskulatur", "TREATMENT", 0, 79]]], ["Im akuten Schub (\"accelerated IPF\") liegt histologisch ein Kombinations bild einer UIP und eines diffusen Alveo larwandschadens (\"diffuse alveolar dama ge\") vor.Differenzialdiagnose.", [["alveolar", "ANATOMY", 138, 146], ["IPF", "DISEASE", 30, 33], ["accelerated IPF\"", "PROBLEM", 18, 34], ["histologisch", "TEST", 42, 54], ["Kombinations", "TEST", 59, 71], ["UIP", "TEST", 83, 86], ["eines", "TEST", 91, 96], ["Alveo larwandschadens", "PROBLEM", 106, 127], ["IPF", "OBSERVATION", 30, 33], ["diffuse", "OBSERVATION_MODIFIER", 130, 137], ["alveolar", "ANATOMY_MODIFIER", 138, 146]]], ["Mitbeteilung derLunge bei rheumatischen Erkrankungen (so genannte Rheumalunge), Medika mentenreaktion (Nitrofurantoin, Chemo therapie usw.), Pneumokoniosen (Asbes tose), Radiatio usw.Nichtspezifische interstitielle Pneumonie (NSIP)Der Begriff der NSIP wurde 1990 von Kitaichi [9] und 1994 von Katzenstein u.", [["Nitrofurantoin", "CHEMICAL", 103, 117], ["Pneumokoniosen", "CHEMICAL", 141, 155], ["NSIP", "DISEASE", 226, 230], ["Mitbeteilung derLunge bei rheumatischen Erkrankungen (so genannte Rheumalunge)", "SPECIES", 0, 78], ["Nichtspezifische interstitielle Pneumonie (NSIP)Der Begriff der NSIP wurde 1990 von Kitaichi [9] und 1994 von Katzenstein u.", "SPECIES", 183, 307], ["Mitbeteilung derLunge bei rheumatischen Erkrankungen", "TREATMENT", 0, 52], ["genannte Rheumalunge)", "TREATMENT", 57, 78], ["Medika mentenreaktion", "TREATMENT", 80, 101], ["Nitrofurantoin", "TREATMENT", 103, 117], ["Chemo therapie usw", "TREATMENT", 119, 137], ["Nichtspezifische interstitielle Pneumonie (NSIP)", "PROBLEM", 183, 231]]], ["Die Erkrankung wurde zun\u00e4chst als provisorische klinisch radiologischpathologische Diagnose in die Konsensusklassifikation von ATS und ERS aufgenommen, da unklar war, ob es sich hierbei um eine einheitliche Entit\u00e4t handelt.", [["Die Erkrankung wurde zun\u00e4chst als provisorische klinisch radiologischpathologische Diagnose in die Konsensusklassifikation von ATS und ERS aufgenommen, da unklar war, ob es sich hierbei um eine einheitliche Entit\u00e4t handelt", "SPECIES", 0, 222], ["Die", "PROBLEM", 0, 3]]], ["Von einigen Autoren der ATS/ ERSKlassifikation wurde die NSIP auch als \"waste basket\" der idiopathischen in terstitiellen Pneumonien bezeichnet.", [["Von einigen Autoren der ATS/ ERSKlassifikation wurde die NSIP auch als \"waste basket\" der idiopathischen", "SPECIES", 0, 104], ["NSIP", "PROBLEM", 57, 61]]], ["Ob wohl die nichtspezifischen interstitiellen Pneumonien wahrscheinlich eine hetero gene Gruppe von interstitiellen Lungener krankungen darstellen, weisen sie insge samt eine bessere Prognose als die UIP auf.", [["krankungen darstellen", "PROBLEM", 125, 146]]], ["Ferner hat der zellreiche Subtyp einer NSIP eine bessere 5 und 10JahresPro gnose als der fibrosierende Subtyp [16] .", [["Ferner hat der zellreiche Subtyp einer NSIP eine bessere", "TREATMENT", 0, 56]]], ["Weitere Untersuchungen haben in der Zwischenzeit Hinweise erbracht, dass der NSIP h\u00e4ufig pulmonale Manifestationen von Autoimmunerkrankungen zugrunde liegen [8, 18] .Desquamative interstitielle Pneumonien (DIP)Die DIP ist charakterisiert durch eine ver mehrte Einwanderung von Makrophagen in die Alveolen (diapedetisch) mit gestei gerter intraalveolarer Akkumulation und nicht, wie f\u00e4lschlicherweise von Liebow [10] angenommen wurde, durch abgel\u00f6ste Epithelzellen (desquamativ).Desquamative interstitielle Pneumonien (DIP)\u00c4tiologie.", [["pulmonale", "DISEASE", 89, 98], ["Desquamative interstitielle Pneumonien (DIP)", "PROBLEM", 166, 210], ["DIP ist charakterisiert durch eine ver mehrte", "TREATMENT", 214, 259], ["Desquamative interstitielle Pneumonien (DIP)\u00c4tiologie", "PROBLEM", 478, 531], ["interstitielle Pneumonien", "OBSERVATION", 179, 204], ["interstitielle Pneumonien", "OBSERVATION", 491, 516]]], ["Meist ist Kondensat von Ziga retten \u00e4tiologisch verantwortlich zu ma chen [7, 15] .", [["Meist ist Kondensat von Ziga retten \u00e4tiologisch verantwortlich zu ma chen", "SPECIES", 0, 73]]]], "6e25364c57f63500a1cfcbbaa59a1c73cd1ed33b": [["C oronavirus disease 2019 (COVID-19) originated in the city of Wuhan, China, on December 31, 2019.", [["COVID-19", "CHEMICAL", 27, 35], ["C oronavirus disease 2019 (COVID-19", "SPECIES", 0, 35], ["C oronavirus disease", "PROBLEM", 0, 20], ["COVID", "TEST", 27, 32]]], ["Since its discovery, a rapid community, regional, and international spread has occurred with exponential growth in cases and deaths.", [["deaths", "DISEASE", 125, 131], ["exponential growth in cases and deaths", "PROBLEM", 93, 131], ["rapid", "OBSERVATION_MODIFIER", 23, 28], ["community", "OBSERVATION_MODIFIER", 29, 38], ["regional", "OBSERVATION_MODIFIER", 40, 48], ["exponential", "OBSERVATION_MODIFIER", 93, 104], ["growth", "OBSERVATION_MODIFIER", 105, 111]]], ["1 The COVID-19 outbreak was confirmed to have reached Mexico on February 28, and on March 30, the Mexico government declared a national health emergency.", [["The COVID", "TEST", 2, 11]]], ["2 In the face of a health crisis, not seen in several years, response efforts by the government in coordination with the Secretar\u00eda de Salud (Ministry of Health) of Mexico have been swift, implementing a series of preventions, actions, and control infections in the country, including extension of school vacation period, home office, restriction of massive events, suspension of \"nonessential activities\" in all economic sectors, and the recommendation of home confinement for the general population.", [["infections", "DISEASE", 248, 258], ["massive events", "PROBLEM", 350, 364], ["massive", "OBSERVATION_MODIFIER", 350, 357]]], ["3 Some negative implications that COVID-19 has had in Mexico include the generation of panic buying and shoplifting, which in turn has led to the eventual shortage of antibacterial hand gel and face masks, 4 a fall in the price of fuel, 5 and the temporary or definitive closure of companies.", [["hand", "ANATOMY", 181, 185], ["panic", "DISEASE", 87, 92], ["shoplifting", "DISEASE", 104, 115], ["panic buying", "PROBLEM", 87, 99], ["antibacterial hand gel", "TREATMENT", 167, 189], ["face masks", "TREATMENT", 194, 204], ["definitive closure of companies", "TREATMENT", 260, 291], ["negative", "OBSERVATION", 7, 15], ["closure", "OBSERVATION", 271, 278]]], ["7 COVID-19 not only threatens people's physical health, but also could affect people's mental health, as many theories indicate.", [["people", "ORGANISM", 30, 36], ["people", "ORGANISM", 78, 84], ["people", "SPECIES", 30, 36], ["people", "SPECIES", 78, 84]]], ["For example, according to Behavioral Immune System theory, 8 people show emotions, such as aversion and anxiety, for selfprotection.", [["anxiety", "DISEASE", 104, 111], ["selfprotection", "DISEASE", 117, 131], ["people", "ORGANISM", 61, 67], ["people", "SPECIES", 61, 67], ["anxiety", "PROBLEM", 104, 111], ["selfprotection", "PROBLEM", 117, 131]]], ["9 ,10 Moreover, stress theory 11 and perceived risk theory 12 mention that public health emergencies trigger negative emotions, which may reduce the immune function of people and destroy the balance of their normal physiological mechanisms.", [["people", "ORGANISM", 168, 174], ["people", "SPECIES", 168, 174], ["stress theory", "TEST", 16, 29]]], ["13 In support, previous studies have shown the immediate psychological sequelae of a pandemic, as occurred with severe acute respiratory syndrome (SARS) and H1N1, include stress, poor sleep, depressed mood, weepiness, nightmares, and poor concentration.", [["pandemic", "DISEASE", 85, 93], ["acute respiratory syndrome", "DISEASE", 119, 145], ["SARS", "DISEASE", 147, 151], ["H1N1", "DISEASE", 157, 161], ["depressed mood", "DISEASE", 191, 205], ["weepiness", "DISEASE", 207, 216], ["previous studies", "TEST", 15, 31], ["a pandemic", "PROBLEM", 83, 93], ["severe acute respiratory syndrome", "PROBLEM", 112, 145], ["SARS", "PROBLEM", 147, 151], ["H1N1", "PROBLEM", 157, 161], ["stress", "PROBLEM", 171, 177], ["poor sleep", "PROBLEM", 179, 189], ["depressed mood", "PROBLEM", 191, 205], ["weepiness", "PROBLEM", 207, 216], ["nightmares", "PROBLEM", 218, 228], ["poor concentration", "PROBLEM", 234, 252], ["pandemic", "OBSERVATION", 85, 93], ["severe", "OBSERVATION_MODIFIER", 112, 118], ["acute", "OBSERVATION_MODIFIER", 119, 124], ["respiratory syndrome", "OBSERVATION", 125, 145], ["poor concentration", "OBSERVATION_MODIFIER", 234, 252]]], ["14 Furthermore, it has also been shown that people experience fear of falling sick or dying themselves, feelings of helplessness, irrational nervousness, loneliness, and stigma.", [["helplessness", "DISEASE", 116, 128], ["nervousness", "DISEASE", 141, 152], ["loneliness", "DISEASE", 154, 164], ["people", "ORGANISM", 44, 50], ["people", "SPECIES", 44, 50], ["falling sick", "PROBLEM", 70, 82], ["helplessness", "PROBLEM", 116, 128], ["irrational nervousness", "PROBLEM", 130, 152], ["loneliness", "PROBLEM", 154, 164], ["stigma", "PROBLEM", 170, 176]]], ["15, 16 Also, it has been identified that certain groups are more vulnerable to high psychological distress during a pandemic.", [["psychological distress", "DISEASE", 84, 106], ["high psychological distress", "PROBLEM", 79, 106], ["a pandemic", "PROBLEM", 114, 124]]], ["Taylor et al. reported that, during an outbreak of equine influenza, younger people, those with no formal educational qualifications, and those with financial dependence on an industry facing a crisis are significantly predisposed to high psychological distress.", [["influenza", "DISEASE", 58, 67], ["high psychological distress", "DISEASE", 234, 261], ["people", "ORGANISM", 77, 83], ["equine", "SPECIES", 51, 57], ["people", "SPECIES", 77, 83], ["equine", "SPECIES", 51, 57], ["equine influenza", "PROBLEM", 51, 67], ["a crisis", "PROBLEM", 192, 200], ["high psychological distress", "PROBLEM", 234, 261]]], ["Finally, the authors also identified that those with 1 child had a 1.2 times higher risk of high psychological distress than those with no children.", [["high psychological distress", "DISEASE", 92, 119], ["children", "ORGANISM", 139, 147], ["children", "SPECIES", 139, 147], ["high psychological distress", "PROBLEM", 92, 119]]], ["17 For their part, during pandemic influenza, Jacobs et al. found that individuals with poor self-rated health reported greater risk perception and concern for self and others than individuals with good self-rated health.", [["influenza", "DISEASE", 35, 44], ["pandemic influenza", "PROBLEM", 26, 44]]], ["18 Finally, di Giuseppe et al. reported that people with lower socioeconomic status and lower education showed significantly higher risk perception during avian influenza.", [["influenza", "DISEASE", 161, 170], ["people", "ORGANISM", 45, 51], ["people", "SPECIES", 45, 51], ["lower socioeconomic status", "PROBLEM", 57, 83], ["significantly higher risk perception", "PROBLEM", 111, 147], ["influenza", "PROBLEM", 161, 170]]], ["19 Therefore, it is essential to understand the potential psychological effects caused by COVID-19 in a timely manner.", [["COVID-19", "CHEMICAL", 90, 98], ["COVID-19", "CHEMICAL", 90, 98]]], ["Based on our understanding, there is no information on the psychological distress and mental health of Mexican populations concerning COVID-19.", [["the psychological distress", "PROBLEM", 55, 81], ["COVID", "TEST", 134, 139]]], ["This is especially pertinent with the uncertainty surrounding an outbreak of such unparalleled magnitude in our country.", [["outbreak", "OBSERVATION_MODIFIER", 65, 73]]], ["Therefore, this study aims to examine the levels of psychological distress (anxiety, depression, and stress) and identify risk factors contributing to worse outcome during the COVID-19 outbreak in a Mexican sample.", [["psychological distress", "DISEASE", 52, 74], ["anxiety", "DISEASE", 76, 83], ["depression", "DISEASE", 85, 95], ["this study", "TEST", 11, 21], ["psychological distress", "PROBLEM", 52, 74], ["anxiety", "PROBLEM", 76, 83], ["depression", "PROBLEM", 85, 95], ["stress", "PROBLEM", 101, 107], ["risk factors", "PROBLEM", 122, 134], ["the COVID", "TEST", 172, 181]]], ["We hypothesized that most of the respondents will show severe psychological distress and moderate depressive, anxiety, and stress levels caused by COVID-19.", [["psychological distress", "DISEASE", 62, 84], ["depressive", "DISEASE", 98, 108], ["anxiety", "DISEASE", 110, 117], ["COVID-19", "CHEMICAL", 147, 155], ["severe psychological distress", "PROBLEM", 55, 84], ["moderate depressive", "PROBLEM", 89, 108], ["anxiety", "PROBLEM", 110, 117], ["stress levels", "PROBLEM", 123, 136], ["COVID", "TEST", 147, 152], ["severe", "OBSERVATION_MODIFIER", 55, 61], ["moderate", "OBSERVATION_MODIFIER", 89, 97], ["depressive", "OBSERVATION", 98, 108]]], ["In addition, age, gender, and financial status will be factors contributing to worse outcomes.Participants and ProcedureWe carried out a cross-sectional study design.", [["Participants", "SPECIES", 94, 106], ["a cross-sectional study", "TEST", 135, 158]]], ["A snowball sampling strategy, focused on recruiting the general public living in the whole country during the epidemic of COVID-19, was used.", [["A snowball sampling strategy", "TREATMENT", 0, 28], ["COVID", "TEST", 122, 127]]], ["This study was conducted in compliance with the Norma Oficial Mexicana-012-SSA3-2012, Declaration of Helsinki and the Ethics Committee of Universidad Jos\u00e9 Mart\u00ed (Approval number 2020-3).", [["This study", "TEST", 0, 10]]], ["Informed consent was obtained from all participants included in the study.", [["participants", "SPECIES", 39, 51], ["the study", "TEST", 64, 73]]], ["Data collection was carried out from March 30 to April 5, that is, immediately after a national health emergency was declared in Mexico.SurveyWe reviewed a previous survey on the psychological distress of COVID-19 performed in China.", [["Data collection", "TEST", 0, 15], ["COVID", "TEST", 205, 210]]], ["20 In addition, we included questions related to employment status during the COVID-19 outbreak.", [["the COVID", "TEST", 74, 83]]], ["The questionnaire consisted of 70 items (about the past 14 days) that covered 8 areas: demographic data, financial status, physical health, contact history, knowledge and concerns, precautionary measures, psychological distress, and mental health status (more details see Appendix 1, online only).SurveyThe psychological distress was examined using the Impact of Event Scale-Revised (IES-R).", [["demographic data", "TEST", 87, 103], ["precautionary measures", "TREATMENT", 181, 203], ["psychological distress", "PROBLEM", 205, 227], ["The psychological distress", "PROBLEM", 303, 329], ["Event Scale", "TEST", 363, 374]]], ["The IES-R is a selfadministered questionnaire that has been applied to the Mexican sample for determining the extent of psychological distress after traumatic and/or stressing experiences.", [["psychological distress", "DISEASE", 120, 142], ["IES", "DNA", 4, 7], ["psychological distress", "PROBLEM", 120, 142], ["traumatic", "PROBLEM", 149, 158]]], ["21 In addition, it has been used in a recent study for determining the extent of psychological distress during COVID-19.", [["psychological distress", "DISEASE", 81, 103], ["a recent study", "TEST", 36, 50], ["psychological distress", "PROBLEM", 81, 103], ["COVID", "TEST", 111, 116]]], ["The total IES-R score was used to perform the inferential statistics, whereas for descriptive statistics, the total IES-R score was divided into normal (0-23), mild (24) (25) (26) (27) (28) (29) (30) (31) (32) , moderate (33) (34) (35) (36) , and severe psychological distress (>37).", [["psychological distress", "DISEASE", 254, 276], ["IES", "DNA", 10, 13], ["IES", "DNA", 116, 119], ["The total IES-R score", "TEST", 0, 21], ["descriptive statistics", "TEST", 82, 104], ["the total IES-R score", "TEST", 106, 127], ["severe psychological distress", "PROBLEM", 247, 276], ["mild", "OBSERVATION_MODIFIER", 160, 164], ["moderate", "OBSERVATION_MODIFIER", 212, 220], ["severe", "OBSERVATION_MODIFIER", 247, 253], ["psychological distress", "OBSERVATION", 254, 276]]], ["22 The mental health status was assessed by the Depression, Anxiety, and Stress Scale .", [["Depression", "DISEASE", 48, 58], ["Anxiety", "DISEASE", 60, 67], ["the Depression", "PROBLEM", 44, 58], ["Anxiety", "PROBLEM", 60, 67], ["Stress Scale", "TEST", 73, 85]]], ["This scale has been used previously in research related to outbreaks as H1N1, 23 SARS, 24 and recently, in COVID-19 outbreak in china (20) .", [["H1N1", "DISEASE", 72, 76], ["SARS", "DISEASE", 81, 85], ["COVID-19", "SPECIES", 107, 115], ["This scale", "TREATMENT", 0, 10], ["H1N1", "PROBLEM", 72, 76], ["COVID", "TEST", 107, 112]]], ["In addition, DASS-21 scale is considered as a reliable and valid measure in assessing mental health in the Mexican population.", [["DASS", "TEST", 13, 17]]], ["25 This 21-item questionnaire aims to measure depression, anxiety, and stress subscales.", [["depression", "DISEASE", 46, 56], ["anxiety", "DISEASE", 58, 65], ["depression", "PROBLEM", 46, 56], ["anxiety", "PROBLEM", 58, 65], ["stress subscales", "PROBLEM", 71, 87]]], ["Questions 3, 5, 10, 13, 16, 17, and 21 formed the depression subscale.", [["depression", "DISEASE", 50, 60], ["the depression subscale", "PROBLEM", 46, 69]]], ["The total depression subscale score was divided into normal (0-9), mild depression (10-12), moderate depression (13) (14) (15) (16) (17) (18) (19) (20) , severe depression (21) (22) (23) (24) (25) (26) (27) , and extremely severe depression (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) .", [["depression", "DISEASE", 10, 20], ["depression", "DISEASE", 72, 82], ["depression", "DISEASE", 101, 111], ["depression", "DISEASE", 161, 171], ["depression", "DISEASE", 230, 240], ["The total depression subscale score", "TEST", 0, 35], ["mild depression", "PROBLEM", 67, 82], ["moderate depression", "PROBLEM", 92, 111], ["severe depression", "PROBLEM", 154, 171], ["extremely severe depression", "PROBLEM", 213, 240], ["total", "OBSERVATION_MODIFIER", 4, 9], ["mild", "OBSERVATION_MODIFIER", 67, 71], ["depression", "OBSERVATION", 72, 82], ["moderate", "OBSERVATION_MODIFIER", 92, 100], ["depression", "OBSERVATION", 101, 111], ["severe", "OBSERVATION_MODIFIER", 154, 160], ["depression", "OBSERVATION", 161, 171], ["severe", "OBSERVATION_MODIFIER", 223, 229], ["depression", "OBSERVATION", 230, 240]]], ["Questions 2, 4, 7, 9, 15, 19 , and 20 formed the anxiety subscale.", [["anxiety", "DISEASE", 49, 56]]], ["The total anxiety subscale score was divided into normal (0-6), mild anxiety (7-9), moderate anxiety (10) (11) (12) (13) (14) , severe anxiety (15) (16) (17) (18) (19) , and extremely severe anxiety .", [["anxiety", "DISEASE", 10, 17], ["anxiety", "DISEASE", 69, 76], ["anxiety", "DISEASE", 93, 100], ["anxiety", "DISEASE", 135, 142], ["anxiety", "DISEASE", 191, 198], ["The total anxiety subscale score", "TEST", 0, 32], ["mild anxiety", "PROBLEM", 64, 76], ["moderate anxiety", "PROBLEM", 84, 100], ["severe anxiety", "PROBLEM", 128, 142], ["extremely severe anxiety", "PROBLEM", 174, 198], ["mild", "OBSERVATION_MODIFIER", 64, 68], ["anxiety", "OBSERVATION", 69, 76], ["moderate", "OBSERVATION_MODIFIER", 84, 92], ["severe", "OBSERVATION_MODIFIER", 184, 190], ["anxiety", "OBSERVATION", 191, 198]]], ["The total stress subscale score was divided into normal (0-10), mild stress (11) (12) (13) (14) (15) (16) (17) (18) , moderate stress (19) (20) (21) (22) (23) (24) (25) (26) , severe stress (27) (28) (29) (30) (31) (32) (33) (34) , and extremely severe stress (35) (36) (37) (38) (39) (40) (41) (42) .", [["The total stress subscale score", "TEST", 0, 31], ["mild stress", "PROBLEM", 64, 75], ["severe stress", "PROBLEM", 176, 189], ["extremely severe stress", "PROBLEM", 236, 259], ["mild", "OBSERVATION_MODIFIER", 64, 68], ["moderate", "OBSERVATION_MODIFIER", 118, 126], ["severe", "OBSERVATION_MODIFIER", 246, 252]]], ["Univariate generalized linear with a main effects model (linear regression) was used to measure the associations between sociodemographic characteristics, financial status, physical status, contact history, knowledge and concerns, and precautionary measures with regard the total IES-R score and DASS-21 subscales scores.", [["Univariate generalized linear", "PROBLEM", 0, 29], ["precautionary measures", "TREATMENT", 235, 257], ["DASS", "TEST", 296, 300], ["linear", "OBSERVATION_MODIFIER", 23, 29], ["main", "OBSERVATION_MODIFIER", 37, 41]]], ["Associations are presented using beta coefficients, confidence intervals, and P-values.", [["beta", "GENE_OR_GENE_PRODUCT", 33, 37], ["P-values", "TEST", 78, 86]]], ["The significance level was set at 0.05.", [["The significance level", "TEST", 0, 22]]], ["Analyses were performed in IBM SPSS Statistics (version 25.0).RESULTSA total of 1105 persons from 32 states in Mexico were included in the study (more details see Appendix 2, online only) from a convenience sample of 1109 respondents (response rate = 99.63).", [["persons", "ORGANISM", 85, 92], ["persons", "SPECIES", 85, 92], ["Analyses", "TEST", 0, 8], ["the study", "TEST", 135, 144], ["response rate", "TEST", 235, 248]]], ["The majority of respondents were female (62.1%), aged 18 to 28 y (68.7%) (SD = 10.46), single (71.1%), with a household size of >3 people (51.6%), without children (67.4%), and well educated (71.2% \u2265 college degree).Psychological Distress and Mental HealthThe psychological distress of COVID-19 outbreak, measured using the IES-R scale, revealed a sample mean score of 26.07 (SD = 19.33).", [["children", "ORGANISM", 155, 163], ["IES", "DNA", 324, 327], ["people", "SPECIES", 131, 137], ["children", "SPECIES", 155, 163], ["SD", "TEST", 74, 76], ["Psychological Distress", "PROBLEM", 216, 238], ["The psychological distress", "PROBLEM", 256, 282], ["COVID", "TEST", 286, 291], ["a sample mean score", "TEST", 346, 365]]], ["Of the total respondents, 33% reported minimal psychological distress, 16.7% rated mild psychological distress, and 50.3% reported moderate or severe psychological distress.", [["psychological distress", "DISEASE", 47, 69], ["psychological distress", "DISEASE", 88, 110], ["psychological distress", "DISEASE", 150, 172], ["minimal psychological distress", "PROBLEM", 39, 69], ["mild psychological distress", "PROBLEM", 83, 110], ["moderate or severe psychological distress", "PROBLEM", 131, 172], ["severe", "OBSERVATION_MODIFIER", 143, 149], ["psychological distress", "OBSERVATION", 150, 172]]], ["About the DASS 21 scale, who assessed mental health, revealed a sample mean score of 13.38 (SD = 4.51).", [["a sample mean score", "TEST", 62, 81]]], ["Results showed that 15.7% reported moderate to severe depressive symptoms, 22.6% of respondents reported moderate to severe anxiety symptoms, and 19.8% reported moderate to severe stress levels.Sociodemographic Characteristics, Psychological Distress, and Mental HealthThe results of the associations of psychological distress and mental health according to the sociodemographic variables are shown in Table 2 .GenderFemale gender was significantly associated with higher scores on the IES-R scale (B = 7.273; 95% confidence interval [CI] = 1.1881 to 9.960).", [["depressive symptoms", "DISEASE", 54, 73], ["anxiety", "DISEASE", 124, 131], ["psychological distress", "DISEASE", 304, 326], ["moderate to severe depressive symptoms", "PROBLEM", 35, 73], ["moderate to severe anxiety symptoms", "PROBLEM", 105, 140], ["moderate to severe stress levels", "PROBLEM", 161, 193], ["Psychological Distress", "PROBLEM", 228, 250], ["psychological distress", "PROBLEM", 304, 326], ["CI", "TEST", 535, 537], ["moderate", "OBSERVATION_MODIFIER", 35, 43], ["severe", "OBSERVATION_MODIFIER", 47, 53], ["moderate", "OBSERVATION_MODIFIER", 105, 113], ["severe", "OBSERVATION_MODIFIER", 117, 123]]], ["In the DASS-21 subscales, women were also the ones who showed higher scores in depression (B = 1.375; 95% CI = 0.3208 to 2.004), anxiety (B = 1.361; 95% CI = 0.3266 to 1.962), and stress (B = 1.682; 95% CI = 0.3542 to 2.376).AgeParticipants of 40-50 y were significantly associated with higher scores on IES-R scale (B = 14.418; 95% CI = 2.018 to 26.818).", [["depression", "DISEASE", 79, 89], ["anxiety", "DISEASE", 129, 136], ["women", "ORGANISM", 26, 31], ["DASS", "DNA", 7, 11], ["women", "SPECIES", 26, 31], ["higher scores in depression", "PROBLEM", 62, 89], ["CI", "TEST", 106, 108], ["anxiety", "PROBLEM", 129, 136], ["CI", "TEST", 153, 155], ["stress", "TEST", 180, 186], ["CI", "TEST", 203, 205], ["AgeParticipants", "TEST", 225, 240], ["IES", "TEST", 304, 307], ["CI", "TEST", 333, 335]]], ["About DASS-21 assessment, participants of 18 to 28 y were significantly associated with higher scores in anxiety (B = 3.607; 95% CI = 0.404 to 6.810) and stress subscale (B = 5.236; 95% CI = 1.552 to 8.920).", [["anxiety", "DISEASE", 105, 112], ["participants", "SPECIES", 26, 38], ["DASS-21 assessment", "TEST", 6, 24], ["higher scores in anxiety", "PROBLEM", 88, 112], ["CI", "TEST", 129, 131], ["stress subscale", "TEST", 154, 169], ["B", "TEST", 171, 172], ["CI", "TEST", 186, 188]]], ["In addition, respondents of 29 to 39 y (B = 4.481; 95% CI = 0.862 to 8.100) and 40 to 50 y (B = 3.898; 95% CI = 0.191 to 7.604) showed a significantly association with higher scores in stress subscale.Marital StatusDivorced status was significantly associated with higher scores in DASS-21 subscale depression (B = 0.630; 95% CI = 0.168 to 1.093).", [["depression", "DISEASE", 299, 309], ["CI", "TEST", 55, 57], ["CI", "TEST", 107, 109], ["higher scores in stress subscale", "PROBLEM", 168, 200], ["DASS", "TEST", 282, 286], ["subscale depression", "PROBLEM", 290, 309], ["CI", "TEST", 326, 328]]], ["Marital status was not associated with IES-R score.Household SizeHousehold size of 2 persons was significantly associated with higher scores in DASS-21 subscale anxiety (B = 0.852; 95% CI = 0.008 to 1.696) and higher scores on IES-R scale (B = 3.722; 95% CI = 0.499 to 0.6.944).Financial Status, Psychological Distress, and Mental HealthEmployed (52.4%) and student (38.8%) status were more frequent for respondents.", [["anxiety", "DISEASE", 161, 168], ["persons", "ORGANISM", 85, 92], ["persons", "SPECIES", 85, 92], ["DASS", "TEST", 144, 148], ["subscale anxiety", "PROBLEM", 152, 168], ["CI", "TEST", 185, 187], ["IES", "TEST", 227, 230], ["CI", "TEST", 255, 257], ["Psychological Distress", "PROBLEM", 296, 318], ["Mental HealthEmployed", "TEST", 324, 345], ["size", "OBSERVATION_MODIFIER", 75, 79]]], ["Most of the employees did not show risk for job loss (56.6%), reduction in working days (58.8%), or reduction in monthly income (52.0%).", [["job loss", "DISEASE", 44, 52], ["job loss", "PROBLEM", 44, 52]]], ["The financial status was not associated with DASS-21 and IES-R subscale scores (see Table 3 ).", [["DASS", "TEST", 45, 49]]], ["Satisfaction level about the amount of health information available about COVID-19 was significantly associated with higher scores in DASS-21 depression subscale.", [["depression", "DISEASE", 142, 152], ["COVID", "TEST", 74, 79], ["DASS", "TEST", 134, 138], ["depression subscale", "PROBLEM", 142, 161]]], ["Finally, the level of satisfaction about amount information that the government provided regarding new cases and treatments of COVID-19 was significantly associated both higher scores in DASS-21 (anxiety and stress subscale) and IES-R scale.", [["anxiety", "DISEASE", 196, 203], ["COVID", "TEST", 127, 132], ["DASS", "TEST", 187, 191], ["anxiety", "PROBLEM", 196, 203], ["stress subscale", "TEST", 208, 223], ["IES", "TEST", 229, 232]]], ["Social network, as the main source of information about COVID-19, was significantly associated with a higher IES-R scale score (B = 3.419; 95% CI = 0.613 to 6.226) (see Table 6 ).Precautionary Measures, Psychological Distress, and Mental HealthThe main precautionary measures about COVID-19 were hand washing behavior (35.74%), home confinement Regarding assessment with the IES-R, respondents that stay at home >9 h showed a significant association with higher scores in the scale IES-R and the DASS-2 depression subscale (see Table 7 ).Psychological Effects and Associated Factors of COVID-19 in a Mexican SampleDisaster Medicine and Public Health Preparedness anxiety symptoms; and 19.8% reported moderate to severe stress levels.", [["hand", "ANATOMY", 296, 300], ["depression", "DISEASE", 503, 513], ["anxiety symptoms", "DISEASE", 663, 679], ["hand", "ORGANISM_SUBDIVISION", 296, 300], ["COVID", "TEST", 56, 61], ["CI", "TEST", 143, 145], ["Precautionary Measures", "TREATMENT", 179, 201], ["Psychological Distress", "PROBLEM", 203, 225], ["COVID", "TEST", 282, 287], ["hand washing behavior", "TEST", 296, 317], ["assessment", "TEST", 355, 365], ["Psychological Effects", "PROBLEM", 538, 559], ["COVID", "TEST", 586, 591], ["anxiety symptoms", "PROBLEM", 663, 679], ["moderate to severe stress levels", "PROBLEM", 700, 732], ["main", "OBSERVATION_MODIFIER", 248, 252]]], ["The prevalence of moderate or severe psychological distress as measured by IES-R was higher than the prevalence of depression, anxiety, and stress as measured by the DASS-21.", [["psychological distress", "DISEASE", 37, 59], ["depression", "DISEASE", 115, 125], ["anxiety", "DISEASE", 127, 134], ["moderate or severe psychological distress", "PROBLEM", 18, 59], ["depression", "PROBLEM", 115, 125], ["anxiety", "PROBLEM", 127, 134], ["stress", "PROBLEM", 140, 146], ["the DASS", "TEST", 162, 170], ["moderate", "OBSERVATION_MODIFIER", 18, 26], ["severe", "OBSERVATION_MODIFIER", 30, 36], ["psychological", "OBSERVATION_MODIFIER", 37, 50], ["distress", "OBSERVATION", 51, 59], ["depression", "OBSERVATION", 115, 125]]], ["The differences in the results obtained between IES-R and DASS-21 may be due to the fact that the IES-R assesses psychological distress after a specific event.", [["psychological distress", "DISEASE", 113, 135], ["IES", "DNA", 98, 101], ["IES", "TEST", 48, 51], ["DASS", "TEST", 58, 62], ["psychological distress", "PROBLEM", 113, 135]]], ["Therefore, respondents might refer the COVID-19 outbreak as the event, while the DASS-21 did not specify any such event, as previously reported.", [["DASS-21", "DNA", 81, 88], ["the COVID", "TEST", 35, 44], ["the DASS", "TEST", 77, 85]]], ["20 According to similar epidemics and pandemics, in such cases, serious concerns, such as fear of death can arise, and feelings of loneliness and anger can develop among people who are quarantined.", [["death", "DISEASE", 98, 103], ["loneliness", "DISEASE", 131, 141], ["anger", "DISEASE", 146, 151], ["people", "ORGANISM", 170, 176], ["people", "SPECIES", 170, 176], ["death", "PROBLEM", 98, 103]]], ["26 In addition, people who are quarantined lose face-to-face connections and traditional social interventions, and this is a stressful phenomenon.", [["people", "ORGANISM", 16, 22], ["people", "SPECIES", 16, 22], ["traditional social interventions", "TREATMENT", 77, 109], ["a stressful phenomenon", "PROBLEM", 123, 145]]], ["27 Therefore, at these points, it was not surprising to find that the Mexican sample showed severe psychological distress during the COVID-19 outbreak, similarly with the findings originating from China, 20,28 Canada, 29 Iran, 27 Japan, 30 and Singapore.", [["psychological distress", "DISEASE", 99, 121], ["the Mexican sample", "TEST", 66, 84], ["severe psychological distress", "PROBLEM", 92, 121], ["the COVID", "TEST", 129, 138], ["severe", "OBSERVATION_MODIFIER", 92, 98]]], ["31 In support, it is recognized that widespread outbreaks of infectious diseases, such as SARS, 32 H1N1, 33 and actually, COVID-19, are associated with psychological distress and symptoms of mental illness.", [["infectious diseases", "DISEASE", 61, 80], ["SARS", "DISEASE", 90, 94], ["psychological distress", "DISEASE", 152, 174], ["mental illness", "DISEASE", 191, 205], ["infectious diseases", "PROBLEM", 61, 80], ["SARS", "PROBLEM", 90, 94], ["H1N1", "PROBLEM", 99, 103], ["COVID", "TEST", 122, 127], ["psychological distress", "PROBLEM", 152, 174], ["symptoms", "PROBLEM", 179, 187], ["mental illness", "PROBLEM", 191, 205], ["widespread", "OBSERVATION_MODIFIER", 37, 47], ["outbreaks", "OBSERVATION_MODIFIER", 48, 57], ["infectious", "OBSERVATION", 61, 71]]], ["34 Both psychologists, psychiatrists, and the health care system at large should be aware of these manifestations to subsequently implement early psychological interventions according the needs of specific populations.Psychological Effects and Associated Factors of COVID-19 in a Mexican SampleOur findings suggest that females suffered greater psychological distress of the outbreak as well as higher levels of stress, anxiety, and depression.", [["anxiety", "DISEASE", 420, 427], ["depression", "DISEASE", 433, 443], ["early psychological interventions", "TREATMENT", 140, 173], ["Psychological Effects", "PROBLEM", 218, 239], ["COVID", "TEST", 266, 271], ["greater psychological distress", "PROBLEM", 337, 367], ["the outbreak", "PROBLEM", 371, 383], ["stress", "PROBLEM", 412, 418], ["anxiety", "PROBLEM", 420, 427], ["depression", "PROBLEM", 433, 443]]], ["This finding corresponds to previous studies which found that women were at higher risk of depression, 35, 36 anxiety, 37 and stress.", [["depression", "DISEASE", 91, 101], ["anxiety", "DISEASE", 110, 117], ["women", "ORGANISM", 62, 67], ["women", "SPECIES", 62, 67], ["previous studies", "TEST", 28, 44], ["depression", "PROBLEM", 91, 101], ["anxiety", "TEST", 110, 117], ["depression", "OBSERVATION", 91, 101]]], ["38 It is likely that genetic, biological, chemical, hormonal, environmental, psychological, and social factors all intersect to contribute to mental disorders in women.", [["women", "ORGANISM", 162, 167], ["women", "SPECIES", 162, 167], ["mental disorders", "PROBLEM", 142, 158], ["is likely", "UNCERTAINTY", 6, 15]]], ["39 In addition, we found that with older age, participants showed greater stress and had a greater psychological distress of COVID-19 outbreak.", [["participants", "SPECIES", 46, 58], ["greater stress", "PROBLEM", 66, 80], ["a greater psychological distress of COVID", "PROBLEM", 89, 130]]], ["Young, middle-aged, and older adults may have different levels of exposure to school-related, work-related, and health-related stressors because of their life stages and associated life events.", [["adults", "ORGANISM", 30, 36]]], ["However, the uncertainty and potential negative distress on academic progression could have an adverse effect on the mental health of young people.Psychological Effects and Associated Factors of COVID-19 in a Mexican SampleWe found that divorced status had a greater likelihood of depression during the epidemic; in support, prior findings showing that the end of marriage through divorce is associated with a significant increase in the probability of a future depressive episode.", [["depression", "DISEASE", 281, 291], ["depressive episode", "DISEASE", 462, 480], ["people", "ORGANISM", 140, 146], ["people", "SPECIES", 140, 146], ["potential negative distress on academic progression", "PROBLEM", 29, 80], ["Psychological Effects", "PROBLEM", 147, 168], ["COVID", "TEST", 195, 200], ["depression", "PROBLEM", 281, 291], ["a future depressive episode", "PROBLEM", 453, 480], ["negative", "OBSERVATION_MODIFIER", 39, 47], ["distress", "OBSERVATION", 48, 56], ["significant", "OBSERVATION_MODIFIER", 410, 421], ["increase", "OBSERVATION_MODIFIER", 422, 430]]], ["41 Participants who live with 1 other person exhibited greater anxiety and greater psychological distress of the COVID-19 outbreak.", [["anxiety", "DISEASE", 63, 70], ["Participants", "SPECIES", 3, 15], ["person", "SPECIES", 38, 44], ["greater anxiety", "PROBLEM", 55, 70], ["greater psychological distress", "PROBLEM", 75, 105], ["the COVID", "TEST", 109, 118]]], ["This finding corresponds to previously extensive epidemiological studies which found that family size predicts anxiety.", [["anxiety", "DISEASE", 111, 118], ["previously extensive epidemiological studies", "TEST", 28, 72], ["anxiety", "PROBLEM", 111, 118], ["size", "OBSERVATION_MODIFIER", 97, 101]]], ["42 On the other hand, it is necessary that the health authorities identify the immediate psychological needs of the general population presenting with physical symptoms during the epidemic.", [["physical symptoms", "PROBLEM", 151, 168]]], ["Our results revealed that the Mexican sample, which presented specific symptoms of COVID-19, experienced greater psychological distress on the outbreak and higher levels of stress, anxiety, and depression.", [["anxiety", "DISEASE", 181, 188], ["depression", "DISEASE", 194, 204], ["COVID", "TEST", 83, 88], ["greater psychological distress", "PROBLEM", 105, 135], ["the outbreak", "PROBLEM", 139, 151], ["stress", "PROBLEM", 173, 179], ["anxiety", "PROBLEM", 181, 188], ["depression", "PROBLEM", 194, 204]]], ["Health professionals should take the opportunity to provide resources for psychological support and interventions for those who present with the above symptoms, especially during clinical consultations.", [["psychological support", "TREATMENT", 74, 95], ["interventions", "TREATMENT", 100, 113], ["the above symptoms", "PROBLEM", 141, 159]]], ["Moreover, such interventions should also be guaranteed for infected individuals and their caregivers.", [["such interventions", "TREATMENT", 10, 28]]], ["20 Taking a family history is essential, and health professionals should enquire about the level of concern for other family members of contracting COVID-19, as these concerns are associated with altered mental status.", [["altered mental status", "PROBLEM", 196, 217]]], ["In support, our results showed respondents had been in direct or indirect contact exhibited higher levels of anxiety, stress, and depression.Psychological Effects and Associated Factors of COVID-19 in a Mexican SampleThe goal of communication before and during a pandemic is to provide and exchange relevant information with the public, partners, and stakeholders to allow them to make wellinformed decisions and take appropriate actions to protect health and reduce the distress of rumors.", [["anxiety", "DISEASE", 109, 116], ["depression", "DISEASE", 130, 140], ["anxiety", "PROBLEM", 109, 116], ["stress", "PROBLEM", 118, 124], ["depression", "PROBLEM", 130, 140], ["Psychological Effects", "PROBLEM", 141, 162], ["COVID", "TEST", 189, 194], ["the distress of rumors", "PROBLEM", 467, 489]]], ["43 In our study, lack of confidence in the COVID-19 test security and lower satisfaction with the health information received were associated with higher psychological distress of the outbreak and higher levels of stress, anxiety, and depression.", [["anxiety", "DISEASE", 222, 229], ["depression", "DISEASE", 235, 245], ["our study", "TEST", 6, 15], ["the COVID", "TEST", 39, 48], ["higher psychological distress", "PROBLEM", 147, 176], ["the outbreak", "PROBLEM", 180, 192], ["stress", "PROBLEM", 214, 220], ["anxiety", "PROBLEM", 222, 229], ["depression", "PROBLEM", 235, 245]]], ["Therefore, it is crucial to provide clear health information, with comprehensible messages and based on evidence to avoid adverse psychological reactions.", [["adverse psychological reactions", "PROBLEM", 122, 153]]], ["44 A major adverse consequence of the COVID-19 pandemic is likely to be increased social isolation and loneliness, which are strongly associated with anxiety, depression, self-harm, and suicide attempts across the lifespan.", [["loneliness", "DISEASE", 103, 113], ["anxiety", "DISEASE", 150, 157], ["depression", "DISEASE", 159, 169], ["self-harm", "DISEASE", 171, 180], ["the COVID", "TEST", 34, 43], ["anxiety", "PROBLEM", 150, 157], ["depression", "PROBLEM", 159, 169], ["self-harm", "PROBLEM", 171, 180], ["likely to be", "UNCERTAINTY", 59, 71], ["increased", "OBSERVATION_MODIFIER", 72, 81], ["social isolation", "OBSERVATION", 82, 98]]], ["45 In our study, the majority of the participants that were homebound for >9 h/d during the epidemic suffered greater psychological distress from the outbreak as well as higher levels of depression.", [["depression", "DISEASE", 187, 197], ["participants", "ORGANISM", 37, 49], ["participants", "SPECIES", 37, 49], ["our study", "TEST", 6, 15], ["greater psychological distress", "PROBLEM", 110, 140], ["depression", "PROBLEM", 187, 197]]], ["Under these conditions, the content of psychological interventions needs to be modified to suit the needs of the general population during the epidemic.", [["psychological interventions", "TREATMENT", 39, 66]]], ["Psychologists should produce and disseminate information materials on the psychological consequences of the quarantine and toll-free numbers should be activated to support all those who are confronted with psychological distress.", [["psychological distress", "DISEASE", 206, 228], ["psychological distress", "PROBLEM", 206, 228]]], ["46 For example, cognitive behavior therapy could be delivered online or by means of telephone to counteract depression in the home environment.", [["cognitive behavior", "DISEASE", 16, 34], ["depression", "DISEASE", 108, 118], ["cognitive behavior therapy", "TREATMENT", 16, 42], ["depression", "PROBLEM", 108, 118]]], ["For this reason, fine tuning effective psychological interventions is a future need, given that, after the public health emergency, a psychological distress emergency seems on the horizon.Psychological Effects and Associated Factors of COVID-19 in a Mexican SampleFinally, our findings showed that specific precautionary measures as hand hygiene and wearing masks were associated with Psychological Effects and Associated Factors of COVID-19 in a Mexican Sample lower levels of psychological distress, depression, anxiety, and stress.", [["hand", "ANATOMY", 333, 337], ["psychological distress", "DISEASE", 478, 500], ["depression", "DISEASE", 502, 512], ["anxiety", "DISEASE", 514, 521], ["hand", "ORGANISM_SUBDIVISION", 333, 337], ["psychological interventions", "TREATMENT", 39, 66], ["a psychological distress", "PROBLEM", 132, 156], ["Psychological Effects", "PROBLEM", 188, 209], ["COVID", "TEST", 236, 241], ["specific precautionary measures", "TREATMENT", 298, 329], ["hand hygiene", "TREATMENT", 333, 345], ["wearing masks", "TREATMENT", 350, 363], ["Psychological Effects", "PROBLEM", 385, 406], ["COVID", "TEST", 433, 438], ["psychological distress", "PROBLEM", 478, 500], ["depression", "PROBLEM", 502, 512], ["anxiety", "PROBLEM", 514, 521], ["stress", "PROBLEM", 527, 533]]], ["Our finding is similar to a previous study, which suggests that the precautionary measures adopted to prevent the spread of COVID-19 could have had protective psychological effects during the early stage of the epidemic.", [["COVID-19", "CHEMICAL", 124, 132], ["COVID-19", "CHEMICAL", 124, 132], ["a previous study", "TEST", 26, 42], ["the precautionary measures", "TREATMENT", 64, 90], ["COVID", "TEST", 124, 129], ["protective psychological effects", "PROBLEM", 148, 180], ["the epidemic", "PROBLEM", 207, 219], ["epidemic", "OBSERVATION", 211, 219]]], ["20 This study has several limitations.", [["This study", "TEST", 3, 13]]], ["First, due the time-sensitivity of the COVID-19 outbreak, we used the snowball sampling strategy; this strategy was not based on a random selection of the sample, and the study population did not reflect the actual pattern of the general population.", [["the COVID", "TEST", 35, 44], ["the snowball sampling strategy", "TREATMENT", 66, 96], ["the study population", "TEST", 167, 187]]], ["Second, the sampling was carried out by students, leading to selection bias.", [["the sampling", "TEST", 8, 20]]], ["Therefore, our conclusion was less generalizable to the entire population, particularly less-educated people.", [["people", "ORGANISM", 102, 108], ["people", "SPECIES", 102, 108]]], ["Last, the number of respondents with contact history and who had sought medical consultations was very small.", [["small", "OBSERVATION_MODIFIER", 103, 108]]], ["As a result, our findings could not be generalized to confirmed or suspected cases of COVID-19.Psychological Effects and Associated Factors of COVID-19 in a Mexican SampleNotwithstanding the above limitations, this study provides invaluable information on the psychological effects in the Mexican sample, 1 wk after the outbreak of COVID-19 was declared a national health emergency in Mexico.", [["COVID-19", "CHEMICAL", 86, 94], ["COVID", "TEST", 86, 91], ["Psychological Effects", "PROBLEM", 95, 116], ["COVID", "TEST", 143, 148], ["this study", "TEST", 210, 220]]], ["In addition, our results could be used as a historical reference and provide a baseline for evaluating prevention, control, and treatment efforts throughout the remainder of the COVID-19 epidemic.CONCLUSIONSTogether, the data show that the COVID-19 outbreak results in considerable psychological distress among the Mexican sample examined.", [["treatment efforts", "TREATMENT", 128, 145], ["the COVID", "TEST", 174, 183], ["the data", "TEST", 217, 225], ["the COVID", "TEST", 236, 245], ["considerable psychological distress", "PROBLEM", 269, 304]]], ["Public health officials, infectious diseases physicians, psychiatrists, psychologists, and the health care system at large need to be made aware of this issue.", [["infectious diseases", "DISEASE", 25, 44]]]], "PMC7387874": [["IntroductionCoronavirus Disease (COVID-19) is a recently emerged disease caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV2), a novel coronavirus that leads to adverse pulmonary pathological features [1].", [["pulmonary", "ANATOMY", 186, 195], ["COVID-19", "CHEMICAL", 33, 41], ["Acute Respiratory Syndrome Coronavirus", "DISEASE", 90, 128], ["SARS-CoV2", "DISEASE", 132, 141], ["coronavirus", "DISEASE", 152, 163], ["Severe Acute Respiratory Syndrome Coronavirus-2", "ORGANISM", 83, 130], ["SARS-CoV2", "ORGANISM", 132, 141], ["coronavirus", "ORGANISM", 152, 163], ["pulmonary", "ORGAN", 186, 195], ["Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV2", "SPECIES", 83, 141], ["IntroductionCoronavirus Disease", "PROBLEM", 0, 31], ["a recently emerged disease", "PROBLEM", 46, 72], ["Severe Acute Respiratory Syndrome Coronavirus", "PROBLEM", 83, 128], ["a novel coronavirus", "PROBLEM", 144, 163], ["adverse pulmonary pathological features", "PROBLEM", 178, 217], ["Severe", "OBSERVATION_MODIFIER", 83, 89], ["Acute", "OBSERVATION_MODIFIER", 90, 95], ["Respiratory Syndrome", "OBSERVATION", 96, 116], ["coronavirus", "OBSERVATION", 152, 163], ["pulmonary", "ANATOMY", 186, 195]]], ["COVID-19 is a global pandemic as in total 205 countries have been affected by the disease around the world.", [["COVID-19", "CHEMICAL", 0, 8], ["COVID", "TEST", 0, 5], ["a global pandemic", "PROBLEM", 12, 29], ["the disease", "PROBLEM", 78, 89], ["global", "OBSERVATION_MODIFIER", 14, 20], ["pandemic", "OBSERVATION", 21, 29], ["disease", "OBSERVATION", 82, 89]]], ["There are 1, 40,43,176 confirmed cases worldwide and 5, 97, 583 deaths, as on July 19th, 2020 [2].", [["deaths", "DISEASE", 64, 70]]], ["The chaotic situation began in China and the number of cases exceeded in other regions than those in China and is still currently rising.", [["The chaotic situation", "PROBLEM", 0, 21], ["chaotic", "OBSERVATION_MODIFIER", 4, 11], ["situation", "OBSERVATION", 12, 21], ["rising", "OBSERVATION", 130, 136]]], ["Furthermore, the number of fatalities in many other countries likes the USA, Brazil, and India has now exceeded the total in China.", [["fatalities", "DISEASE", 27, 37]]], ["COVID-19 enhances morbidity in patients with cardiovascular diseases (CVDs) via interacting with the cardiovascular system on multiple levels, thereby, worsening the diseased conditions and leading to myocardial injury and dysfunction [1].", [["cardiovascular", "ANATOMY", 45, 59], ["cardiovascular system", "ANATOMY", 101, 122], ["myocardial", "ANATOMY", 201, 211], ["COVID-19", "CHEMICAL", 0, 8], ["cardiovascular diseases", "DISEASE", 45, 68], ["CVDs", "DISEASE", 70, 74], ["myocardial injury", "DISEASE", 201, 218], ["COVID-19", "CHEMICAL", 0, 8], ["patients", "ORGANISM", 31, 39], ["cardiovascular", "ANATOMICAL_SYSTEM", 45, 59], ["cardiovascular", "ANATOMICAL_SYSTEM", 101, 115], ["system", "ANATOMICAL_SYSTEM", 116, 122], ["myocardial", "MULTI-TISSUE_STRUCTURE", 201, 211], ["patients", "SPECIES", 31, 39], ["COVID", "TEST", 0, 5], ["cardiovascular diseases (CVDs)", "PROBLEM", 45, 75], ["worsening the diseased conditions", "PROBLEM", 152, 185], ["myocardial injury", "PROBLEM", 201, 218], ["dysfunction", "PROBLEM", 223, 234], ["cardiovascular", "ANATOMY", 45, 59], ["diseases", "OBSERVATION", 60, 68], ["diseased", "OBSERVATION", 166, 174], ["myocardial", "ANATOMY", 201, 211], ["injury", "OBSERVATION", 212, 218]]], ["Due to such a high mortality and morbidity as well as widespread occurrence, SARS-CoV2 should be eradicated from every part of the world.IntroductionCardiovascular diseases (CVDs) are one of the major reasons of death globally, contributing to almost a third of total deaths [3].", [["Cardiovascular", "ANATOMY", 149, 163], ["SARS", "DISEASE", 77, 81], ["Cardiovascular diseases", "DISEASE", 149, 172], ["CVDs", "DISEASE", 174, 178], ["death", "DISEASE", 212, 217], ["deaths", "DISEASE", 268, 274], ["a high mortality", "PROBLEM", 12, 28], ["morbidity", "PROBLEM", 33, 42], ["SARS", "PROBLEM", 77, 81], ["Cardiovascular diseases (CVDs)", "PROBLEM", 149, 179], ["death", "PROBLEM", 212, 217], ["diseases", "OBSERVATION", 164, 172]]], ["However, proper attention has not been paid to CVD patients suffering from COVID-19.", [["CVD", "DISEASE", 47, 50], ["COVID-19", "CHEMICAL", 75, 83], ["patients", "ORGANISM", 51, 59], ["patients", "SPECIES", 51, 59], ["COVID", "TEST", 75, 80]]], ["Various studies focusing on the clinical features of COVID-19 have not classified CVDs, but these CVDs might have links with prognosis of COVID-19.", [["CVDs", "DISEASE", 82, 86], ["CVDs", "DISEASE", 98, 102], ["Various studies", "TEST", 0, 15], ["COVID", "TEST", 53, 58], ["COVID", "TEST", 138, 143]]], ["According to a study [4], out of 1099 COVID-19 cases, 173 suffered from comorbidities such as hypertension (23.7%), coronary heart diseases (5.8%), cerebrovascular disease (2.3%), and diabetes mellitus (16.2%).", [["coronary", "ANATOMY", 116, 124], ["heart", "ANATOMY", 125, 130], ["cerebrovascular", "ANATOMY", 148, 163], ["hypertension", "DISEASE", 94, 106], ["coronary heart diseases", "DISEASE", 116, 139], ["cerebrovascular disease", "DISEASE", 148, 171], ["diabetes mellitus", "DISEASE", 184, 201], ["heart", "ORGAN", 125, 130], ["cerebrovascular", "MULTI-TISSUE_STRUCTURE", 148, 163], ["a study", "TEST", 13, 20], ["COVID", "TEST", 38, 43], ["comorbidities", "PROBLEM", 72, 85], ["hypertension", "PROBLEM", 94, 106], ["coronary heart diseases", "PROBLEM", 116, 139], ["cerebrovascular disease", "PROBLEM", 148, 171], ["diabetes mellitus", "PROBLEM", 184, 201], ["hypertension", "OBSERVATION", 94, 106], ["coronary heart", "ANATOMY", 116, 130], ["diseases", "OBSERVATION", 131, 139], ["cerebrovascular", "ANATOMY", 148, 163], ["disease", "OBSERVATION", 164, 171], ["diabetes", "OBSERVATION", 184, 192]]], ["Notably, the most recurrent comorbidities demonstrated in these studies are often treated with angiotensin-converting enzyme (ACE) inhibitor.", [["angiotensin-converting enzyme (ACE) inhibitor", "CHEMICAL", 95, 140], ["angiotensin-converting enzyme", "GENE_OR_GENE_PRODUCT", 95, 124], ["ACE", "GENE_OR_GENE_PRODUCT", 126, 129], ["angiotensin-converting enzyme", "PROTEIN", 95, 124], ["ACE", "PROTEIN", 126, 129], ["the most recurrent comorbidities", "PROBLEM", 9, 41], ["these studies", "TEST", 58, 71], ["angiotensin-converting enzyme (ACE) inhibitor", "TREATMENT", 95, 140], ["most", "OBSERVATION_MODIFIER", 13, 17], ["recurrent", "OBSERVATION_MODIFIER", 18, 27], ["comorbidities", "OBSERVATION", 28, 41]]], ["As, it has been demonstrated that the spike protein of SARS-CoV-2 helps in the viral entry inside the cell via ACE2 receptors present on the surface of epithelial cells of lung and other tissues [5], it can, therefore, be hypothesized that the levels of ACE2 are associated with SARS-CoV-2 infection susceptibility.", [["cell", "ANATOMY", 102, 106], ["surface", "ANATOMY", 141, 148], ["epithelial cells", "ANATOMY", 152, 168], ["lung", "ANATOMY", 172, 176], ["tissues", "ANATOMY", 187, 194], ["infection", "DISEASE", 290, 299], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 55, 65], ["cell", "CELL", 102, 106], ["ACE2", "GENE_OR_GENE_PRODUCT", 111, 115], ["surface", "CELLULAR_COMPONENT", 141, 148], ["epithelial cells", "CELL", 152, 168], ["lung", "ORGAN", 172, 176], ["tissues", "TISSUE", 187, 194], ["ACE2", "GENE_OR_GENE_PRODUCT", 254, 258], ["SARS-CoV-2", "ORGANISM", 279, 289], ["spike protein", "PROTEIN", 38, 51], ["ACE2 receptors", "PROTEIN", 111, 125], ["epithelial cells", "CELL_TYPE", 152, 168], ["ACE2", "PROTEIN", 254, 258], ["SARS-CoV", "SPECIES", 279, 287], ["the spike protein", "TEST", 34, 51], ["SARS", "PROBLEM", 55, 59], ["CoV", "TEST", 60, 63], ["ACE2 receptors", "TEST", 111, 125], ["ACE2", "TEST", 254, 258], ["SARS", "PROBLEM", 279, 283], ["CoV-2 infection susceptibility", "PROBLEM", 284, 314], ["epithelial cells", "OBSERVATION", 152, 168], ["lung", "ANATOMY", 172, 176], ["infection", "OBSERVATION", 290, 299]]], ["Some of the studies have shown that ACE inhibitor improves the clinical outcome of COVID-19 patients with hypertension and recommends the continuation of these medicines [6,7].", [["ACE inhibitor", "CHEMICAL", 36, 49], ["COVID", "DISEASE", 83, 88], ["hypertension", "DISEASE", 106, 118], ["ACE", "GENE_OR_GENE_PRODUCT", 36, 39], ["patients", "ORGANISM", 92, 100], ["patients", "SPECIES", 92, 100], ["the studies", "TEST", 8, 19], ["ACE inhibitor", "TREATMENT", 36, 49], ["COVID", "TEST", 83, 88], ["hypertension", "PROBLEM", 106, 118], ["these medicines", "TREATMENT", 154, 169]]], ["Several other studies in this regard are ambiguous to the use of ACE inhibitors to manage hypertension in the setting of COVID-19 [8,9].", [["hypertension", "DISEASE", 90, 102], ["COVID-19", "CHEMICAL", 121, 129], ["ACE", "GENE_OR_GENE_PRODUCT", 65, 68], ["Several other studies", "TEST", 0, 21], ["ACE inhibitors", "TREATMENT", 65, 79], ["hypertension", "PROBLEM", 90, 102], ["COVID", "TEST", 121, 126], ["hypertension", "OBSERVATION", 90, 102]]], ["Further, it has also been studied that the cellular ACE2 expression levels are not same in all individuals and polymorphisms of ACE2 may show effect on ACE2 levels [10].", [["cellular", "ANATOMY", 43, 51], ["cellular", "CELL", 43, 51], ["ACE2", "GENE_OR_GENE_PRODUCT", 52, 56], ["ACE2", "GENE_OR_GENE_PRODUCT", 128, 132], ["ACE2", "GENE_OR_GENE_PRODUCT", 152, 156], ["ACE2", "PROTEIN", 52, 56], ["ACE2", "PROTEIN", 128, 132], ["ACE2", "PROTEIN", 152, 156], ["the cellular ACE2 expression levels", "TEST", 39, 74], ["ACE2", "TEST", 128, 132], ["ACE2 levels", "TEST", 152, 163]]], ["Therefore, in the present review, the role of ACE2 receptors in the viral entry into the host cell, the effect of COVID-19 on the symptoms and prognosis of CVDs, impact of ACE inhibitors (ACEI), and angiotensin receptor blockers (ARBs) on patients of CVDs suffering from COVID-19 have been discussed.", [["cell", "ANATOMY", 94, 98], ["CVDs", "DISEASE", 156, 160], ["ACEI", "CHEMICAL", 188, 192], ["angiotensin", "CHEMICAL", 199, 210], ["CVDs", "DISEASE", 251, 255], ["COVID-19", "CHEMICAL", 271, 279], ["COVID-19", "CHEMICAL", 114, 122], ["COVID-19", "CHEMICAL", 271, 279], ["ACE2", "GENE_OR_GENE_PRODUCT", 46, 50], ["host cell", "CELL", 89, 98], ["COVID-19", "GENE_OR_GENE_PRODUCT", 114, 122], ["ACE", "GENE_OR_GENE_PRODUCT", 172, 175], ["ACEI", "SIMPLE_CHEMICAL", 188, 192], ["angiotensin receptor blockers", "SIMPLE_CHEMICAL", 199, 228], ["ARBs", "SIMPLE_CHEMICAL", 230, 234], ["patients", "ORGANISM", 239, 247], ["ACE2 receptors", "PROTEIN", 46, 60], ["patients", "SPECIES", 239, 247], ["ACE2 receptors", "TREATMENT", 46, 60], ["COVID", "TEST", 114, 119], ["the symptoms", "PROBLEM", 126, 138], ["CVDs", "PROBLEM", 156, 160], ["ACE inhibitors", "TREATMENT", 172, 186], ["ACEI", "TREATMENT", 188, 192], ["angiotensin receptor blockers", "TREATMENT", 199, 228], ["ARBs", "TREATMENT", 230, 234], ["CVDs", "PROBLEM", 251, 255], ["COVID", "TEST", 271, 276], ["host cell", "OBSERVATION", 89, 98]]], ["Further, the role of ACE2 genetic polymorphism in SARS-CoV-2 infection in CVD patients has been brought into light.", [["SARS", "DISEASE", 50, 54], ["infection", "DISEASE", 61, 70], ["CVD", "DISEASE", 74, 77], ["ACE2", "GENE_OR_GENE_PRODUCT", 21, 25], ["SARS-CoV-2", "ORGANISM", 50, 60], ["patients", "ORGANISM", 78, 86], ["ACE2", "PROTEIN", 21, 25], ["patients", "SPECIES", 78, 86], ["SARS-CoV", "SPECIES", 50, 58], ["ACE2 genetic polymorphism", "PROBLEM", 21, 46], ["SARS", "PROBLEM", 50, 54], ["CoV", "PROBLEM", 55, 58], ["2 infection", "PROBLEM", 59, 70], ["infection", "OBSERVATION", 61, 70]]], ["Based on this information, modulation in ACE2 medications can be an alternative for the treatment of CVD patients infected with COVID-19.Origin of SARS-CoV-2The present pandemic of SARS-CoV-2 infection affected the health and economy worldwide.", [["CVD", "DISEASE", 101, 104], ["SARS", "DISEASE", 147, 151], ["SARS-CoV-2 infection", "DISEASE", 181, 201], ["ACE2", "GENE_OR_GENE_PRODUCT", 41, 45], ["patients", "ORGANISM", 105, 113], ["SARS-CoV-2", "ORGANISM", 181, 191], ["ACE2", "PROTEIN", 41, 45], ["patients", "SPECIES", 105, 113], ["CoV-2", "SPECIES", 186, 191], ["SARS-CoV", "SPECIES", 147, 155], ["SARS-CoV-2", "SPECIES", 181, 191], ["modulation in ACE2 medications", "TREATMENT", 27, 57], ["the treatment", "TREATMENT", 84, 97], ["CVD", "PROBLEM", 101, 104], ["COVID", "TEST", 128, 133], ["SARS", "PROBLEM", 147, 151], ["CoV", "TEST", 152, 155], ["SARS", "PROBLEM", 181, 185], ["CoV", "PROBLEM", 186, 189], ["2 infection", "PROBLEM", 190, 201], ["SARS", "OBSERVATION", 147, 151], ["pandemic", "OBSERVATION_MODIFIER", 169, 177], ["SARS", "OBSERVATION", 181, 185], ["infection", "OBSERVATION", 192, 201]]], ["The first report came from the Wuhan Jinyintan hospital, China [11] and WHO-led laboratory network made it possible to identify this virus as the causative agent of COVID-19.", [["this virus", "PROBLEM", 128, 138], ["COVID", "TEST", 165, 170]]], ["The properties like mutability and SARS-CoV genome open reading frames have contributed to the severe virulence of this virus [12].Origin of SARS-CoV-2The full-length genome sequencing of the virus demonstrates that this is a member of \u03b2-coronavirus 2b lineage [13] and as it is not being detected in animals or humans previously, it is known as the so called novel corona virus.", [["SARS", "DISEASE", 141, 145], ["\u03b2-coronavirus 2b", "ORGANISM", 236, 252], ["humans", "ORGANISM", 312, 318], ["corona virus", "ORGANISM", 366, 378], ["SARS-CoV genome", "DNA", 35, 50], ["humans", "SPECIES", 312, 318], ["SARS-CoV", "SPECIES", 35, 43], ["SARS-CoV", "SPECIES", 141, 149], ["humans", "SPECIES", 312, 318], ["SARS", "PROBLEM", 35, 39], ["the severe virulence of this virus", "PROBLEM", 91, 125], ["SARS", "PROBLEM", 141, 145], ["CoV", "TEST", 146, 149], ["the virus", "PROBLEM", 188, 197], ["novel corona virus", "PROBLEM", 360, 378], ["severe", "OBSERVATION_MODIFIER", 95, 101], ["SARS", "OBSERVATION", 141, 145], ["not being", "UNCERTAINTY", 279, 288]]], ["Being similar to the coronavirus responsible for severe acute respiratory syndrome (SARS-CoV), International Committee on Taxonomy of Viruses named it SARS-CoV-2 [14].Origin of SARS-CoV-2SARS-CoV-2, the causative organism for COVID-19, is a novel RNA virus with single positive strand.", [["coronavirus", "DISEASE", 21, 32], ["acute respiratory syndrome", "DISEASE", 56, 82], ["SARS-CoV)", "DISEASE", 84, 93], ["SARS", "DISEASE", 177, 181], ["SARS-CoV-2SARS-CoV-2", "ORGANISM", 177, 197], ["COVID-19", "CELL", 226, 234], ["SARS-CoV-2SARS-CoV-2", "DNA", 177, 197], ["COVID-19", "DNA", 226, 234], ["coronavirus", "SPECIES", 21, 32], ["CoV-2SARS-CoV", "SPECIES", 182, 195], ["SARS-CoV", "SPECIES", 84, 92], ["SARS-CoV-2SARS-CoV", "SPECIES", 177, 195], ["the coronavirus", "PROBLEM", 17, 32], ["severe acute respiratory syndrome", "PROBLEM", 49, 82], ["Taxonomy of Viruses", "TREATMENT", 122, 141], ["SARS", "PROBLEM", 177, 181], ["CoV", "TEST", 182, 185], ["2SARS", "TEST", 186, 191], ["CoV", "TEST", 192, 195], ["the causative organism", "PROBLEM", 199, 221], ["COVID", "TEST", 226, 231], ["a novel RNA virus", "PROBLEM", 239, 256], ["single positive strand", "PROBLEM", 262, 284], ["severe", "OBSERVATION_MODIFIER", 49, 55], ["acute", "OBSERVATION_MODIFIER", 56, 61], ["respiratory syndrome", "OBSERVATION", 62, 82], ["SARS", "OBSERVATION", 177, 181]]], ["It is the seventh identified human coronavirus [15].", [["human", "ORGANISM", 29, 34], ["human", "SPECIES", 29, 34], ["human coronavirus", "SPECIES", 29, 46]]], ["It is thought that this virus is originated in bats, like various other coronaviruses, since it shares 89\u201396% nucleotide similarity with bat coronaviruses [16].", [["nucleotide", "CHEMICAL", 110, 120], ["coronaviruses", "ORGANISM", 72, 85], ["bat coronaviruses", "ORGANISM", 137, 154], ["this virus", "PROBLEM", 19, 29], ["various other coronaviruses", "PROBLEM", 58, 85], ["nucleotide similarity", "TEST", 110, 131], ["bat coronaviruses", "PROBLEM", 137, 154], ["virus", "OBSERVATION", 24, 29]]], ["Like SARS and Middle East respiratory syndrome coronavirus (MERS-CoV), it is believed that it is transmitted from bats to human via an intermediate host (probably a Malayan Pangolin, which shares 91% nucleotide homology) [17].", [["SARS", "DISEASE", 5, 9], ["Middle East respiratory syndrome coronavirus", "DISEASE", 14, 58], ["nucleotide", "CHEMICAL", 200, 210], ["nucleotide", "CHEMICAL", 200, 210], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 14, 58], ["MERS-CoV", "ORGANISM", 60, 68], ["human", "ORGANISM", 122, 127], ["human", "SPECIES", 122, 127], ["Middle East respiratory syndrome coronavirus", "SPECIES", 14, 58], ["MERS-CoV", "SPECIES", 60, 68], ["human", "SPECIES", 122, 127], ["SARS", "PROBLEM", 5, 9], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 14, 58], ["a Malayan Pangolin", "TREATMENT", 163, 181], ["SARS", "OBSERVATION", 5, 9], ["Middle", "ANATOMY_MODIFIER", 14, 20], ["respiratory syndrome", "OBSERVATION", 26, 46]]], ["SARS-CoV-2 invades host cells via (ACE2) receptor via its spike protein [18].", [["cells", "ANATOMY", 24, 29], ["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["host cells", "CELL", 19, 29], ["ACE2", "GENE_OR_GENE_PRODUCT", 35, 39], ["ACE2", "PROTEIN", 35, 39], ["SARS", "TEST", 0, 4], ["host cells via (ACE2) receptor", "TREATMENT", 19, 49], ["its spike protein", "TEST", 54, 71]]], ["The surface spike protein of the virus attaches to the human ACE2 receptor followed by the spike protein activation by transmembrane protease serine 2 (TMPRSS2).", [["surface", "ANATOMY", 4, 11], ["serine", "CHEMICAL", 142, 148], ["surface", "CELLULAR_COMPONENT", 4, 11], ["human", "ORGANISM", 55, 60], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 61, 74], ["transmembrane protease serine 2", "GENE_OR_GENE_PRODUCT", 119, 150], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 152, 159], ["surface spike protein", "PROTEIN", 4, 25], ["human ACE2 receptor", "PROTEIN", 55, 74], ["spike protein", "PROTEIN", 91, 104], ["transmembrane protease serine 2", "PROTEIN", 119, 150], ["TMPRSS2", "PROTEIN", 152, 159], ["human", "SPECIES", 55, 60], ["human", "SPECIES", 55, 60], ["The surface spike protein", "PROBLEM", 0, 25], ["the virus attaches", "PROBLEM", 29, 47], ["the human ACE2 receptor", "TREATMENT", 51, 74], ["the spike protein activation", "TREATMENT", 87, 115], ["transmembrane protease serine", "TREATMENT", 119, 148]]], ["This protease cleaves the spike protein and brings about conformational changes in the spike protein that facilitates viral entry into the host cell [19].Origin of SARS-CoV-2Presently, the studies have shown that the range of incubation period of this virus is 1 to 14 days and the median is 5\u20136 days in most of the individuals; however, certain studies have shown that it may be upto 24 days [20].", [["cell", "ANATOMY", 144, 148], ["SARS", "DISEASE", 164, 168], ["cell", "CELL", 144, 148], ["SARS-CoV", "ORGANISM", 164, 172], ["protease", "PROTEIN", 5, 13], ["spike protein", "PROTEIN", 26, 39], ["spike protein", "PROTEIN", 87, 100], ["SARS-CoV", "SPECIES", 164, 172], ["This protease", "TREATMENT", 0, 13], ["the spike protein", "PROBLEM", 22, 39], ["conformational changes", "PROBLEM", 57, 79], ["the spike protein", "PROBLEM", 83, 100], ["SARS", "PROBLEM", 164, 168], ["the studies", "TEST", 185, 196], ["this virus", "PROBLEM", 247, 257], ["certain studies", "TEST", 338, 353], ["host cell", "OBSERVATION", 139, 148], ["SARS", "OBSERVATION", 164, 168]]], ["The SARS-CoV-2 reproductive number (R0) comes out to be in between 2 and 3, suggesting that its pandemic potential is higher than SARS [21].", [["SARS", "DISEASE", 4, 8], ["SARS", "DISEASE", 130, 134], ["The SARS", "TEST", 0, 8], ["CoV", "OBSERVATION_MODIFIER", 9, 12], ["higher", "OBSERVATION_MODIFIER", 118, 124]]], ["Although, the major symptoms are fever or cough, but most of the patients are asymptomatic [22].", [["fever", "DISEASE", 33, 38], ["cough", "DISEASE", 42, 47], ["patients", "ORGANISM", 65, 73], ["patients", "SPECIES", 65, 73], ["the major symptoms", "PROBLEM", 10, 28], ["fever", "PROBLEM", 33, 38], ["cough", "PROBLEM", 42, 47], ["asymptomatic", "PROBLEM", 78, 90], ["fever", "OBSERVATION", 33, 38], ["cough", "OBSERVATION", 42, 47]]], ["At present, it is thought that the transmission of this virus is mainly via close contact and respiratory droplets; however, asymptomatic carrier may also be a souce of transmission [23].", [["respiratory droplets", "ANATOMY", 94, 114], ["this virus", "PROBLEM", 51, 61], ["asymptomatic carrier", "PROBLEM", 125, 145], ["respiratory droplets", "OBSERVATION", 94, 114]]], ["Further, a study proposed that perinatal transmission is improbable; nonetheless, more studies are required to ensure this finding [24].", [["a study", "TEST", 9, 16], ["perinatal transmission", "PROBLEM", 31, 53]]], ["Similarly, transmission through fecal\u2013oral route is yet to be established by further research [25].Adverse Cardiac Outcomes and COVID -19The most common affected organ in COVID-19 is lungs and results in pulmonary vascular endothelialitis, thrombosis, angiogenesis, interstitial pneumonitis, and severe acute respiratory distress syndrome [26].", [["Cardiac", "ANATOMY", 107, 114], ["organ", "ANATOMY", 162, 167], ["lungs", "ANATOMY", 183, 188], ["pulmonary vascular", "ANATOMY", 204, 222], ["interstitial", "ANATOMY", 266, 278], ["respiratory", "ANATOMY", 309, 320], ["pulmonary vascular endothelialitis", "DISEASE", 204, 238], ["thrombosis", "DISEASE", 240, 250], ["interstitial pneumonitis", "DISEASE", 266, 290], ["acute respiratory distress syndrome", "DISEASE", 303, 338], ["COVID -19", "CHEMICAL", 128, 137], ["organ", "ORGAN", 162, 167], ["COVID-19", "CELL", 171, 179], ["lungs", "ORGAN", 183, 188], ["pulmonary vascular", "MULTI-TISSUE_STRUCTURE", 204, 222], ["COVID-19", "SPECIES", 171, 179], ["fecal\u2013oral route", "TREATMENT", 32, 48], ["COVID", "TEST", 128, 133], ["COVID", "TEST", 171, 176], ["pulmonary vascular endothelialitis", "PROBLEM", 204, 238], ["thrombosis", "PROBLEM", 240, 250], ["angiogenesis", "PROBLEM", 252, 264], ["interstitial pneumonitis", "PROBLEM", 266, 290], ["severe acute respiratory distress syndrome", "PROBLEM", 296, 338], ["lungs", "ANATOMY", 183, 188], ["pulmonary vascular", "ANATOMY", 204, 222], ["endothelialitis", "OBSERVATION", 223, 238], ["thrombosis", "OBSERVATION", 240, 250], ["interstitial", "ANATOMY_MODIFIER", 266, 278], ["pneumonitis", "OBSERVATION", 279, 290], ["severe", "OBSERVATION_MODIFIER", 296, 302], ["acute", "OBSERVATION_MODIFIER", 303, 308], ["respiratory distress syndrome", "OBSERVATION", 309, 338]]], ["Besides, multiple organs are also involved, particularly the cardiovascular system.", [["organs", "ANATOMY", 18, 24], ["cardiovascular system", "ANATOMY", 61, 82], ["organs", "ORGAN", 18, 24], ["cardiovascular", "ANATOMICAL_SYSTEM", 61, 75], ["system", "ANATOMICAL_SYSTEM", 76, 82], ["multiple", "OBSERVATION_MODIFIER", 9, 17], ["organs", "OBSERVATION", 18, 24], ["cardiovascular system", "ANATOMY", 61, 82]]], ["Various cardiac complications like cardiovascular disease, arrhythmia (ventricular tachyarrhythmia, atrial fibrillation and ventricular fibrillation), hypertension, cardiac injury, heart failure, and fulminant myocarditis have been found to influence the mortality of the COVID -19 patients [27].", [["cardiac", "ANATOMY", 8, 15], ["cardiovascular", "ANATOMY", 35, 49], ["ventricular", "ANATOMY", 71, 82], ["atrial", "ANATOMY", 100, 106], ["ventricular", "ANATOMY", 124, 135], ["cardiac", "ANATOMY", 165, 172], ["heart", "ANATOMY", 181, 186], ["cardiac complications", "DISEASE", 8, 29], ["cardiovascular disease", "DISEASE", 35, 57], ["arrhythmia", "DISEASE", 59, 69], ["ventricular tachyarrhythmia", "DISEASE", 71, 98], ["atrial fibrillation", "DISEASE", 100, 119], ["ventricular fibrillation", "DISEASE", 124, 148], ["hypertension", "DISEASE", 151, 163], ["cardiac injury", "DISEASE", 165, 179], ["heart failure", "DISEASE", 181, 194], ["myocarditis", "DISEASE", 210, 221], ["cardiac", "ORGAN", 8, 15], ["cardiovascular", "ANATOMICAL_SYSTEM", 35, 49], ["ventricular", "MULTI-TISSUE_STRUCTURE", 71, 82], ["atrial", "MULTI-TISSUE_STRUCTURE", 100, 106], ["ventricular", "MULTI-TISSUE_STRUCTURE", 124, 135], ["cardiac", "ORGAN", 165, 172], ["heart", "ORGAN", 181, 186], ["patients", "ORGANISM", 282, 290], ["patients", "SPECIES", 282, 290], ["Various cardiac complications", "PROBLEM", 0, 29], ["cardiovascular disease", "PROBLEM", 35, 57], ["arrhythmia", "PROBLEM", 59, 69], ["ventricular tachyarrhythmia", "PROBLEM", 71, 98], ["atrial fibrillation", "PROBLEM", 100, 119], ["ventricular fibrillation", "PROBLEM", 124, 148], ["hypertension", "PROBLEM", 151, 163], ["cardiac injury", "PROBLEM", 165, 179], ["heart failure", "PROBLEM", 181, 194], ["fulminant myocarditis", "PROBLEM", 200, 221], ["the COVID", "TEST", 268, 277], ["cardiac", "ANATOMY", 8, 15], ["complications", "OBSERVATION", 16, 29], ["cardiovascular disease", "OBSERVATION", 35, 57], ["ventricular", "ANATOMY", 71, 82], ["tachyarrhythmia", "OBSERVATION", 83, 98], ["atrial", "ANATOMY", 100, 106], ["fibrillation", "OBSERVATION", 107, 119], ["ventricular", "ANATOMY", 124, 135], ["fibrillation", "OBSERVATION", 136, 148], ["hypertension", "OBSERVATION", 151, 163], ["cardiac", "ANATOMY", 165, 172], ["injury", "OBSERVATION", 173, 179], ["heart", "ANATOMY", 181, 186], ["failure", "OBSERVATION", 187, 194], ["fulminant", "OBSERVATION_MODIFIER", 200, 209], ["myocarditis", "OBSERVATION", 210, 221]]], ["There is a higher prevalence of CVDs in COVID -19 patients and 7% of the patients experience myocardial injury (22% of the critically ill).", [["myocardial", "ANATOMY", 93, 103], ["CVDs", "DISEASE", 32, 36], ["myocardial injury", "DISEASE", 93, 110], ["critically ill", "DISEASE", 123, 137], ["patients", "ORGANISM", 50, 58], ["patients", "ORGANISM", 73, 81], ["myocardial", "MULTI-TISSUE_STRUCTURE", 93, 103], ["patients", "SPECIES", 50, 58], ["patients", "SPECIES", 73, 81], ["CVDs", "PROBLEM", 32, 36], ["myocardial injury", "PROBLEM", 93, 110], ["higher", "OBSERVATION_MODIFIER", 11, 17], ["prevalence", "OBSERVATION_MODIFIER", 18, 28], ["myocardial", "ANATOMY", 93, 103], ["injury", "OBSERVATION", 104, 110]]], ["It is possible that the CVDs, such as ischemic heart disease, heart failure, and cardiac arrhythmia, may have different associations with prognosis of COVID-19.", [["heart", "ANATOMY", 47, 52], ["heart", "ANATOMY", 62, 67], ["cardiac", "ANATOMY", 81, 88], ["CVDs", "DISEASE", 24, 28], ["ischemic heart disease", "DISEASE", 38, 60], ["heart failure", "DISEASE", 62, 75], ["cardiac arrhythmia", "DISEASE", 81, 99], ["heart", "ORGAN", 47, 52], ["heart", "ORGAN", 62, 67], ["cardiac", "ORGAN", 81, 88], ["the CVDs", "PROBLEM", 20, 28], ["ischemic heart disease", "PROBLEM", 38, 60], ["heart failure", "PROBLEM", 62, 75], ["cardiac arrhythmia", "PROBLEM", 81, 99], ["COVID", "TEST", 151, 156], ["CVDs", "OBSERVATION", 24, 28], ["ischemic", "OBSERVATION_MODIFIER", 38, 46], ["heart", "ANATOMY", 47, 52], ["disease", "OBSERVATION", 53, 60], ["heart", "ANATOMY", 62, 67], ["failure", "OBSERVATION", 68, 75], ["cardiac", "ANATOMY", 81, 88], ["arrhythmia", "OBSERVATION", 89, 99]]], ["Fatigue and dyspnea and are the two cardinal symptoms of heart failure, which are generally present in COVID-19 patients, especially in severe condition [11].", [["heart", "ANATOMY", 57, 62], ["Fatigue", "DISEASE", 0, 7], ["dyspnea", "DISEASE", 12, 19], ["heart failure", "DISEASE", 57, 70], ["heart", "ORGAN", 57, 62], ["patients", "ORGANISM", 112, 120], ["patients", "SPECIES", 112, 120], ["Fatigue", "PROBLEM", 0, 7], ["dyspnea", "PROBLEM", 12, 19], ["the two cardinal symptoms", "PROBLEM", 28, 53], ["heart failure", "PROBLEM", 57, 70], ["dyspnea", "OBSERVATION", 12, 19], ["heart", "ANATOMY", 57, 62], ["failure", "OBSERVATION", 63, 70]]], ["Therefore, COVID-19 diagnosis in patients with chronic heart failure is a serious issue.", [["heart", "ANATOMY", 55, 60], ["heart failure", "DISEASE", 55, 68], ["patients", "ORGANISM", 33, 41], ["heart", "ORGAN", 55, 60], ["patients", "SPECIES", 33, 41], ["COVID", "TEST", 11, 16], ["chronic heart failure", "PROBLEM", 47, 68], ["chronic", "OBSERVATION_MODIFIER", 47, 54], ["heart", "ANATOMY", 55, 60], ["failure", "OBSERVATION", 61, 68], ["serious", "OBSERVATION_MODIFIER", 74, 81]]], ["Moreover, both heart failure and COVID-19 lead to hypoxemia that leads to death [28].", [["heart", "ANATOMY", 15, 20], ["heart failure", "DISEASE", 15, 28], ["COVID-19", "CHEMICAL", 33, 41], ["hypoxemia", "DISEASE", 50, 59], ["death", "DISEASE", 74, 79], ["COVID-19", "CHEMICAL", 33, 41], ["heart", "ORGAN", 15, 20], ["COVID-19", "GENE_OR_GENE_PRODUCT", 33, 41], ["both heart failure", "PROBLEM", 10, 28], ["COVID", "TEST", 33, 38], ["hypoxemia", "PROBLEM", 50, 59], ["death", "PROBLEM", 74, 79], ["heart", "ANATOMY", 15, 20], ["failure", "OBSERVATION", 21, 28], ["hypoxemia", "OBSERVATION", 50, 59]]], ["Nevertheless, proper attention has not been given to CVD patients having COVID-19.", [["CVD", "DISEASE", 53, 56], ["patients", "ORGANISM", 57, 65], ["patients", "SPECIES", 57, 65], ["COVID", "TEST", 73, 78]]], ["Furthermore, it has been demonstrated that the response of inflammatory reactions occurring in COVID-19 may cause the coronary plaques rupture in CAD patients [29].", [["coronary", "ANATOMY", 118, 126], ["COVID-19", "CHEMICAL", 95, 103], ["coronary plaques rupture", "DISEASE", 118, 142], ["CAD", "DISEASE", 146, 149], ["COVID-19", "CHEMICAL", 95, 103], ["COVID-19", "GENE_OR_GENE_PRODUCT", 95, 103], ["coronary plaques", "PATHOLOGICAL_FORMATION", 118, 134], ["patients", "ORGANISM", 150, 158], ["patients", "SPECIES", 150, 158], ["inflammatory reactions", "PROBLEM", 59, 81], ["COVID", "TEST", 95, 100], ["the coronary plaques rupture", "PROBLEM", 114, 142], ["inflammatory", "OBSERVATION_MODIFIER", 59, 71], ["coronary", "ANATOMY", 118, 126], ["plaques", "OBSERVATION", 127, 134]]], ["The active COVID-19 patients may barely survive after a myocardial infarction.", [["myocardial", "ANATOMY", 56, 66], ["myocardial infarction", "DISEASE", 56, 77], ["patients", "ORGANISM", 20, 28], ["myocardial", "MULTI-TISSUE_STRUCTURE", 56, 66], ["patients", "SPECIES", 20, 28], ["a myocardial infarction", "PROBLEM", 54, 77], ["active", "OBSERVATION_MODIFIER", 4, 10], ["myocardial", "ANATOMY", 56, 66], ["infarction", "OBSERVATION", 67, 77]]], ["Notably, COVID-19-induced hypoxemia may, consequently, lead to atrial fibrillation, which could be intractable prior to the improvement in pulmonary function [30].", [["atrial", "ANATOMY", 63, 69], ["pulmonary", "ANATOMY", 139, 148], ["COVID-19", "CHEMICAL", 9, 17], ["hypoxemia", "DISEASE", 26, 35], ["atrial fibrillation", "DISEASE", 63, 82], ["COVID-19", "CHEMICAL", 9, 17], ["COVID-19", "GENE_OR_GENE_PRODUCT", 9, 17], ["atrial", "MULTI-TISSUE_STRUCTURE", 63, 69], ["pulmonary", "ORGAN", 139, 148], ["COVID", "TEST", 9, 14], ["hypoxemia", "PROBLEM", 26, 35], ["atrial fibrillation", "PROBLEM", 63, 82], ["hypoxemia", "OBSERVATION", 26, 35], ["atrial", "ANATOMY", 63, 69], ["fibrillation", "OBSERVATION", 70, 82], ["pulmonary", "ANATOMY", 139, 148]]], ["At present, the data concerning COVID-19 and cardiovascular complications is not sufficient [29].", [["cardiovascular", "ANATOMY", 45, 59], ["cardiovascular complications", "DISEASE", 45, 73], ["cardiovascular", "ANATOMICAL_SYSTEM", 45, 59], ["the data", "TEST", 12, 20], ["COVID", "TEST", 32, 37], ["cardiovascular complications", "PROBLEM", 45, 73]]], ["According to a report, the heart failure was reported in 23% of COVID patients admitted in hospital in China.", [["heart", "ANATOMY", 27, 32], ["heart failure", "DISEASE", 27, 40], ["COVID", "DISEASE", 64, 69], ["heart", "ORGAN", 27, 32], ["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 70, 78], ["the heart failure", "PROBLEM", 23, 40], ["heart", "ANATOMY", 27, 32], ["failure", "OBSERVATION", 33, 40]]], ["Approximately 52% of non-survivors suffered from heart failure as compared with 12% of survivors [31].", [["heart", "ANATOMY", 49, 54], ["heart failure", "DISEASE", 49, 62], ["heart", "ORGAN", 49, 54], ["heart failure", "PROBLEM", 49, 62], ["heart", "ANATOMY", 49, 54], ["failure", "OBSERVATION", 55, 62]]], ["According to a study by Wang et al. [32], acute cardiac injury or new abnormalities detected by echocardiography and electrocardiography has been reported in 7.2% of the COVID-19 patients.", [["cardiac", "ANATOMY", 48, 55], ["cardiac injury", "DISEASE", 48, 62], ["cardiac", "ORGAN", 48, 55], ["patients", "ORGANISM", 179, 187], ["patients", "SPECIES", 179, 187], ["a study", "TEST", 13, 20], ["acute cardiac injury", "PROBLEM", 42, 62], ["new abnormalities", "PROBLEM", 66, 83], ["echocardiography", "TEST", 96, 112], ["electrocardiography", "TEST", 117, 136], ["the COVID", "TEST", 166, 175], ["acute", "OBSERVATION_MODIFIER", 42, 47], ["cardiac", "ANATOMY", 48, 55], ["injury", "OBSERVATION", 56, 62]]], ["In addition, Guan et al. found that 90 of 675 (13.3%) COVID-19 patients showed an increased creatinine kinase level and 277 of 675 (41%) patients showed elevated lactate dehydrogenase level.", [["creatinine", "CHEMICAL", 92, 102], ["lactate", "CHEMICAL", 162, 169], ["creatinine", "CHEMICAL", 92, 102], ["lactate", "CHEMICAL", 162, 169], ["patients", "ORGANISM", 63, 71], ["creatinine", "SIMPLE_CHEMICAL", 92, 102], ["patients", "ORGANISM", 137, 145], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 162, 183], ["creatinine kinase", "PROTEIN", 92, 109], ["lactate dehydrogenase", "PROTEIN", 162, 183], ["patients", "SPECIES", 63, 71], ["patients", "SPECIES", 137, 145], ["COVID", "TEST", 54, 59], ["an increased creatinine kinase level", "PROBLEM", 79, 115], ["elevated lactate dehydrogenase level", "PROBLEM", 153, 189], ["increased", "OBSERVATION", 82, 91], ["elevated", "OBSERVATION_MODIFIER", 153, 161], ["lactate dehydrogenase", "OBSERVATION", 162, 183]]], ["Furthermore, arrhythmia has been observed in 16.7% of the patients.", [["arrhythmia", "DISEASE", 13, 23], ["patients", "ORGANISM", 58, 66], ["patients", "SPECIES", 58, 66], ["arrhythmia", "PROBLEM", 13, 23], ["arrhythmia", "OBSERVATION", 13, 23]]], ["However, there is no clear categorization of parameters for arrhythmia and echocardiography [33].", [["arrhythmia", "DISEASE", 60, 70], ["arrhythmia", "PROBLEM", 60, 70], ["echocardiography", "TEST", 75, 91], ["no", "UNCERTAINTY", 18, 20]]], ["As, SARS-CoV is considered as a sister to SARS-CoV-2 [34], there is a possibility of having similar effects on the heart by these two viruses.", [["heart", "ANATOMY", 115, 120], ["SARS", "DISEASE", 4, 8], ["SARS", "DISEASE", 42, 46], ["SARS-CoV", "ORGANISM", 4, 12], ["SARS-CoV-2", "ORGANISM", 42, 52], ["heart", "ORGAN", 115, 120], ["SARS-CoV", "SPECIES", 4, 12], ["SARS-CoV", "SPECIES", 42, 50], ["CoV", "TEST", 47, 50], ["similar effects on the heart", "PROBLEM", 92, 120], ["heart", "ANATOMY", 115, 120], ["viruses", "OBSERVATION", 134, 141]]], ["Yu et al., [35] observed that tachycardia in 71.9% and bradycardia in 14.9% were present transiently in COVID -19 patients.", [["tachycardia", "DISEASE", 30, 41], ["bradycardia", "DISEASE", 55, 66], ["patients", "ORGANISM", 114, 122], ["patients", "SPECIES", 114, 122], ["tachycardia", "PROBLEM", 30, 41], ["bradycardia", "PROBLEM", 55, 66]]], ["Consequently, common arrhythmia in COVID-19 patients might be tachycardia.", [["arrhythmia", "DISEASE", 21, 31], ["COVID", "DISEASE", 35, 40], ["tachycardia", "DISEASE", 62, 73], ["patients", "ORGANISM", 44, 52], ["patients", "SPECIES", 44, 52], ["common arrhythmia", "PROBLEM", 14, 31], ["COVID", "TEST", 35, 40], ["tachycardia", "PROBLEM", 62, 73], ["common", "OBSERVATION_MODIFIER", 14, 20], ["arrhythmia", "OBSERVATION", 21, 31], ["tachycardia", "OBSERVATION", 62, 73]]], ["Nevertheless, acute cardiac injury has been observed in 14% of COVID-19 patients [11].", [["cardiac", "ANATOMY", 20, 27], ["cardiac injury", "DISEASE", 20, 34], ["cardiac", "ORGAN", 20, 27], ["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 72, 80], ["acute cardiac injury", "PROBLEM", 14, 34], ["COVID", "TEST", 63, 68], ["acute", "OBSERVATION_MODIFIER", 14, 19], ["cardiac", "ANATOMY", 20, 27], ["injury", "OBSERVATION", 28, 34]]], ["The cardiac injury might be due to hypoxemia, viral infection, or worsening of cardiac diseases.", [["cardiac", "ANATOMY", 4, 11], ["cardiac", "ANATOMY", 79, 86], ["cardiac injury", "DISEASE", 4, 18], ["hypoxemia", "DISEASE", 35, 44], ["viral infection", "DISEASE", 46, 61], ["cardiac diseases", "DISEASE", 79, 95], ["cardiac", "ORGAN", 4, 11], ["cardiac", "ORGAN", 79, 86], ["The cardiac injury", "PROBLEM", 0, 18], ["hypoxemia", "PROBLEM", 35, 44], ["viral infection", "PROBLEM", 46, 61], ["cardiac diseases", "PROBLEM", 79, 95], ["cardiac", "ANATOMY", 4, 11], ["injury", "OBSERVATION", 12, 18], ["might be due to", "UNCERTAINTY", 19, 34], ["hypoxemia", "OBSERVATION", 35, 44], ["viral", "OBSERVATION_MODIFIER", 46, 51], ["infection", "OBSERVATION", 52, 61], ["worsening", "OBSERVATION_MODIFIER", 66, 75], ["cardiac", "ANATOMY", 79, 86], ["diseases", "OBSERVATION", 87, 95]]], ["Furthermore, the pathological investigation from biopsy samples of COVID-19 cadaver indicated infiltration of myocardial interstitial by mononuclear inflammatory cells, without excessive injury to the heart tissue [36].", [["biopsy samples", "ANATOMY", 49, 63], ["cadaver", "ANATOMY", 76, 83], ["myocardial interstitial", "ANATOMY", 110, 133], ["mononuclear inflammatory cells", "ANATOMY", 137, 167], ["heart tissue", "ANATOMY", 201, 213], ["biopsy samples", "CANCER", 49, 63], ["myocardial interstitial", "CELL", 110, 133], ["mononuclear inflammatory cells", "CELL", 137, 167], ["heart tissue", "TISSUE", 201, 213], ["mononuclear inflammatory cells", "CELL_TYPE", 137, 167], ["the pathological investigation", "TEST", 13, 43], ["biopsy samples", "TEST", 49, 63], ["COVID", "TEST", 67, 72], ["infiltration", "PROBLEM", 94, 106], ["myocardial interstitial by mononuclear inflammatory cells", "PROBLEM", 110, 167], ["excessive injury to the heart tissue", "PROBLEM", 177, 213], ["infiltration", "OBSERVATION", 94, 106], ["myocardial", "ANATOMY", 110, 120], ["interstitial", "ANATOMY_MODIFIER", 121, 133], ["mononuclear inflammatory cells", "OBSERVATION", 137, 167], ["without", "UNCERTAINTY", 169, 176], ["excessive", "OBSERVATION_MODIFIER", 177, 186], ["injury", "OBSERVATION", 187, 193], ["heart", "ANATOMY", 201, 206], ["tissue", "ANATOMY_MODIFIER", 207, 213]]], ["This observation indicates that myocarditis may be caused by SARS-CoV-2.", [["myocarditis", "DISEASE", 32, 43], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 61, 71], ["SARS-CoV", "SPECIES", 61, 69], ["This observation", "TEST", 0, 16], ["myocarditis", "PROBLEM", 32, 43], ["SARS", "PROBLEM", 61, 65], ["CoV", "TEST", 66, 69], ["myocarditis", "OBSERVATION", 32, 43]]], ["It has been reported by Li et al. [37] that subclinical diastolic impairment is present in SARS patients that would reverse the clinical recovery of COVID-19 patients.", [["diastolic impairment", "DISEASE", 56, 76], ["SARS", "DISEASE", 91, 95], ["patients", "ORGANISM", 96, 104], ["patients", "ORGANISM", 158, 166], ["patients", "SPECIES", 96, 104], ["patients", "SPECIES", 158, 166], ["subclinical diastolic impairment", "PROBLEM", 44, 76], ["COVID", "TEST", 149, 154], ["impairment", "OBSERVATION", 66, 76]]], ["However, no lymphocytic infiltration or myocytes necrosis has been observed in the patients\u2019 heart with the least ejection fraction of left ventricle [37].", [["lymphocytic", "ANATOMY", 12, 23], ["myocytes", "ANATOMY", 40, 48], ["heart", "ANATOMY", 93, 98], ["left ventricle", "ANATOMY", 135, 149], ["necrosis", "DISEASE", 49, 57], ["myocytes", "CELL", 40, 48], ["patients", "ORGANISM", 83, 91], ["heart", "ORGAN", 93, 98], ["ventricle", "MULTI-TISSUE_STRUCTURE", 140, 149], ["patients", "SPECIES", 83, 91], ["lymphocytic infiltration", "PROBLEM", 12, 36], ["myocytes necrosis", "PROBLEM", 40, 57], ["no", "UNCERTAINTY", 9, 11], ["lymphocytic", "OBSERVATION_MODIFIER", 12, 23], ["infiltration", "OBSERVATION", 24, 36], ["myocytes", "ANATOMY", 40, 48], ["necrosis", "OBSERVATION", 49, 57], ["heart", "ANATOMY", 93, 98], ["least", "OBSERVATION_MODIFIER", 108, 113], ["ejection fraction", "OBSERVATION", 114, 131], ["left ventricle", "ANATOMY", 135, 149]]], ["Therefore, it has been hypothesized that these cardiac dysfunction may be indirect, caused by reduced oxygen supply, severe lung failure, and the systemic \"cytokines storm\u201d as a result of immune response by host to viral infection, where a number of cytokines, like tumor necrosis factor and the interleukin-6 family, have significant negative influence clinically.", [["cardiac", "ANATOMY", 47, 54], ["lung", "ANATOMY", 124, 128], ["cardiac dysfunction", "DISEASE", 47, 66], ["oxygen", "CHEMICAL", 102, 108], ["lung failure", "DISEASE", 124, 136], ["viral infection", "DISEASE", 215, 230], ["tumor necrosis", "DISEASE", 266, 280], ["oxygen", "CHEMICAL", 102, 108], ["cardiac", "ORGAN", 47, 54], ["oxygen", "SIMPLE_CHEMICAL", 102, 108], ["lung", "ORGAN", 124, 128], ["tumor necrosis factor", "GENE_OR_GENE_PRODUCT", 266, 287], ["interleukin-6", "GENE_OR_GENE_PRODUCT", 296, 309], ["cytokines", "PROTEIN", 156, 165], ["cytokines", "PROTEIN", 250, 259], ["tumor necrosis factor", "PROTEIN", 266, 287], ["interleukin-6 family", "PROTEIN", 296, 316], ["these cardiac dysfunction", "PROBLEM", 41, 66], ["reduced oxygen supply", "PROBLEM", 94, 115], ["severe lung failure", "PROBLEM", 117, 136], ["the systemic \"cytokines storm", "PROBLEM", 142, 171], ["immune response", "PROBLEM", 188, 203], ["viral infection", "PROBLEM", 215, 230], ["cytokines", "PROBLEM", 250, 259], ["tumor necrosis factor", "PROBLEM", 266, 287], ["cardiac", "ANATOMY", 47, 54], ["dysfunction", "OBSERVATION", 55, 66], ["reduced", "OBSERVATION_MODIFIER", 94, 101], ["oxygen supply", "OBSERVATION", 102, 115], ["severe", "OBSERVATION_MODIFIER", 117, 123], ["lung", "ANATOMY", 124, 128], ["failure", "OBSERVATION", 129, 136], ["infection", "OBSERVATION", 221, 230], ["tumor", "OBSERVATION_MODIFIER", 266, 271], ["necrosis", "OBSERVATION", 272, 280]]], ["Further, whole-genome sequencing, cardiac magnetic resonance imaging, polymerase chain reaction, and culture of biopsy samples may confirmwhether SARS-CoV-2 is present in the myocardium [34].ACE 2, Cardiovascular Disease, and COVID-19ACE2 receptors are abundantly present in the lungs and therefore are the pre-dominant gateway of entry of SARS-CoV-2.", [["biopsy samples", "ANATOMY", 112, 126], ["myocardium", "ANATOMY", 175, 185], ["Cardiovascular", "ANATOMY", 198, 212], ["lungs", "ANATOMY", 279, 284], ["SARS", "DISEASE", 146, 150], ["Cardiovascular Disease", "DISEASE", 198, 220], ["SARS", "DISEASE", 340, 344], ["biopsy samples", "CANCER", 112, 126], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 146, 156], ["myocardium", "ORGAN", 175, 185], ["ACE 2", "GENE_OR_GENE_PRODUCT", 191, 196], ["COVID-19ACE2 receptors", "GENE_OR_GENE_PRODUCT", 226, 248], ["lungs", "ORGAN", 279, 284], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 340, 350], ["COVID-19ACE2 receptors", "PROTEIN", 226, 248], ["cardiac magnetic resonance imaging", "TEST", 34, 68], ["polymerase chain reaction", "PROBLEM", 70, 95], ["culture of biopsy samples", "TEST", 101, 126], ["SARS", "TEST", 146, 150], ["CoV", "TEST", 151, 154], ["ACE 2", "PROBLEM", 191, 196], ["Cardiovascular Disease", "PROBLEM", 198, 220], ["COVID", "TEST", 226, 231], ["CoV", "TEST", 345, 348], ["myocardium", "ANATOMY", 175, 185], ["Cardiovascular", "ANATOMY", 198, 212], ["Disease", "OBSERVATION", 213, 220], ["lungs", "ANATOMY", 279, 284]]], ["ACE2 is abundantly present in the heart [38] as well, and it excessively activates the renin-angiotensin system (RAS) resulting in various cardiac complications such as congestive heart failure, hypertension, and atherosclerosis [39].", [["heart", "ANATOMY", 34, 39], ["cardiac", "ANATOMY", 139, 146], ["heart", "ANATOMY", 180, 185], ["angiotensin", "CHEMICAL", 93, 104], ["cardiac complications", "DISEASE", 139, 160], ["congestive heart failure", "DISEASE", 169, 193], ["hypertension", "DISEASE", 195, 207], ["atherosclerosis", "DISEASE", 213, 228], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["heart", "ORGAN", 34, 39], ["renin-angiotensin system", "GENE_OR_GENE_PRODUCT", 87, 111], ["RAS", "GENE_OR_GENE_PRODUCT", 113, 116], ["cardiac", "ORGAN", 139, 146], ["heart", "ORGAN", 180, 185], ["ACE2", "PROTEIN", 0, 4], ["renin", "PROTEIN", 87, 92], ["ACE2", "TEST", 0, 4], ["various cardiac complications", "PROBLEM", 131, 160], ["congestive heart failure", "PROBLEM", 169, 193], ["hypertension", "PROBLEM", 195, 207], ["atherosclerosis", "PROBLEM", 213, 228], ["heart", "ANATOMY", 34, 39], ["cardiac", "ANATOMY", 139, 146], ["complications", "OBSERVATION", 147, 160], ["congestive", "OBSERVATION_MODIFIER", 169, 179], ["heart", "ANATOMY", 180, 185], ["failure", "OBSERVATION", 186, 193], ["hypertension", "OBSERVATION", 195, 207], ["atherosclerosis", "OBSERVATION", 213, 228]]], ["Besides the heart and lung, ACE2 receptors are also present in the vascular endothelium, intestinal epithelium, and the kidneys, thereby, leading to multi-organ dysfunction [40].ACE 2, Cardiovascular Disease, and COVID-19Recently, it has been revealed that SARS-CoV-2 binding affinity to ACE2 receptor is 10- to 20- fold elevated as compared to SARS-CoV, suggesting that human-to-human transmission of SARS-CoV-2 could be easily possible [29].", [["heart", "ANATOMY", 12, 17], ["lung", "ANATOMY", 22, 26], ["vascular endothelium", "ANATOMY", 67, 87], ["intestinal epithelium", "ANATOMY", 89, 110], ["kidneys", "ANATOMY", 120, 127], ["multi-organ", "ANATOMY", 149, 160], ["Cardiovascular", "ANATOMY", 185, 199], ["multi-organ dysfunction", "DISEASE", 149, 172], ["Cardiovascular Disease", "DISEASE", 185, 207], ["SARS", "DISEASE", 345, 349], ["SARS", "DISEASE", 402, 406], ["heart", "ORGAN", 12, 17], ["lung", "ORGAN", 22, 26], ["ACE2", "GENE_OR_GENE_PRODUCT", 28, 32], ["vascular endothelium", "TISSUE", 67, 87], ["intestinal epithelium", "TISSUE", 89, 110], ["kidneys", "ORGAN", 120, 127], ["ACE 2", "GENE_OR_GENE_PRODUCT", 178, 183], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 257, 267], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 288, 301], ["SARS-CoV", "ORGANISM", 345, 353], ["human", "ORGANISM", 371, 376], ["human", "ORGANISM", 380, 385], ["SARS-CoV-2", "ORGANISM", 402, 412], ["ACE2 receptors", "PROTEIN", 28, 42], ["ACE2 receptor", "PROTEIN", 288, 301], ["human", "SPECIES", 371, 376], ["human", "SPECIES", 380, 385], ["SARS-CoV", "SPECIES", 345, 353], ["human", "SPECIES", 371, 376], ["human", "SPECIES", 380, 385], ["SARS-CoV", "SPECIES", 402, 410], ["ACE2 receptors", "TEST", 28, 42], ["multi-organ dysfunction", "PROBLEM", 149, 172], ["ACE 2", "PROBLEM", 178, 183], ["Cardiovascular Disease", "PROBLEM", 185, 207], ["COVID", "TEST", 213, 218], ["SARS", "TEST", 257, 261], ["CoV", "TEST", 262, 265], ["ACE2 receptor", "TEST", 288, 301], ["fold elevated", "PROBLEM", 316, 329], ["SARS", "PROBLEM", 345, 349], ["CoV", "TEST", 350, 353], ["SARS", "PROBLEM", 402, 406], ["heart", "ANATOMY", 12, 17], ["lung", "ANATOMY", 22, 26], ["ACE2 receptors", "OBSERVATION", 28, 42], ["vascular endothelium", "ANATOMY", 67, 87], ["intestinal epithelium", "ANATOMY", 89, 110], ["kidneys", "ANATOMY", 120, 127], ["multi-organ dysfunction", "OBSERVATION", 149, 172], ["Cardiovascular", "ANATOMY", 185, 199], ["Disease", "OBSERVATION", 200, 207]]], ["Angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) are majorly used for the treatment of CVDs.", [["Angiotensin", "CHEMICAL", 0, 11], ["angiotensin", "CHEMICAL", 49, 60], ["CVDs", "DISEASE", 124, 128], ["Angiotensin-converting enzyme", "GENE_OR_GENE_PRODUCT", 0, 29], ["ACEIs", "SIMPLE_CHEMICAL", 42, 47], ["angiotensin receptor blockers", "SIMPLE_CHEMICAL", 49, 78], ["ARBs", "SIMPLE_CHEMICAL", 80, 84], ["Angiotensin", "TREATMENT", 0, 11], ["enzyme inhibitors", "TREATMENT", 23, 40], ["ACEIs", "TREATMENT", 42, 47], ["angiotensin receptor blockers", "TREATMENT", 49, 78], ["ARBs", "TREATMENT", 80, 84], ["CVDs", "PROBLEM", 124, 128]]], ["Notably, various reports have shown that ACEIs/ARBs upregulate ACE2 expression besides their key pharmacological effect, that is, inhibition of angiotensin-converting enzyme 1 (ACE1) or blocking angiotensin II type 1 receptor [41].", [["ACEIs", "CHEMICAL", 41, 46], ["angiotensin", "CHEMICAL", 144, 155], ["angiotensin II", "CHEMICAL", 195, 209], ["ACEIs", "SIMPLE_CHEMICAL", 41, 46], ["ARBs", "SIMPLE_CHEMICAL", 47, 51], ["ACE2", "GENE_OR_GENE_PRODUCT", 63, 67], ["angiotensin-converting enzyme 1", "GENE_OR_GENE_PRODUCT", 144, 175], ["ACE1", "GENE_OR_GENE_PRODUCT", 177, 181], ["angiotensin II type 1 receptor", "GENE_OR_GENE_PRODUCT", 195, 225], ["ACE2", "PROTEIN", 63, 67], ["angiotensin-converting enzyme 1", "PROTEIN", 144, 175], ["ACE1", "PROTEIN", 177, 181], ["angiotensin II type 1 receptor", "PROTEIN", 195, 225], ["ACEIs", "TREATMENT", 41, 46], ["ARBs", "TREATMENT", 47, 51], ["ACE2 expression", "TREATMENT", 63, 78], ["angiotensin", "TREATMENT", 144, 155], ["blocking angiotensin II type 1 receptor", "TREATMENT", 186, 225]]], ["Thus, ACE2 may have contradictory roles in COVID- 19 patients, particularly those suffering from CVDs.", [["CVDs", "DISEASE", 97, 101], ["ACE2", "GENE_OR_GENE_PRODUCT", 6, 10], ["patients", "ORGANISM", 53, 61], ["ACE2", "PROTEIN", 6, 10], ["patients", "SPECIES", 53, 61], ["CVDs", "PROBLEM", 97, 101]]], ["ACE2 inhibitors may protect against hypertension, myocardial hypertrophy myocardial fibrosis, and arrhythmia, [42] along with acting as an entry gate for SARS-CoV-2 [34].", [["myocardial", "ANATOMY", 50, 60], ["myocardial", "ANATOMY", 73, 83], ["hypertension", "DISEASE", 36, 48], ["myocardial hypertrophy myocardial fibrosis", "DISEASE", 50, 92], ["arrhythmia", "DISEASE", 98, 108], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["myocardial", "MULTI-TISSUE_STRUCTURE", 50, 60], ["myocardial", "MULTI-TISSUE_STRUCTURE", 73, 83], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 154, 164], ["ACE2", "PROTEIN", 0, 4], ["ACE2 inhibitors", "TREATMENT", 0, 15], ["hypertension", "PROBLEM", 36, 48], ["myocardial hypertrophy myocardial fibrosis", "PROBLEM", 50, 92], ["arrhythmia", "PROBLEM", 98, 108], ["SARS", "TEST", 154, 158], ["CoV", "TEST", 159, 162], ["myocardial", "ANATOMY", 50, 60], ["hypertrophy", "OBSERVATION", 61, 72], ["myocardial", "ANATOMY", 73, 83], ["fibrosis", "OBSERVATION", 84, 92]]], ["Previously, various studies have demonstrated that ACEI and ARB could enhance the ACE2 receptors expression [42].", [["ACEI", "CHEMICAL", 51, 55], ["ARB", "CHEMICAL", 60, 63], ["ACEI", "SIMPLE_CHEMICAL", 51, 55], ["ARB", "SIMPLE_CHEMICAL", 60, 63], ["ACE2 receptors", "GENE_OR_GENE_PRODUCT", 82, 96], ["ACE2", "PROTEIN", 82, 86], ["various studies", "TEST", 12, 27], ["ACEI", "TREATMENT", 51, 55], ["ARB", "TREATMENT", 60, 63]]], ["It is, hence, reasonable to think, that treatment with ACEI/ARB might augment the SARS-CoV-2 infection risk.", [["ACEI", "CHEMICAL", 55, 59], ["ARB", "CHEMICAL", 60, 63], ["SARS", "DISEASE", 82, 86], ["infection", "DISEASE", 93, 102], ["ACEI", "SIMPLE_CHEMICAL", 55, 59], ["ARB", "SIMPLE_CHEMICAL", 60, 63], ["CoV-2", "ORGANISM", 87, 92], ["ACEI", "TREATMENT", 55, 59], ["ARB", "TREATMENT", 60, 63], ["the SARS", "PROBLEM", 78, 86], ["2 infection risk", "PROBLEM", 91, 107]]], ["Conversely, reports illustrated that the ARB losartan and recombinant human ACE2 can protect experimental animal from severe lung injury.", [["lung", "ANATOMY", 125, 129], ["ARB", "CHEMICAL", 41, 44], ["losartan", "CHEMICAL", 45, 53], ["lung injury", "DISEASE", 125, 136], ["losartan", "CHEMICAL", 45, 53], ["ARB", "SIMPLE_CHEMICAL", 41, 44], ["losartan", "SIMPLE_CHEMICAL", 45, 53], ["human", "ORGANISM", 70, 75], ["ACE2", "GENE_OR_GENE_PRODUCT", 76, 80], ["lung", "ORGAN", 125, 129], ["recombinant human ACE2", "PROTEIN", 58, 80], ["human", "SPECIES", 70, 75], ["human", "SPECIES", 70, 75], ["the ARB losartan", "TREATMENT", 37, 53], ["recombinant human ACE2", "TREATMENT", 58, 80], ["severe lung injury", "PROBLEM", 118, 136], ["severe", "OBSERVATION_MODIFIER", 118, 124], ["lung", "ANATOMY", 125, 129], ["injury", "OBSERVATION", 130, 136]]], ["Taken into consideration that ACEI/ARB therapy is being given to patients with ischemic heart disease, hypertension, and heart failure, however, special consideration should be provided to patients with COVID-19 using ACEI/ARB therapy [32].ACE 2, Cardiovascular Disease, and COVID-19A further aspect that should be highlighted is the genetic polymorphism that might be one of the reasons for augmented risk of SARS-CoV-2 infection.", [["heart", "ANATOMY", 88, 93], ["heart", "ANATOMY", 121, 126], ["Cardiovascular", "ANATOMY", 247, 261], ["ACEI", "CHEMICAL", 30, 34], ["ARB", "CHEMICAL", 35, 38], ["ischemic heart disease", "DISEASE", 79, 101], ["hypertension", "DISEASE", 103, 115], ["heart failure", "DISEASE", 121, 134], ["ACEI/ARB", "CHEMICAL", 218, 226], ["Cardiovascular Disease", "DISEASE", 247, 269], ["SARS-CoV-2 infection", "DISEASE", 410, 430], ["ACEI", "SIMPLE_CHEMICAL", 30, 34], ["ARB", "SIMPLE_CHEMICAL", 35, 38], ["patients", "ORGANISM", 65, 73], ["heart", "ORGAN", 88, 93], ["heart", "ORGAN", 121, 126], ["patients", "ORGANISM", 189, 197], ["ACEI", "SIMPLE_CHEMICAL", 218, 222], ["ARB", "SIMPLE_CHEMICAL", 223, 226], ["ACE 2", "GENE_OR_GENE_PRODUCT", 240, 245], ["COVID-19A", "GENE_OR_GENE_PRODUCT", 275, 284], ["SARS-CoV-2", "ORGANISM", 410, 420], ["patients", "SPECIES", 65, 73], ["patients", "SPECIES", 189, 197], ["SARS-CoV-2", "SPECIES", 410, 420], ["ACEI", "TREATMENT", 30, 34], ["ARB therapy", "TREATMENT", 35, 46], ["ischemic heart disease", "PROBLEM", 79, 101], ["hypertension", "PROBLEM", 103, 115], ["heart failure", "PROBLEM", 121, 134], ["COVID", "TEST", 203, 208], ["ACEI", "TREATMENT", 218, 222], ["ARB therapy", "TREATMENT", 223, 234], ["ACE 2", "PROBLEM", 240, 245], ["Cardiovascular Disease", "PROBLEM", 247, 269], ["COVID", "TEST", 275, 280], ["the genetic polymorphism", "PROBLEM", 330, 354], ["SARS", "PROBLEM", 410, 414], ["CoV", "PROBLEM", 415, 418], ["2 infection", "PROBLEM", 419, 430], ["heart", "ANATOMY", 88, 93], ["disease", "OBSERVATION", 94, 101], ["hypertension", "OBSERVATION", 103, 115], ["heart", "ANATOMY", 121, 126], ["failure", "OBSERVATION", 127, 134], ["Cardiovascular", "ANATOMY", 247, 261], ["Disease", "OBSERVATION", 262, 269], ["SARS", "OBSERVATION", 410, 414], ["infection", "OBSERVATION", 421, 430]]], ["There is a possibility that polymorphism in ACE2 gene, linked to hypertension, particularly, in Asian populations, affects the susceptibility of SARS-CoV-2 infection and COVID-19 disease outcome.", [["hypertension", "DISEASE", 65, 77], ["SARS-CoV-2 infection", "DISEASE", 145, 165], ["ACE2", "GENE_OR_GENE_PRODUCT", 44, 48], ["SARS-CoV-2", "ORGANISM", 145, 155], ["ACE2 gene", "DNA", 44, 53], ["CoV-2", "SPECIES", 150, 155], ["SARS-CoV", "SPECIES", 145, 153], ["polymorphism in ACE2 gene", "PROBLEM", 28, 53], ["hypertension", "PROBLEM", 65, 77], ["SARS", "PROBLEM", 145, 149], ["CoV", "TEST", 150, 153], ["2 infection", "PROBLEM", 154, 165], ["COVID", "TEST", 170, 175], ["19 disease outcome", "PROBLEM", 176, 194], ["possibility", "UNCERTAINTY", 11, 22], ["polymorphism", "OBSERVATION", 28, 40], ["hypertension", "OBSERVATION", 65, 77]]], ["It has been proposed that ACE2 gene polymorphisms may reduce the affinity of spike protein to the ACE2 receptors and lead to subsequent decreased susceptibility to SARS-COV 2 infection.", [["SARS", "DISEASE", 164, 168], ["infection", "DISEASE", 175, 184], ["ACE2", "GENE_OR_GENE_PRODUCT", 26, 30], ["ACE2", "GENE_OR_GENE_PRODUCT", 98, 102], ["SARS-COV 2", "GENE_OR_GENE_PRODUCT", 164, 174], ["ACE2", "PROTEIN", 26, 30], ["spike protein", "PROTEIN", 77, 90], ["ACE2 receptors", "PROTEIN", 98, 112], ["ACE2 gene polymorphisms", "TREATMENT", 26, 49], ["spike protein", "PROBLEM", 77, 90], ["the ACE2 receptors", "TREATMENT", 94, 112], ["decreased susceptibility to SARS", "PROBLEM", 136, 168], ["COV 2 infection", "PROBLEM", 169, 184], ["decreased", "OBSERVATION_MODIFIER", 136, 145], ["infection", "OBSERVATION", 175, 184]]], ["On the basis of this information, the variability in rate of infection and/or lethality worldwide could be explained by ethnical/geographical variation of ACE 2 gene polymorphism [43].ACE 2, Cardiovascular Disease, and COVID-19Another study suggested that the genotypes of ACE2 gene polymorphism in different populations may be linked with higher ACE2 expression level [44].", [["Cardiovascular", "ANATOMY", 191, 205], ["infection", "DISEASE", 61, 70], ["Cardiovascular Disease", "DISEASE", 191, 213], ["ACE 2", "GENE_OR_GENE_PRODUCT", 155, 160], ["ACE 2", "GENE_OR_GENE_PRODUCT", 184, 189], ["ACE2", "GENE_OR_GENE_PRODUCT", 273, 277], ["ACE2", "GENE_OR_GENE_PRODUCT", 347, 351], ["ACE 2 gene", "DNA", 155, 165], ["ACE2", "PROTEIN", 273, 277], ["ACE2", "PROTEIN", 347, 351], ["infection", "PROBLEM", 61, 70], ["lethality", "PROBLEM", 78, 87], ["ACE 2 gene polymorphism", "TREATMENT", 155, 178], ["Cardiovascular Disease", "PROBLEM", 191, 213], ["COVID", "TEST", 219, 224], ["19Another study", "TEST", 225, 240], ["ACE2 gene polymorphism", "PROBLEM", 273, 295], ["higher ACE2 expression level", "PROBLEM", 340, 368], ["infection", "OBSERVATION", 61, 70], ["Cardiovascular", "ANATOMY", 191, 205], ["Disease", "OBSERVATION", 206, 213]]], ["Therefore, patients with cardiac diseases or hypertension, treated with the drugs that enhance the levels of ACE2 pose a greater risk for severe COVID-19 infection and, hence, should be recommended for ACE2-modulating medications [45].ACE 2, Cardiovascular Disease, and COVID-19Since ACE2 expression may associate with the susceptibility to infection of SARS-CoV- 2 and taking ACEIs/ ARBs may predispose CVD patients to the SARS-CoV- 2 infection, certain cardiologists may recommend that ACEIs/ARBs should be discontinued to avoid the potential risk of infection of SARS-CoV- 2.", [["cardiac", "ANATOMY", 25, 32], ["Cardiovascular", "ANATOMY", 242, 256], ["cardiac diseases", "DISEASE", 25, 41], ["hypertension", "DISEASE", 45, 57], ["COVID", "DISEASE", 145, 150], ["infection", "DISEASE", 154, 163], ["Cardiovascular Disease", "DISEASE", 242, 264], ["infection", "DISEASE", 341, 350], ["SARS", "DISEASE", 354, 358], ["ACEIs/ ARBs", "CHEMICAL", 377, 388], ["CVD", "DISEASE", 404, 407], ["SARS", "DISEASE", 424, 428], ["infection", "DISEASE", 436, 445], ["ACEIs/ARBs", "CHEMICAL", 488, 498], ["infection", "DISEASE", 553, 562], ["SARS", "DISEASE", 566, 570], ["patients", "ORGANISM", 11, 19], ["cardiac", "ORGAN", 25, 32], ["ACE2", "GENE_OR_GENE_PRODUCT", 109, 113], ["ACE2", "GENE_OR_GENE_PRODUCT", 202, 206], ["ACE 2", "GENE_OR_GENE_PRODUCT", 235, 240], ["COVID-19Since ACE2", "GENE_OR_GENE_PRODUCT", 270, 288], ["SARS-CoV- 2", "ORGANISM", 354, 365], ["ACEIs", "GENE_OR_GENE_PRODUCT", 377, 382], ["ARBs", "SIMPLE_CHEMICAL", 384, 388], ["patients", "ORGANISM", 408, 416], ["SARS-CoV- 2", "ORGANISM", 424, 435], ["ACEIs", "SIMPLE_CHEMICAL", 488, 493], ["ARBs", "SIMPLE_CHEMICAL", 494, 498], ["SARS-CoV- 2", "GENE_OR_GENE_PRODUCT", 566, 577], ["ACE2", "PROTEIN", 109, 113], ["ACE2", "PROTEIN", 202, 206], ["ACE2", "PROTEIN", 284, 288], ["patients", "SPECIES", 11, 19], ["patients", "SPECIES", 408, 416], ["SARS-CoV", "SPECIES", 354, 362], ["SARS-CoV", "SPECIES", 424, 432], ["SARS-CoV", "SPECIES", 566, 574], ["cardiac diseases", "PROBLEM", 25, 41], ["hypertension", "PROBLEM", 45, 57], ["the drugs", "TREATMENT", 72, 81], ["severe COVID-19 infection", "PROBLEM", 138, 163], ["ACE2-modulating medications", "TREATMENT", 202, 229], ["ACE 2", "PROBLEM", 235, 240], ["Cardiovascular Disease", "PROBLEM", 242, 264], ["COVID", "TEST", 270, 275], ["ACE2 expression", "PROBLEM", 284, 299], ["the susceptibility to infection of SARS", "PROBLEM", 319, 358], ["CoV", "TEST", 359, 362], ["ACEIs", "TREATMENT", 377, 382], ["ARBs", "TREATMENT", 384, 388], ["CVD", "PROBLEM", 404, 407], ["the SARS", "PROBLEM", 420, 428], ["CoV- 2 infection", "PROBLEM", 429, 445], ["ACEIs", "TREATMENT", 488, 493], ["ARBs", "TREATMENT", 494, 498], ["infection of SARS", "PROBLEM", 553, 570], ["CoV", "TEST", 571, 574], ["cardiac", "ANATOMY", 25, 32], ["diseases", "OBSERVATION", 33, 41], ["hypertension", "OBSERVATION", 45, 57], ["infection", "OBSERVATION", 154, 163], ["Cardiovascular", "ANATOMY", 242, 256], ["Disease", "OBSERVATION", 257, 264], ["infection", "OBSERVATION", 553, 562]]], ["Even if so, it is demonstrated that the activation of RAS and ACE2 expression downregulation is implicated in SARS-CoV-2 infection-associated lung injury.", [["lung", "ANATOMY", 142, 146], ["infection", "DISEASE", 121, 130], ["lung injury", "DISEASE", 142, 153], ["RAS", "GENE_OR_GENE_PRODUCT", 54, 57], ["ACE2", "GENE_OR_GENE_PRODUCT", 62, 66], ["SARS-CoV-2", "ORGANISM", 110, 120], ["lung", "ORGAN", 142, 146], ["RAS", "PROTEIN", 54, 57], ["ACE2", "PROTEIN", 62, 66], ["SARS-CoV", "SPECIES", 110, 118], ["ACE2 expression downregulation", "PROBLEM", 62, 92], ["SARS", "PROBLEM", 110, 114], ["CoV-2 infection", "PROBLEM", 115, 130], ["lung injury", "PROBLEM", 142, 153], ["infection", "OBSERVATION", 121, 130], ["lung", "ANATOMY", 142, 146], ["injury", "OBSERVATION", 147, 153]]], ["It has also been demonstrated that serum level of angiotensin II is considerably increased in COVID-19 patients and showed an association with lung injury and viral load.", [["serum", "ANATOMY", 35, 40], ["lung", "ANATOMY", 143, 147], ["angiotensin II", "CHEMICAL", 50, 64], ["lung injury", "DISEASE", 143, 154], ["serum", "ORGANISM_SUBSTANCE", 35, 40], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 50, 64], ["patients", "ORGANISM", 103, 111], ["lung", "ORGAN", 143, 147], ["angiotensin II", "PROTEIN", 50, 64], ["patients", "SPECIES", 103, 111], ["serum level", "TEST", 35, 46], ["angiotensin II", "TEST", 50, 64], ["COVID", "TEST", 94, 99], ["lung injury", "PROBLEM", 143, 154], ["viral load", "PROBLEM", 159, 169], ["considerably", "OBSERVATION_MODIFIER", 68, 80], ["increased", "OBSERVATION_MODIFIER", 81, 90], ["lung", "ANATOMY", 143, 147], ["injury", "OBSERVATION", 148, 154], ["viral load", "OBSERVATION", 159, 169]]], ["The activation of RAS may cause extensive dysfunction of endothelial cells and varying degrees of multiple organ injuries [46].ACE 2, Cardiovascular Disease, and COVID-19Thus, intake of ACEIs/ARBs might probably decrease heart damage caused from the activation of RAS.", [["endothelial cells", "ANATOMY", 57, 74], ["organ", "ANATOMY", 107, 112], ["Cardiovascular", "ANATOMY", 134, 148], ["heart", "ANATOMY", 221, 226], ["organ injuries", "DISEASE", 107, 121], ["Cardiovascular Disease", "DISEASE", 134, 156], ["ACEIs", "CHEMICAL", 186, 191], ["ARBs", "CHEMICAL", 192, 196], ["heart damage", "DISEASE", 221, 233], ["RAS", "GENE_OR_GENE_PRODUCT", 18, 21], ["endothelial cells", "CELL", 57, 74], ["organ", "ORGAN", 107, 112], ["ACE 2", "GENE_OR_GENE_PRODUCT", 127, 132], ["ACEIs", "SIMPLE_CHEMICAL", 186, 191], ["ARBs", "SIMPLE_CHEMICAL", 192, 196], ["heart", "ORGAN", 221, 226], ["RAS", "GENE_OR_GENE_PRODUCT", 264, 267], ["RAS", "PROTEIN", 18, 21], ["endothelial cells", "CELL_TYPE", 57, 74], ["RAS", "PROTEIN", 264, 267], ["extensive dysfunction of endothelial cells", "PROBLEM", 32, 74], ["multiple organ injuries", "PROBLEM", 98, 121], ["ACE 2", "PROBLEM", 127, 132], ["Cardiovascular Disease", "PROBLEM", 134, 156], ["COVID", "TEST", 162, 167], ["ACEIs", "TREATMENT", 186, 191], ["ARBs", "TREATMENT", 192, 196], ["heart damage", "PROBLEM", 221, 233], ["may cause", "UNCERTAINTY", 22, 31], ["extensive", "OBSERVATION_MODIFIER", 32, 41], ["dysfunction", "OBSERVATION", 42, 53], ["endothelial cells", "OBSERVATION", 57, 74], ["varying", "OBSERVATION_MODIFIER", 79, 86], ["degrees", "OBSERVATION_MODIFIER", 87, 94], ["multiple", "OBSERVATION_MODIFIER", 98, 106], ["organ", "ANATOMY", 107, 112], ["injuries", "OBSERVATION", 113, 121], ["Cardiovascular", "ANATOMY", 134, 148], ["Disease", "OBSERVATION", 149, 156], ["heart", "ANATOMY", 221, 226], ["damage", "OBSERVATION", 227, 233]]], ["These possibilities pose a dilemma for the cardiologists in terms of recommending whether to discontinue ACEIs/ARBs or not.ConclusionThe association of CVDs with outcomes of COVID-19 is very complex and the scientific community has not yet arrived at any conclusion for the use of ACE inhibitors.", [["ACEIs", "CHEMICAL", 105, 110], ["CVDs", "DISEASE", 152, 156], ["ACEIs", "SIMPLE_CHEMICAL", 105, 110], ["ACE", "GENE_OR_GENE_PRODUCT", 281, 284], ["ACEIs", "TREATMENT", 105, 110], ["ARBs", "TREATMENT", 111, 115], ["CVDs", "PROBLEM", 152, 156], ["COVID", "TEST", 174, 179], ["ACE inhibitors", "TREATMENT", 281, 295]]], ["Further, as various reports showed the comorbidities of CVDs and COVID-19, the ACE inhibitors should be used with preventative measures.", [["CVDs", "DISEASE", 56, 60], ["COVID-19", "CHEMICAL", 65, 73], ["ACE", "GENE_OR_GENE_PRODUCT", 79, 82], ["the comorbidities of CVDs", "PROBLEM", 35, 60], ["COVID", "TEST", 65, 70], ["the ACE inhibitors", "TREATMENT", 75, 93], ["preventative measures", "TREATMENT", 114, 135]]], ["In addition, the association of ACE polymorphism and the COVID-19 outcome in the CVD patients should be studied in a large cohort to identify the role of ACE polymorphism in the prognosis and outcome of the COVID-19 in CVD patients using ACEIs/ARBs.", [["CVD", "DISEASE", 81, 84], ["CVD", "DISEASE", 219, 222], ["ACEIs/ARBs", "CHEMICAL", 238, 248], ["ACE", "GENE_OR_GENE_PRODUCT", 32, 35], ["patients", "ORGANISM", 85, 93], ["ACE", "GENE_OR_GENE_PRODUCT", 154, 157], ["patients", "ORGANISM", 223, 231], ["ACE", "PROTEIN", 32, 35], ["ACE", "PROTEIN", 154, 157], ["patients", "SPECIES", 85, 93], ["patients", "SPECIES", 223, 231], ["ACE polymorphism", "PROBLEM", 32, 48], ["the COVID", "TREATMENT", 53, 62], ["ACE polymorphism", "PROBLEM", 154, 170], ["the COVID", "TEST", 203, 212], ["ACEIs", "TREATMENT", 238, 243], ["ARBs", "TREATMENT", 244, 248]]]], "74813899dfd7ad7de15228fd014c735c3410d9d9": [["IntroductionNipah virus (NiV) together with Hendra virus (HeV) are closely related highly pathogenic zoonoses and are the type species within the paramyxovirus genus Henipavirus.", [["zoonoses", "DISEASE", 101, 109], ["IntroductionNipah virus", "ORGANISM", 0, 23], ["NiV", "ORGANISM", 25, 28], ["Hendra virus", "ORGANISM", 44, 56], ["HeV", "ORGANISM", 58, 61], ["paramyxovirus", "ORGANISM", 146, 159], ["Hendra virus", "SPECIES", 44, 56], ["IntroductionNipah virus", "SPECIES", 0, 23], ["NiV", "SPECIES", 25, 28], ["Hendra virus", "SPECIES", 44, 56], ["HeV", "SPECIES", 58, 61], ["IntroductionNipah virus (NiV", "TREATMENT", 0, 28], ["Hendra virus", "PROBLEM", 44, 56], ["highly pathogenic zoonoses", "PROBLEM", 83, 109], ["the type species", "PROBLEM", 118, 134], ["highly", "OBSERVATION_MODIFIER", 83, 89], ["pathogenic", "OBSERVATION_MODIFIER", 90, 100], ["zoonoses", "OBSERVATION", 101, 109], ["paramyxovirus genus Henipavirus", "OBSERVATION", 146, 177]]], ["Both viruses can cause significant morbidity and mortality in a variety of vertebrate species including humans.", [["humans", "ORGANISM", 104, 110], ["humans", "SPECIES", 104, 110], ["humans", "SPECIES", 104, 110], ["significant morbidity", "PROBLEM", 23, 44], ["viruses", "OBSERVATION", 5, 12], ["significant", "OBSERVATION_MODIFIER", 23, 34], ["morbidity", "OBSERVATION", 35, 44], ["vertebrate species", "OBSERVATION", 75, 93]]], ["The henipaviruses are categorized as zoonotic biosafety level 4 (BSL-4) agents which has limited an extensive examination of their in vivo pathogenic features and the development and evaluation of therapeutics or vaccines.", [["henipaviruses", "ANATOMY", 4, 17], ["zoonotic biosafety level", "TEST", 37, 61], ["BSL", "TEST", 65, 68], ["an extensive examination", "TEST", 97, 121], ["evaluation", "TEST", 183, 193], ["therapeutics", "TREATMENT", 197, 209], ["vaccines", "TREATMENT", 213, 221]]], ["NiV and HeV are select agents of biodefense concern that are classified as priority pathogens in category C by the National Institute of Allergy and Infectious Diseases and the Centers for Disease Control and Prevention, with the potential to cause significant morbidity and mortality in humans and major economic and public health impacts (reviewed [1] ).", [["Allergy and Infectious Diseases", "DISEASE", 137, 168], ["NiV", "ORGANISM", 0, 3], ["HeV", "ORGANISM", 8, 11], ["humans", "ORGANISM", 288, 294], ["humans", "SPECIES", 288, 294], ["NiV", "SPECIES", 0, 3], ["HeV", "SPECIES", 8, 11], ["humans", "SPECIES", 288, 294], ["NiV", "TREATMENT", 0, 3], ["Disease Control", "TREATMENT", 189, 204], ["significant morbidity", "PROBLEM", 249, 270], ["significant", "OBSERVATION_MODIFIER", 249, 260], ["morbidity", "OBSERVATION", 261, 270]]], ["Pteropid bats (family Pteropodidae), commonly known as flying foxes, are the predominate natural reservoirs for both HeV and NiV (reviewed [2] ) although evidence of henipavirus infection has now been reported in a wider range of both frugivorous and insectivorous bats [3, 4] .IntroductionSince their initial recognition, both viruses have repeatedly reemerged.", [["henipavirus infection", "DISEASE", 166, 187], ["Pteropid bats", "ORGANISM", 0, 13], ["HeV", "ORGANISM", 117, 120], ["NiV", "ORGANISM", 125, 128], ["henipavirus", "ORGANISM", 166, 177], ["HeV", "SPECIES", 117, 120], ["NiV", "SPECIES", 125, 128], ["henipavirus", "SPECIES", 166, 177], ["HeV and NiV", "TREATMENT", 117, 128], ["henipavirus infection", "PROBLEM", 166, 187], ["evidence of", "UNCERTAINTY", 154, 165], ["henipavirus", "OBSERVATION_MODIFIER", 166, 177], ["infection", "OBSERVATION", 178, 187], ["frugivorous", "OBSERVATION_MODIFIER", 235, 246], ["insectivorous bats", "OBSERVATION", 251, 269]]], ["In total, 13 HeV outbreaks have occurred in Australia in 1994, 1999, 2004, and 2006-2009 , and have always involved horses as an intermediate host with some human infections including four fatalities, the most recent in September 2009 (reviewed [2] ) [5, 6] .", [["infections", "DISEASE", 163, 173], ["fatalities", "DISEASE", 189, 199], ["HeV", "ORGANISM", 13, 16], ["horses", "ORGANISM", 116, 122], ["human", "ORGANISM", 157, 162], ["human", "SPECIES", 157, 162], ["HeV", "SPECIES", 13, 16], ["horses", "SPECIES", 116, 122], ["human", "SPECIES", 157, 162], ["some human infections", "PROBLEM", 152, 173]]], ["NiV has also repeatedly caused spill-over events involving hundreds of human cases since 1998 with at least nine recognized occurrences primarily in Bangladesh and India since 2001 (reviewed [2] ) with the most recent in March 2008 [7] .", [["NiV", "ORGANISM", 0, 3], ["human", "ORGANISM", 71, 76], ["human", "SPECIES", 71, 76], ["NiV", "SPECIES", 0, 3], ["human", "SPECIES", 71, 76], ["NiV", "TREATMENT", 0, 3]]], ["Several of the more recent NiV outbreaks have had higher rates of acute respiratory distress syndrome in conjunction with encephalitis, epidemiological findings consistent with multiple rounds of person-to-person transmission [8] , higher case fatality rates (,75%), and direct transmission of virus from flying foxes to humans via contaminated food has been demonstrated [9, 10] .IntroductionIn addition to their highly pathogenic nature, the henipaviruses are also distinguished from all other paramyxoviruses by their unusually broad host tropism.", [["respiratory", "ANATOMY", 72, 83], ["respiratory distress syndrome", "DISEASE", 72, 101], ["encephalitis", "DISEASE", 122, 134], ["NiV", "ORGANISM", 27, 30], ["humans", "ORGANISM", 321, 327], ["henipaviruses", "GENE_OR_GENE_PRODUCT", 444, 457], ["person", "SPECIES", 196, 202], ["person", "SPECIES", 206, 212], ["humans", "SPECIES", 321, 327], ["humans", "SPECIES", 321, 327], ["acute respiratory distress syndrome", "PROBLEM", 66, 101], ["encephalitis", "PROBLEM", 122, 134], ["direct transmission of virus", "PROBLEM", 271, 299], ["all other paramyxoviruses", "PROBLEM", 486, 511], ["acute", "OBSERVATION_MODIFIER", 66, 71], ["respiratory distress", "OBSERVATION", 72, 92], ["syndrome", "OBSERVATION", 93, 101], ["encephalitis", "OBSERVATION", 122, 134], ["consistent with", "UNCERTAINTY", 161, 176], ["multiple", "OBSERVATION_MODIFIER", 177, 185], ["host tropism", "OBSERVATION", 537, 549]]], ["Host cell infection by NiV and HeV requires two membrane-anchored envelope glycoproteins; the attachment (G) glycoprotein which binds the viral receptor, and the fusion (F) glycoprotein which drives virus-host cell membrane merger [11] .", [["cell", "ANATOMY", 5, 9], ["membrane", "ANATOMY", 48, 56], ["cell membrane", "ANATOMY", 210, 223], ["infection", "DISEASE", 10, 19], ["Host cell", "CELL", 0, 9], ["NiV", "ORGANISM", 23, 26], ["HeV", "ORGANISM", 31, 34], ["membrane", "CELLULAR_COMPONENT", 48, 56], ["attachment (G) glycoprotein", "GENE_OR_GENE_PRODUCT", 94, 121], ["fusion (F) glycoprotein", "GENE_OR_GENE_PRODUCT", 162, 185], ["cell membrane", "CELLULAR_COMPONENT", 210, 223], ["membrane-anchored envelope glycoproteins", "PROTEIN", 48, 88], ["attachment (G) glycoprotein", "PROTEIN", 94, 121], ["viral receptor", "PROTEIN", 138, 152], ["fusion (F) glycoprotein", "PROTEIN", 162, 185], ["NiV", "SPECIES", 23, 26], ["HeV", "SPECIES", 31, 34], ["Host cell infection", "PROBLEM", 0, 19], ["NiV", "TREATMENT", 23, 26], ["two membrane-anchored envelope glycoproteins", "TREATMENT", 44, 88], ["the attachment (G) glycoprotein", "TREATMENT", 90, 121], ["the viral receptor", "TREATMENT", 134, 152], ["the fusion (F) glycoprotein", "TREATMENT", 158, 185], ["cell", "OBSERVATION_MODIFIER", 5, 9], ["infection", "OBSERVATION", 10, 19], ["two membrane", "OBSERVATION_MODIFIER", 44, 56], ["host cell", "OBSERVATION", 205, 214]]], ["The henipavirus G glycoprotein lacks hemagglutinin and neuraminidase activities and the F glycoprotein is a typical class I fusion glycoprotein (reviewed in [12] ).", [["henipavirus G glycoprotein", "GENE_OR_GENE_PRODUCT", 4, 30], ["hemagglutinin", "GENE_OR_GENE_PRODUCT", 37, 50], ["F glycoprotein", "GENE_OR_GENE_PRODUCT", 88, 102], ["henipavirus G glycoprotein", "PROTEIN", 4, 30], ["hemagglutinin", "PROTEIN", 37, 50], ["neuraminidase", "PROTEIN", 55, 68], ["F glycoprotein", "PROTEIN", 88, 102], ["class I fusion glycoprotein", "PROTEIN", 116, 143], ["The henipavirus G glycoprotein lacks hemagglutinin", "TREATMENT", 0, 50], ["neuraminidase activities", "TREATMENT", 55, 79], ["the F glycoprotein", "TREATMENT", 84, 102], ["a typical class I fusion glycoprotein", "TREATMENT", 106, 143]]], ["The host cell membrane anchored proteins, ephrin-B2 and ephrin-B3 ligands, have been shown to be the receptors employed by the henipaviruses [13, 14, 15, 16] .", [["cell membrane", "ANATOMY", 9, 22], ["cell membrane", "CELLULAR_COMPONENT", 9, 22], ["ephrin-B2", "GENE_OR_GENE_PRODUCT", 42, 51], ["ephrin-B3", "GENE_OR_GENE_PRODUCT", 56, 65], ["host cell membrane anchored proteins", "PROTEIN", 4, 40], ["ephrin", "PROTEIN", 42, 48], ["B2", "PROTEIN", 49, 51], ["ephrin", "PROTEIN", 56, 62], ["B3 ligands", "PROTEIN", 63, 73], ["ephrin", "TEST", 42, 48], ["ephrin-B3 ligands", "TREATMENT", 56, 73], ["host cell membrane", "OBSERVATION", 4, 22]]], ["There are presently no licensed therapeutics available to treat infection caused by the henipaviruses.", [["infection", "DISEASE", 64, 73], ["licensed therapeutics", "TREATMENT", 23, 44], ["infection", "PROBLEM", 64, 73], ["the henipaviruses", "PROBLEM", 84, 101], ["no", "UNCERTAINTY", 20, 22]]], ["Recently, we isolated and extensively characterized a neutralizing human monoclonal antibody (hmAb), m102.4, which recognizes the receptor binding domain of the HeV and NiV G glycoproteins.", [["human", "ORGANISM", 67, 72], ["HeV", "ORGANISM", 161, 164], ["NiV G glycoproteins", "GENE_OR_GENE_PRODUCT", 169, 188], ["neutralizing human monoclonal antibody", "PROTEIN", 54, 92], ["hmAb", "PROTEIN", 94, 98], ["m102.4", "PROTEIN", 101, 107], ["receptor binding domain", "PROTEIN", 130, 153], ["HeV and NiV G glycoproteins", "PROTEIN", 161, 188], ["human", "SPECIES", 67, 72], ["human", "SPECIES", 67, 72], ["HeV", "SPECIES", 161, 164], ["a neutralizing human monoclonal antibody", "PROBLEM", 52, 92], ["NiV G glycoproteins", "TREATMENT", 169, 188], ["neutralizing", "OBSERVATION_MODIFIER", 54, 66], ["monoclonal antibody", "OBSERVATION", 73, 92], ["HeV", "ANATOMY", 161, 164]]], ["This hmAb potently neutralized both viruses in vitro and maintained its biological activity in vivo suggesting its possible utility as a passive therapeutic modality following henipavirus infection [17] .", [["hmAb", "CHEMICAL", 5, 9], ["infection", "DISEASE", 188, 197], ["hmAb", "GENE_OR_GENE_PRODUCT", 5, 9], ["henipavirus", "SPECIES", 176, 187], ["vitro", "TREATMENT", 47, 52], ["a passive therapeutic modality", "TREATMENT", 135, 165], ["henipavirus infection", "PROBLEM", 176, 197], ["viruses", "OBSERVATION", 36, 43]]], ["Here we report the development and characterization of a novel ferret model of acute NiV infection and associated disease as well as conduct the first henipavirus therapeutic antibody trial using the hmAb m102.4.", [["NiV infection", "DISEASE", 85, 98], ["ferret", "ORGANISM", 63, 69], ["NiV", "ORGANISM", 85, 88], ["ferret", "SPECIES", 63, 69], ["NiV", "SPECIES", 85, 88], ["acute NiV infection", "PROBLEM", 79, 98], ["associated disease", "PROBLEM", 103, 121], ["the first henipavirus therapeutic antibody trial", "TREATMENT", 141, 189], ["acute", "OBSERVATION_MODIFIER", 79, 84], ["NiV infection", "OBSERVATION", 85, 98]]], ["Together, our data demonstrate that NiV-mediated disease in the ferret closely resembles that seen in humans with the presence of both respiratory and neurological disease.", [["respiratory", "ANATOMY", 135, 146], ["neurological", "ANATOMY", 151, 163], ["respiratory and neurological disease", "DISEASE", 135, 171], ["NiV", "GENE_OR_GENE_PRODUCT", 36, 39], ["ferret", "ORGANISM", 64, 70], ["humans", "ORGANISM", 102, 108], ["ferret", "SPECIES", 64, 70], ["humans", "SPECIES", 102, 108], ["ferret", "SPECIES", 64, 70], ["humans", "SPECIES", 102, 108], ["our data", "TEST", 10, 18], ["NiV-mediated disease", "PROBLEM", 36, 56], ["both respiratory and neurological disease", "PROBLEM", 130, 171], ["disease", "OBSERVATION", 49, 56], ["both", "ANATOMY_MODIFIER", 130, 134], ["respiratory", "ANATOMY", 135, 146], ["neurological disease", "OBSERVATION", 151, 171]]], ["We further demonstrate that m102.4 is an effective post-exposure therapeutic representing the first antiviral drug candidate showing in vivo efficacy in treating lethal NiV-mediated disease, and it is the first human mAb therapeutic developed and tested for the treatment of henipavirus infection.Nipah virus infection and disease in ferretsIn humans, disease resulting from NiV infection can vary in intensity from an acute febrile illness or one progressing to severe central nervous and respiratory disease.", [["central nervous", "ANATOMY", 470, 485], ["respiratory", "ANATOMY", 490, 501], ["NiV-mediated disease", "DISEASE", 169, 189], ["henipavirus infection", "DISEASE", 275, 296], ["Nipah virus infection", "DISEASE", 297, 318], ["NiV infection", "DISEASE", 375, 388], ["febrile illness", "DISEASE", 425, 440], ["central nervous and respiratory disease", "DISEASE", 470, 509], ["NiV", "ORGANISM", 169, 172], ["human", "ORGANISM", 211, 216], ["henipavirus", "ORGANISM", 275, 286], ["Nipah virus", "ORGANISM", 297, 308], ["ferrets", "ORGANISM", 334, 341], ["humans", "ORGANISM", 344, 350], ["NiV", "ORGANISM", 375, 378], ["nervous", "ANATOMICAL_SYSTEM", 478, 485], ["human", "SPECIES", 211, 216], ["Nipah virus", "SPECIES", 297, 308], ["ferrets", "SPECIES", 334, 341], ["humans", "SPECIES", 344, 350], ["NiV", "SPECIES", 169, 172], ["human", "SPECIES", 211, 216], ["henipavirus", "SPECIES", 275, 286], ["Nipah virus", "SPECIES", 297, 308], ["ferrets", "SPECIES", 334, 341], ["humans", "SPECIES", 344, 350], ["NiV", "SPECIES", 375, 378], ["lethal NiV", "TREATMENT", 162, 172], ["mediated disease", "PROBLEM", 173, 189], ["henipavirus infection", "PROBLEM", 275, 296], ["Nipah virus infection", "PROBLEM", 297, 318], ["disease in ferrets", "PROBLEM", 323, 341], ["disease", "PROBLEM", 352, 359], ["NiV infection", "PROBLEM", 375, 388], ["an acute febrile illness", "PROBLEM", 416, 440], ["severe central nervous and respiratory disease", "PROBLEM", 463, 509], ["disease", "OBSERVATION", 182, 189], ["infection", "OBSERVATION", 287, 296], ["virus infection", "OBSERVATION", 303, 318], ["ferrets", "OBSERVATION_MODIFIER", 334, 341], ["disease", "OBSERVATION", 352, 359], ["NiV infection", "OBSERVATION", 375, 388], ["acute", "OBSERVATION_MODIFIER", 419, 424], ["febrile", "OBSERVATION", 425, 432], ["severe", "OBSERVATION_MODIFIER", 463, 469], ["central", "ANATOMY_MODIFIER", 470, 477], ["nervous", "ANATOMY", 478, 485], ["respiratory disease", "OBSERVATION", 490, 509]]], ["Pathological findings show systemic vasculitis, necrotizing alveolitis and meningoencephalitis [18, 19] .", [["vasculitis", "DISEASE", 36, 46], ["alveolitis", "DISEASE", 60, 70], ["meningoencephalitis", "DISEASE", 75, 94], ["Pathological findings", "TEST", 0, 21], ["systemic vasculitis", "PROBLEM", 27, 46], ["necrotizing alveolitis", "PROBLEM", 48, 70], ["meningoencephalitis", "PROBLEM", 75, 94], ["systemic", "OBSERVATION_MODIFIER", 27, 35], ["vasculitis", "OBSERVATION", 36, 46], ["necrotizing", "OBSERVATION_MODIFIER", 48, 59], ["alveolitis", "OBSERVATION", 60, 70], ["meningoencephalitis", "OBSERVATION", 75, 94]]], ["The disease in experimentally infected cats and hamsters is similar [20, 21] ; but in hamsters meninoencephalitis is more prominent, while cats develop an acute respiratory disease [22] .", [["respiratory", "ANATOMY", 161, 172], ["meninoencephalitis", "DISEASE", 95, 113], ["acute respiratory disease", "DISEASE", 155, 180], ["cats", "ORGANISM", 39, 43], ["hamsters", "ORGANISM", 48, 56], ["hamsters meninoencephalitis", "ORGANISM", 86, 113], ["cats", "ORGANISM", 139, 143], ["cats", "SPECIES", 39, 43], ["hamsters", "SPECIES", 86, 94], ["cats", "SPECIES", 139, 143], ["hamsters", "SPECIES", 48, 56], ["hamsters", "SPECIES", 86, 94], ["The disease in experimentally infected cats", "PROBLEM", 0, 43], ["an acute respiratory disease", "PROBLEM", 152, 180], ["disease", "OBSERVATION", 4, 11], ["experimentally", "OBSERVATION_MODIFIER", 15, 29], ["infected", "OBSERVATION", 30, 38], ["more prominent", "OBSERVATION_MODIFIER", 117, 131], ["acute", "OBSERVATION_MODIFIER", 155, 160], ["respiratory disease", "OBSERVATION", 161, 180]]], ["Here, we sought to assess a new ferret model of NiV pathogenesis where our preliminary observations had confirmed susceptibility to NiV infection, with development of systemic vasculitis and involvement of the central nervous and respiratory systems.", [["central nervous", "ANATOMY", 210, 225], ["NiV infection", "DISEASE", 132, 145], ["vasculitis", "DISEASE", 176, 186], ["ferret", "ORGANISM", 32, 38], ["NiV", "ORGANISM", 48, 51], ["NiV", "ORGANISM", 132, 135], ["central nervous", "ANATOMICAL_SYSTEM", 210, 225], ["NiV", "SPECIES", 48, 51], ["NiV", "SPECIES", 132, 135], ["NiV infection", "PROBLEM", 132, 145], ["systemic vasculitis", "PROBLEM", 167, 186], ["the central nervous and respiratory systems", "PROBLEM", 206, 249], ["infection", "OBSERVATION", 136, 145], ["systemic", "OBSERVATION_MODIFIER", 167, 175], ["vasculitis", "OBSERVATION", 176, 186], ["central", "ANATOMY_MODIFIER", 210, 217], ["nervous", "ANATOMY", 218, 225], ["respiratory systems", "ANATOMY", 230, 249]]], ["Ferrets have emerged as a model for several viral respiratory diseases including avian influenza [23] , severe acute respiratory syndrome [24] ), and morbilliviruses [25] , close relatives of henipaviruses [26] .", [["respiratory", "ANATOMY", 50, 61], ["viral respiratory diseases", "DISEASE", 44, 70], ["avian influenza", "DISEASE", 81, 96], ["acute respiratory syndrome", "DISEASE", 111, 137], ["henipaviruses", "DISEASE", 192, 205], ["avian influenza", "ORGANISM", 81, 96], ["avian influenza", "SPECIES", 81, 96], ["several viral respiratory diseases", "PROBLEM", 36, 70], ["avian influenza", "PROBLEM", 81, 96], ["severe acute respiratory syndrome", "PROBLEM", 104, 137], ["severe", "OBSERVATION_MODIFIER", 104, 110], ["acute", "OBSERVATION_MODIFIER", 111, 116], ["respiratory syndrome", "OBSERVATION", 117, 137]]], ["They offer the combined advantages over either of the aforementioned laboratory animal species of being relatively small mammals, while displaying complex behaviors especially in relation to their handlers that may be used to advantage in clinical assessments.", [["clinical assessments", "TEST", 239, 259]]], ["They are however also sufficiently large to enable repeated collection of a wide range of clinical samples throughout the course of an experimental infection, as well as administration of potential therapies in a manner similar and consistent with human medicine.Nipah virus infection and disease in ferretsWe initiated a NiV minimal infectious dose study (MID 50 ) for the purpose of determining an appropriate challenge dose for subsequent work that would reliably productively infect na\u00efve ferrets.", [["samples", "ANATOMY", 99, 106], ["infection", "DISEASE", 148, 157], ["Nipah virus infection", "DISEASE", 263, 284], ["samples", "CANCER", 99, 106], ["human", "ORGANISM", 248, 253], ["Nipah virus", "ORGANISM", 263, 274], ["ferrets", "ORGANISM", 300, 307], ["ferrets", "ORGANISM", 493, 500], ["human", "SPECIES", 248, 253], ["Nipah virus", "SPECIES", 263, 274], ["ferrets", "SPECIES", 300, 307], ["ferrets", "SPECIES", 493, 500], ["human", "SPECIES", 248, 253], ["Nipah virus", "SPECIES", 263, 274], ["ferrets", "SPECIES", 300, 307], ["an experimental infection", "PROBLEM", 132, 157], ["potential therapies", "TREATMENT", 188, 207], ["human medicine", "TREATMENT", 248, 262], ["Nipah virus infection", "PROBLEM", 263, 284], ["disease in ferrets", "PROBLEM", 289, 307], ["a NiV", "TREATMENT", 320, 325], ["large", "OBSERVATION_MODIFIER", 35, 40], ["wide", "OBSERVATION_MODIFIER", 76, 80], ["experimental", "OBSERVATION_MODIFIER", 135, 147], ["infection", "OBSERVATION", 148, 157], ["consistent with", "UNCERTAINTY", 232, 247], ["virus infection", "OBSERVATION", 269, 284], ["ferrets", "OBSERVATION_MODIFIER", 300, 307]]], ["Doses of 50, 500, 5,000 or 50,000 TCID 50 were each administered to groups of two ferrets oral-nasally; the most likely route of natural infection.", [["oral", "ANATOMY", 90, 94], ["infection", "DISEASE", 137, 146], ["ferrets", "ORGANISM", 82, 89], ["oral", "ORGANISM_SUBDIVISION", 90, 94], ["ferrets", "SPECIES", 82, 89], ["natural infection", "PROBLEM", 129, 146], ["infection", "OBSERVATION", 137, 146]]], ["Based on prior experience with NiV infection in cats [22, 27, 28] and using similar parameters, we defined infection endpoints in ferrets for the purpose of humane euthanasia; these were used as surrogates for lethality.", [["NiV infection", "DISEASE", 31, 44], ["infection", "DISEASE", 107, 116], ["NiV", "ORGANISM", 31, 34], ["cats", "ORGANISM", 48, 52], ["ferrets", "ORGANISM", 130, 137], ["cats", "SPECIES", 48, 52], ["ferrets", "SPECIES", 130, 137], ["NiV", "SPECIES", 31, 34], ["ferrets", "SPECIES", 130, 137], ["NiV infection", "PROBLEM", 31, 44], ["infection endpoints", "PROBLEM", 107, 126], ["humane euthanasia", "TREATMENT", 157, 174], ["lethality", "PROBLEM", 210, 219], ["infection", "OBSERVATION", 35, 44], ["infection", "OBSERVATION", 107, 116]]], ["Endpoints were fever plus signs of rapidly progressing clinical illness including both generalized (e.g. inappetance, depression) and localizing (e.g.dyspnea, neurological signs) disease signs.", [["neurological", "ANATOMY", 159, 171], ["fever", "DISEASE", 15, 20], ["illness", "DISEASE", 64, 71], ["depression", "DISEASE", 118, 128], ["e.g.dyspnea", "DISEASE", 146, 157], ["fever", "PROBLEM", 15, 20], ["rapidly progressing clinical illness", "PROBLEM", 35, 71], ["generalized (e.g. inappetance", "PROBLEM", 87, 116], ["depression", "PROBLEM", 118, 128], ["localizing (e.g.dyspnea, neurological signs) disease signs", "PROBLEM", 134, 192], ["rapidly", "OBSERVATION_MODIFIER", 35, 42], ["progressing", "OBSERVATION_MODIFIER", 43, 54]]], ["Ferrets that received 50 TCID50 (1-50 and 2-50), and one animal that received 500 TCID50 (3-500) remained well throughout the period of observation, did not shed detectable virus or viral RNA, did not seroconvert, and their tissues were normal at post mortem and histological examination.", [["tissues", "ANATOMY", 224, 231], ["tissues", "TISSUE", 224, 231], ["viral RNA", "RNA", 182, 191], ["Ferrets", "TEST", 0, 7], ["detectable virus", "PROBLEM", 162, 178], ["viral RNA", "PROBLEM", 182, 191], ["histological examination", "TEST", 263, 287], ["viral RNA", "OBSERVATION", 182, 191], ["normal", "OBSERVATION", 237, 243]]], ["The remaining ferrets developed fever (4-7 days post-infection (dpi)) and rapidly progressive clinical illness (6-8 dpi) .", [["fever", "DISEASE", 32, 37], ["infection", "DISEASE", 53, 62], ["ferrets", "ORGANISM", 14, 21], ["ferrets", "SPECIES", 14, 21], ["fever", "PROBLEM", 32, 37], ["infection (dpi)", "PROBLEM", 53, 68], ["rapidly progressive clinical illness", "PROBLEM", 74, 110], ["ferrets", "OBSERVATION_MODIFIER", 14, 21], ["fever", "OBSERVATION", 32, 37], ["infection", "OBSERVATION", 53, 62], ["rapidly", "OBSERVATION_MODIFIER", 74, 81], ["progressive", "OBSERVATION_MODIFIER", 82, 93]]], ["Ferrets inoculated with 50,000 TCID50 (7-50000 and 8-50000) were euthanized 6 and 7 dpi, respectively; those inoculated with 5,000 TCID50 (5-5000 and 6-5000) were euthanized 8 and 10 dpi, respectively, and one ferret inoculated with 500 TCID50 (4-500) was euthanized 9 dpi.Nipah virus infection and disease in ferretsClinical signs in affected ferrets included severe depression, cough, serous nasal discharge, dyspnea and subcutaneous edema of the head (8-50000); severe depression, orthopnea, and expiratory dyspnea (7-50000); severe depression, orthopnea and cutaneous ecchymoses (6-5000); severe depression, vomiting and hypothermia (5-5000); and obtunded with tremor and hind limb paresis (4-500).", [["serous nasal", "ANATOMY", 387, 399], ["subcutaneous edema", "ANATOMY", 423, 441], ["head", "ANATOMY", 449, 453], ["orthopnea", "ANATOMY", 548, 557], ["cutaneous ecchymoses", "ANATOMY", 562, 582], ["hind limb", "ANATOMY", 676, 685], ["Nipah virus infection", "DISEASE", 273, 294], ["depression", "DISEASE", 368, 378], ["cough", "DISEASE", 380, 385], ["dyspnea", "DISEASE", 411, 418], ["edema", "DISEASE", 436, 441], ["depression", "DISEASE", 472, 482], ["orthopnea", "DISEASE", 484, 493], ["expiratory dyspnea", "DISEASE", 499, 517], ["depression", "DISEASE", 536, 546], ["orthopnea", "DISEASE", 548, 557], ["ecchymoses", "DISEASE", 572, 582], ["depression", "DISEASE", 600, 610], ["vomiting", "DISEASE", 612, 620], ["hypothermia", "DISEASE", 625, 636], ["tremor", "DISEASE", 665, 671], ["paresis", "DISEASE", 686, 693], ["ferret", "ORGANISM", 210, 216], ["Nipah virus", "ORGANISM", 273, 284], ["ferrets", "ORGANISM", 310, 317], ["ferrets", "ORGANISM", 344, 351], ["nasal", "ORGANISM_SUBDIVISION", 394, 399], ["head", "ORGANISM_SUBDIVISION", 449, 453], ["hind limb", "ORGANISM_SUBDIVISION", 676, 685], ["ferret", "SPECIES", 210, 216], ["Nipah virus", "SPECIES", 273, 284], ["ferrets", "SPECIES", 310, 317], ["ferrets", "SPECIES", 344, 351], ["ferret", "SPECIES", 210, 216], ["Nipah virus", "SPECIES", 273, 284], ["ferrets", "SPECIES", 310, 317], ["Ferrets", "TEST", 0, 7], ["Nipah virus infection", "PROBLEM", 273, 294], ["disease in ferrets", "PROBLEM", 299, 317], ["Clinical signs in affected ferrets", "PROBLEM", 317, 351], ["severe depression", "PROBLEM", 361, 378], ["cough", "PROBLEM", 380, 385], ["serous nasal discharge", "PROBLEM", 387, 409], ["dyspnea", "PROBLEM", 411, 418], ["subcutaneous edema of the head", "PROBLEM", 423, 453], ["severe depression", "PROBLEM", 465, 482], ["orthopnea", "PROBLEM", 484, 493], ["expiratory dyspnea", "PROBLEM", 499, 517], ["severe depression", "PROBLEM", 529, 546], ["orthopnea", "PROBLEM", 548, 557], ["cutaneous ecchymoses", "PROBLEM", 562, 582], ["severe depression", "PROBLEM", 593, 610], ["vomiting", "PROBLEM", 612, 620], ["hypothermia", "PROBLEM", 625, 636], ["obtunded", "PROBLEM", 651, 659], ["tremor", "PROBLEM", 665, 671], ["hind limb paresis", "PROBLEM", 676, 693], ["virus infection", "OBSERVATION", 279, 294], ["ferrets", "OBSERVATION_MODIFIER", 310, 317], ["severe", "OBSERVATION_MODIFIER", 361, 367], ["depression", "OBSERVATION", 368, 378], ["cough", "OBSERVATION", 380, 385], ["serous", "OBSERVATION_MODIFIER", 387, 393], ["nasal", "ANATOMY", 394, 399], ["discharge", "OBSERVATION", 400, 409], ["dyspnea", "OBSERVATION", 411, 418], ["subcutaneous", "ANATOMY", 423, 435], ["edema", "OBSERVATION", 436, 441], ["head", "ANATOMY", 449, 453], ["severe", "OBSERVATION_MODIFIER", 465, 471], ["depression", "OBSERVATION", 472, 482], ["expiratory", "ANATOMY", 499, 509], ["dyspnea", "OBSERVATION", 510, 517], ["severe", "OBSERVATION_MODIFIER", 529, 535], ["depression", "OBSERVATION", 536, 546], ["cutaneous", "ANATOMY", 562, 571], ["ecchymoses", "OBSERVATION", 572, 582], ["severe", "OBSERVATION_MODIFIER", 593, 599], ["depression", "OBSERVATION", 600, 610], ["hypothermia", "OBSERVATION", 625, 636], ["hind limb", "ANATOMY", 676, 685], ["paresis", "OBSERVATION", 686, 693]]], ["Gross pathological findings comprised varying degrees of subcutaneous hemorrhagic edema of the head and neck, centered upon local lymph nodes in all diseased ferrets; focal raised pin-head hemorrhagic nodules scattered throughout the pulmonary parenchyma; and scattered intra-abdominal petechial hemorrhages.", [["subcutaneous", "ANATOMY", 57, 69], ["head", "ANATOMY", 95, 99], ["neck", "ANATOMY", 104, 108], ["lymph nodes", "ANATOMY", 130, 141], ["nodules", "ANATOMY", 201, 208], ["pulmonary parenchyma", "ANATOMY", 234, 254], ["intra-abdominal petechial", "ANATOMY", 270, 295], ["hemorrhagic edema", "DISEASE", 70, 87], ["hemorrhagic", "DISEASE", 189, 200], ["hemorrhages", "DISEASE", 296, 307], ["head", "ORGAN", 95, 99], ["neck", "ORGAN", 104, 108], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 130, 141], ["ferrets", "ORGANISM", 158, 165], ["pulmonary parenchyma", "MULTI-TISSUE_STRUCTURE", 234, 254], ["intra-abdominal petechial", "PATHOLOGICAL_FORMATION", 270, 295], ["ferrets", "SPECIES", 158, 165], ["Gross pathological findings", "PROBLEM", 0, 27], ["subcutaneous hemorrhagic edema of the head and neck", "PROBLEM", 57, 108], ["local lymph nodes", "PROBLEM", 124, 141], ["all diseased ferrets", "PROBLEM", 145, 165], ["focal raised pin-head hemorrhagic nodules", "PROBLEM", 167, 208], ["scattered intra-abdominal petechial hemorrhages", "PROBLEM", 260, 307], ["pathological", "OBSERVATION", 6, 18], ["varying", "OBSERVATION_MODIFIER", 38, 45], ["degrees", "OBSERVATION_MODIFIER", 46, 53], ["subcutaneous", "OBSERVATION_MODIFIER", 57, 69], ["hemorrhagic", "OBSERVATION_MODIFIER", 70, 81], ["edema", "OBSERVATION", 82, 87], ["head", "ANATOMY", 95, 99], ["neck", "ANATOMY", 104, 108], ["local", "OBSERVATION_MODIFIER", 124, 129], ["lymph nodes", "OBSERVATION", 130, 141], ["all", "OBSERVATION_MODIFIER", 145, 148], ["diseased", "OBSERVATION_MODIFIER", 149, 157], ["ferrets", "OBSERVATION_MODIFIER", 158, 165], ["focal", "OBSERVATION_MODIFIER", 167, 172], ["raised", "OBSERVATION_MODIFIER", 173, 179], ["pin-head", "OBSERVATION_MODIFIER", 180, 188], ["hemorrhagic", "OBSERVATION_MODIFIER", 189, 200], ["nodules", "OBSERVATION", 201, 208], ["scattered", "OBSERVATION_MODIFIER", 209, 218], ["pulmonary", "ANATOMY", 234, 243], ["parenchyma", "ANATOMY_MODIFIER", 244, 254], ["scattered", "OBSERVATION_MODIFIER", 260, 269], ["intra-abdominal", "ANATOMY", 270, 285], ["petechial", "OBSERVATION_MODIFIER", 286, 295], ["hemorrhages", "OBSERVATION", 296, 307]]], ["Histopathology of diseased ferrets revealed acute focal necrotizing alveolitis and pulmonary vasculitis, acute glomerular necrosis, focal necrosis of the spleen, and severe diffuse subacute inflammation of the organs and connective tissues of the head and neck.", [["pulmonary", "ANATOMY", 83, 92], ["glomerular", "ANATOMY", 111, 121], ["spleen", "ANATOMY", 154, 160], ["organs", "ANATOMY", 210, 216], ["connective tissues", "ANATOMY", 221, 239], ["head", "ANATOMY", 247, 251], ["neck", "ANATOMY", 256, 260], ["alveolitis", "DISEASE", 68, 78], ["pulmonary vasculitis", "DISEASE", 83, 103], ["acute glomerular necrosis", "DISEASE", 105, 130], ["necrosis", "DISEASE", 138, 146], ["ferrets", "ORGANISM", 27, 34], ["pulmonary", "ORGAN", 83, 92], ["spleen", "ORGAN", 154, 160], ["organs", "ORGAN", 210, 216], ["connective tissues", "TISSUE", 221, 239], ["head", "ORGANISM_SUBDIVISION", 247, 251], ["neck", "ORGAN", 256, 260], ["ferrets", "SPECIES", 27, 34], ["diseased ferrets", "PROBLEM", 18, 34], ["acute focal necrotizing alveolitis", "PROBLEM", 44, 78], ["pulmonary vasculitis", "PROBLEM", 83, 103], ["acute glomerular necrosis", "PROBLEM", 105, 130], ["focal necrosis of the spleen", "PROBLEM", 132, 160], ["severe diffuse subacute inflammation of the organs and connective tissues of the head and neck", "PROBLEM", 166, 260], ["diseased", "OBSERVATION", 18, 26], ["acute", "OBSERVATION_MODIFIER", 44, 49], ["focal", "OBSERVATION_MODIFIER", 50, 55], ["necrotizing", "OBSERVATION_MODIFIER", 56, 67], ["alveolitis", "OBSERVATION", 68, 78], ["pulmonary", "ANATOMY", 83, 92], ["vasculitis", "OBSERVATION", 93, 103], ["acute", "OBSERVATION_MODIFIER", 105, 110], ["glomerular", "OBSERVATION_MODIFIER", 111, 121], ["necrosis", "OBSERVATION", 122, 130], ["focal", "OBSERVATION_MODIFIER", 132, 137], ["necrosis", "OBSERVATION", 138, 146], ["spleen", "ANATOMY", 154, 160], ["severe", "OBSERVATION_MODIFIER", 166, 172], ["diffuse", "OBSERVATION_MODIFIER", 173, 180], ["subacute", "OBSERVATION_MODIFIER", 181, 189], ["inflammation", "OBSERVATION", 190, 202], ["organs", "ANATOMY", 210, 216], ["connective tissues", "OBSERVATION", 221, 239], ["head", "ANATOMY", 247, 251], ["neck", "ANATOMY", 256, 260]]], ["Less commonly, there was mild focal nonsuppurative meningitis (4-500, 5-5000 and 8-50000), focal cystitis (4-500), severe acute necrotizing salpingitis (4-500), acute focal coagulative necrosis of the adrenal cortex (4-500 and 5-5000), and severe acute thyroiditis .", [["focal cystitis", "ANATOMY", 91, 105], ["adrenal cortex", "ANATOMY", 201, 215], ["meningitis", "DISEASE", 51, 61], ["focal cystitis", "DISEASE", 91, 105], ["salpingitis", "DISEASE", 140, 151], ["necrosis", "DISEASE", 185, 193], ["acute thyroiditis", "DISEASE", 247, 264], ["adrenal cortex", "CANCER", 201, 215], ["mild focal nonsuppurative meningitis", "PROBLEM", 25, 61], ["focal cystitis", "PROBLEM", 91, 105], ["severe acute necrotizing salpingitis", "PROBLEM", 115, 151], ["acute focal coagulative necrosis of the adrenal cortex", "PROBLEM", 161, 215], ["severe acute thyroiditis", "PROBLEM", 240, 264], ["mild", "OBSERVATION_MODIFIER", 25, 29], ["focal", "OBSERVATION_MODIFIER", 30, 35], ["nonsuppurative", "OBSERVATION_MODIFIER", 36, 50], ["meningitis", "OBSERVATION", 51, 61], ["focal", "OBSERVATION_MODIFIER", 91, 96], ["cystitis", "OBSERVATION", 97, 105], ["severe", "OBSERVATION_MODIFIER", 115, 121], ["acute", "OBSERVATION_MODIFIER", 122, 127], ["necrotizing", "OBSERVATION_MODIFIER", 128, 139], ["salpingitis", "OBSERVATION", 140, 151], ["acute", "OBSERVATION_MODIFIER", 161, 166], ["focal", "OBSERVATION_MODIFIER", 167, 172], ["coagulative", "OBSERVATION_MODIFIER", 173, 184], ["necrosis", "OBSERVATION", 185, 193], ["adrenal", "ANATOMY", 201, 208], ["cortex", "ANATOMY_MODIFIER", 209, 215], ["severe", "OBSERVATION_MODIFIER", 240, 246], ["acute", "OBSERVATION_MODIFIER", 247, 252], ["thyroiditis", "OBSERVATION", 253, 264]]], ["Two ferrets demonstrated neurological signs (4-500, 5-5000) and had nonsuppurative meningitis.", [["neurological", "ANATOMY", 25, 37], ["neurological signs", "DISEASE", 25, 43], ["meningitis", "DISEASE", 83, 93], ["ferrets", "ORGANISM", 4, 11], ["ferrets", "SPECIES", 4, 11], ["neurological signs", "TEST", 25, 43], ["nonsuppurative meningitis", "PROBLEM", 68, 93], ["nonsuppurative", "OBSERVATION_MODIFIER", 68, 82], ["meningitis", "OBSERVATION", 83, 93]]], ["Syncytia were usually present in lesions and often contained abundant viral antigen ( Figure 1 ).", [["lesions", "ANATOMY", 33, 40], ["Syncytia", "DISEASE", 0, 8], ["lesions", "PATHOLOGICAL_FORMATION", 33, 40], ["viral antigen", "PROTEIN", 70, 83], ["Syncytia", "PROBLEM", 0, 8], ["lesions", "PROBLEM", 33, 40], ["lesions", "OBSERVATION", 33, 40], ["abundant", "OBSERVATION_MODIFIER", 61, 69], ["viral antigen", "OBSERVATION", 70, 83]]], ["In mildly affected lymph nodes there was focal mononuclear cell and neutrophilic inflammation of the capsule, accompanied by a zone of subcapsular lymphocyte depletion.", [["lymph nodes", "ANATOMY", 19, 30], ["focal mononuclear cell", "ANATOMY", 41, 63], ["neutrophilic", "ANATOMY", 68, 80], ["capsule", "ANATOMY", 101, 108], ["subcapsular lymphocyte", "ANATOMY", 135, 157], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 19, 30], ["focal mononuclear cell", "CELL", 41, 63], ["capsule", "CANCER", 101, 108], ["subcapsular lymphocyte", "CELL", 135, 157], ["mildly affected lymph nodes", "PROBLEM", 3, 30], ["focal mononuclear cell", "PROBLEM", 41, 63], ["neutrophilic inflammation of the capsule", "PROBLEM", 68, 108], ["subcapsular lymphocyte depletion", "PROBLEM", 135, 167], ["mildly", "OBSERVATION_MODIFIER", 3, 9], ["affected", "OBSERVATION_MODIFIER", 10, 18], ["lymph nodes", "OBSERVATION", 19, 30], ["focal", "OBSERVATION_MODIFIER", 41, 46], ["mononuclear cell", "OBSERVATION", 47, 63], ["neutrophilic", "OBSERVATION_MODIFIER", 68, 80], ["inflammation", "OBSERVATION", 81, 93], ["capsule", "ANATOMY", 101, 108], ["zone", "OBSERVATION_MODIFIER", 127, 131], ["subcapsular lymphocyte depletion", "OBSERVATION", 135, 167]]], ["In more severely affected lymph nodes, there was severe extensive hemorrhagic and coagulative necrosis, often resulting in the destruction of the entire node with antigen staining mainly in syncytia at the living margin of the necrotic focus ( Figure 1 ).", [["lymph nodes", "ANATOMY", 26, 37], ["node", "ANATOMY", 153, 157], ["syncytia", "ANATOMY", 190, 198], ["necrotic focus", "ANATOMY", 227, 241], ["hemorrhagic", "DISEASE", 66, 77], ["necrosis", "DISEASE", 94, 102], ["necrotic", "DISEASE", 227, 235], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 26, 37], ["node", "MULTI-TISSUE_STRUCTURE", 153, 157], ["antigen", "GENE_OR_GENE_PRODUCT", 163, 170], ["syncytia", "CELL", 190, 198], ["more severely affected lymph nodes", "PROBLEM", 3, 37], ["severe extensive hemorrhagic and coagulative necrosis", "PROBLEM", 49, 102], ["the destruction of the entire node", "PROBLEM", 123, 157], ["antigen staining", "PROBLEM", 163, 179], ["syncytia", "PROBLEM", 190, 198], ["more", "OBSERVATION_MODIFIER", 3, 7], ["severely", "OBSERVATION_MODIFIER", 8, 16], ["affected", "OBSERVATION_MODIFIER", 17, 25], ["lymph nodes", "OBSERVATION", 26, 37], ["severe", "OBSERVATION_MODIFIER", 49, 55], ["extensive", "OBSERVATION_MODIFIER", 56, 65], ["hemorrhagic", "OBSERVATION_MODIFIER", 66, 77], ["coagulative", "OBSERVATION_MODIFIER", 82, 93], ["necrosis", "OBSERVATION", 94, 102], ["destruction", "OBSERVATION", 127, 138], ["entire", "OBSERVATION_MODIFIER", 146, 152], ["node", "OBSERVATION", 153, 157], ["antigen", "OBSERVATION_MODIFIER", 163, 170], ["staining", "OBSERVATION_MODIFIER", 171, 179], ["mainly", "OBSERVATION_MODIFIER", 180, 186], ["syncytia", "OBSERVATION", 190, 198], ["living", "OBSERVATION_MODIFIER", 206, 212], ["margin", "OBSERVATION_MODIFIER", 213, 219], ["necrotic", "OBSERVATION_MODIFIER", 227, 235], ["focus", "OBSERVATION", 236, 241]]], ["Clinically healthy ferretsAuthor SummaryNipah virus and Hendra virus are closely related and highly pathogenic zoonoses whose primary natural reservoirs are several species of Pteropus fruit bats.", [["Hendra virus", "DISEASE", 56, 68], ["zoonoses", "DISEASE", 111, 119], ["ferrets", "ORGANISM", 19, 26], ["Author", "ORGANISM", 26, 32], ["SummaryNipah virus", "ORGANISM", 33, 51], ["Hendra virus", "ORGANISM", 56, 68], ["Pteropus fruit bats", "ORGANISM", 176, 195], ["ferrets", "SPECIES", 19, 26], ["Hendra virus", "SPECIES", 56, 68], ["Pteropus fruit", "SPECIES", 176, 190], ["SummaryNipah virus", "SPECIES", 33, 51], ["Hendra virus", "SPECIES", 56, 68], ["Pteropus fruit bats", "SPECIES", 176, 195], ["Author SummaryNipah virus", "PROBLEM", 26, 51], ["Hendra virus", "PROBLEM", 56, 68], ["highly pathogenic zoonoses", "PROBLEM", 93, 119], ["Hendra virus", "OBSERVATION", 56, 68], ["Pteropus fruit bats", "OBSERVATION", 176, 195]]], ["Both Nipah and Hendra viruses can cause severe and often fatal disease in a variety of mammalian hosts, including humans.", [["Nipah and Hendra viruses", "DISEASE", 5, 29], ["Nipah", "ORGANISM", 5, 10], ["Hendra viruses", "ORGANISM", 15, 29], ["humans", "ORGANISM", 114, 120], ["humans", "SPECIES", 114, 120], ["Hendra viruses", "SPECIES", 15, 29], ["humans", "SPECIES", 114, 120], ["Hendra viruses", "TREATMENT", 15, 29], ["severe and often fatal disease", "PROBLEM", 40, 70], ["Nipah", "OBSERVATION", 5, 10], ["Hendra viruses", "OBSERVATION", 15, 29], ["severe", "OBSERVATION_MODIFIER", 40, 46], ["often", "OBSERVATION_MODIFIER", 51, 56], ["fatal", "OBSERVATION_MODIFIER", 57, 62], ["disease", "OBSERVATION", 63, 70], ["mammalian hosts", "OBSERVATION", 87, 102]]], ["The henipaviruses are categorized as biosafety level 4 (BSL-4) agents, which has limited the development of animal models and the testing of potential therapeutics and vaccine countermeasures.", [["henipaviruses", "ANATOMY", 4, 17], ["biosafety level", "TEST", 37, 52], ["BSL", "TEST", 56, 59], ["the testing", "TEST", 126, 137], ["potential therapeutics", "TREATMENT", 141, 163], ["vaccine countermeasures", "TREATMENT", 168, 191]]], ["We show here a new ferret model of Nipah virus pathogenesis in which the underlying pathology closely mirrors the illness seen in Nipah virus-infected humans, including both respiratory and neurological disease.", [["respiratory", "ANATOMY", 174, 185], ["neurological", "ANATOMY", 190, 202], ["Nipah virus", "DISEASE", 35, 46], ["Nipah virus-infected", "DISEASE", 130, 150], ["respiratory and neurological disease", "DISEASE", 174, 210], ["ferret", "ORGANISM", 19, 25], ["Nipah virus", "ORGANISM", 35, 46], ["Nipah virus", "ORGANISM", 130, 141], ["humans", "ORGANISM", 151, 157], ["Nipah virus", "SPECIES", 35, 46], ["Nipah virus", "SPECIES", 130, 141], ["humans", "SPECIES", 151, 157], ["Nipah virus", "SPECIES", 35, 46], ["Nipah virus", "SPECIES", 130, 141], ["humans", "SPECIES", 151, 157], ["Nipah virus pathogenesis", "PROBLEM", 35, 59], ["the illness", "PROBLEM", 110, 121], ["Nipah virus", "PROBLEM", 130, 141], ["both respiratory and neurological disease", "PROBLEM", 169, 210], ["Nipah virus", "OBSERVATION", 35, 46], ["Nipah virus", "OBSERVATION", 130, 141], ["infected", "OBSERVATION", 142, 150], ["both", "ANATOMY_MODIFIER", 169, 173], ["respiratory", "ANATOMY", 174, 185], ["neurological disease", "OBSERVATION", 190, 210]]], ["We also show that m102.4, a crossreactive neutralizing human monoclonal antibody that targets the viral attachment glycoprotein, completely protected ferrets from disease when given ten hours after a lethal Nipah virus challenge.", [["Nipah virus", "DISEASE", 207, 218], ["human", "ORGANISM", 55, 60], ["ferrets", "ORGANISM", 150, 157], ["Nipah virus", "ORGANISM", 207, 218], ["crossreactive neutralizing human monoclonal antibody", "PROTEIN", 28, 80], ["viral attachment glycoprotein", "PROTEIN", 98, 127], ["human", "SPECIES", 55, 60], ["ferrets", "SPECIES", 150, 157], ["human", "SPECIES", 55, 60], ["ferrets", "SPECIES", 150, 157], ["Nipah virus", "SPECIES", 207, 218], ["a crossreactive neutralizing human monoclonal antibody", "PROBLEM", 26, 80], ["the viral attachment glycoprotein", "PROBLEM", 94, 127], ["a lethal Nipah virus challenge", "TREATMENT", 198, 228], ["monoclonal antibody", "OBSERVATION", 61, 80]]], ["This study is the first successful and viable post-exposure passive antibody therapy for Nipah virus using a human monoclonal antibody.Author Summaryhad no gross pathological changes, and no viral antigen or significant histological lesions were found in any tissues.Nipah viral loads and tissue tropismTo examine virus dissemination and tissue tropism, NiV N gene RNA was measured in pharyngeal and rectal swabs, blood sampled over the course of infection and in a variety of tissues recovered at necropsy.", [["lesions", "ANATOMY", 233, 240], ["tissues", "ANATOMY", 259, 266], ["tissue", "ANATOMY", 289, 295], ["tissue", "ANATOMY", 338, 344], ["pharyngeal", "ANATOMY", 385, 395], ["rectal swabs", "ANATOMY", 400, 412], ["blood", "ANATOMY", 414, 419], ["tissues", "ANATOMY", 477, 484], ["Nipah virus", "DISEASE", 89, 100], ["infection", "DISEASE", 447, 456], ["Nipah virus", "ORGANISM", 89, 100], ["human", "ORGANISM", 109, 114], ["lesions", "PATHOLOGICAL_FORMATION", 233, 240], ["tissues", "TISSUE", 259, 266], ["Nipah", "ORGANISM", 267, 272], ["tissue", "TISSUE", 289, 295], ["tissue", "TISSUE", 338, 344], ["NiV N gene", "GENE_OR_GENE_PRODUCT", 354, 364], ["pharyngeal", "ORGANISM_SUBDIVISION", 385, 395], ["rectal swabs", "MULTI-TISSUE_STRUCTURE", 400, 412], ["blood", "ORGANISM_SUBSTANCE", 414, 419], ["tissues", "TISSUE", 477, 484], ["human monoclonal antibody", "PROTEIN", 109, 134], ["viral antigen", "PROTEIN", 191, 204], ["NiV N gene RNA", "RNA", 354, 368], ["Nipah virus", "SPECIES", 89, 100], ["human", "SPECIES", 109, 114], ["Nipah", "SPECIES", 267, 272], ["Nipah virus", "SPECIES", 89, 100], ["human", "SPECIES", 109, 114], ["NiV", "SPECIES", 354, 357], ["This study", "TEST", 0, 10], ["passive antibody therapy", "TREATMENT", 60, 84], ["Nipah virus", "PROBLEM", 89, 100], ["a human monoclonal antibody", "TEST", 107, 134], ["gross pathological changes", "PROBLEM", 156, 182], ["viral antigen", "PROBLEM", 191, 204], ["significant histological lesions", "PROBLEM", 208, 240], ["Nipah viral loads", "TREATMENT", 267, 284], ["tissue tropism", "TEST", 289, 303], ["virus dissemination", "TREATMENT", 314, 333], ["tissue tropism", "TEST", 338, 352], ["NiV N gene RNA", "TREATMENT", 354, 368], ["pharyngeal and rectal swabs", "TEST", 385, 412], ["infection", "PROBLEM", 447, 456], ["no", "UNCERTAINTY", 153, 155], ["gross", "OBSERVATION_MODIFIER", 156, 161], ["pathological", "OBSERVATION", 162, 174], ["no", "UNCERTAINTY", 188, 190], ["significant", "OBSERVATION_MODIFIER", 208, 219], ["histological", "OBSERVATION_MODIFIER", 220, 232], ["lesions", "OBSERVATION", 233, 240], ["viral loads", "OBSERVATION", 273, 284], ["tissue tropism", "OBSERVATION", 289, 303], ["pharyngeal", "ANATOMY", 385, 395], ["rectal", "ANATOMY", 400, 406], ["infection", "OBSERVATION", 447, 456]]], ["Among ferrets that developed clinical disease, NiV RNA was detected in the blood (Figure 2A ) at the time of euthanasia and, in two of these (5-5000, 6-5000), also in the sample collected two days earlier.", [["blood", "ANATOMY", 75, 80], ["sample", "ANATOMY", 171, 177], ["ferrets", "ORGANISM", 6, 13], ["NiV", "ORGANISM", 47, 50], ["blood", "ORGANISM_SUBSTANCE", 75, 80], ["NiV RNA", "RNA", 47, 54], ["ferrets", "SPECIES", 6, 13], ["ferrets", "SPECIES", 6, 13], ["NiV", "SPECIES", 47, 50], ["clinical disease", "PROBLEM", 29, 45], ["NiV RNA", "TREATMENT", 47, 54], ["euthanasia", "PROBLEM", 109, 119], ["euthanasia", "OBSERVATION", 109, 119]]], ["One ferret (3-500) that had remained healthy during the period of observation demonstrated a low level of viral RNA in blood 21 dpi.", [["blood", "ANATOMY", 119, 124], ["ferret", "ORGANISM", 4, 10], ["blood", "ORGANISM_SUBSTANCE", 119, 124], ["viral RNA", "RNA", 106, 115], ["a low level of viral RNA", "PROBLEM", 91, 115], ["viral RNA", "OBSERVATION", 106, 115]]], ["Interestingly, this ferret shared a cage with ferret 4-500, from which viral RNA was recovered in pharyngeal and rectal swabs 9 dpi suggesting viral shedding.", [["pharyngeal", "ANATOMY", 98, 108], ["rectal swabs", "ANATOMY", 113, 125], ["ferret 4-500", "CHEMICAL", 46, 58], ["ferret", "ORGANISM", 20, 26], ["pharyngeal", "ORGANISM_SUBDIVISION", 98, 108], ["rectal swabs", "MULTI-TISSUE_STRUCTURE", 113, 125], ["viral RNA", "RNA", 71, 80], ["viral RNA", "PROBLEM", 71, 80], ["pharyngeal and rectal swabs", "TEST", 98, 125], ["viral shedding", "PROBLEM", 143, 157], ["pharyngeal", "ANATOMY", 98, 108], ["rectal swabs", "ANATOMY", 113, 125], ["viral shedding", "OBSERVATION", 143, 157]]], ["Viral RNA (albeit some at low level) was detected in pharyngeal swabs from all ferrets demonstrating clinical disease ( Figure 2A ) and in rectal swabs from two of these ( Figure 2A) .", [["pharyngeal swabs", "ANATOMY", 53, 69], ["rectal swabs", "ANATOMY", 139, 151], ["pharyngeal swabs", "MULTI-TISSUE_STRUCTURE", 53, 69], ["ferrets", "ORGANISM", 79, 86], ["rectal swabs", "MULTI-TISSUE_STRUCTURE", 139, 151], ["Viral RNA", "RNA", 0, 9], ["ferrets", "SPECIES", 79, 86], ["ferrets", "SPECIES", 79, 86], ["Viral RNA", "PROBLEM", 0, 9], ["pharyngeal swabs", "TEST", 53, 69], ["clinical disease", "PROBLEM", 101, 117], ["rectal swabs", "TEST", 139, 151], ["RNA", "OBSERVATION", 6, 9], ["pharyngeal swabs", "ANATOMY", 53, 69], ["rectal swabs", "ANATOMY", 139, 151]]], ["Notably, NiV RNA was not detected in any tissues from clinically healthy ferrets.", [["tissues", "ANATOMY", 41, 48], ["NiV", "ORGANISM", 9, 12], ["tissues", "TISSUE", 41, 48], ["ferrets", "ORGANISM", 73, 80], ["NiV RNA", "RNA", 9, 16], ["ferrets", "SPECIES", 73, 80], ["NiV", "SPECIES", 9, 12], ["NiV RNA", "PROBLEM", 9, 16], ["NiV RNA", "OBSERVATION", 9, 16]]], ["For all other animals with clinical signs, significant levels of viral RNA were detected in adrenal, kidney, lung, bronchial lymph node and spleen tissues ( Figure 2B ).", [["adrenal", "ANATOMY", 92, 99], ["kidney", "ANATOMY", 101, 107], ["lung", "ANATOMY", 109, 113], ["bronchial lymph node", "ANATOMY", 115, 135], ["spleen tissues", "ANATOMY", 140, 154], ["adrenal", "ORGAN", 92, 99], ["kidney", "ORGAN", 101, 107], ["lung", "ORGAN", 109, 113], ["bronchial lymph node", "MULTI-TISSUE_STRUCTURE", 115, 135], ["spleen tissues", "TISSUE", 140, 154], ["viral RNA", "RNA", 65, 74], ["clinical signs", "TEST", 27, 41], ["significant levels of viral RNA", "PROBLEM", 43, 74], ["viral RNA", "OBSERVATION", 65, 74], ["adrenal", "ANATOMY", 92, 99], ["kidney", "ANATOMY", 101, 107], ["lung", "ANATOMY", 109, 113], ["bronchial", "ANATOMY", 115, 124], ["lymph node", "OBSERVATION", 125, 135], ["spleen", "ANATOMY", 140, 146]]], ["Although at lower relative levels, NiV RNA was also detected in the bladder, liver, ovary or testes, uterine horn and in the brain ( Figure 2B ).", [["bladder", "ANATOMY", 68, 75], ["liver", "ANATOMY", 77, 82], ["ovary", "ANATOMY", 84, 89], ["testes", "ANATOMY", 93, 99], ["uterine horn", "ANATOMY", 101, 113], ["brain", "ANATOMY", 125, 130], ["NiV", "ORGANISM", 35, 38], ["bladder", "ORGAN", 68, 75], ["liver", "ORGAN", 77, 82], ["ovary", "ORGAN", 84, 89], ["testes", "ORGAN", 93, 99], ["uterine horn", "MULTI-TISSUE_STRUCTURE", 101, 113], ["brain", "ORGAN", 125, 130], ["NiV RNA", "RNA", 35, 42], ["NiV", "SPECIES", 35, 38], ["NiV RNA", "TREATMENT", 35, 42], ["NiV RNA", "OBSERVATION", 35, 42], ["bladder", "ANATOMY", 68, 75], ["liver", "ANATOMY", 77, 82], ["ovary", "ANATOMY", 84, 89], ["testes", "ANATOMY", 93, 99], ["uterine horn", "ANATOMY", 101, 113], ["brain", "ANATOMY", 125, 130]]], ["All infected ferrets had NiV RNA in the olfactory lobe of the brain and ferret 4-500, which showed tremors and hind limb weakness, had the highest level in the occipital lobe.Nipah viral loads and tissue tropismAlthough real-time PCR can help discern virus distribution in an infected animal, it does not discriminate between infectious and non-infectious genetic material.", [["olfactory lobe", "ANATOMY", 40, 54], ["brain", "ANATOMY", 62, 67], ["hind limb", "ANATOMY", 111, 120], ["occipital lobe", "ANATOMY", 160, 174], ["tissue", "ANATOMY", 197, 203], ["tremors", "DISEASE", 99, 106], ["limb weakness", "DISEASE", 116, 129], ["ferrets", "ORGANISM", 13, 20], ["NiV", "ORGANISM", 25, 28], ["olfactory lobe", "MULTI-TISSUE_STRUCTURE", 40, 54], ["brain", "ORGAN", 62, 67], ["hind limb", "ORGANISM_SUBDIVISION", 111, 120], ["occipital lobe", "MULTI-TISSUE_STRUCTURE", 160, 174], ["Nipah", "ORGANISM", 175, 180], ["tissue", "TISSUE", 197, 203], ["NiV RNA", "RNA", 25, 32], ["ferrets", "SPECIES", 13, 20], ["ferret", "SPECIES", 72, 78], ["Nipah", "SPECIES", 175, 180], ["NiV", "SPECIES", 25, 28], ["All infected ferrets", "PROBLEM", 0, 20], ["NiV RNA", "TEST", 25, 32], ["tremors", "PROBLEM", 99, 106], ["hind limb weakness", "PROBLEM", 111, 129], ["Nipah viral loads", "TEST", 175, 192], ["tissue tropismAlthough", "TEST", 197, 219], ["PCR", "TEST", 230, 233], ["virus distribution", "PROBLEM", 251, 269], ["infectious and non-infectious genetic material", "PROBLEM", 326, 372], ["infected", "OBSERVATION_MODIFIER", 4, 12], ["ferrets", "OBSERVATION", 13, 20], ["NiV RNA", "OBSERVATION", 25, 32], ["olfactory lobe", "ANATOMY", 40, 54], ["brain", "ANATOMY", 62, 67], ["tremors", "OBSERVATION", 99, 106], ["hind limb", "ANATOMY", 111, 120], ["weakness", "OBSERVATION", 121, 129], ["occipital lobe", "ANATOMY", 160, 174], ["viral loads", "OBSERVATION", 181, 192], ["infected", "OBSERVATION", 276, 284], ["infectious", "OBSERVATION", 326, 336], ["non-infectious", "OBSERVATION", 341, 355]]], ["For these reasons, virus isolation was attempted from samples and tissues with NiV RNA relative expression levels above 10.", [["samples", "ANATOMY", 54, 61], ["tissues", "ANATOMY", 66, 73], ["samples", "TISSUE", 54, 61], ["tissues", "TISSUE", 66, 73], ["NiV", "ORGANISM", 79, 82], ["NiV RNA", "RNA", 79, 86], ["NiV", "SPECIES", 79, 82], ["virus isolation", "TREATMENT", 19, 34], ["NiV RNA relative expression levels", "TEST", 79, 113]]], ["NiV was recovered from almost all tissues that had high levels of NiV RNA ( Figure 2B , top panel) as indicated by the (+) above individual data bars.", [["tissues", "ANATOMY", 34, 41], ["NiV", "ORGANISM", 0, 3], ["tissues", "TISSUE", 34, 41], ["NiV", "ORGANISM", 66, 69], ["NiV RNA", "RNA", 66, 73], ["NiV", "SPECIES", 0, 3], ["NiV", "SPECIES", 66, 69], ["NiV", "TREATMENT", 0, 3], ["NiV RNA", "TREATMENT", 66, 73], ["top panel", "TEST", 88, 97]]], ["Lungs and lymphoid tissues were sites of extensive virus replication.", [["Lungs", "ANATOMY", 0, 5], ["lymphoid tissues", "ANATOMY", 10, 26], ["sites", "ANATOMY", 32, 37], ["Lungs", "TISSUE", 0, 5], ["lymphoid tissues", "TISSUE", 10, 26], ["extensive virus replication", "TREATMENT", 41, 68], ["lymphoid tissues", "OBSERVATION", 10, 26], ["extensive", "OBSERVATION_MODIFIER", 41, 50], ["virus replication", "OBSERVATION", 51, 68]]], ["Virus was also isolated from tissues with lower NiV RNA levels, including the occipital lobe, uterine horn and ovary from ferret 4-500 and the olfactory lobe from ferret 8-50000 ( Figure 2B , bottom panel).", [["tissues", "ANATOMY", 29, 36], ["occipital lobe", "ANATOMY", 78, 92], ["uterine horn", "ANATOMY", 94, 106], ["ovary", "ANATOMY", 111, 116], ["olfactory lobe", "ANATOMY", 143, 157], ["Virus", "ORGANISM", 0, 5], ["tissues", "TISSUE", 29, 36], ["NiV", "GENE_OR_GENE_PRODUCT", 48, 51], ["occipital lobe", "MULTI-TISSUE_STRUCTURE", 78, 92], ["uterine horn", "MULTI-TISSUE_STRUCTURE", 94, 106], ["ovary", "ORGAN", 111, 116], ["olfactory lobe", "MULTI-TISSUE_STRUCTURE", 143, 157], ["NiV RNA", "RNA", 48, 55], ["ferret", "SPECIES", 122, 128], ["NiV", "SPECIES", 48, 51], ["Virus", "PROBLEM", 0, 5], ["lower NiV RNA levels", "TEST", 42, 62], ["ferret", "TEST", 122, 128], ["ferret", "TEST", 163, 169], ["bottom panel", "TEST", 192, 204], ["lower", "ANATOMY_MODIFIER", 42, 47], ["NiV RNA levels", "OBSERVATION", 48, 62], ["occipital lobe", "ANATOMY", 78, 92], ["uterine horn", "ANATOMY", 94, 106], ["ovary", "ANATOMY", 111, 116], ["olfactory lobe", "ANATOMY", 143, 157]]], ["For ferrets where NiV was isolated from brain, histological lesions included nonsuppurative meningitis.Antibody m102.4 prevents NiV disease in ferretsRecently, we described a hmAb, m102.4 which engages the receptor-binding site of the viral attachment G glycoprotein, potently neutralizes HeV and NiV in vitro, and retained its biological activity in vivo [17] .", [["brain", "ANATOMY", 40, 45], ["lesions", "ANATOMY", 60, 67], ["meningitis", "DISEASE", 92, 102], ["NiV disease", "DISEASE", 128, 139], ["ferrets", "ORGANISM", 4, 11], ["NiV", "ORGANISM", 18, 21], ["brain", "ORGAN", 40, 45], ["lesions", "PATHOLOGICAL_FORMATION", 60, 67], ["Antibody m102.4", "GENE_OR_GENE_PRODUCT", 103, 118], ["NiV", "ORGANISM", 128, 131], ["ferrets", "ORGANISM", 143, 150], ["G glycoprotein", "GENE_OR_GENE_PRODUCT", 252, 266], ["HeV", "ORGANISM", 289, 292], ["NiV", "ORGANISM", 297, 300], ["receptor-binding site", "PROTEIN", 206, 227], ["viral attachment G glycoprotein", "PROTEIN", 235, 266], ["ferrets", "SPECIES", 4, 11], ["ferrets", "SPECIES", 143, 150], ["NiV", "SPECIES", 18, 21], ["NiV", "SPECIES", 128, 131], ["ferrets", "SPECIES", 143, 150], ["HeV", "SPECIES", 289, 292], ["NiV", "SPECIES", 297, 300], ["ferrets", "PROBLEM", 4, 11], ["NiV", "TREATMENT", 18, 21], ["histological lesions", "PROBLEM", 47, 67], ["nonsuppurative meningitis", "PROBLEM", 77, 102], ["Antibody m", "TEST", 103, 113], ["NiV disease in ferrets", "PROBLEM", 128, 150], ["the viral attachment G glycoprotein", "TREATMENT", 231, 266], ["NiV in vitro", "TREATMENT", 297, 309], ["brain", "ANATOMY", 40, 45], ["lesions", "OBSERVATION", 60, 67], ["nonsuppurative", "OBSERVATION_MODIFIER", 77, 91], ["meningitis", "OBSERVATION", 92, 102], ["NiV disease", "OBSERVATION", 128, 139]]], ["For the evaluation of m102.4 Figure 1 .", [["the evaluation", "TEST", 4, 18]]], ["NiV in ferret tissues.", [["ferret tissues", "ANATOMY", 7, 21], ["NiV", "ORGANISM", 0, 3], ["ferret tissues", "TISSUE", 7, 21], ["ferret", "SPECIES", 7, 13], ["NiV", "SPECIES", 0, 3], ["ferret", "SPECIES", 7, 13], ["NiV", "TREATMENT", 0, 3], ["ferret tissues", "OBSERVATION", 7, 21]]], ["Immunohistochemistry was done using a rabbit antiserum against Nipah virus nucleoprotein with haematoxylin counterstain as previously described [22] .", [["haematoxylin", "CHEMICAL", 94, 106], ["rabbit", "ORGANISM", 38, 44], ["antiserum", "ORGANISM_SUBSTANCE", 45, 54], ["Nipah virus nucleoprotein", "ORGANISM", 63, 88], ["Nipah virus nucleoprotein", "PROTEIN", 63, 88], ["rabbit", "SPECIES", 38, 44], ["Nipah virus", "SPECIES", 63, 74], ["rabbit", "SPECIES", 38, 44], ["Nipah virus", "SPECIES", 63, 74], ["Immunohistochemistry", "TEST", 0, 20], ["a rabbit antiserum", "TREATMENT", 36, 54], ["Nipah virus nucleoprotein", "TREATMENT", 63, 88]]], ["(A) ferret 7-50000, lung tissue with severe acute necrotizing alveolitis and vasculitis.", [["lung tissue", "ANATOMY", 20, 31], ["alveolitis", "DISEASE", 62, 72], ["vasculitis", "DISEASE", 77, 87], ["lung tissue", "TISSUE", 20, 31], ["lung tissue", "PROBLEM", 20, 31], ["severe acute necrotizing alveolitis", "PROBLEM", 37, 72], ["vasculitis", "PROBLEM", 77, 87], ["lung", "ANATOMY", 20, 24], ["tissue", "ANATOMY", 25, 31], ["severe", "OBSERVATION_MODIFIER", 37, 43], ["acute", "OBSERVATION_MODIFIER", 44, 49], ["necrotizing", "OBSERVATION_MODIFIER", 50, 61], ["alveolitis", "OBSERVATION", 62, 72], ["vasculitis", "OBSERVATION", 77, 87]]], ["Antigen present in syncytia (long arrow) and blood vessel wall (short arrow).", [["syncytia", "ANATOMY", 19, 27], ["blood vessel wall", "ANATOMY", 45, 62], ["syncytia", "CELL", 19, 27], ["blood vessel wall", "MULTI-TISSUE_STRUCTURE", 45, 62], ["syncytia", "PROBLEM", 19, 27], ["blood vessel wall (short arrow)", "PROBLEM", 45, 76], ["syncytia", "OBSERVATION", 19, 27], ["blood vessel", "ANATOMY", 45, 57], ["wall", "ANATOMY_MODIFIER", 58, 62]]], ["(B) ferret 4-500, antigen staining in arachnoid membrane of the meninges, with nonsuppurative inflammation.", [["arachnoid membrane", "ANATOMY", 38, 56], ["meninges", "ANATOMY", 64, 72], ["ferret 4-500", "CHEMICAL", 4, 16], ["inflammation", "DISEASE", 94, 106], ["antigen", "GENE_OR_GENE_PRODUCT", 18, 25], ["arachnoid membrane", "MULTI-TISSUE_STRUCTURE", 38, 56], ["meninges", "ORGAN", 64, 72], ["antigen staining", "TEST", 18, 34], ["nonsuppurative inflammation", "PROBLEM", 79, 106], ["arachnoid membrane", "ANATOMY", 38, 56], ["meninges", "ANATOMY", 64, 72], ["nonsuppurative", "OBSERVATION_MODIFIER", 79, 93], ["inflammation", "OBSERVATION", 94, 106]]], ["(C) ferret 7-50000, kidney with antigen staining in necrotic glomerular tuft and tubular epithelium; syncytia present in the epithelium of Bowman's capsule (arrow).", [["kidney", "ANATOMY", 20, 26], ["necrotic glomerular tuft", "ANATOMY", 52, 76], ["tubular epithelium", "ANATOMY", 81, 99], ["syncytia", "ANATOMY", 101, 109], ["epithelium", "ANATOMY", 125, 135], ["Bowman's capsule", "ANATOMY", 139, 155], ["ferret 7-50000", "ORGANISM", 4, 18], ["kidney", "ORGAN", 20, 26], ["necrotic glomerular tuft", "TISSUE", 52, 76], ["tubular epithelium", "TISSUE", 81, 99], ["epithelium", "TISSUE", 125, 135], ["Bowman's capsule", "TISSUE", 139, 155], ["ferret", "SPECIES", 4, 10], ["ferret", "TEST", 4, 10], ["antigen staining in necrotic glomerular tuft", "PROBLEM", 32, 76], ["tubular epithelium", "PROBLEM", 81, 99], ["syncytia", "PROBLEM", 101, 109], ["kidney", "ANATOMY", 20, 26], ["antigen staining", "OBSERVATION", 32, 48], ["necrotic", "OBSERVATION_MODIFIER", 52, 60], ["glomerular", "ANATOMY_MODIFIER", 61, 71], ["tuft", "ANATOMY_MODIFIER", 72, 76], ["tubular", "ANATOMY_MODIFIER", 81, 88], ["epithelium", "ANATOMY_MODIFIER", 89, 99], ["syncytia", "OBSERVATION", 101, 109], ["epithelium", "ANATOMY_MODIFIER", 125, 135], ["Bowman", "ANATOMY", 139, 145]]], ["(D) ferret 4-500, inflammation of the peri-tracheal tissues.", [["peri-tracheal tissues", "ANATOMY", 38, 59], ["peri-tracheal tissues", "TISSUE", 38, 59], ["inflammation of the peri-tracheal tissues", "PROBLEM", 18, 59], ["inflammation", "OBSERVATION", 18, 30], ["peri-tracheal tissues", "ANATOMY", 38, 59]]], ["Antigen present in blood vessel walls, syncytial cell (arrow).", [["blood vessel walls", "ANATOMY", 19, 37], ["syncytial cell", "ANATOMY", 39, 53], ["blood vessel walls", "MULTI-TISSUE_STRUCTURE", 19, 37], ["syncytial cell", "CELL", 39, 53], ["syncytial cell", "CELL_TYPE", 39, 53], ["Antigen", "TEST", 0, 7], ["syncytial cell", "PROBLEM", 39, 53], ["blood vessel", "ANATOMY", 19, 31], ["walls", "ANATOMY_MODIFIER", 32, 37], ["syncytial cell", "OBSERVATION", 39, 53]]], ["Scale bars = 50 mm. doi:10.1371/journal.ppat.1000642.g001 efficacy in the ferret model two time points were selected, 24 hrs before (pre-) or 10 hrs after (post-) NiV challenge.", [["ferret", "ORGANISM", 74, 80], ["NiV", "ORGANISM", 163, 166], ["ferret", "SPECIES", 74, 80], ["NiV", "SPECIES", 163, 166], ["NiV challenge", "TREATMENT", 163, 176], ["50 mm", "OBSERVATION_MODIFIER", 13, 18]]], ["Each treatment group contained three ferrets except for the control group (n = 2).", [["ferrets", "ORGANISM", 37, 44], ["Each treatment group", "TREATMENT", 0, 20]]], ["At the indicated time, 50 mg of m102.4 was administered via intravenous catheter.", [["intravenous", "ANATOMY", 60, 71], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 60, 71], ["intravenous catheter", "TREATMENT", 60, 80], ["catheter", "OBSERVATION", 72, 80]]], ["One ferret in the post-challenge group (28post) was given m102.4 intraperitoneally due to difficulty in venous catheterization.", [["venous", "ANATOMY", 104, 110], ["ferret", "ORGANISM", 4, 10], ["venous", "MULTI-TISSUE_STRUCTURE", 104, 110], ["venous catheterization", "TEST", 104, 126], ["venous", "ANATOMY", 104, 110], ["catheterization", "OBSERVATION", 111, 126]]], ["Control ferrets (22-con and 25-con) were given PBS.", [["ferrets", "ORGANISM", 8, 15], ["ferrets", "SPECIES", 8, 15]]], ["Ferrets were challenged oral-nasally with a 5,000 TCID 50 dose of NiV (ten-fold the MID 50 as determined by the doseranging study above).", [["Ferrets", "ANATOMY", 0, 7], ["oral", "ANATOMY", 24, 28], ["oral", "ORGANISM_SUBDIVISION", 24, 28], ["NiV", "ORGANISM", 66, 69], ["NiV", "SPECIES", 66, 69], ["NiV", "TREATMENT", 66, 69], ["the doseranging study", "TEST", 108, 129]]], ["By 6 dpi, ferrets 22-con, 25-con and 23-pre were febrile (.40uC) and control animals started to demonstrate signs of clinical illness similar to those seen in the initial MID 50 study.", [["febrile", "DISEASE", 49, 56], ["ferrets", "ORGANISM", 10, 17], ["ferrets", "SPECIES", 10, 17], ["ferrets", "TEST", 10, 17], ["febrile", "PROBLEM", 49, 56], ["clinical illness", "PROBLEM", 117, 133]]], ["By 8 dpi the controls were severely depressed, had subcutaneous edema of the head and cutaneous hemorrhages and they were euthanized.", [["subcutaneous edema", "ANATOMY", 51, 69], ["head", "ANATOMY", 77, 81], ["cutaneous", "ANATOMY", 86, 95], ["depressed", "DISEASE", 36, 45], ["edema", "DISEASE", 64, 69], ["hemorrhages", "DISEASE", 96, 107], ["edema", "PATHOLOGICAL_FORMATION", 64, 69], ["head", "ORGANISM_SUBDIVISION", 77, 81], ["cutaneous hemorrhages", "PATHOLOGICAL_FORMATION", 86, 107], ["severely depressed", "PROBLEM", 27, 45], ["subcutaneous edema of the head", "PROBLEM", 51, 81], ["cutaneous hemorrhages", "PROBLEM", 86, 107], ["severely", "OBSERVATION_MODIFIER", 27, 35], ["depressed", "OBSERVATION", 36, 45], ["subcutaneous", "ANATOMY", 51, 63], ["edema", "OBSERVATION", 64, 69], ["head", "ANATOMY", 77, 81], ["cutaneous", "ANATOMY", 86, 95], ["hemorrhages", "OBSERVATION", 96, 107]]], ["By 8 dpi, 24-pre and all ferrets in the post-group were also febrile with variable levels of depression and suppression of play activity; a notable sign of abnormal ferret behavior.", [["febrile", "DISEASE", 61, 68], ["depression", "DISEASE", 93, 103], ["abnormal ferret behavior", "DISEASE", 156, 180], ["ferrets", "ORGANISM", 25, 32], ["ferret", "ORGANISM", 165, 171], ["ferrets", "SPECIES", 25, 32], ["febrile", "PROBLEM", 61, 68], ["depression", "PROBLEM", 93, 103], ["suppression of play activity", "PROBLEM", 108, 136], ["abnormal ferret behavior", "PROBLEM", 156, 180], ["abnormal", "OBSERVATION_MODIFIER", 156, 164], ["ferret behavior", "OBSERVATION", 165, 180]]], ["At 10 dpi, the temperatures of 23-pre and 27-post had started to fall, and each demonstrated moderate (23-pre) or mild (27-post) edema of the throat.", [["throat", "ANATOMY", 142, 148], ["edema", "DISEASE", 129, 134], ["edema", "PATHOLOGICAL_FORMATION", 129, 134], ["throat", "ORGANISM_SUBDIVISION", 142, 148], ["the temperatures", "TEST", 11, 27], ["moderate (23-pre) or mild (27-post) edema of the throat", "PROBLEM", 93, 148], ["moderate", "OBSERVATION_MODIFIER", 93, 101], ["mild", "OBSERVATION_MODIFIER", 114, 118], ["edema", "OBSERVATION", 129, 134], ["throat", "ANATOMY", 142, 148]]], ["24-pre and 26-post remained febrile with no localizing signs.", [["febrile", "DISEASE", 28, 35], ["febrile", "PROBLEM", 28, 35], ["localizing signs", "PROBLEM", 44, 60]]], ["By 13 dpi, ferrets 23-pre and 24-pre were depressed and inappetant with cutaneous ecchymoses; ferret 23pre had marked hind limb paresis and generalized tremor and both animals were euthanized.", [["cutaneous ecchymoses", "ANATOMY", 72, 92], ["hind limb", "ANATOMY", 118, 127], ["depressed", "DISEASE", 42, 51], ["cutaneous ecchymoses", "DISEASE", 72, 92], ["paresis", "DISEASE", 128, 135], ["tremor", "DISEASE", 152, 158], ["hind limb", "ORGANISM_SUBDIVISION", 118, 127], ["ferrets", "SPECIES", 11, 18], ["ferret", "SPECIES", 94, 100], ["ferrets", "TEST", 11, 18], ["depressed", "PROBLEM", 42, 51], ["cutaneous ecchymoses", "PROBLEM", 72, 92], ["marked hind limb paresis", "PROBLEM", 111, 135], ["generalized tremor", "PROBLEM", 140, 158], ["cutaneous", "ANATOMY", 72, 81], ["ecchymoses", "OBSERVATION", 82, 92], ["marked", "OBSERVATION_MODIFIER", 111, 117], ["hind limb", "ANATOMY", 118, 127], ["paresis", "OBSERVATION", 128, 135], ["generalized", "OBSERVATION_MODIFIER", 140, 151], ["tremor", "OBSERVATION", 152, 158]]], ["All other ferrets (three in the postand one in the pre-group) were well and free of any disease signs and remained so until the end of the study ( Table 1) .", [["ferrets", "ORGANISM", 10, 17], ["ferrets", "SPECIES", 10, 17], ["any disease signs", "PROBLEM", 84, 101], ["the study", "TEST", 135, 144], ["disease", "OBSERVATION", 88, 95]]], ["Upon study completion (20 dpi) all surviving animals were euthanized.", [["animals", "ORGANISM", 45, 52]]], ["For the controls and two ferrets in the pre-challenge group that succumbed to infection, gross and microscopic pathology revealed findings similar to those described above in the MID 50 study.", [["infection", "DISEASE", 78, 87], ["ferrets", "ORGANISM", 25, 32], ["ferrets", "SPECIES", 25, 32], ["infection", "PROBLEM", 78, 87], ["microscopic pathology", "TEST", 99, 120], ["infection", "OBSERVATION", 78, 87]]], ["However, in ferrets 23-pre and 24-pre the frequency of pinpoint hemorrhagic lesions observed in the pulmonary parenchyma was reduced and lesions were much smaller suggesting the disease progression in the respiratory tract had been dampened (Figure 3) , consistent with their survival to 13 dpi.", [["hemorrhagic lesions", "ANATOMY", 64, 83], ["pulmonary parenchyma", "ANATOMY", 100, 120], ["lesions", "ANATOMY", 137, 144], ["respiratory tract", "ANATOMY", 205, 222], ["hemorrhagic", "DISEASE", 64, 75], ["ferrets", "ORGANISM", 12, 19], ["hemorrhagic lesions", "PATHOLOGICAL_FORMATION", 64, 83], ["pulmonary parenchyma", "MULTI-TISSUE_STRUCTURE", 100, 120], ["lesions", "PATHOLOGICAL_FORMATION", 137, 144], ["respiratory tract", "ORGANISM_SUBDIVISION", 205, 222], ["ferrets", "SPECIES", 12, 19], ["ferrets", "TEST", 12, 19], ["pinpoint hemorrhagic lesions", "PROBLEM", 55, 83], ["lesions", "PROBLEM", 137, 144], ["the disease progression in the respiratory tract", "PROBLEM", 174, 222], ["pinpoint", "OBSERVATION_MODIFIER", 55, 63], ["hemorrhagic", "OBSERVATION_MODIFIER", 64, 75], ["lesions", "OBSERVATION", 76, 83], ["pulmonary", "ANATOMY", 100, 109], ["parenchyma", "ANATOMY_MODIFIER", 110, 120], ["reduced", "OBSERVATION_MODIFIER", 125, 132], ["lesions", "OBSERVATION", 137, 144], ["smaller", "OBSERVATION_MODIFIER", 155, 162], ["disease", "OBSERVATION", 178, 185], ["progression", "OBSERVATION_MODIFIER", 186, 197], ["respiratory tract", "ANATOMY", 205, 222], ["dampened", "OBSERVATION_MODIFIER", 232, 240], ["consistent with", "UNCERTAINTY", 254, 269]]], ["Histopathological findings in controls and in the two diseased pre-challenge group ferrets were similar to those described in the MID 50 study.", [["ferrets", "ORGANISM", 83, 90], ["ferrets", "SPECIES", 83, 90], ["Histopathological findings", "TEST", 0, 26], ["diseased", "OBSERVATION", 54, 62]]], ["However, for ferret 23-pre, NiV antigen was present in ependymal tissue ( Figure 4A ) and for ferret 24-pre NiV antigen was present within neurons and neuropil of the cerebellum ( Figure 4B) , further supporting the suggestion that ferrets could be an appropriate model for NiV-mediated meningoencephalitic disease.", [["ependymal tissue", "ANATOMY", 55, 71], ["neurons", "ANATOMY", 139, 146], ["neuropil", "ANATOMY", 151, 159], ["cerebellum", "ANATOMY", 167, 177], ["meningoencephalitic", "ANATOMY", 287, 306], ["meningoencephalitic disease", "DISEASE", 287, 314], ["ferret 23", "ORGANISM", 13, 22], ["NiV antigen", "GENE_OR_GENE_PRODUCT", 28, 39], ["ependymal tissue", "TISSUE", 55, 71], ["NiV antigen", "GENE_OR_GENE_PRODUCT", 108, 119], ["neurons", "CELL", 139, 146], ["neuropil", "IMMATERIAL_ANATOMICAL_ENTITY", 151, 159], ["cerebellum", "ORGAN", 167, 177], ["ferrets", "ORGANISM", 232, 239], ["NiV", "ORGANISM", 274, 277], ["NiV antigen", "PROTEIN", 28, 39], ["ferret 24-pre NiV antigen", "PROTEIN", 94, 119], ["NiV", "SPECIES", 28, 31], ["NiV", "SPECIES", 274, 277], ["ferret", "TEST", 13, 19], ["NiV antigen", "TEST", 28, 39], ["ferret", "TEST", 94, 100], ["NiV antigen", "TEST", 108, 119], ["NiV-mediated meningoencephalitic disease", "PROBLEM", 274, 314], ["ependymal tissue", "ANATOMY", 55, 71], ["neuropil", "ANATOMY_MODIFIER", 151, 159], ["cerebellum", "ANATOMY", 167, 177], ["meningoencephalitic disease", "OBSERVATION", 287, 314]]], ["No significant pathological abnormalities were found in any of the surviving ferrets.Nipah viral loads and tissue tropism in m102.4 treated ferretsBlood, swabs and tissues were tested for the presence of NiV RNA and results are shown in Figure 5 .", [["tissue", "ANATOMY", 107, 113], ["Blood", "ANATOMY", 147, 152], ["swabs", "ANATOMY", 154, 159], ["tissues", "ANATOMY", 164, 171], ["ferrets", "ORGANISM", 77, 84], ["Nipah", "ORGANISM", 85, 90], ["tissue", "TISSUE", 107, 113], ["ferrets", "ORGANISM", 140, 147], ["Blood", "ORGANISM_SUBSTANCE", 147, 152], ["swabs", "TISSUE", 154, 159], ["tissues", "TISSUE", 164, 171], ["NiV", "ORGANISM", 204, 207], ["NiV RNA", "RNA", 204, 211], ["ferrets", "SPECIES", 77, 84], ["Nipah", "SPECIES", 85, 90], ["ferrets", "SPECIES", 140, 147], ["NiV", "SPECIES", 204, 207], ["significant pathological abnormalities", "PROBLEM", 3, 41], ["Nipah viral loads", "TREATMENT", 85, 102], ["tissue tropism", "TEST", 107, 121], ["Blood, swabs and tissues", "TEST", 147, 171], ["NiV RNA", "TEST", 204, 211], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["pathological", "OBSERVATION_MODIFIER", 15, 27], ["abnormalities", "OBSERVATION", 28, 41], ["viral loads", "OBSERVATION", 91, 102]]], ["Ferret 21-pre, the only animal to survive in the pre-challenge group, had detectable levels of viral RNA in the blood 3 dpi ( Figure 5A ) whereas all other samples were negative.", [["blood", "ANATOMY", 112, 117], ["samples", "ANATOMY", 156, 163], ["blood", "ORGANISM_SUBSTANCE", 112, 117], ["samples", "CANCER", 156, 163], ["viral RNA", "RNA", 95, 104], ["Ferret", "TEST", 0, 6], ["viral RNA", "PROBLEM", 95, 104], ["all other samples", "TEST", 146, 163], ["viral RNA", "OBSERVATION", 95, 104], ["negative", "OBSERVATION", 169, 177]]], ["All other ferrets had significant viremia by 8 dpi with the highest levels of NiV RNA in the controls.", [["viremia", "DISEASE", 34, 41], ["ferrets", "ORGANISM", 10, 17], ["NiV", "ORGANISM", 78, 81], ["NiV RNA", "RNA", 78, 85], ["ferrets", "SPECIES", 10, 17], ["NiV", "SPECIES", 78, 81], ["significant viremia", "PROBLEM", 22, 41], ["NiV RNA", "TREATMENT", 78, 85], ["significant", "OBSERVATION_MODIFIER", 22, 33], ["viremia", "OBSERVATION", 34, 41], ["NiV RNA", "OBSERVATION", 78, 85]]], ["By 13 dpi, viral RNA levels in ferrets 23-pre and 24-pre were similar to those found in controls whereas NiV RNA levels had decreased in ferret 26-post and were undetectable in the other post-challenge group ferrets.", [["ferrets 23-pre", "ORGANISM", 31, 45], ["NiV", "ORGANISM", 105, 108], ["ferrets", "ORGANISM", 208, 215], ["viral RNA", "RNA", 11, 20], ["NiV RNA", "RNA", 105, 112], ["ferrets", "SPECIES", 31, 38], ["ferrets", "SPECIES", 208, 215], ["NiV", "SPECIES", 105, 108], ["ferret", "SPECIES", 137, 143], ["viral RNA levels", "TEST", 11, 27], ["ferrets", "TEST", 31, 38], ["NiV RNA levels", "TEST", 105, 119], ["decreased", "OBSERVATION_MODIFIER", 124, 133]]], ["Viral RNA levels in oral swabs were highest among the controls and pre-challenge group; however, post-challenge group ferrets shed virus over the course of infection ( Figure 5A) .Nipah viral loads and tissue tropism in m102.4 treated ferretsNiV RNA levels in rectal swabs were low except in 23-pre and 24pre ( Figure 5A ).", [["oral swabs", "ANATOMY", 20, 30], ["tissue", "ANATOMY", 202, 208], ["rectal swabs", "ANATOMY", 260, 272], ["infection", "DISEASE", 156, 165], ["Viral", "ORGANISM", 0, 5], ["oral swabs", "ORGAN", 20, 30], ["ferrets", "ORGANISM", 118, 125], ["Nipah", "ORGANISM", 180, 185], ["tissue", "TISSUE", 202, 208], ["ferrets", "ORGANISM", 235, 242], ["NiV", "ORGANISM", 242, 245], ["rectal swabs", "MULTI-TISSUE_STRUCTURE", 260, 272], ["ferrets", "SPECIES", 118, 125], ["Nipah", "SPECIES", 180, 185], ["ferrets", "SPECIES", 235, 242], ["ferrets shed virus", "SPECIES", 118, 136], ["NiV", "SPECIES", 242, 245], ["Viral RNA levels", "TEST", 0, 16], ["oral swabs", "TEST", 20, 30], ["infection", "PROBLEM", 156, 165], ["Nipah viral loads", "TREATMENT", 180, 197], ["tissue tropism", "TEST", 202, 216], ["NiV RNA levels", "TEST", 242, 256], ["rectal swabs", "TEST", 260, 272], ["RNA", "OBSERVATION", 6, 9], ["infection", "OBSERVATION", 156, 165], ["viral loads", "OBSERVATION", 186, 197], ["rectal swabs", "ANATOMY", 260, 272]]], ["Together these data demonstrated that all treated ferrets (except 21-pre) had significant amounts of systemic and mucosal NiV for at least 10 dpi.", [["mucosal", "ANATOMY", 114, 121], ["ferrets", "ORGANISM", 50, 57], ["mucosal NiV", "ORGANISM", 114, 125], ["ferrets", "SPECIES", 50, 57], ["NiV", "SPECIES", 122, 125], ["these data", "TEST", 9, 19], ["all treated ferrets", "PROBLEM", 38, 57], ["systemic and mucosal NiV", "TREATMENT", 101, 125], ["mucosal NiV", "ANATOMY", 114, 125]]], ["Controls and the two diseased pre-group ferrets had similar high levels of viral RNA in all tissues ( Figure 5B) .", [["tissues", "ANATOMY", 92, 99], ["ferrets", "ORGANISM", 40, 47], ["tissues", "TISSUE", 92, 99], ["viral RNA", "RNA", 75, 84], ["ferrets", "SPECIES", 40, 47], ["the two diseased pre-group ferrets", "PROBLEM", 13, 47], ["viral RNA in all tissues", "PROBLEM", 75, 99], ["two", "OBSERVATION_MODIFIER", 17, 20], ["diseased", "OBSERVATION", 21, 29], ["viral RNA", "OBSERVATION", 75, 84], ["all tissues", "ANATOMY", 88, 99]]], ["Conversely, 21-pre and all post-challenge group ferrets had significantly reduced levels of viral RNA ( Figure 5B ).", [["ferrets", "ORGANISM", 48, 55], ["viral RNA", "RNA", 92, 101], ["ferrets", "SPECIES", 48, 55], ["ferrets", "SPECIES", 48, 55], ["significantly reduced levels of viral RNA", "PROBLEM", 60, 101], ["viral RNA", "OBSERVATION", 92, 101]]], ["Virus isolation was attempted on all samples with detectable NiV RNA ( Figure 5 ).", [["samples", "ANATOMY", 37, 44], ["Virus", "ORGANISM", 0, 5], ["NiV", "ORGANISM", 61, 64], ["NiV RNA", "RNA", 61, 68], ["NiV", "SPECIES", 61, 64], ["Virus isolation", "TREATMENT", 0, 15], ["NiV RNA", "OBSERVATION", 61, 68]]], ["On day 8 post-infection, NiV was isolated from the blood of one control animal (22-con), from a pharyngeal swab from the other control animal (25-con) and from a rectal swab from ferret 23-pre.", [["blood", "ANATOMY", 51, 56], ["pharyngeal swab", "ANATOMY", 96, 111], ["rectal swab", "ANATOMY", 162, 173], ["NiV", "ORGANISM", 25, 28], ["blood", "ORGANISM_SUBSTANCE", 51, 56], ["pharyngeal swab", "MULTI-TISSUE_STRUCTURE", 96, 111], ["rectal swab", "MULTI-TISSUE_STRUCTURE", 162, 173], ["ferret", "ORGANISM", 179, 185], ["ferret", "SPECIES", 179, 185], ["NiV", "SPECIES", 25, 28], ["infection", "PROBLEM", 14, 23], ["NiV", "TREATMENT", 25, 28], ["a pharyngeal swab", "TEST", 94, 111], ["a rectal swab", "TEST", 160, 173], ["infection", "OBSERVATION", 14, 23], ["pharyngeal", "ANATOMY", 96, 106], ["rectal", "ANATOMY", 162, 168]]], ["All other blood and swab samples were negative for virus isolation despite the high levels of viral RNA detected.", [["blood", "ANATOMY", 10, 15], ["swab samples", "ANATOMY", 20, 32], ["blood", "ORGANISM_SUBSTANCE", 10, 15], ["swab samples", "ORGANISM_SUBSTANCE", 20, 32], ["viral RNA", "RNA", 94, 103], ["All other blood and swab samples", "TEST", 0, 32], ["virus isolation", "PROBLEM", 51, 66], ["viral RNA", "PROBLEM", 94, 103], ["blood", "ANATOMY", 10, 15], ["viral RNA", "OBSERVATION", 94, 103]]], ["Virus was isolated from the majority of control animal tissues and the two diseased pre-group ferret tissues; whereas, for 21-pre and all post-group ferrets, tissues were negative for NiV.", [["tissues", "ANATOMY", 55, 62], ["tissues", "ANATOMY", 101, 108], ["tissues", "ANATOMY", 158, 165], ["Virus", "ORGANISM", 0, 5], ["tissues", "TISSUE", 55, 62], ["ferret tissues", "TISSUE", 94, 108], ["ferrets", "ORGANISM", 149, 156], ["tissues", "TISSUE", 158, 165], ["NiV", "ORGANISM", 184, 187], ["ferret", "SPECIES", 94, 100], ["ferrets", "SPECIES", 149, 156], ["ferret", "SPECIES", 94, 100], ["ferrets", "SPECIES", 149, 156], ["NiV", "SPECIES", 184, 187], ["Virus", "PROBLEM", 0, 5], ["the two diseased pre-group ferret tissues", "PROBLEM", 67, 108], ["NiV", "TREATMENT", 184, 187], ["two", "OBSERVATION_MODIFIER", 71, 74], ["diseased", "OBSERVATION_MODIFIER", 75, 83], ["pre-group ferret tissues", "OBSERVATION", 84, 108]]], ["Together, these data demonstrate that treatment with m102.4 reduced viral replication and spread, and provided a significant therapeutic benefit leading to the survival of all infected animals in the post-challenge group.In vivo m102.4 concentrationTo evaluate whether a correlation between m102.4 concentration and protection existed, levels of m102.4 in serum were measured ( Figure 6) .", [["serum", "ANATOMY", 356, 361], ["serum", "ORGANISM_SUBSTANCE", 356, 361], ["treatment", "TREATMENT", 38, 47], ["m", "TREATMENT", 53, 54], ["viral replication", "TREATMENT", 68, 85], ["all infected animals", "PROBLEM", 172, 192], ["protection", "TREATMENT", 316, 326], ["levels of m", "TEST", 336, 347], ["serum", "TEST", 356, 361], ["infected", "OBSERVATION", 176, 184]]], ["Coincidently, ferret 21-pre had the highest levels of serum m102.4 pre-challenge along with the longest-lasting serum levels ( Figure 6A) and was the only animal from this group were low on 10 dpi with higher amounts of antibody present in the post-challenge group.", [["serum", "ANATOMY", 54, 59], ["serum", "ANATOMY", 112, 117], ["ferret 21", "ORGANISM", 14, 23], ["serum", "ORGANISM_SUBSTANCE", 54, 59], ["serum", "ORGANISM_SUBSTANCE", 112, 117], ["serum m", "TEST", 54, 61], ["serum levels", "TEST", 112, 124], ["higher amounts of antibody", "PROBLEM", 202, 228]]], ["By 13 dpi, NiV-G specific antibody responses had increased further in all ferrets with the highest levels found in the 27-post and 28-post ferrets.Monoclonal antibody resistance and virus strain specificityIn the present study, we have described m102.4, a potent neutralizing human monoclonal antibody.", [["NiV-G", "GENE_OR_GENE_PRODUCT", 11, 16], ["ferrets", "ORGANISM", 74, 81], ["ferrets", "ORGANISM", 139, 146], ["human", "ORGANISM", 276, 281], ["Monoclonal antibody", "PROTEIN", 147, 166], ["neutralizing human monoclonal antibody", "PROTEIN", 263, 301], ["ferrets", "SPECIES", 74, 81], ["ferrets", "SPECIES", 139, 146], ["human", "SPECIES", 276, 281], ["ferrets", "SPECIES", 74, 81], ["human", "SPECIES", 276, 281], ["NiV", "TEST", 11, 14], ["G specific antibody responses", "TEST", 15, 44], ["the highest levels", "TEST", 87, 105], ["Monoclonal antibody resistance", "TEST", 147, 177], ["virus strain specificity", "TEST", 182, 206], ["a potent neutralizing human monoclonal antibody", "PROBLEM", 254, 301], ["increased", "OBSERVATION_MODIFIER", 49, 58], ["antibody resistance", "OBSERVATION", 158, 177]]], ["Its mechanism of action involves binding a single epitope within the receptor binding domain of the henipavirus G glycoprotein and affectively blocking receptor engagement and virus infection.", [["infection", "DISEASE", 182, 191], ["henipavirus G glycoprotein", "GENE_OR_GENE_PRODUCT", 100, 126], ["receptor binding domain", "PROTEIN", 69, 92], ["henipavirus G glycoprotein", "PROTEIN", 100, 126], ["a single epitope", "PROBLEM", 41, 57], ["the henipavirus G glycoprotein", "TREATMENT", 96, 126], ["affectively blocking receptor engagement", "TREATMENT", 131, 171], ["virus infection", "PROBLEM", 176, 191]]], ["HeV and NiV cause acute and often fatal disease in animals and humans and although virus neutralization escape mutants are unlikely in 7-10 days; we evaluated whether resistant virus was present in ferrets 23-pre and 24-pre.", [["HeV", "ORGANISM", 0, 3], ["NiV", "ORGANISM", 8, 11], ["humans", "ORGANISM", 63, 69], ["ferrets", "ORGANISM", 198, 205], ["humans", "SPECIES", 63, 69], ["ferrets", "SPECIES", 198, 205], ["HeV", "SPECIES", 0, 3], ["humans", "SPECIES", 63, 69], ["HeV", "PROBLEM", 0, 3], ["acute and often fatal disease in animals", "PROBLEM", 18, 58], ["virus neutralization escape mutants", "PROBLEM", 83, 118], ["resistant virus", "PROBLEM", 167, 182], ["ferrets", "TEST", 198, 205], ["acute", "OBSERVATION_MODIFIER", 18, 23], ["often", "OBSERVATION_MODIFIER", 28, 33], ["fatal", "OBSERVATION_MODIFIER", 34, 39], ["disease", "OBSERVATION", 40, 47]]], ["Virus isolation was repeated on all tissues homogenates in the presence and absence of m102.4.", [["tissues homogenates", "ANATOMY", 36, 55], ["Virus", "ORGANISM", 0, 5], ["tissues homogenates", "TISSUE", 36, 55], ["Virus isolation", "TREATMENT", 0, 15]]], ["Virus was isolated from all samples in the absence of m102.4 as before; however, no virus was isolated from tissues when m102.4 was present (data not shown).", [["samples", "ANATOMY", 28, 35], ["tissues", "ANATOMY", 108, 115], ["Virus", "ORGANISM", 0, 5], ["tissues", "TISSUE", 108, 115], ["Virus", "PROBLEM", 0, 5], ["virus", "PROBLEM", 84, 89], ["no", "UNCERTAINTY", 81, 83], ["virus", "OBSERVATION", 84, 89]]], ["Together, these data demonstrate that the virus circulating in ferrets 23-pre and 24-pre at the time of euthanasia was still highly sensitive to m102.4 and no evidence of escape mutants was found.", [["ferrets 23-pre", "ORGANISM", 63, 77], ["ferrets", "SPECIES", 63, 70], ["these data", "TEST", 10, 20], ["the virus circulating in ferrets", "TEST", 38, 70], ["euthanasia", "TEST", 104, 114], ["escape mutants", "PROBLEM", 171, 185], ["euthanasia", "OBSERVATION", 104, 114], ["no evidence of", "UNCERTAINTY", 156, 170], ["escape mutants", "OBSERVATION", 171, 185]]], ["In addition, we also examined m102.4 neutralizing activity against different isolates of NiV and HeV, including, NiV-Malaysia, NiV-Bangladesh, HeV-1994 and HeV-Redlands.", [["NiV", "ORGANISM", 89, 92], ["HeV", "ORGANISM", 97, 100], ["NiV-Malaysia", "ORGANISM", 113, 125], ["NiV", "ORGANISM", 127, 130], ["HeV-1994", "ORGANISM", 143, 151], ["HeV-Redlands", "ORGANISM", 156, 168], ["NiV", "SPECIES", 89, 92], ["HeV", "SPECIES", 97, 100], ["NiV", "TREATMENT", 89, 92], ["NiV", "TREATMENT", 113, 116], ["NiV", "TREATMENT", 127, 130]]], ["Importantly, m102.4 neutralized all viruses potently: HeV-Redlands was completely neutralized at 1.25 mg/ml m102.4 and all other isolates were even more sensitive with complete neutralization occurring at 0.63 mg/ ml m102.4.", [["HeV-Redlands", "ORGANISM", 54, 66], ["HeV-Redlands", "TREATMENT", 54, 66], ["all other isolates", "TEST", 119, 137]]], ["These data support the potential broad applicability of m102.4 as a post-exposure therapeutic option for henipavirusinfected individuals.DiscussionA new ferret model of NiV infection and pathogenesis has been developed in the present study.", [["NiV infection", "DISEASE", 169, 182], ["ferret", "ORGANISM", 153, 159], ["NiV", "ORGANISM", 169, 172], ["NiV", "SPECIES", 169, 172], ["a post-exposure therapeutic option", "TREATMENT", 66, 100], ["henipavirusinfected individuals", "PROBLEM", 105, 136], ["NiV infection", "PROBLEM", 169, 182], ["pathogenesis", "PROBLEM", 187, 199], ["the present study", "TEST", 222, 239], ["NiV", "OBSERVATION_MODIFIER", 169, 172], ["infection", "OBSERVATION", 173, 182]]], ["Unlike the cat and hamster models, the ferret model is unique and exhibits both severe respiratory and neurological disease, and generalized vasculitis.", [["respiratory", "ANATOMY", 87, 98], ["neurological", "ANATOMY", 103, 115], ["respiratory and neurological disease", "DISEASE", 87, 123], ["vasculitis", "DISEASE", 141, 151], ["cat", "ORGANISM", 11, 14], ["hamster", "ORGANISM", 19, 26], ["ferret", "ORGANISM", 39, 45], ["hamster", "SPECIES", 19, 26], ["hamster", "SPECIES", 19, 26], ["both severe respiratory and neurological disease", "PROBLEM", 75, 123], ["generalized vasculitis", "PROBLEM", 129, 151], ["both", "OBSERVATION_MODIFIER", 75, 79], ["severe", "OBSERVATION_MODIFIER", 80, 86], ["respiratory", "ANATOMY", 87, 98], ["neurological disease", "OBSERVATION", 103, 123], ["generalized", "OBSERVATION_MODIFIER", 129, 140], ["vasculitis", "OBSERVATION", 141, 151]]], ["NiV-mediated disease in humans has been described as a systemic endothelial infection accompanied by vasculitis, thrombosis, ischaemia and necrosis [18] .", [["endothelial", "ANATOMY", 64, 75], ["endothelial infection", "DISEASE", 64, 85], ["vasculitis", "DISEASE", 101, 111], ["thrombosis", "DISEASE", 113, 123], ["ischaemia", "DISEASE", 125, 134], ["necrosis", "DISEASE", 139, 147], ["NiV", "GENE_OR_GENE_PRODUCT", 0, 3], ["humans", "ORGANISM", 24, 30], ["endothelial", "CELL", 64, 75], ["humans", "SPECIES", 24, 30], ["humans", "SPECIES", 24, 30], ["NiV", "TREATMENT", 0, 3], ["mediated disease in humans", "PROBLEM", 4, 30], ["a systemic endothelial infection", "PROBLEM", 53, 85], ["vasculitis", "PROBLEM", 101, 111], ["thrombosis", "PROBLEM", 113, 123], ["ischaemia", "PROBLEM", 125, 134], ["necrosis", "PROBLEM", 139, 147], ["disease", "OBSERVATION", 13, 20], ["systemic", "OBSERVATION_MODIFIER", 55, 63], ["endothelial", "ANATOMY", 64, 75], ["infection", "OBSERVATION", 76, 85], ["vasculitis", "OBSERVATION", 101, 111], ["thrombosis", "OBSERVATION", 113, 123], ["ischaemia", "OBSERVATION_MODIFIER", 125, 134], ["necrosis", "OBSERVATION", 139, 147]]], ["Histopathological changes in infected individuals were especially noted in the central nervous system (CNS) with widespread presence of viral antigen in neurons and other parenchymal cells in necrotic foci in the CNS and also in endothelial cells of affected blood vessels.", [["central nervous system", "ANATOMY", 79, 101], ["CNS", "ANATOMY", 103, 106], ["neurons", "ANATOMY", 153, 160], ["parenchymal cells", "ANATOMY", 171, 188], ["necrotic foci", "ANATOMY", 192, 205], ["CNS", "ANATOMY", 213, 216], ["endothelial cells", "ANATOMY", 229, 246], ["blood vessels", "ANATOMY", 259, 272], ["necrotic", "DISEASE", 192, 200], ["central nervous system", "ANATOMICAL_SYSTEM", 79, 101], ["CNS", "ANATOMICAL_SYSTEM", 103, 106], ["neurons", "CELL", 153, 160], ["parenchymal cells", "CELL", 171, 188], ["necrotic foci", "CELL", 192, 205], ["CNS", "ANATOMICAL_SYSTEM", 213, 216], ["endothelial cells", "CELL", 229, 246], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 259, 272], ["viral antigen", "PROTEIN", 136, 149], ["neurons", "CELL_TYPE", 153, 160], ["parenchymal cells", "CELL_TYPE", 171, 188], ["endothelial cells", "CELL_TYPE", 229, 246], ["Histopathological changes in infected individuals", "PROBLEM", 0, 49], ["viral antigen in neurons", "PROBLEM", 136, 160], ["other parenchymal cells", "PROBLEM", 165, 188], ["necrotic foci in the CNS", "PROBLEM", 192, 216], ["affected blood vessels", "PROBLEM", 250, 272], ["infected", "OBSERVATION", 29, 37], ["central", "ANATOMY_MODIFIER", 79, 86], ["nervous system", "ANATOMY", 87, 101], ["CNS", "ANATOMY", 103, 106], ["viral", "OBSERVATION", 136, 141], ["parenchymal cells", "OBSERVATION", 171, 188], ["necrotic", "OBSERVATION_MODIFIER", 192, 200], ["foci", "OBSERVATION", 201, 205], ["CNS", "ANATOMY", 213, 216], ["endothelial cells", "OBSERVATION", 229, 246], ["affected", "ANATOMY_MODIFIER", 250, 258], ["blood vessels", "ANATOMY", 259, 272]]], ["Both vasculitis and endothelial infection was also seen in most organs examined.", [["endothelial", "ANATOMY", 20, 31], ["organs", "ANATOMY", 64, 70], ["vasculitis", "DISEASE", 5, 15], ["endothelial infection", "DISEASE", 20, 41], ["endothelial", "CELL", 20, 31], ["organs", "ORGAN", 64, 70], ["Both vasculitis", "PROBLEM", 0, 15], ["endothelial infection", "PROBLEM", 20, 41], ["vasculitis", "OBSERVATION", 5, 15], ["endothelial", "ANATOMY", 20, 31], ["infection", "OBSERVATION", 32, 41]]], ["In ferrets, clinical disease included vascular fibrinoid necrosis in multiple organs, necrotizing alveolitis, syncytia of endothelium and alveolar epithelium, and necrotizing lymphadenitis.", [["vascular fibrinoid", "ANATOMY", 38, 56], ["organs", "ANATOMY", 78, 84], ["syncytia", "ANATOMY", 110, 118], ["endothelium", "ANATOMY", 122, 133], ["alveolar epithelium", "ANATOMY", 138, 157], ["vascular fibrinoid necrosis", "DISEASE", 38, 65], ["alveolitis", "DISEASE", 98, 108], ["lymphadenitis", "DISEASE", 175, 188], ["ferrets", "ORGANISM", 3, 10], ["vascular fibrinoid", "PATHOLOGICAL_FORMATION", 38, 56], ["organs", "ORGAN", 78, 84], ["endothelium", "TISSUE", 122, 133], ["alveolar epithelium", "TISSUE", 138, 157], ["ferrets", "SPECIES", 3, 10], ["clinical disease", "PROBLEM", 12, 28], ["vascular fibrinoid necrosis", "PROBLEM", 38, 65], ["multiple organs", "PROBLEM", 69, 84], ["necrotizing alveolitis", "PROBLEM", 86, 108], ["syncytia of endothelium", "PROBLEM", 110, 133], ["alveolar epithelium", "PROBLEM", 138, 157], ["necrotizing lymphadenitis", "PROBLEM", 163, 188], ["vascular", "ANATOMY", 38, 46], ["fibrinoid", "OBSERVATION_MODIFIER", 47, 56], ["necrosis", "OBSERVATION", 57, 65], ["multiple", "OBSERVATION_MODIFIER", 69, 77], ["organs", "ANATOMY", 78, 84], ["necrotizing", "OBSERVATION_MODIFIER", 86, 97], ["alveolitis", "OBSERVATION", 98, 108], ["syncytia", "OBSERVATION", 110, 118], ["endothelium", "ANATOMY", 122, 133], ["alveolar", "ANATOMY_MODIFIER", 138, 146], ["epithelium", "ANATOMY_MODIFIER", 147, 157], ["necrotizing", "OBSERVATION_MODIFIER", 163, 174], ["lymphadenitis", "OBSERVATION", 175, 188]]], ["Histopathological lesions included severe focal necrotizing alveolitis, vasculitis, degeneration of glomerular tufts, and focal necrosis in a widerange of other tissues.", [["lesions", "ANATOMY", 18, 25], ["glomerular tufts", "ANATOMY", 100, 116], ["tissues", "ANATOMY", 161, 168], ["alveolitis", "DISEASE", 60, 70], ["vasculitis", "DISEASE", 72, 82], ["degeneration of glomerular tufts", "DISEASE", 84, 116], ["necrosis", "DISEASE", 128, 136], ["glomerular tufts", "TISSUE", 100, 116], ["tissues", "TISSUE", 161, 168], ["Histopathological lesions", "PROBLEM", 0, 25], ["severe focal necrotizing alveolitis", "PROBLEM", 35, 70], ["vasculitis", "PROBLEM", 72, 82], ["degeneration of glomerular tufts", "PROBLEM", 84, 116], ["focal necrosis", "PROBLEM", 122, 136], ["lesions", "OBSERVATION", 18, 25], ["severe", "OBSERVATION_MODIFIER", 35, 41], ["focal", "OBSERVATION_MODIFIER", 42, 47], ["necrotizing", "OBSERVATION_MODIFIER", 48, 59], ["alveolitis", "OBSERVATION", 60, 70], ["vasculitis", "OBSERVATION", 72, 82], ["degeneration", "OBSERVATION", 84, 96], ["glomerular", "ANATOMY", 100, 110], ["tufts", "OBSERVATION", 111, 116], ["focal", "OBSERVATION_MODIFIER", 122, 127], ["necrosis", "OBSERVATION", 128, 136]]], ["Significant quantities of viral antigen in blood vessel walls and syncytial cells were frequently present.", [["blood vessel walls", "ANATOMY", 43, 61], ["syncytial cells", "ANATOMY", 66, 81], ["viral antigen", "GENE_OR_GENE_PRODUCT", 26, 39], ["blood vessel walls", "MULTI-TISSUE_STRUCTURE", 43, 61], ["syncytial cells", "CELL", 66, 81], ["viral antigen", "PROTEIN", 26, 39], ["syncytial cells", "CELL_TYPE", 66, 81], ["viral antigen", "PROBLEM", 26, 39], ["syncytial cells", "PROBLEM", 66, 81], ["viral antigen", "OBSERVATION", 26, 39], ["blood vessel", "ANATOMY", 43, 55], ["walls", "ANATOMY_MODIFIER", 56, 61], ["syncytial cells", "OBSERVATION", 66, 81]]], ["Viral antigen was present in neurons and infectious NiV was isolated from multiple organs including the brain.", [["neurons", "ANATOMY", 29, 36], ["organs", "ANATOMY", 83, 89], ["brain", "ANATOMY", 104, 109], ["Viral", "ORGANISM", 0, 5], ["neurons", "CELL", 29, 36], ["NiV", "ORGANISM", 52, 55], ["organs", "ORGAN", 83, 89], ["brain", "ORGAN", 104, 109], ["Viral antigen", "PROTEIN", 0, 13], ["neurons", "CELL_TYPE", 29, 36], ["NiV", "SPECIES", 52, 55], ["Viral antigen", "TEST", 0, 13], ["infectious NiV", "TREATMENT", 41, 55], ["infectious", "OBSERVATION_MODIFIER", 41, 51], ["brain", "ANATOMY", 104, 109]]], ["Several animals also demonstrated significant neurological disease.", [["neurological", "ANATOMY", 46, 58], ["neurological disease", "DISEASE", 46, 66], ["significant neurological disease", "PROBLEM", 34, 66], ["significant", "OBSERVATION_MODIFIER", 34, 45], ["neurological disease", "OBSERVATION", 46, 66]]], ["A widespread presence of NiV antigens in neurons and other parenchymal cells in the CNS was not as extensive as in NiV-infected ferrets as compared to infected humans, and this could relate to the length of disease course between these experimental versus natural infections.", [["neurons", "ANATOMY", 41, 48], ["parenchymal cells", "ANATOMY", 59, 76], ["CNS", "ANATOMY", 84, 87], ["infections", "DISEASE", 264, 274], ["NiV antigens", "GENE_OR_GENE_PRODUCT", 25, 37], ["neurons", "CELL", 41, 48], ["parenchymal cells", "CELL", 59, 76], ["CNS", "ANATOMICAL_SYSTEM", 84, 87], ["NiV", "ORGANISM", 115, 118], ["ferrets", "ORGANISM", 128, 135], ["humans", "ORGANISM", 160, 166], ["NiV antigens", "PROTEIN", 25, 37], ["neurons", "CELL_TYPE", 41, 48], ["parenchymal cells", "CELL_TYPE", 59, 76], ["ferrets", "SPECIES", 128, 135], ["humans", "SPECIES", 160, 166], ["NiV", "SPECIES", 115, 118], ["ferrets", "SPECIES", 128, 135], ["humans", "SPECIES", 160, 166], ["NiV antigens in neurons", "PROBLEM", 25, 48], ["other parenchymal cells", "PROBLEM", 53, 76], ["infected ferrets", "PROBLEM", 119, 135], ["natural infections", "PROBLEM", 256, 274], ["NiV antigens", "OBSERVATION", 25, 37], ["parenchymal cells", "OBSERVATION", 59, 76], ["CNS", "ANATOMY", 84, 87], ["infected", "OBSERVATION_MODIFIER", 119, 127], ["ferrets", "OBSERVATION", 128, 135], ["length", "OBSERVATION_MODIFIER", 197, 203], ["disease", "OBSERVATION", 207, 214], ["experimental", "OBSERVATION_MODIFIER", 236, 248], ["infections", "OBSERVATION", 264, 274]]], ["We speculate that a more widespread infection in the CNS would have developed if animals were allowed to succumb to disease without euthanasia.", [["CNS", "ANATOMY", 53, 56], ["infection", "DISEASE", 36, 45], ["CNS", "ANATOMICAL_SYSTEM", 53, 56], ["a more widespread infection in the CNS", "PROBLEM", 18, 56], ["euthanasia", "PROBLEM", 132, 142], ["more", "OBSERVATION_MODIFIER", 20, 24], ["widespread", "OBSERVATION_MODIFIER", 25, 35], ["infection", "OBSERVATION", 36, 45], ["CNS", "ANATOMY", 53, 56]]], ["Overall, NiV-mediated disease in ferrets has all the hallmarks of NiV-infected humans and represents a novel relevant animal model.DiscussionRecent vaccine studies have demonstrated that henipavirus Gspecific antibodies are critical for protection from disease [22, 28] .", [["NiV-infected", "DISEASE", 66, 78], ["NiV", "ORGANISM", 9, 12], ["ferrets", "ORGANISM", 33, 40], ["NiV", "ORGANISM", 66, 69], ["humans", "ORGANISM", 79, 85], ["henipavirus Gspecific antibodies", "GENE_OR_GENE_PRODUCT", 187, 219], ["henipavirus Gspecific antibodies", "PROTEIN", 187, 219], ["ferrets", "SPECIES", 33, 40], ["humans", "SPECIES", 79, 85], ["ferrets", "SPECIES", 33, 40], ["humans", "SPECIES", 79, 85], ["henipavirus", "SPECIES", 187, 198], ["NiV-mediated disease in ferrets", "PROBLEM", 9, 40], ["DiscussionRecent vaccine studies", "TEST", 131, 163], ["henipavirus Gspecific antibodies", "PROBLEM", 187, 219], ["disease", "PROBLEM", 253, 260], ["disease", "OBSERVATION", 22, 29], ["infected", "OBSERVATION", 70, 78]]], ["Evidence of passive protection against NiV, and more recently HeV, challenge using hamster polyclonal antiserum or murine mAbs reactive to NiV glycoproteins was provided in the hamster [29, 30, 31] .", [["hamster", "ANATOMY", 177, 184], ["NiV", "ORGANISM", 39, 42], ["HeV", "ORGANISM", 62, 65], ["hamster", "ORGANISM", 83, 90], ["antiserum", "ORGANISM_SUBSTANCE", 102, 111], ["murine", "ORGANISM", 115, 121], ["mAbs reactive to NiV glycoproteins", "GENE_OR_GENE_PRODUCT", 122, 156], ["hamster", "ORGANISM", 177, 184], ["hamster polyclonal antiserum", "PROTEIN", 83, 111], ["murine mAbs", "PROTEIN", 115, 126], ["NiV glycoproteins", "PROTEIN", 139, 156], ["hamster", "SPECIES", 83, 90], ["murine", "SPECIES", 115, 121], ["hamster", "SPECIES", 177, 184], ["NiV", "SPECIES", 39, 42], ["HeV", "SPECIES", 62, 65], ["hamster", "SPECIES", 83, 90], ["NiV", "SPECIES", 139, 142], ["hamster", "SPECIES", 177, 184], ["passive protection", "TREATMENT", 12, 30], ["NiV", "TREATMENT", 39, 42], ["hamster polyclonal antiserum", "TREATMENT", 83, 111], ["murine mAbs", "TREATMENT", 115, 126], ["NiV glycoproteins", "TREATMENT", 139, 156], ["passive", "OBSERVATION_MODIFIER", 12, 19], ["protection", "OBSERVATION", 20, 30]]], ["However, in those prior studies, both the challenge virus and antibodies were administered by intraperitoneal injection either simultaneously or immediately before or following challenge.", [["intraperitoneal", "ANATOMY", 94, 109], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 94, 109], ["antibodies", "PROTEIN", 62, 72], ["those prior studies", "TEST", 12, 31], ["the challenge virus", "TREATMENT", 38, 57], ["antibodies", "TREATMENT", 62, 72], ["intraperitoneal injection", "TREATMENT", 94, 119]]], ["Here we examined a neutralizing fully-human mAb, with the potential for human use, in a consistently susceptible animal model where challenge and drug delivery mimicked a potential real-life scenario.DiscussionThe hmAb m102.4 is an ideal therapeutic, targeting a critical functional domain of the G glycoprotein, and is a fully human IgG.", [["human", "ORGANISM", 38, 43], ["mAb", "GENE_OR_GENE_PRODUCT", 44, 47], ["human", "ORGANISM", 72, 77], ["G glycoprotein", "GENE_OR_GENE_PRODUCT", 297, 311], ["human", "ORGANISM", 328, 333], ["IgG", "GENE_OR_GENE_PRODUCT", 334, 337], ["human mAb", "PROTEIN", 38, 47], ["G glycoprotein", "PROTEIN", 297, 311], ["human IgG", "PROTEIN", 328, 337], ["human", "SPECIES", 38, 43], ["human", "SPECIES", 72, 77], ["human", "SPECIES", 328, 333], ["human", "SPECIES", 38, 43], ["human", "SPECIES", 72, 77], ["human", "SPECIES", 328, 333], ["drug delivery", "TREATMENT", 146, 159], ["the G glycoprotein", "TREATMENT", 293, 311], ["a fully human IgG", "TREATMENT", 320, 337]]], ["We achieved full protection from NiV-mediated disease in ferrets who received a single infusion of antibody 10 hrs postchallenge and protection in one animal treated prior to challenge.", [["NiV", "ORGANISM", 33, 36], ["ferrets", "ORGANISM", 57, 64], ["ferrets", "SPECIES", 57, 64], ["NiV", "SPECIES", 33, 36], ["ferrets", "SPECIES", 57, 64], ["full protection", "TREATMENT", 12, 27], ["a single infusion of antibody", "TREATMENT", 78, 107], ["protection", "TREATMENT", 133, 143]]], ["Ferret 21-pre was the only survivor in the pre-group and it had the highest pre-challenge level of m102.4 and the best antibody longevity.", [["Ferret", "TEST", 0, 6]]], ["Uniquely, fever, clinical signs and virus were not Figure 6 .", [["fever", "DISEASE", 10, 15], ["fever", "PROBLEM", 10, 15], ["clinical signs and virus", "PROBLEM", 17, 41], ["fever", "OBSERVATION", 10, 15]]], ["In vivo m102.4 concentrations in ferrets following NiV challenge.", [["ferrets", "ORGANISM", 33, 40], ["NiV", "ORGANISM", 51, 54], ["ferrets", "SPECIES", 33, 40], ["ferrets", "SPECIES", 33, 40], ["NiV", "SPECIES", 51, 54], ["NiV challenge", "TREATMENT", 51, 64]]], ["Blood was collected at various time points post-challenge (X-axis).", [["Blood", "ANATOMY", 0, 5], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["Blood", "TEST", 0, 5]]], ["Serum was collected and frozen at 280uC until the completion of the study.", [["Serum", "ANATOMY", 0, 5], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["Serum", "TEST", 0, 5], ["the study", "TEST", 64, 73]]], ["All sera were c-irradiated to facilitate removal from the BSL4 laboratory.", [["sera", "ANATOMY", 4, 8], ["sera", "ORGANISM_SUBSTANCE", 4, 8], ["All sera", "TEST", 0, 8], ["removal", "TREATMENT", 41, 48]]], ["Sera was diluted and assayed using a NiV G-specific microsphere assay described previously [17, 37] .", [["Sera", "ANATOMY", 0, 4], ["Sera", "ORGANISM_SUBSTANCE", 0, 4], ["NiV G", "GENE_OR_GENE_PRODUCT", 37, 42], ["NiV", "SPECIES", 37, 40], ["a NiV G", "TREATMENT", 35, 42], ["specific microsphere assay", "TEST", 43, 69]]], ["An m102.4 standard curve ranging from 500 ng/ml to 0.5 ng/ml and all sera samples were assayed in duplicate simultaneously.", [["sera samples", "ANATOMY", 69, 81], ["sera samples", "ORGANISM_SUBSTANCE", 69, 81], ["An m", "TEST", 0, 4], ["all sera samples", "TEST", 65, 81]]], ["Serum m102. detected at any time in this animal, with the exception of an extremely low level viremia 3 dpi.", [["viremia", "DISEASE", 94, 101], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["Serum m", "TEST", 0, 7], ["an extremely low level viremia", "PROBLEM", 71, 101], ["viremia", "OBSERVATION", 94, 101]]], ["These findings suggest that the combination of an initial high level of antibody and subsequent longevity may provide protection.", [["an initial high level of antibody", "PROBLEM", 47, 80]]], ["For the remaining ferrets, higher levels of m102.4 on day 3 post-challenge correlated with protection from disease whereas levels thereafter did not, potentially highlighting the first 3 days following infection as an important therapeutic window.", [["infection", "DISEASE", 202, 211], ["ferrets", "ORGANISM", 18, 25], ["ferrets", "SPECIES", 18, 25], ["disease", "PROBLEM", 107, 114], ["infection", "PROBLEM", 202, 211], ["infection", "OBSERVATION", 202, 211]]], ["On day 3, lower m102.4 concentrations in the pre-group may not have been sufficient to neutralize all virus, allowing the initiation of infection.", [["infection", "DISEASE", 136, 145], ["all virus", "PROBLEM", 98, 107], ["infection", "PROBLEM", 136, 145], ["infection", "OBSERVATION", 136, 145]]], ["In the postgroup the higher concentrations 3 dpi may have sufficiently neutralized enough virus and/or prevented widespread dissemination of virus, providing a window for the animal to mount an effective immune response.", [["sufficiently neutralized enough virus", "PROBLEM", 58, 95], ["widespread dissemination of virus", "PROBLEM", 113, 146], ["a window", "TREATMENT", 158, 166], ["widespread", "OBSERVATION_MODIFIER", 113, 123], ["dissemination", "OBSERVATION", 124, 137], ["virus", "OBSERVATION", 141, 146]]], ["In the post-challenge group, the host immune system may have had an opportunity (10 hrs) to initiate a primary response before antibody-mediated depletion of virus.", [["immune system", "ANATOMY", 38, 51], ["antibody-mediated depletion of virus", "PROBLEM", 127, 163], ["virus", "OBSERVATION", 158, 163]]], ["In the pre-challenge group, the antibody-virus complexes most likely formed almost immediately following challenge and the primary or innate response may have been dampened.", [["antibody-virus complexes", "PROTEIN", 32, 56], ["the antibody-virus complexes", "PROBLEM", 28, 56], ["dampened", "OBSERVATION_MODIFIER", 164, 172]]], ["As m102.4 levels decreased over time and virus replication initiated, the postchallenge group may have had a more potent secondary response allowing survival.", [["virus replication", "TREATMENT", 41, 58]]], ["Indeed, the animals in the pre-challenge group developed severe disease 7 days after m102.4 levels decreased, a timeline similar to the disease progression in naive animals.", [["severe disease", "PROBLEM", 57, 71], ["the disease progression in naive animals", "PROBLEM", 132, 172], ["severe", "OBSERVATION_MODIFIER", 57, 63], ["disease", "OBSERVATION", 64, 71], ["disease", "OBSERVATION", 136, 143], ["progression", "OBSERVATION_MODIFIER", 144, 155]]], ["Whether primary or secondary, the antibody responses in the postchallenge group appeared earlier (10 dpi) and were more robust.DiscussionThe survival of all ferrets in the post-challenge group represents a major step forward towards a viable passive antiviral therapeutic for treating henipavirus infection.", [["henipavirus infection", "DISEASE", 285, 306], ["ferrets", "ORGANISM", 157, 164], ["henipavirus", "ORGANISM", 285, 296], ["henipavirus", "SPECIES", 285, 296], ["the antibody responses", "TEST", 30, 52], ["a viable passive antiviral therapeutic", "TREATMENT", 233, 271], ["treating henipavirus infection", "PROBLEM", 276, 306], ["secondary", "OBSERVATION_MODIFIER", 19, 28], ["infection", "OBSERVATION", 297, 306]]], ["Since m102.4 targets the receptor-binding domain of G [32] and is a conformationdependent antibody, we believe it will maintain efficacy in vivo during the course of its application in an infected host.", [["G [32]", "GENE_OR_GENE_PRODUCT", 52, 58], ["receptor-binding domain", "PROTEIN", 25, 48], ["conformationdependent antibody", "PROTEIN", 68, 98], ["a conformationdependent antibody", "PROBLEM", 66, 98], ["its application", "TREATMENT", 166, 181], ["an infected host", "TREATMENT", 185, 201], ["infected", "OBSERVATION", 188, 196]]], ["Given the acute nature of henipavirus infection and its receptor specificity, mutation and escape from m102.4 sensitivity seems unlikely.", [["infection", "DISEASE", 38, 47], ["henipavirus", "CANCER", 26, 37], ["henipavirus", "SPECIES", 26, 37], ["henipavirus infection", "PROBLEM", 26, 47], ["mutation", "PROBLEM", 78, 86], ["escape from m102.4 sensitivity", "TEST", 91, 121], ["acute", "OBSERVATION_MODIFIER", 10, 15], ["infection", "OBSERVATION", 38, 47]]], ["Mutations generating m102.4 neutralization escape variant viruses would likely also acquire defects in receptor binding and fitness.", [["Mutations", "PROBLEM", 0, 9], ["neutralization escape variant viruses", "PROBLEM", 28, 65], ["defects in receptor binding", "PROBLEM", 92, 119], ["defects", "OBSERVATION", 92, 99], ["receptor binding", "OBSERVATION", 103, 119]]], ["Our data support this notion as no escape mutants were found in treated animals that succumbed to disease.", [["escape mutants", "PROBLEM", 35, 49], ["disease", "PROBLEM", 98, 105]]], ["Further examination of m102.4 has confirmed its potent cross-reactive neutralization activity against the NiV-Malaysia [33] , the original HeV-1994 [34] , the recent HeV-Redlands [5] and NiV-Bangladesh isolates [35] .", [["NiV", "ORGANISM", 106, 109], ["HeV", "ORGANISM", 139, 142], ["HeV-Redlands [5", "ORGANISM", 166, 181], ["NiV", "ORGANISM", 187, 190], ["Further examination of m", "TEST", 0, 24], ["NiV", "TREATMENT", 187, 190]]], ["Examination of m102.4 effectiveness in treating animals exposed to these henipavirus isolates will be important.", [["Examination of m", "TEST", 0, 16], ["these henipavirus isolates", "TREATMENT", 67, 93]]], ["In future studies, it will also be critical to increase the number of animals studied and further explore the therapeutic window postchallenge.", [["future studies", "TEST", 3, 17]]], ["These data represent the first human antibody therapy successfully evaluated in vivo for prevention of lethal henipavirus infection and strongly suggests m102.4 may prove to be a useful therapeutic used to treat disease in people caused by these important emerging pathogens.Animal handling and husbandryEight adult (1-2 year old) ferrets were used for the NiV minimal infectious dose study and eight adult ferrets were used for the in vivo m102.4 efficacy study.", [["henipavirus infection", "DISEASE", 110, 131], ["human", "ORGANISM", 31, 36], ["people", "ORGANISM", 223, 229], ["ferrets", "ORGANISM", 331, 338], ["NiV", "ORGANISM", 357, 360], ["ferrets", "ORGANISM", 407, 414], ["human", "SPECIES", 31, 36], ["people", "SPECIES", 223, 229], ["ferrets", "SPECIES", 331, 338], ["ferrets", "SPECIES", 407, 414], ["human", "SPECIES", 31, 36], ["henipavirus", "SPECIES", 110, 121], ["ferrets", "SPECIES", 331, 338], ["ferrets", "SPECIES", 407, 414], ["the first human antibody therapy", "TREATMENT", 21, 53], ["lethal henipavirus infection", "PROBLEM", 103, 131], ["disease", "PROBLEM", 212, 219], ["the NiV minimal infectious dose study", "TREATMENT", 353, 390], ["efficacy study", "TEST", 448, 462]]], ["All animal studies were endorsed by the CSIRO, AAHL, Animal Ethics Committee.", [["All animal studies", "TEST", 0, 18]]], ["Ferrets were housed in pairs in cages in a BSL4 room, fed twice daily with a complete premium dry food and provided with water ad lib.", [["Ferrets", "ANATOMY", 0, 7]]], ["For implantation of temperature transponders, NiV challenge, administration of m102.4 and specimen collection, ferrets were anaesthetised by intramuscular injection of ketamine (Ketamil, Troy Laboratories, New South Wales (NSW), AU) and medetomidine (Domitor, Pfizer Animal Health, NSW, AU) at dose rates of approximately 3 mg/kg and 0.03 mg/kg, respectively.", [["specimen", "ANATOMY", 90, 98], ["intramuscular", "ANATOMY", 141, 154], ["ketamine", "CHEMICAL", 168, 176], ["Ketamil", "CHEMICAL", 178, 185], ["medetomidine", "CHEMICAL", 237, 249], ["ketamine", "CHEMICAL", 168, 176], ["Ketamil", "CHEMICAL", 178, 185], ["medetomidine", "CHEMICAL", 237, 249], ["Domitor", "CHEMICAL", 251, 258], ["NiV", "ORGANISM", 46, 49], ["ferrets", "ORGANISM", 111, 118], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 141, 154], ["ketamine", "SIMPLE_CHEMICAL", 168, 176], ["Ketamil", "SIMPLE_CHEMICAL", 178, 185], ["medetomidine", "SIMPLE_CHEMICAL", 237, 249], ["ferrets", "SPECIES", 111, 118], ["implantation of temperature transponders", "TREATMENT", 4, 44], ["NiV challenge", "TREATMENT", 46, 59], ["specimen collection", "TEST", 90, 109], ["ketamine", "TREATMENT", 168, 176], ["medetomidine", "TREATMENT", 237, 249]]], ["For anesthetic reversal, atimepazole (Antisedan; Novartis, Pendle Hill, NSW, AU) was given intramuscularly at 50% the dose of medetomidine.", [["atimepazole", "CHEMICAL", 25, 36], ["Antisedan", "CHEMICAL", 38, 47], ["medetomidine", "CHEMICAL", 126, 138], ["atimepazole", "CHEMICAL", 25, 36], ["Antisedan", "CHEMICAL", 38, 47], ["medetomidine", "CHEMICAL", 126, 138], ["atimepazole", "SIMPLE_CHEMICAL", 25, 36], ["Antisedan", "SIMPLE_CHEMICAL", 38, 47], ["medetomidine", "SIMPLE_CHEMICAL", 126, 138], ["anesthetic reversal", "TREATMENT", 4, 23], ["atimepazole (Antisedan", "TREATMENT", 25, 47], ["medetomidine", "TREATMENT", 126, 138]]], ["Following challenge, ferrets were assessed daily and scored out of 10 for a range of clinical observations, including alertness, playfulness, curiosity, depression, food consumption, feces production and respiration rate.", [["playfulness", "DISEASE", 129, 140], ["depression", "DISEASE", 153, 163], ["ferrets", "ORGANISM", 21, 28], ["feces", "ORGANISM_SUBDIVISION", 183, 188], ["ferrets", "SPECIES", 21, 28], ["ferrets", "SPECIES", 21, 28], ["alertness", "PROBLEM", 118, 127], ["depression", "PROBLEM", 153, 163], ["food consumption", "PROBLEM", 165, 181], ["respiration rate", "TEST", 204, 220]]], ["Ferret immune responses to NiV G. Blood was collected at various time points post-challenge, as indicated by the X-axis.", [["Blood", "ANATOMY", 34, 39], ["NiV", "ORGANISM", 27, 30], ["Blood", "ORGANISM_SUBSTANCE", 34, 39], ["NiV G.", "SPECIES", 27, 33], ["Blood", "TEST", 34, 39]]], ["Serum was collected and frozen at 280uC until the completion of the study.", [["Serum", "ANATOMY", 0, 5], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["Serum", "TEST", 0, 5], ["the study", "TEST", 64, 73]]], ["All sera were c-irradiated to facilitate removal from the BSL-4 laboratory.", [["sera", "ANATOMY", 4, 8], ["sera", "ORGANISM_SUBSTANCE", 4, 8], ["All sera", "TEST", 0, 8]]], ["Ferret sera were diluted and assayed using the NiV G-specific microsphere assay described previously [37] .", [["sera", "ANATOMY", 7, 11], ["Ferret", "ORGANISM_SUBSTANCE", 0, 6], ["sera", "ORGANISM_SUBSTANCE", 7, 11], ["NiV G", "GENE_OR_GENE_PRODUCT", 47, 52], ["NiV", "SPECIES", 47, 50], ["Ferret sera", "TEST", 0, 11], ["the NiV G", "TREATMENT", 43, 52], ["specific microsphere assay", "TEST", 53, 79]]], ["Ferret # and corresponding treatment group (control body temperature for all animals was done using transponders implanted subcutaneously [28] .", [["body", "ANATOMY", 52, 56], ["subcutaneously", "ANATOMY", 123, 137], ["body", "ORGANISM_SUBDIVISION", 52, 56], ["corresponding treatment group (control body temperature", "TREATMENT", 13, 68]]], ["Rectal temperatures and body weights were recorded on sampling days.", [["Rectal", "ANATOMY", 0, 6], ["body", "ANATOMY", 24, 28], ["Rectal", "ORGAN", 0, 6], ["body", "ORGANISM_SUBDIVISION", 24, 28], ["Rectal temperatures", "TEST", 0, 19], ["body weights", "TEST", 24, 36]]], ["Once ferrets were clinically assessed to be exhibiting signs of severe disease from which natural recovery was considered unlikely, animals were euthanized by intravenous injection of sodium pentabarbitone.Virus isolate and challengeFerrets were inoculated oronasally with a low passage NiV isolate (NiV-Malaysia; EUKK 19817; stock virus titer 4.3610 6 TCID 50 /ml) [36] .", [["intravenous", "ANATOMY", 159, 170], ["challengeFerrets", "ANATOMY", 224, 240], ["sodium pentabarbitone", "CHEMICAL", 184, 205], ["sodium pentabarbitone", "CHEMICAL", 184, 205], ["ferrets", "ORGANISM", 5, 12], ["animals", "ORGANISM", 132, 139], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 159, 170], ["sodium pentabarbitone", "SIMPLE_CHEMICAL", 184, 205], ["Virus", "ORGANISM", 206, 211], ["challengeFerrets", "CANCER", 224, 240], ["NiV", "ORGANISM", 287, 290], ["NiV", "ORGANISM", 300, 303], ["EUKK 19817", "ORGANISM", 314, 324], ["ferrets", "SPECIES", 5, 12], ["ferrets", "SPECIES", 5, 12], ["NiV", "SPECIES", 287, 290], ["NiV-Malaysia; EUKK 19817; stock virus", "SPECIES", 300, 337], ["severe disease", "PROBLEM", 64, 78], ["sodium pentabarbitone", "TREATMENT", 184, 205], ["Virus isolate", "TREATMENT", 206, 219], ["challengeFerrets", "TREATMENT", 224, 240], ["a low passage NiV isolate", "TREATMENT", 273, 298], ["EUKK", "TEST", 314, 318], ["stock virus titer", "TEST", 326, 343], ["severe", "OBSERVATION_MODIFIER", 64, 70], ["disease", "OBSERVATION", 71, 78]]], ["For the MID 50 study NiV doses were: 5610 4 , 5610 3 , 5610 2 and 50 TCID 50 (2 ferrets per dose).", [["NiV", "ORGANISM", 21, 24]]], ["Based on the outcome of the MID50 study, for the m102.4 efficacy study all ferrets were challenged with 5610 3 TCID 50 .Virus isolate and challengePreparation and administration of m102.4Virus isolate and challengeThe m102.4 hmAb was prepared as previously described [17] .", [["ferrets", "ORGANISM", 75, 82], ["Virus", "ORGANISM", 120, 125], ["Virus", "ORGANISM", 187, 192], ["m102.4 hmAb", "DNA", 218, 229], ["ferrets", "SPECIES", 75, 82], ["ferrets", "SPECIES", 75, 82], ["the MID50 study", "TEST", 24, 39], ["efficacy study", "TEST", 56, 70], ["Virus isolate", "TREATMENT", 120, 133], ["Virus isolate", "TREATMENT", 187, 200]]], ["Ferrets were anaesthetised and a 20-g intravenous catheter placed in the left jugular vein. m102.4 was administered via catheter by slow infusion over 4 minutes to 6 ferrets (50 mg per ferret); 3 ferrets received antibody 24 hours before NiV challenge and 3 ferrets received antibody 10 hours after challenge.", [["intravenous", "ANATOMY", 38, 49], ["left jugular vein", "ANATOMY", 73, 90], ["m102.4", "CHEMICAL", 92, 98], ["left jugular vein", "MULTI-TISSUE_STRUCTURE", 73, 90], ["ferrets", "ORGANISM", 166, 173], ["ferret", "ORGANISM", 185, 191], ["ferrets", "ORGANISM", 196, 203], ["NiV", "ORGANISM", 238, 241], ["ferrets", "ORGANISM", 258, 265], ["ferrets", "SPECIES", 196, 203], ["ferrets", "SPECIES", 258, 265], ["NiV", "SPECIES", 238, 241], ["ferrets", "SPECIES", 258, 265], ["a 20-g intravenous catheter", "TREATMENT", 31, 58], ["antibody", "TREATMENT", 213, 221], ["NiV challenge", "TREATMENT", 238, 251], ["antibody", "TREATMENT", 275, 283], ["catheter", "OBSERVATION", 50, 58], ["left jugular vein", "ANATOMY", 73, 90]]], ["Two ferrets received PBS, one at 24 hours before challenge and the other at 10 hours after challenge.", [["ferrets", "ORGANISM", 4, 11], ["ferrets", "SPECIES", 4, 11], ["PBS", "TREATMENT", 21, 24]]], ["Catheters were withdrawn and animals were allowed to recover from the anaesthesia.Sample collection post-challengeBlood, oral swabs and rectal swabs were collected 6, 8, 10, 13 and 20 or 21 days post-infection (dpi) for the purpose of assisting in establishing the infection status of each animal.", [["Blood", "ANATOMY", 114, 119], ["oral swabs", "ANATOMY", 121, 131], ["rectal swabs", "ANATOMY", 136, 148], ["infection", "DISEASE", 265, 274], ["Blood", "ORGANISM_SUBSTANCE", 114, 119], ["oral swabs", "ORGANISM_SUBSTANCE", 121, 131], ["rectal swabs", "MULTI-TISSUE_STRUCTURE", 136, 148], ["Catheters", "TREATMENT", 0, 9], ["the anaesthesia", "TREATMENT", 66, 81], ["Sample collection", "TEST", 82, 99], ["Blood", "TEST", 114, 119], ["oral swabs", "TEST", 121, 131], ["rectal swabs", "TEST", 136, 148], ["the infection status", "PROBLEM", 261, 281], ["rectal", "ANATOMY", 136, 142], ["infection", "OBSERVATION", 265, 274]]], ["For the m102.4 study an additional sample was collected during incubation period (3 dpi).", [["sample", "ANATOMY", 35, 41]]], ["Two aliquots of whole blood were removed from each sample and serum was collected and aliquoted.", [["whole blood", "ANATOMY", 16, 27], ["sample", "ANATOMY", 51, 57], ["serum", "ANATOMY", 62, 67], ["blood", "ORGANISM_SUBSTANCE", 22, 27], ["serum", "ORGANISM_SUBSTANCE", 62, 67], ["whole blood", "PROBLEM", 16, 27], ["each sample and serum", "TEST", 46, 67]]], ["One aliquot of whole blood was added to RiboPure lysis buffer (Ambion Inc. Austin, TX, USA) containing sodium acetate.", [["whole blood", "ANATOMY", 15, 26], ["sodium acetate", "CHEMICAL", 103, 117], ["sodium acetate", "CHEMICAL", 103, 117], ["blood", "ORGANISM_SUBSTANCE", 21, 26], ["sodium acetate", "SIMPLE_CHEMICAL", 103, 117], ["whole blood", "TREATMENT", 15, 26], ["RiboPure lysis buffer", "TREATMENT", 40, 61], ["sodium acetate", "TREATMENT", 103, 117]]], ["Duplicate swabs were placed in AVL viral lysis buffer (Qiagen Pty Ltd, Clifton Hill, Victoria, AU) or PBS.", [["swabs", "ANATOMY", 10, 15], ["Duplicate swabs", "TEST", 0, 15], ["AVL viral lysis buffer", "TREATMENT", 31, 53], ["PBS", "TREATMENT", 102, 105]]], ["After euthanasia, tissue samples were collected aseptically from lung (apical and diaphragmatic lobes), brain (olfactory and occipital lobes), heart, bronchial lymph nodes, spleen, liver, kidney, bladder, and adrenal gland.", [["tissue samples", "ANATOMY", 18, 32], ["lung", "ANATOMY", 65, 69], ["apical", "ANATOMY", 71, 77], ["diaphragmatic lobes", "ANATOMY", 82, 101], ["brain", "ANATOMY", 104, 109], ["olfactory", "ANATOMY", 111, 120], ["occipital lobes", "ANATOMY", 125, 140], ["heart", "ANATOMY", 143, 148], ["bronchial lymph nodes", "ANATOMY", 150, 171], ["spleen", "ANATOMY", 173, 179], ["liver", "ANATOMY", 181, 186], ["kidney", "ANATOMY", 188, 194], ["bladder", "ANATOMY", 196, 203], ["adrenal gland", "ANATOMY", 209, 222], ["tissue samples", "CANCER", 18, 32], ["lung", "ORGAN", 65, 69], ["apical", "MULTI-TISSUE_STRUCTURE", 71, 77], ["diaphragmatic lobes", "MULTI-TISSUE_STRUCTURE", 82, 101], ["brain", "ORGAN", 104, 109], ["olfactory", "ORGAN", 111, 120], ["occipital lobes", "MULTI-TISSUE_STRUCTURE", 125, 140], ["heart", "ORGAN", 143, 148], ["bronchial lymph nodes", "MULTI-TISSUE_STRUCTURE", 150, 171], ["spleen", "ORGAN", 173, 179], ["liver", "ORGAN", 181, 186], ["kidney", "ORGAN", 188, 194], ["bladder", "ORGAN", 196, 203], ["adrenal gland", "ORGAN", 209, 222], ["euthanasia", "PROBLEM", 6, 16], ["tissue samples", "TEST", 18, 32], ["brain (olfactory and occipital lobes), heart, bronchial lymph nodes, spleen, liver, kidney, bladder, and adrenal gland", "PROBLEM", 104, 222], ["euthanasia", "OBSERVATION", 6, 16], ["lung", "ANATOMY", 65, 69], ["apical", "ANATOMY_MODIFIER", 71, 77], ["diaphragmatic lobes", "ANATOMY", 82, 101], ["brain", "ANATOMY", 104, 109], ["olfactory", "ANATOMY_MODIFIER", 111, 120], ["occipital lobes", "ANATOMY", 125, 140], ["heart", "ANATOMY", 143, 148], ["bronchial", "ANATOMY", 150, 159], ["lymph nodes", "OBSERVATION", 160, 171], ["spleen", "ANATOMY", 173, 179], ["liver", "ANATOMY", 181, 186], ["kidney", "ANATOMY", 188, 194], ["bladder", "ANATOMY", 196, 203], ["adrenal gland", "ANATOMY", 209, 222]]], ["In females, the uterine horn and ovaries were collected and in males the testes were collected.", [["uterine horn", "ANATOMY", 16, 28], ["ovaries", "ANATOMY", 33, 40], ["testes", "ANATOMY", 73, 79], ["uterine horn", "ORGAN", 16, 28], ["ovaries", "ORGAN", 33, 40], ["testes", "ORGAN", 73, 79], ["uterine horn", "ANATOMY", 16, 28], ["ovaries", "ANATOMY", 33, 40], ["testes", "ANATOMY", 73, 79]]], ["Tissues were either fixed in 10% neutral buffered formalin, submerged in RLT lysis buffer (Qiagen Pty Ltd) containing b-mercaptethanol and 1 mm stainless steel beads (BioSpec Products Inc., Bartlesville, OK, USA) or submerged in PBS containing 1 mm stainless steel beads.", [["Tissues", "ANATOMY", 0, 7], ["b-mercaptethanol", "CHEMICAL", 118, 134], ["formalin", "CHEMICAL", 50, 58], ["b-mercaptethanol", "CHEMICAL", 118, 134], ["Tissues", "CANCER", 0, 7], ["formalin", "SIMPLE_CHEMICAL", 50, 58], ["b-mercaptethanol", "SIMPLE_CHEMICAL", 118, 134], ["neutral buffered formalin", "TREATMENT", 33, 58], ["RLT lysis buffer", "TREATMENT", 73, 89], ["Qiagen Pty Ltd)", "TREATMENT", 91, 106], ["b-mercaptethanol", "TREATMENT", 118, 134], ["1 mm stainless steel beads", "TREATMENT", 139, 165], ["BioSpec Products", "TREATMENT", 167, 183], ["1 mm stainless steel beads", "TREATMENT", 244, 270], ["1 mm", "OBSERVATION_MODIFIER", 244, 248], ["stainless steel beads", "OBSERVATION", 249, 270]]], ["For the MID 50 study, all specimens were placed at 280uC.", [["specimens", "ANATOMY", 26, 35], ["specimens", "CANCER", 26, 35], ["the MID 50 study", "TEST", 4, 20], ["all specimens", "TEST", 22, 35]]], ["For the m102.4 efficacy study, all blood, swab and tissue samples were processed immediately for RNA extraction and duplicate samples in PBS were stored at 280uC for virus isolation.RNA isolationRNA was purified from blood cells using the RiboPure-Blood kit (Ambion Inc.), from swabs using the QIAamp viral RNA kit (Qiagen Pty Ltd) and from tissues using the RNeasy Mini kit (Qiagen Pty Ltd).", [["blood", "ANATOMY", 35, 40], ["swab", "ANATOMY", 42, 46], ["tissue samples", "ANATOMY", 51, 65], ["samples", "ANATOMY", 126, 133], ["blood cells", "ANATOMY", 217, 228], ["tissues", "ANATOMY", 341, 348], ["blood", "ORGANISM_SUBSTANCE", 35, 40], ["swab", "ORGANISM_SUBSTANCE", 42, 46], ["tissue samples", "ORGANISM_SUBSTANCE", 51, 65], ["blood cells", "CELL", 217, 228], ["Ambion", "ORGANISM", 259, 265], ["tissues", "TISSUE", 341, 348], ["blood cells", "CELL_TYPE", 217, 228], ["efficacy study", "TEST", 15, 29], ["all blood", "TEST", 31, 40], ["swab and tissue samples", "TEST", 42, 65], ["RNA extraction", "TREATMENT", 97, 111], ["duplicate samples in PBS", "TEST", 116, 140], ["virus isolation", "TREATMENT", 166, 181], ["RNA isolationRNA", "TEST", 182, 198], ["blood cells", "TEST", 217, 228], ["the RiboPure-Blood kit", "TREATMENT", 235, 257], ["swabs", "TEST", 278, 283], ["the QIAamp viral RNA kit", "TREATMENT", 290, 314], ["the RNeasy Mini kit", "TREATMENT", 355, 374]]], ["Prior to processing, tissues were homogenized for 2 cycles of 30 sec using a Mini-Bead Beater (Biospec Products Inc.) and centrifuged to pellet debris.NiV Taqman PCR assayTaqman PCR assays were preformed as previously described [28] .", [["tissues", "ANATOMY", 21, 28], ["tissues", "TISSUE", 21, 28], ["NiV", "ORGANISM", 151, 154], ["NiV", "SPECIES", 151, 154], ["a Mini-Bead Beater (Biospec Products", "TREATMENT", 75, 111], ["pellet debris", "PROBLEM", 137, 150], ["NiV Taqman PCR assayTaqman", "TEST", 151, 177], ["PCR assays", "TEST", 178, 188], ["pellet debris", "OBSERVATION", 137, 150]]], ["Samples were amplified in a GeneAmp 7500 Sequence Detection System (Applied Biosystems, Foster City, CA).", [["Samples", "ANATOMY", 0, 7], ["Samples", "TEST", 0, 7]]], ["Ct values representing NiV nucleocapsid (N) gene expression were analyzed and data were recorded as relative NiV N gene expression levels.Virus isolationVirus isolation was performed as previously described [28] and only attempted from specimens positive for NiV RNA.Histopathology and immunohistochemistryTissues were processed by routine histological methods and sections of tissue were stained with hematoxylin and eosin to examine histopathological changes.", [["specimens", "ANATOMY", 236, 245], ["Tissues", "ANATOMY", 306, 313], ["sections", "ANATOMY", 365, 373], ["tissue", "ANATOMY", 377, 383], ["hematoxylin", "CHEMICAL", 402, 413], ["eosin", "CHEMICAL", 418, 423], ["NiV nucleocapsid (N)", "GENE_OR_GENE_PRODUCT", 23, 43], ["NiV N", "GENE_OR_GENE_PRODUCT", 109, 114], ["Virus", "ORGANISM", 138, 143], ["specimens", "CANCER", 236, 245], ["NiV", "ORGANISM", 259, 262], ["Tissues", "CANCER", 306, 313], ["tissue", "TISSUE", 377, 383], ["hematoxylin", "SIMPLE_CHEMICAL", 402, 413], ["eosin", "SIMPLE_CHEMICAL", 418, 423], ["NiV nucleocapsid (N) gene", "DNA", 23, 48], ["NiV RNA", "RNA", 259, 266], ["NiV", "SPECIES", 109, 112], ["NiV", "SPECIES", 259, 262], ["Ct values", "TEST", 0, 9], ["NiV nucleocapsid", "TREATMENT", 23, 39], ["gene expression", "TEST", 44, 59], ["Virus isolationVirus isolation", "TREATMENT", 138, 168], ["specimens", "TEST", 236, 245], ["NiV RNA", "PROBLEM", 259, 266], ["Histopathology", "TEST", 267, 281], ["immunohistochemistry", "TEST", 286, 306], ["routine histological methods", "TEST", 332, 360], ["hematoxylin and eosin", "TEST", 402, 423], ["histopathological changes", "PROBLEM", 435, 460], ["NiV nucleocapsid", "OBSERVATION", 23, 39]]], ["Separate sections were stained by immunohistochemical techniques as previously described [20] using a rabbit polyclonal antiserum against NiV nucleoprotein.Measurement of m102.4 and NiV G-specific antibodies in ferret serumMultiplexed microsphere assays were performed as previously described [37] .", [["sections", "ANATOMY", 9, 17], ["sections", "MULTI-TISSUE_STRUCTURE", 9, 17], ["rabbit", "ORGANISM", 102, 108], ["NiV", "ORGANISM", 138, 141], ["NiV G", "GENE_OR_GENE_PRODUCT", 182, 187], ["ferret", "ORGANISM", 211, 217], ["NiV nucleoprotein", "PROTEIN", 138, 155], ["NiV G-specific antibodies", "PROTEIN", 182, 207], ["rabbit", "SPECIES", 102, 108], ["ferret", "SPECIES", 211, 217], ["rabbit", "SPECIES", 102, 108], ["NiV", "SPECIES", 138, 141], ["ferret", "SPECIES", 211, 217], ["immunohistochemical techniques", "TEST", 34, 64], ["a rabbit polyclonal antiserum", "TREATMENT", 100, 129], ["NiV nucleoprotein", "TREATMENT", 138, 155], ["Measurement of m", "TEST", 156, 172], ["NiV G", "TEST", 182, 187], ["specific antibodies", "TEST", 188, 207], ["ferret serumMultiplexed microsphere assays", "TEST", 211, 253]]], ["A LuminexH 100 IS TM machine and MiraiBio software (MiraiBio Group, South San Francisco, CA) were utilized for all assays: Master Plex CT v1.0 for data acquisition and MasterPlex QT v 2.0 for data analysis.", [["A LuminexH", "TREATMENT", 0, 10], ["Master Plex CT v", "TEST", 123, 139], ["data acquisition", "TEST", 147, 163], ["MasterPlex QT v", "TEST", 168, 183], ["data analysis", "TEST", 192, 205]]], ["All samples were assayed simultaneously and concentrations were extrapolated from a standard curve using non-linear regression analysis (GraphPad Software, San Diego, CA).", [["samples", "ANATOMY", 4, 11], ["All samples", "TEST", 0, 11], ["non-linear regression analysis", "TEST", 105, 135]]]], "94784aa7952526edcce83b7ed6042a0d5fe2bc2c": [["Most countries worldwide have taken restrictive measures to limit face-to-face contacts and called on their population to adopt social distancing behaviours, in order to curb the progression of the COVID-19 pandemic.", [["restrictive measures", "TREATMENT", 36, 56], ["the COVID", "TEST", 194, 203], ["pandemic", "PROBLEM", 207, 215]]], ["1 While several European countries have started easing lockdown measures after reaching the declared objective of 'flattening the curve', the continent (and the world) is on its way into new uncertainties: Are first waves of infections only the start of a longer, multifaceted, crisis?", [["infections", "DISEASE", 225, 235], ["lockdown measures", "TREATMENT", 55, 72], ["infections", "PROBLEM", 225, 235], ["crisis", "PROBLEM", 278, 284], ["infections", "OBSERVATION", 225, 235]]], ["Is solidarity with the most vulnerable enduring, or does it turn out to be short-lived?", [["solidarity", "OBSERVATION", 3, 13], ["most vulnerable", "OBSERVATION_MODIFIER", 23, 38]]]], "PMC7186538": [["The excellent update on the COVID-19 pandemic by Darlenski and Tsankov1 notes that the conjunctiva is a potential entry point for the infection.", [["conjunctiva", "ANATOMY", 87, 98], ["infection", "DISEASE", 134, 143], ["conjunctiva", "ORGAN", 87, 98], ["the COVID", "TEST", 24, 33], ["the infection", "PROBLEM", 130, 143], ["conjunctiva", "ANATOMY", 87, 98], ["infection", "OBSERVATION", 134, 143]]], ["With respect to the eye, the American Academy of Ophthalmology has just released an advisory on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) stating that there have been several reports to suggest that the virus can cause a mild follicular conjunctivitis.2", [["eye", "ANATOMY", 20, 23], ["follicular", "ANATOMY", 245, 255], ["acute respiratory syndrome coronavirus", "DISEASE", 103, 141], ["conjunctivitis", "DISEASE", 256, 270], ["eye", "ORGAN", 20, 23], ["SARS-CoV-2", "ORGANISM", 145, 155], ["severe acute respiratory syndrome coronavirus", "SPECIES", 96, 141], ["SARS-CoV", "SPECIES", 145, 153], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 96, 141], ["SARS-CoV", "TEST", 145, 153], ["the virus", "PROBLEM", 218, 227], ["a mild follicular conjunctivitis", "PROBLEM", 238, 270], ["eye", "ANATOMY", 20, 23], ["severe", "OBSERVATION_MODIFIER", 96, 102], ["acute", "OBSERVATION_MODIFIER", 103, 108], ["respiratory syndrome", "OBSERVATION", 109, 129], ["mild", "OBSERVATION_MODIFIER", 240, 244], ["follicular conjunctivitis", "OBSERVATION", 245, 270]]]], "bd39c84f8adcab358c6e3527f9e90a898819fd57": [["T HE new coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a continuing pandemic [1] [2] [3] [4] .", [["coronavirus disease", "DISEASE", 9, 28], ["COVID-19", "CHEMICAL", 35, 43], ["acute respiratory syndrome coronavirus", "DISEASE", 66, 104], ["COVID-19", "ORGANISM", 35, 43], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 59, 106], ["SARS-CoV-2", "ORGANISM", 108, 118], ["[1] [2] [3] [4]", "SIMPLE_CHEMICAL", 153, 168], ["T HE new coronavirus disease 2019 (COVID-19", "SPECIES", 0, 43], ["severe acute respiratory syndrome coronavirus", "SPECIES", 59, 104], ["SARS-CoV-2", "SPECIES", 108, 118], ["new coronavirus disease", "PROBLEM", 5, 28], ["COVID", "TEST", 35, 40], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 55, 104], ["CoV", "TEST", 113, 116], ["a continuing pandemic", "TEST", 131, 152], ["coronavirus disease", "OBSERVATION", 9, 28], ["severe", "OBSERVATION_MODIFIER", 59, 65], ["acute", "OBSERVATION_MODIFIER", 66, 71], ["respiratory syndrome", "OBSERVATION", 72, 92]]], ["As of 9 September 2020, there have been 212 countries with outbreaks, a total of 27,486,960 cases diagnosed, and 894,983 deaths, even though the number of infected people continues to increase [5] .", [["deaths", "DISEASE", 121, 127], ["people", "ORGANISM", 164, 170], ["people", "SPECIES", 164, 170], ["infected", "OBSERVATION", 155, 163]]], ["Clinically, reverse transcription-polymerase chain reaction (PT-PCR) is the gold standard for diagnosing COVID-19 [6] , but it also has the disadvantages of a high false-negative rate [7] [8] [9] and the inability to understand the patient's condition.", [["patient", "ORGANISM", 232, 239], ["patient", "SPECIES", 232, 239], ["polymerase chain reaction", "PROBLEM", 34, 59], ["PT-PCR", "TEST", 61, 67], ["diagnosing COVID", "TEST", 94, 110]]]], "5a8c0291039599bb9d66a4c35de8a09a6759b70d": [["Pathogens evolve quickly, allowing them to jump from multiple host species to humans (e.g. SARS coronavirus or Ebola virus; Woolhouse et al. 2005) , to become more virulent and evade immune pressure within humans (e.g. influenza virus; Grenfell et al. 2004) and to become resistant to drugs used to combat them (WHO 2014d).", [["SARS coronavirus or Ebola virus", "DISEASE", 91, 122], ["influenza virus", "DISEASE", 219, 234], ["humans", "ORGANISM", 78, 84], ["SARS coronavirus", "ORGANISM", 91, 107], ["Ebola virus", "ORGANISM", 111, 122], ["humans", "ORGANISM", 206, 212], ["influenza virus", "ORGANISM", 219, 234], ["humans", "SPECIES", 78, 84], ["SARS coronavirus", "SPECIES", 91, 107], ["Ebola virus", "SPECIES", 111, 122], ["humans", "SPECIES", 206, 212], ["influenza virus", "SPECIES", 219, 234], ["humans", "SPECIES", 78, 84], ["SARS coronavirus", "SPECIES", 91, 107], ["Ebola virus", "SPECIES", 111, 122], ["humans", "SPECIES", 206, 212], ["Pathogens", "PROBLEM", 0, 9], ["SARS coronavirus", "PROBLEM", 91, 107], ["Ebola virus", "PROBLEM", 111, 122], ["influenza virus", "PROBLEM", 219, 234], ["drugs", "TREATMENT", 285, 290]]], ["In particular, drug resistance results in numerous deaths, increased hospitalizations and prolonged treatments (WHO 2014d) .", [["deaths", "DISEASE", 51, 57], ["prolonged treatments", "TREATMENT", 90, 110], ["drug resistance", "OBSERVATION", 15, 30], ["numerous", "OBSERVATION_MODIFIER", 42, 50], ["deaths", "OBSERVATION", 51, 57], ["increased", "OBSERVATION_MODIFIER", 59, 68]]], ["In addition to the costs borne by human health, the Centers for Disease Control and Prevention estimate the economic costs of drug resistance to be on the order of tens of billions of dollars a year in the United States alone (CDC 2011) .", [["human", "ORGANISM", 34, 39], ["human", "SPECIES", 34, 39], ["human", "SPECIES", 34, 39], ["Disease Control", "TREATMENT", 64, 79], ["drug resistance", "PROBLEM", 126, 141]]], ["While pharmaceutical intervention has played a critical role in our efforts to control epidemic pathogens, there is an urgent need to understand the evolution and spread of drug resistance.IntroductionPathogens share common biological features that allow them to adapt rapidly under extreme selective pressures (imposed, for example, by drugs) on observable timescales.", [["pharmaceutical intervention", "TREATMENT", 6, 33], ["epidemic pathogens", "PROBLEM", 87, 105], ["drug resistance", "PROBLEM", 173, 188], ["drug resistance", "OBSERVATION", 173, 188]]], ["Pathogen populations with large sizes, high mutation rates and short generation times are likely to generate drug resistance mutations in a short amount of time.", [["Pathogen populations", "PROBLEM", 0, 20], ["large sizes", "PROBLEM", 26, 37], ["high mutation rates", "PROBLEM", 39, 58], ["short generation times", "PROBLEM", 63, 85], ["drug resistance mutations", "PROBLEM", 109, 134], ["large", "OBSERVATION_MODIFIER", 26, 31], ["sizes", "OBSERVATION_MODIFIER", 32, 37], ["high mutation", "OBSERVATION", 39, 52], ["drug resistance", "OBSERVATION", 109, 124]]], ["Pathogens also encompass a wide variety of organisms that include eukaryotes, prokaryotes and viruses.", [["Pathogens", "PROBLEM", 0, 9], ["a wide variety of organisms", "PROBLEM", 25, 52], ["viruses", "PROBLEM", 94, 101], ["wide", "OBSERVATION_MODIFIER", 27, 31], ["variety", "OBSERVATION_MODIFIER", 32, 39]]], ["This means that our efforts to understand how pathogens evolve drug resistance need to account for factors such as: variable genome sizes [ranging from a few kilobases (Kb) in RNA viruses to many megabases (Mb) in Plasmodium falciparum], variable mutation rates (from 10 \u00c09 per base pair per generation in eukaryotes to 10 \u00c05 in some RNA viruses), alternative methods of genetic exchange (including viral re-assortment and horizontal gene transfer in bacteria) and clonal vs. recombinant forms of reproduction (see Box 1 for more on diverse modes of genetic exchange and recombination).", [["Plasmodium falciparum", "DISEASE", 214, 235], ["Plasmodium falciparum", "ORGANISM", 214, 235], ["Plasmodium falciparum", "SPECIES", 214, 235], ["Plasmodium falciparum", "SPECIES", 214, 235], ["drug resistance", "PROBLEM", 63, 78], ["variable genome sizes", "PROBLEM", 116, 137], ["a few kilobases (Kb) in RNA viruses", "PROBLEM", 152, 187], ["many megabases (Mb)", "PROBLEM", 191, 210], ["Plasmodium falciparum", "PROBLEM", 214, 235], ["variable mutation rates", "PROBLEM", 238, 261], ["genetic exchange", "TREATMENT", 371, 387], ["viral re-assortment", "TREATMENT", 399, 418], ["horizontal gene transfer in bacteria", "TREATMENT", 423, 459], ["genetic exchange", "TREATMENT", 550, 566], ["sizes", "OBSERVATION_MODIFIER", 132, 137]]], ["In addition, the scale at which drug resistance evolves varies widely.", [["the scale", "TREATMENT", 13, 22], ["drug resistance", "OBSERVATION", 32, 47]]], ["For example, in HIV drug resistance mostly evolves within patients and is rarely transmitted (Wheeler et al. 2010) , whereas in other pathogens (e.g. malaria), drug resistance is often transmitted between hosts, making certain drugs ineffective for a large fraction of new patients (Hyde 2005) .IntroductionTo prevent or at least manage drug resistance in pathogens, it is imperative to understand the evolutionary aspects of the problem.", [["HIV drug resistance", "DISEASE", 16, 35], ["malaria", "DISEASE", 150, 157], ["HIV", "ORGANISM", 16, 19], ["patients", "ORGANISM", 58, 66], ["patients", "ORGANISM", 273, 281], ["HIV", "SPECIES", 16, 19], ["patients", "SPECIES", 58, 66], ["patients", "SPECIES", 273, 281], ["HIV", "SPECIES", 16, 19], ["HIV drug resistance", "PROBLEM", 16, 35], ["malaria", "PROBLEM", 150, 157], ["drug resistance", "PROBLEM", 160, 175], ["certain drugs", "TREATMENT", 219, 232], ["drug resistance in pathogens", "PROBLEM", 337, 365], ["HIV", "OBSERVATION", 16, 19], ["drug resistance", "OBSERVATION", 20, 35]]], ["However, evolutionary biologists have traditionally left most of the study of drug resistance to the medicine and epidemiology communities (Read & Huijben 2009 ).", [["the study", "TEST", 65, 74]]], ["This has changed in recent years with interesting population genetic work being done on natural populations of pathogens, some of which is featured in this review.", [["pathogens", "PROBLEM", 111, 120], ["pathogens", "OBSERVATION", 111, 120]]], ["This change is, at least in part, driven by the availability of genetic data for a variety of pathogens.", [["genetic data", "TEST", 64, 76], ["pathogens", "PROBLEM", 94, 103]]], ["A new cross-disciplinary field is emerging that uses large amounts of genetic data and new theoretical advances from the world of population genetics.", [["genetic data", "TEST", 70, 82], ["new", "OBSERVATION_MODIFIER", 2, 5], ["large", "OBSERVATION_MODIFIER", 53, 58], ["amounts", "OBSERVATION_MODIFIER", 59, 66]]], ["Some of this work is directly aimed at finding ways to prevent drug resistance evolution or spread, whereas other work is more basic in nature and mostly uses the pathogen as a model system to learn about evolution in general.", [["drug resistance evolution", "PROBLEM", 63, 88]]], ["In the best cases, we learn lessons on how to prevent resistance and on general evolutionary principles simultaneously.IntroductionThe aim of this review was to introduce researchers from different fields to new and exciting work on drug resistance evolution happening at the intersection of population genetics and medical fields such as virology and infectious disease.", [["infectious disease", "DISEASE", 352, 370], ["resistance", "PROBLEM", 54, 64], ["drug resistance evolution", "PROBLEM", 233, 258], ["infectious", "OBSERVATION", 352, 362]]], ["Perhaps more importantly this review is intended as an advertisement of the strengths of using natural pathogen populations to study evolutionary principles as well as the strengths of using evolutionary theory to better understand the dynamics of infectious diseases.", [["infectious diseases", "DISEASE", 248, 267], ["natural pathogen populations", "TREATMENT", 95, 123], ["infectious diseases", "PROBLEM", 248, 267], ["infectious", "OBSERVATION", 248, 258]]], ["To this end, we present five case studies at the intersection of evolutionary theory and pathogen drug resistance.", [["pathogen drug resistance", "PROBLEM", 89, 113], ["drug resistance", "OBSERVATION", 98, 113]]], ["While the five examples we have chosen are not meant to be exhaustive in any way, each example showcases an evolutionary question in the context of a different pathogen, each with a unique biology and differences in genome size, methods of genetic exchange, reproduction and recombination (see Box 1).IntroductionWe will describe the following five examples:Introduction1 Selective sweep mapping in the malaria parasite P. falciparum resistant to the antimalarial drug artemisinin.", [["malaria parasite P. falciparum", "DISEASE", 403, 433], ["artemisinin", "CHEMICAL", 469, 480], ["artemisinin", "CHEMICAL", 469, 480], ["P. falciparum", "ORGANISM", 420, 433], ["artemisinin", "SIMPLE_CHEMICAL", 469, 480], ["P. falciparum", "SPECIES", 420, 433], ["P. falciparum", "SPECIES", 420, 433], ["a different pathogen", "PROBLEM", 148, 168], ["genetic exchange", "TREATMENT", 240, 256], ["Selective sweep mapping", "TREATMENT", 372, 395], ["the malaria parasite", "PROBLEM", 399, 419], ["falciparum", "PROBLEM", 423, 433], ["the antimalarial drug artemisinin", "TREATMENT", 447, 480], ["different", "OBSERVATION_MODIFIER", 150, 159], ["pathogen", "OBSERVATION", 160, 168], ["size", "OBSERVATION_MODIFIER", 223, 227], ["antimalarial drug", "OBSERVATION", 451, 468]]], ["This is a great example of how population genetic methods originally developed for other sexually recombining eukaryotic organisms, such as humans, could be applied to P. falciparum, which experiences a very high rate of sexual recombination.", [["P. falciparum", "DISEASE", 168, 181], ["humans", "ORGANISM", 140, 146], ["P. falciparum", "ORGANISM", 168, 181], ["humans", "SPECIES", 140, 146], ["P. falciparum", "SPECIES", 168, 181], ["humans", "SPECIES", 140, 146], ["P. falciparum", "SPECIES", 168, 181], ["other sexually recombining eukaryotic organisms", "PROBLEM", 83, 130], ["P. falciparum", "PROBLEM", 168, 181]]], ["The mapping of the drug resistance mutations in P. falciparum has allowed researchers to track the prevalence of artemisinin resistance worldwide.", [["P. falciparum", "DISEASE", 48, 61], ["artemisinin", "CHEMICAL", 113, 124], ["artemisinin", "CHEMICAL", 113, 124], ["P. falciparum", "ORGANISM", 48, 61], ["artemisinin", "SIMPLE_CHEMICAL", 113, 124], ["P. falciparum", "SPECIES", 48, 61], ["P. falciparum", "SPECIES", 48, 61], ["the drug resistance mutations", "TREATMENT", 15, 44], ["P. falciparum", "PROBLEM", 48, 61], ["artemisinin resistance worldwide", "TREATMENT", 113, 145], ["drug resistance", "OBSERVATION", 19, 34], ["artemisinin resistance", "OBSERVATION", 113, 135]]], ["2 The role of epistasis in oseltamivir (Tamiflu) resistance in influenza.", [["oseltamivir", "CHEMICAL", 27, 38], ["Tamiflu", "CHEMICAL", 40, 47], ["influenza", "DISEASE", 63, 72], ["oseltamivir", "CHEMICAL", 27, 38], ["Tamiflu", "CHEMICAL", 40, 47], ["oseltamivir", "SIMPLE_CHEMICAL", 27, 38], ["Tamiflu", "SIMPLE_CHEMICAL", 40, 47], ["epistasis", "PROBLEM", 14, 23], ["oseltamivir (Tamiflu", "TREATMENT", 27, 47], ["influenza", "PROBLEM", 63, 72], ["epistasis", "OBSERVATION", 14, 23], ["influenza", "OBSERVATION", 63, 72]]], ["The evolution and spread of oseltamivir resistance in influenza in 2007-2008 was unexpected.", [["oseltamivir", "CHEMICAL", 28, 39], ["influenza", "DISEASE", 54, 63], ["oseltamivir", "CHEMICAL", 28, 39], ["oseltamivir", "SIMPLE_CHEMICAL", 28, 39], ["oseltamivir resistance", "PROBLEM", 28, 50], ["influenza", "PROBLEM", 54, 63], ["spread", "OBSERVATION_MODIFIER", 18, 24], ["oseltamivir resistance", "OBSERVATION", 28, 50]]], ["Even though the causal mutation for oseltamivir resistance was known, it was thought to be too costly to viral fitness to spread widely.", [["oseltamivir", "CHEMICAL", 36, 47], ["oseltamivir", "CHEMICAL", 36, 47], ["oseltamivir", "SIMPLE_CHEMICAL", 36, 47], ["the causal mutation", "PROBLEM", 12, 31], ["oseltamivir resistance", "PROBLEM", 36, 58], ["viral fitness", "PROBLEM", 105, 118]]], ["Phylogenetic methods allowed researchers to discover mutations that interacted with the resistance mutation to ameliorate its detrimental effects, allowing the resistance mutation to spread.", [["Phylogenetic methods", "TREATMENT", 0, 20], ["mutations", "PROBLEM", 53, 62], ["the resistance mutation", "PROBLEM", 84, 107], ["the resistance mutation", "PROBLEM", 156, 179]]], ["Influenza has become a model that helps researchers understand the importance of genetic interactions between sites during the course of evolution and the potential for predicting future evolution.", [["Influenza", "DISEASE", 0, 9], ["Influenza", "PROBLEM", 0, 9], ["genetic interactions between sites", "PROBLEM", 81, 115]]], ["3 The importance of standing genetic variation (SGV) (also referred to as minority variants) to treatment failure for human immunodeficiency virus (HIV).", [["human immunodeficiency virus (HIV)", "DISEASE", 118, 152], ["human immunodeficiency virus", "ORGANISM", 118, 146], ["HIV", "ORGANISM", 148, 151], ["human", "SPECIES", 118, 123], ["immunodeficiency virus", "SPECIES", 124, 146], ["HIV", "SPECIES", 148, 151], ["human immunodeficiency virus", "SPECIES", 118, 146], ["HIV", "SPECIES", 148, 151], ["treatment failure", "PROBLEM", 96, 113], ["human immunodeficiency virus", "PROBLEM", 118, 146]]], ["Drug resistance mutations are well known in HIV and the evolution of drug resistance happens independently in different patients.", [["HIV", "ORGANISM", 44, 47], ["patients", "ORGANISM", 120, 128], ["HIV", "SPECIES", 44, 47], ["patients", "SPECIES", 120, 128], ["HIV", "SPECIES", 44, 47], ["Drug resistance mutations", "PROBLEM", 0, 25], ["HIV", "PROBLEM", 44, 47], ["drug resistance", "PROBLEM", 69, 84], ["drug resistance", "OBSERVATION", 69, 84]]], ["This makes it possible to determine the importance of SGV for drug resistance in HIV.", [["SGV", "CHEMICAL", 54, 57], ["SGV", "GENE_OR_GENE_PRODUCT", 54, 57], ["HIV", "ORGANISM", 81, 84], ["HIV", "SPECIES", 81, 84], ["HIV", "SPECIES", 81, 84], ["drug resistance", "PROBLEM", 62, 77], ["HIV", "PROBLEM", 81, 84]]], ["Several studies found that both SGV and de novo mutations contribute to drug resistance in HIV.", [["SGV", "GENE_OR_GENE_PRODUCT", 32, 35], ["HIV", "ORGANISM", 91, 94], ["HIV", "SPECIES", 91, 94], ["HIV", "SPECIES", 91, 94], ["Several studies", "TEST", 0, 15], ["both SGV and de novo mutations", "PROBLEM", 27, 57], ["drug resistance in HIV", "PROBLEM", 72, 94], ["drug resistance", "OBSERVATION", 72, 87]]], ["4 Clonal interference dynamics in Mycobacterium tuberculosis.", [["Mycobacterium tuberculosis", "DISEASE", 34, 60], ["Mycobacterium tuberculosis", "ORGANISM", 34, 60], ["Mycobacterium tuberculosis", "SPECIES", 34, 60], ["Mycobacterium tuberculosis", "SPECIES", 34, 60], ["Mycobacterium tuberculosis", "PROBLEM", 34, 60], ["Mycobacterium tuberculosis", "OBSERVATION", 34, 60]]], ["Drug resistance mutations are also well known in M. tuberculosis.", [["tuberculosis", "DISEASE", 52, 64], ["M. tuberculosis", "ORGANISM", 49, 64], ["M. tuberculosis", "SPECIES", 49, 64], ["M. tuberculosis", "SPECIES", 49, 64], ["Drug resistance mutations", "PROBLEM", 0, 25], ["tuberculosis", "OBSERVATION", 52, 64]]], ["Through tracking these mutations, recent studies have revealed that clonal interference plays a large role in the evolutionary dynamics within patients.", [["patients", "ORGANISM", 143, 151], ["patients", "SPECIES", 143, 151], ["recent studies", "TEST", 34, 48], ["clonal interference", "PROBLEM", 68, 87], ["large", "OBSERVATION_MODIFIER", 96, 101]]], ["An examination of these dynamics offers insights into how multiply-resistant strains emerge and also provides a rare look into a natural population evolving without recombination.", [["An examination", "TEST", 0, 14], ["resistant strains", "PROBLEM", 67, 84]]], ["5 Population structure analysis of the core and accessory genome of methicillin-resistant Staphylococcus aureus (MRSA).", [["methicillin", "CHEMICAL", 68, 79], ["Staphylococcus aureus", "DISEASE", 90, 111], ["methicillin", "CHEMICAL", 68, 79], ["methicillin-resistant Staphylococcus aureus", "ORGANISM", 68, 111], ["MRSA", "CANCER", 113, 117], ["core and accessory genome", "DNA", 39, 64], ["Staphylococcus aureus", "SPECIES", 90, 111], ["MRSA", "SPECIES", 113, 117], ["Staphylococcus aureus", "SPECIES", 90, 111], ["MRSA", "SPECIES", 113, 117], ["Population structure analysis", "TEST", 2, 31], ["the core", "TEST", 35, 43], ["methicillin-resistant Staphylococcus aureus", "PROBLEM", 68, 111], ["MRSA", "PROBLEM", 113, 117], ["accessory", "ANATOMY_MODIFIER", 48, 57], ["genome", "ANATOMY", 58, 64], ["methicillin", "OBSERVATION_MODIFIER", 68, 79], ["resistant", "OBSERVATION_MODIFIER", 80, 89], ["Staphylococcus aureus", "OBSERVATION", 90, 111], ["MRSA", "OBSERVATION", 113, 117]]], ["Staphylococcus aureus reproduces clonally, yet drug resistance is often acquired via the spread of mobile genetic elements (or horizontal gene transfer), such as the gene cassette SCCmec that confers methicillin resistance.", [["Staphylococcus aureus", "DISEASE", 0, 21], ["methicillin", "CHEMICAL", 200, 211], ["methicillin", "CHEMICAL", 200, 211], ["Staphylococcus aureus", "ORGANISM", 0, 21], ["methicillin", "SIMPLE_CHEMICAL", 200, 211], ["mobile genetic elements", "DNA", 99, 122], ["SCCmec", "DNA", 180, 186], ["Staphylococcus aureus", "SPECIES", 0, 21], ["Staphylococcus aureus", "SPECIES", 0, 21], ["Staphylococcus aureus", "PROBLEM", 0, 21], ["drug resistance", "PROBLEM", 47, 62], ["the gene cassette SCCmec", "TREATMENT", 162, 186], ["methicillin resistance", "PROBLEM", 200, 222], ["aureus", "OBSERVATION", 15, 21], ["methicillin resistance", "OBSERVATION", 200, 222]]], ["While the genealogy of the core genome of MRSA reveals that relatively few lineages have spread across the globe, phylogenetic analysis been deployed, but resistance to these drugs has developed repeatedly.", [["MRSA", "CANCER", 42, 46], ["core genome", "DNA", 27, 38], ["MRSA", "SPECIES", 42, 46], ["MRSA", "PROBLEM", 42, 46], ["these drugs", "TREATMENT", 169, 180], ["MRSA", "OBSERVATION", 42, 46], ["relatively", "OBSERVATION_MODIFIER", 60, 70], ["few", "OBSERVATION_MODIFIER", 71, 74], ["lineages", "OBSERVATION_MODIFIER", 75, 83], ["spread", "OBSERVATION_MODIFIER", 89, 95], ["globe", "ANATOMY", 107, 112]]], ["The current front-line treatment, artemisinin-based combination therapies (ACTs), was introduced in the 1990s at a time when all other drugs were failing.", [["artemisinin", "CHEMICAL", 34, 45], ["artemisinin", "CHEMICAL", 34, 45], ["artemisinin", "SIMPLE_CHEMICAL", 34, 45], ["The current front-line treatment", "TREATMENT", 0, 32], ["artemisinin", "TREATMENT", 34, 45], ["all other drugs", "TREATMENT", 125, 140], ["line treatment", "OBSERVATION", 18, 32]]], ["While ACTs were initially very effective, by 2003, the first signs of resistance to artemisinin emerged in South-East Asia, and now resistance is widespread (Noedl et al. 2008; Dondorp et al. 2009 Dondorp et al. , 2010 Kyaw et al. 2013; Ashley et al. 2014) .IntroductionTo better track the global spread of resistance to antimalarial drugs and understand the mechanism by which resistance develops, it is essential to know the locations in the P. falciparum genome conferring resistance.", [["artemisinin", "CHEMICAL", 84, 95], ["P. falciparum", "DISEASE", 444, 457], ["artemisinin", "CHEMICAL", 84, 95], ["ACTs", "SIMPLE_CHEMICAL", 6, 10], ["artemisinin", "SIMPLE_CHEMICAL", 84, 95], ["P. falciparum", "ORGANISM", 444, 457], ["P. falciparum", "SPECIES", 444, 457], ["P. falciparum", "SPECIES", 444, 457], ["Introduction", "TREATMENT", 258, 270], ["antimalarial drugs", "TREATMENT", 321, 339], ["the P. falciparum genome", "TREATMENT", 440, 464], ["widespread", "OBSERVATION_MODIFIER", 146, 156]]], ["Here, we review the population genetic methods used to identify the kelch gene on chromosome 13 conferring resistance to artemisinin-a locus that until recently had gone relatively unnoticed and whose biological function is still unknown-and the experimental methods used to confirm the causal mutations.", [["artemisinin", "CHEMICAL", 121, 132], ["artemisinin", "CHEMICAL", 121, 132], ["kelch", "GENE_OR_GENE_PRODUCT", 68, 73], ["chromosome 13", "CELLULAR_COMPONENT", 82, 95], ["artemisinin", "SIMPLE_CHEMICAL", 121, 132], ["kelch gene", "DNA", 68, 78], ["chromosome 13", "DNA", 82, 95], ["artemisinin", "TREATMENT", 121, 132], ["the experimental methods", "TEST", 242, 266]]], ["We highlight P. falciparum in this review because it is a pathogen that experiences strong selective pressures and, unlike most human pathogens, it is a eukaryotic organism that experiences high rates of recombination (see Box 2).", [["P. falciparum", "DISEASE", 13, 26], ["P. falciparum", "ORGANISM", 13, 26], ["human", "ORGANISM", 128, 133], ["P. falciparum", "SPECIES", 13, 26], ["human", "SPECIES", 128, 133], ["P. falciparum", "SPECIES", 13, 26], ["human", "SPECIES", 128, 133], ["a pathogen", "PROBLEM", 56, 66], ["most human pathogens", "PROBLEM", 123, 143], ["a eukaryotic organism", "PROBLEM", 151, 172], ["pressures", "OBSERVATION_MODIFIER", 101, 110], ["most human", "OBSERVATION_MODIFIER", 123, 133], ["pathogens", "OBSERVATION", 134, 143]]], ["As we show, these properties of Box 2.", [["Box 2", "GENE_OR_GENE_PRODUCT", 32, 37], ["Box 2", "PROTEIN", 32, 37]]], ["Common methods to detect selective sweeps in recombining eukaryotes, including Plasmodium falciparum In a selective sweep, an adaptive mutation rises in frequency in the population, dragging with it the linked genetic material on the same haplotype background to high frequency via hitchhiking (Maynard Smith & Haigh 1974; Kaplan et al. 1989; Kim & Stephan 2002) .", [["Plasmodium falciparum", "DISEASE", 79, 100], ["Plasmodium falciparum", "ORGANISM", 79, 100], ["Plasmodium falciparum", "SPECIES", 79, 100], ["Plasmodium falciparum", "SPECIES", 79, 100], ["Common methods", "TREATMENT", 0, 14], ["selective sweeps in recombining eukaryotes", "PROBLEM", 25, 67], ["Plasmodium falciparum", "TREATMENT", 79, 100], ["a selective sweep", "TREATMENT", 104, 121], ["an adaptive mutation rises", "PROBLEM", 123, 149], ["rises", "OBSERVATION_MODIFIER", 144, 149], ["high frequency", "OBSERVATION_MODIFIER", 263, 277]]], ["This can result in a pattern of low genetic variation, high linkage disequilibrium (LD) and high haplotype homozygosity in the vicinity of the adaptive mutation.", [["low genetic variation", "PROBLEM", 32, 53], ["high linkage disequilibrium (LD)", "PROBLEM", 55, 87], ["high haplotype homozygosity", "PROBLEM", 92, 119], ["the adaptive mutation", "PROBLEM", 139, 160], ["low genetic variation", "OBSERVATION", 32, 53], ["high haplotype homozygosity", "OBSERVATION", 92, 119], ["adaptive mutation", "OBSERVATION", 143, 160]]], ["Plasmodium falciparum experiences a high rate of recombination [58 cM/Mb (Su et al. 1999; Jiang et al. 2011) in contrast to 0.6, 0.56, 1.26, and 2.32 cM/Mb in rats, mice, humans and Drosophila melanogaster respectively (Jensen-Seaman et al. 2004; Comeron et al. 2012) ] and strong selective pressures from the presence of antimalarial drugs, thereby allowing LDbased statistics to identify regions in its 23 Mb genome under selection with high resolution.IntroductionThere are several statistics that utilize LD and haplotype homozygosity information to identify selective sweeps, including extended haplotype homozygosity (EHH), cross population extended haplotype homozygosity (XP-EHH), as well as iHS, nSL and H12 (Sabeti et al. 2002 (Sabeti et al. , 2007 Voight et al. 2006; Ferrer-Admetlla et al. 2014; Garud et al. 2015) .", [["Plasmodium falciparum", "DISEASE", 0, 21], ["Plasmodium falciparum", "ORGANISM", 0, 21], ["rats", "ORGANISM", 159, 163], ["mice", "ORGANISM", 165, 169], ["humans", "ORGANISM", 171, 177], ["Drosophila melanogaster", "ORGANISM", 182, 205], ["23 Mb genome", "DNA", 405, 417], ["EHH", "DNA", 624, 627], ["XP", "DNA", 680, 682], ["EHH", "DNA", 683, 686], ["iHS", "DNA", 700, 703], ["nSL", "DNA", 705, 708], ["H12", "DNA", 713, 716], ["Plasmodium falciparum", "SPECIES", 0, 21], ["rats", "SPECIES", 159, 163], ["mice", "SPECIES", 165, 169], ["humans", "SPECIES", 171, 177], ["Drosophila melanogaster", "SPECIES", 182, 205], ["Plasmodium falciparum", "SPECIES", 0, 21], ["mice", "SPECIES", 165, 169], ["humans", "SPECIES", 171, 177], ["Drosophila melanogaster", "SPECIES", 182, 205], ["Plasmodium falciparum", "PROBLEM", 0, 21], ["Mb in rats", "TEST", 153, 163], ["strong selective pressures", "TREATMENT", 274, 300], ["antimalarial drugs", "TREATMENT", 322, 340], ["selective sweeps", "PROBLEM", 563, 579], ["extended haplotype homozygosity", "PROBLEM", 591, 622], ["falciparum", "OBSERVATION", 11, 21], ["antimalarial drugs", "OBSERVATION", 322, 340], ["high resolution", "OBSERVATION_MODIFIER", 439, 454], ["H12", "ANATOMY", 713, 716]]], ["EHH and XP-EHH have been particularly popular and successful in the detection of sites under selection in P. falciparum.", [["EHH", "CHEMICAL", 0, 3], ["XP", "CHEMICAL", 8, 10], ["P. falciparum", "DISEASE", 106, 119], ["XP-EHH", "GENE_OR_GENE_PRODUCT", 8, 14], ["P. falciparum", "ORGANISM", 106, 119], ["P. falciparum", "SPECIES", 106, 119], ["P. falciparum", "SPECIES", 106, 119], ["EHH", "TEST", 0, 3], ["XP", "TEST", 8, 10], ["P. falciparum", "PROBLEM", 106, 119]]], ["EHH measures the decay in tracts of homozygosity radiating away from a SNP at a partial frequency in a single population (Sabeti et al. 2002) .", [["SNP", "CHEMICAL", 71, 74], ["EHH", "DNA", 0, 3], ["homozygosity", "PROBLEM", 36, 48], ["a SNP", "PROBLEM", 69, 74]]], ["However, EHH is not powerful in detecting a selective sweep that has gone to fixation (Sabeti et al. 2002) .", [["a selective sweep", "PROBLEM", 42, 59], ["fixation", "TREATMENT", 77, 85]]], ["In contrast, XP-EHH utilizes information from two populations, one where a sweep has presumably occurred, and another where a sweep has not (Sabeti et al. 2007) .", [["XP-EHH", "GENE_OR_GENE_PRODUCT", 13, 19], ["XP-EHH", "DNA", 13, 19]]], ["XP-EHH is thus powerful in detecting partial and complete sweeps that have occurred in one of the two populations considered.", [["XP", "CHEMICAL", 0, 2], ["partial and complete sweeps", "PROBLEM", 37, 64], ["partial", "OBSERVATION_MODIFIER", 37, 44], ["sweeps", "OBSERVATION", 58, 64]]], ["In addition to LD-based statistics, there are several site frequency spectrum (SFS) statistics which treat individual polymorphic sites in a sample independently from one another.", [["LD", "DNA", 15, 17], ["polymorphic sites", "DNA", 118, 135], ["individual polymorphic sites", "PROBLEM", 107, 135]]], ["Statistics such as Tajima's D (Tajima 1989) , Fay and Wu's H (Fay & Wu 2000; Fay et al. 2002) , and Sweepfinder (Nielsen et al. 2005 ) are sensitive to dips in neutral diversity and excesses in low and high frequency polymorphisms in the SFS (Braverman et al. 1995; Vitti et al. 2013) .", [["dips in neutral diversity", "PROBLEM", 152, 177], ["excesses in low and high frequency polymorphisms", "PROBLEM", 182, 230], ["high frequency", "OBSERVATION_MODIFIER", 202, 216]]], ["Another widely used SFS statistic is F ST (Lewontin & Krakauer 1973) , which compares genomic patterns between two populations.", [["ST (Lewontin & Krakauer", "TREATMENT", 39, 62]]], ["More specifically, F ST measures the difference in average pairwise diversity measured in randomly sampled individuals across two different populations vs. within a single population, and can thus be an indicator of positive selection if one population diverges extremely in diversity from another.", [["F ST", "DNA", 19, 23], ["average pairwise diversity", "PROBLEM", 51, 77], ["difference", "OBSERVATION_MODIFIER", 37, 47], ["average", "OBSERVATION_MODIFIER", 51, 58], ["pairwise", "OBSERVATION_MODIFIER", 59, 67], ["diversity", "OBSERVATION_MODIFIER", 68, 77], ["different", "OBSERVATION_MODIFIER", 130, 139], ["populations", "OBSERVATION_MODIFIER", 140, 151]]], ["As we explain in this review, F ST has been successfully used in conjunction with EHH and XP-EHH to detect selected sites in P. falciparum across multiple populations.IntroductionAssociation tests are a LD-based approach often used to identify drug resistance loci in multiple study systems.", [["P. falciparum", "DISEASE", 125, 138], ["XP-EHH", "GENE_OR_GENE_PRODUCT", 90, 96], ["P. falciparum", "ORGANISM", 125, 138], ["P. falciparum", "SPECIES", 125, 138], ["P. falciparum", "SPECIES", 125, 138], ["XP", "TEST", 90, 92], ["selected sites", "PROBLEM", 107, 121], ["P. falciparum across multiple populations", "PROBLEM", 125, 166], ["IntroductionAssociation tests", "TEST", 167, 196], ["a LD-based approach", "TREATMENT", 201, 220], ["drug resistance loci in multiple study systems", "PROBLEM", 244, 290], ["P. falciparum", "OBSERVATION", 125, 138], ["multiple", "OBSERVATION_MODIFIER", 146, 154]]], ["Association tests correlate a phenotype with the allelic states of polymorphisms in a sample from a single population (Anderson et al. 2011 ).", [["Association tests", "TEST", 0, 17], ["a phenotype", "PROBLEM", 28, 39]]], ["In the case of P. falciparum, artemisinin resistance is characterized by slow parasite clearance rates, measured as the rate of decay in parasite density in the blood over time (Noedl et al. 2008; Dondorp et al. 2009 ).", [["blood", "ANATOMY", 161, 166], ["P. falciparum", "DISEASE", 15, 28], ["artemisinin", "CHEMICAL", 30, 41], ["artemisinin", "CHEMICAL", 30, 41], ["P. falciparum", "ORGANISM", 15, 28], ["artemisinin", "SIMPLE_CHEMICAL", 30, 41], ["blood", "ORGANISM_SUBSTANCE", 161, 166], ["P. falciparum", "SPECIES", 15, 28], ["P. falciparum", "SPECIES", 15, 28], ["P. falciparum", "PROBLEM", 15, 28], ["artemisinin resistance", "TREATMENT", 30, 52], ["slow parasite clearance rates", "PROBLEM", 73, 102], ["parasite density", "PROBLEM", 137, 153], ["falciparum", "OBSERVATION", 18, 28], ["artemisinin resistance", "OBSERVATION", 30, 52], ["parasite", "OBSERVATION_MODIFIER", 137, 145], ["density", "OBSERVATION", 146, 153], ["blood", "ANATOMY", 161, 166]]], ["Therefore, this phenotype is used in studies to identify the underlying mutations conferring resistance to artemisinin.", [["artemisinin", "CHEMICAL", 107, 118], ["artemisinin", "CHEMICAL", 107, 118], ["artemisinin", "SIMPLE_CHEMICAL", 107, 118], ["the underlying mutations", "PROBLEM", 57, 81], ["artemisinin", "TREATMENT", 107, 118]]], ["Association studies can result in many false positives because of a number of confounding factors such as population substructure and relatedness between individuals in a sample.", [["Association studies", "TEST", 0, 19], ["many false positives", "PROBLEM", 34, 54], ["confounding factors", "PROBLEM", 78, 97], ["population substructure", "PROBLEM", 106, 129], ["false positives", "OBSERVATION", 39, 54]]], ["Furthermore, association studies can be computationally slow in large sample sizes with large numbers of polymorphic sites.", [["polymorphic sites", "DNA", 105, 122], ["association studies", "TEST", 13, 32], ["computationally slow in large sample sizes", "PROBLEM", 40, 82], ["large numbers of polymorphic sites", "PROBLEM", 88, 122], ["large", "OBSERVATION_MODIFIER", 64, 69], ["sizes", "OBSERVATION_MODIFIER", 77, 82], ["large", "OBSERVATION_MODIFIER", 88, 93], ["numbers", "OBSERVATION_MODIFIER", 94, 101], ["polymorphic sites", "OBSERVATION", 105, 122]]], ["Efficient mixed models association (EMMA) is an association technique that aims to address these factors (Kang et al. 2008) .", [["mixed models", "OBSERVATION", 10, 22]]], ["P. falciparum make it relatively straightforward to apply standard population genetics methods to malaria in order to detect selected sites with great success, even though these methods were often designed for other eukaryotic model organisms.IntroductionUsing a variety of methods, several loci that confer resistance to older antimalarial drugs such as mefloquine, chloroquine, sulfadoxine-pyrimethamine and atovaquone (e.g. genes encoding the chloroquine resistance transporter, multidrug resistance protein, GTP-cyclohydrolase I, dihydropteroate synthetase, dihydrofolate reductase and cytochrome B) have been identified (Wootton et al. 2002; Nair et al. 2003; Ferdig et al. 2004; Sidhu et al. 2005; Musset et al. 2007; Vinayak et al. 2010; Anderson et al. 2011; Mita et al. 2011) .", [["P. falciparum", "DISEASE", 0, 13], ["malaria", "DISEASE", 98, 105], ["mefloquine", "CHEMICAL", 355, 365], ["chloroquine", "CHEMICAL", 367, 378], ["sulfadoxine-pyrimethamine", "CHEMICAL", 380, 405], ["atovaquone", "CHEMICAL", 410, 420], ["chloroquine", "CHEMICAL", 446, 457], ["dihydropteroate", "CHEMICAL", 534, 549], ["mefloquine", "CHEMICAL", 355, 365], ["chloroquine", "CHEMICAL", 367, 378], ["sulfadoxine-pyrimethamine", "CHEMICAL", 380, 405], ["atovaquone", "CHEMICAL", 410, 420], ["chloroquine", "CHEMICAL", 446, 457], ["dihydropteroate", "CHEMICAL", 534, 549], ["P. falciparum", "ORGANISM", 0, 13], ["mefloquine", "SIMPLE_CHEMICAL", 355, 365], ["chloroquine", "SIMPLE_CHEMICAL", 367, 378], ["sulfadoxine-pyrimethamine", "SIMPLE_CHEMICAL", 380, 405], ["atovaquone", "SIMPLE_CHEMICAL", 410, 420], ["chloroquine", "SIMPLE_CHEMICAL", 446, 457], ["multidrug resistance protein", "GENE_OR_GENE_PRODUCT", 482, 510], ["GTP-cyclohydrolase I", "GENE_OR_GENE_PRODUCT", 512, 532], ["dihydropteroate synthetase", "GENE_OR_GENE_PRODUCT", 534, 560], ["dihydrofolate reductase", "GENE_OR_GENE_PRODUCT", 562, 585], ["cytochrome B", "GENE_OR_GENE_PRODUCT", 590, 602], ["chloroquine resistance transporter", "PROTEIN", 446, 480], ["multidrug resistance protein", "PROTEIN", 482, 510], ["GTP-cyclohydrolase I", "PROTEIN", 512, 532], ["dihydropteroate synthetase", "PROTEIN", 534, 560], ["dihydrofolate reductase", "PROTEIN", 562, 585], ["cytochrome B", "PROTEIN", 590, 602], ["P. falciparum", "SPECIES", 0, 13], ["P. falciparum", "SPECIES", 0, 13], ["P. falciparum", "PROBLEM", 0, 13], ["malaria", "PROBLEM", 98, 105], ["these methods", "TEST", 172, 185], ["other eukaryotic model organisms", "PROBLEM", 210, 242], ["a variety of methods", "TREATMENT", 261, 281], ["older antimalarial drugs", "TREATMENT", 322, 346], ["mefloquine", "TREATMENT", 355, 365], ["chloroquine", "TREATMENT", 367, 378], ["sulfadoxine", "TREATMENT", 380, 391], ["pyrimethamine", "TREATMENT", 392, 405], ["atovaquone", "TREATMENT", 410, 420], ["(e.g. genes", "TREATMENT", 421, 432], ["the chloroquine resistance transporter", "TREATMENT", 442, 480], ["multidrug resistance protein", "TREATMENT", 482, 510], ["GTP", "TEST", 512, 515], ["cyclohydrolase I", "TREATMENT", 516, 532], ["dihydropteroate synthetase", "TREATMENT", 534, 560], ["dihydrofolate reductase", "TREATMENT", 562, 585], ["cytochrome B", "TREATMENT", 590, 602]]], ["Close examination of the genomic signatures immediately surrounding these loci reveals patterns of reduced diversity, elevated linkage disequilibrium (LD), and the presence of long haplotypes at high frequency (Wootton et al. 2002; Nair et al. 2003; Roper et al. 2004; Vinayak et al. 2010) , all of which are associated with signatures of selective sweeps (Maynard Smith & Haigh 1974; Kaplan et al. 1989; Kim & Stephan 2002) .", [["Close examination", "TEST", 0, 17], ["the genomic signatures", "TEST", 21, 43], ["reduced diversity", "PROBLEM", 99, 116], ["elevated linkage disequilibrium (LD)", "PROBLEM", 118, 154], ["long haplotypes", "PROBLEM", 176, 191], ["reduced", "OBSERVATION_MODIFIER", 99, 106], ["diversity", "OBSERVATION_MODIFIER", 107, 116], ["elevated", "OBSERVATION_MODIFIER", 118, 126], ["linkage disequilibrium", "OBSERVATION", 127, 149]]], ["The distinct genomic signatures resulting from drug resistance in P. falciparum suggest that novel loci conferring resistance to artemisinin can be discovered by searching for patterns of elevated LD and haplotype homozygosity.", [["P. falciparum", "DISEASE", 66, 79], ["artemisinin", "CHEMICAL", 129, 140], ["artemisinin", "CHEMICAL", 129, 140], ["P. falciparum", "ORGANISM", 66, 79], ["artemisinin", "SIMPLE_CHEMICAL", 129, 140], ["P. falciparum", "SPECIES", 66, 79], ["P. falciparum", "SPECIES", 66, 79], ["The distinct genomic signatures", "PROBLEM", 0, 31], ["drug resistance in P. falciparum", "PROBLEM", 47, 79], ["novel loci conferring resistance to artemisinin", "PROBLEM", 93, 140], ["elevated LD and haplotype homozygosity", "PROBLEM", 188, 226], ["distinct", "OBSERVATION_MODIFIER", 4, 12], ["genomic signatures", "OBSERVATION", 13, 31], ["drug resistance", "OBSERVATION", 47, 62]]], ["In Box 2, we discuss some of the popular population genomic methods used to identify selective sweeps and resistant loci in P. falciparum, including LD statistics such as XP-EHH (Sabeti et al. 2007) , SFS statistics used to corroborate findings made with LD statistics, such as F ST (Lewontin & Krakauer 1973) and genomewide association studies.IntroductionPopulation genomic methods identify a region on chromosome 13 associated with artemisinin resistance Three recent studies by Cheeseman et al. (2012) , Takala-Harrison et al. (2013) , and Miotto et al. (2013) examined patterns of LD and haplotype homozygosity in the P. falciparum genome and identified a region on chromosome 13 associated with artemisinin resistance.", [["chromosome 13", "ANATOMY", 405, 418], ["chromosome", "ANATOMY", 671, 681], ["P. falciparum", "DISEASE", 124, 137], ["artemisinin", "CHEMICAL", 435, 446], ["P. falciparum", "DISEASE", 623, 636], ["artemisinin", "CHEMICAL", 701, 712], ["artemisinin", "CHEMICAL", 435, 446], ["artemisinin", "CHEMICAL", 701, 712], ["P. falciparum", "ORGANISM", 124, 137], ["chromosome 13", "CELLULAR_COMPONENT", 405, 418], ["artemisinin", "SIMPLE_CHEMICAL", 435, 446], ["P. falciparum", "ORGANISM", 623, 636], ["chromosome 13", "CELLULAR_COMPONENT", 671, 684], ["artemisinin", "SIMPLE_CHEMICAL", 701, 712], ["chromosome 13", "DNA", 405, 418], ["P. falciparum genome", "DNA", 623, 643], ["chromosome 13", "DNA", 671, 684], ["P. falciparum", "SPECIES", 124, 137], ["P. falciparum", "SPECIES", 623, 636], ["P. falciparum", "SPECIES", 124, 137], ["P. falciparum", "SPECIES", 623, 636], ["selective sweeps", "PROBLEM", 85, 101], ["resistant loci in P. falciparum", "PROBLEM", 106, 137], ["genomewide association studies", "TEST", 314, 344], ["IntroductionPopulation genomic methods", "TREATMENT", 345, 383], ["artemisinin resistance", "PROBLEM", 435, 457], ["LD and haplotype homozygosity", "PROBLEM", 586, 615], ["the P. falciparum genome", "PROBLEM", 619, 643], ["artemisinin resistance", "PROBLEM", 701, 723], ["falciparum genome", "OBSERVATION", 626, 643], ["artemisinin resistance", "OBSERVATION", 701, 723]]], ["This locus was later characterized as the kelch13 locus (Ariey et al. 2014) .", [["locus", "CELLULAR_COMPONENT", 5, 10], ["kelch13 locus", "DNA", 42, 55]]], ["These three studies benefited greatly from deep samples of P. falciparum from multiple populations, some of which displayed the artemisinin drug resistance phenotype of slow parasite clearance rate while others did not (Noedl et al. 2008; Dondorp et al. 2009 ).", [["samples", "ANATOMY", 48, 55], ["P. falciparum", "DISEASE", 59, 72], ["artemisinin", "CHEMICAL", 128, 139], ["artemisinin", "CHEMICAL", 128, 139], ["P. falciparum", "ORGANISM", 59, 72], ["artemisinin", "SIMPLE_CHEMICAL", 128, 139], ["P. falciparum", "SPECIES", 59, 72], ["P. falciparum", "SPECIES", 59, 72], ["These three studies", "TEST", 0, 19], ["P. falciparum", "PROBLEM", 59, 72], ["slow parasite clearance rate", "PROBLEM", 169, 197], ["artemisinin", "OBSERVATION", 128, 139], ["drug resistance", "OBSERVATION", 140, 155]]], ["This data allowed the authors to contrast genomic patterns in strains from geographical locations displaying the slow parasite clearance rate phenotype vs. those that did not.IntroductionIn the first major study, Cheeseman et al. (2012) examined genomic data from samples from three popu-lations: Laos, Thailand and Cambodia, where resistance is observed only in Thailand and Cambodia (Cheeseman et al. 2012) .", [["the slow parasite clearance rate phenotype", "PROBLEM", 109, 151], ["genomic data", "TEST", 246, 258]]], ["This data set offered the opportunity to contrast the Thai and Cambodia samples with Laos to discover putative loci conferring resistance to artemisinin.", [["artemisinin", "CHEMICAL", 141, 152], ["artemisinin", "CHEMICAL", 141, 152], ["artemisinin", "SIMPLE_CHEMICAL", 141, 152]]], ["Cheeseman et al. (2012) utilized a two-step approach to identify genomic regions underlying resistance to artemisinin.", [["artemisinin", "CHEMICAL", 106, 117], ["artemisinin", "CHEMICAL", 106, 117], ["artemisinin", "SIMPLE_CHEMICAL", 106, 117], ["a two-step approach", "TREATMENT", 33, 52], ["genomic regions underlying resistance to artemisinin", "PROBLEM", 65, 117], ["resistance", "OBSERVATION", 92, 102], ["artemisinin", "OBSERVATION_MODIFIER", 106, 117]]], ["These statistics were particularly appropriate for their multipopulation data set because they are designed to contrast genomic signatures in two populations (Box 2).", [["their multipopulation data", "TEST", 51, 77]]], ["Cheeseman et al. (2012) found that 10 of the 33 regions discovered were associated with positive selection in studies examining different drugs, validating their approach.", [["positive selection in studies", "PROBLEM", 88, 117], ["different drugs", "TREATMENT", 128, 143]]], ["Second, Cheeseman et al. (Kang et al. 2008) to test the association of each SNP in their data set and the parasite clearance phenotype, thereby identifying four SNPs significantly associated, including two on chromosome 13.", [["SNP", "CHEMICAL", 76, 79], ["chromosome", "CELLULAR_COMPONENT", 209, 219], ["chromosome 13", "DNA", 209, 222], ["each SNP", "TREATMENT", 71, 79], ["the parasite clearance phenotype", "PROBLEM", 102, 134], ["four SNPs", "PROBLEM", 156, 165]]], ["In conjunction with the association test, Takala-Harrison et al. (2013) applied XP-EHH (Sabeti et al. 2007 ) and F ST (Lewontin & Krakauer 1973) to the Cambodia population, using the Thai and Bangladeshi populations as comparison populations.", [["the association test", "TEST", 20, 40], ["ST (Lewontin & Krakauer", "TREATMENT", 115, 138]]], ["The authors found that only the polymorphisms on chromosome 13 previously identified with the EMMA test also had significant XP-EHH and F ST values.", [["chromosome", "ANATOMY", 49, 59], ["chromosome 13", "CELLULAR_COMPONENT", 49, 62], ["XP-EHH", "GENE_OR_GENE_PRODUCT", 125, 131], ["F ST", "GENE_OR_GENE_PRODUCT", 136, 140], ["chromosome 13", "DNA", 49, 62], ["EMMA", "DNA", 94, 98], ["the polymorphisms on chromosome", "PROBLEM", 28, 59], ["the EMMA test", "TEST", 90, 103], ["significant", "OBSERVATION_MODIFIER", 113, 124], ["XP", "OBSERVATION", 125, 127]]], ["Takala-Harrison et al. (2013) used HAPLOVIEW (Barrett et al. 2005) to visualize the extended haplotype homozygosity in the region.", [["the extended haplotype homozygosity in the region", "PROBLEM", 80, 129], ["region", "ANATOMY_MODIFIER", 123, 129]]], ["Miotto et al. (2013) examined 10 locations in West Africa and South-East Asia and found that there was an exceptionally high amount of population substructure within Cambodia.", [["exceptionally", "OBSERVATION_MODIFIER", 106, 119], ["high", "OBSERVATION_MODIFIER", 120, 124], ["amount", "OBSERVATION_MODIFIER", 125, 131], ["population substructure", "OBSERVATION", 135, 158]]], ["Upon closer examination, the authors found that three of four clusters of P. falciparum found in western Cambodia showed slow parasite clearance rates, slow decay in LD, and loss of haplotype diversity, while the fourth cluster prevalent in northeastern Cambodia did not show any of these characteristics.", [["P. falciparum", "DISEASE", 74, 87], ["P. falciparum", "ORGANISM", 74, 87], ["P. falciparum", "SPECIES", 74, 87], ["P. falciparum", "SPECIES", 74, 87], ["closer examination", "TEST", 5, 23], ["P. falciparum", "PROBLEM", 74, 87], ["slow parasite clearance rates", "PROBLEM", 121, 150], ["slow decay in LD", "PROBLEM", 152, 168], ["loss of haplotype diversity", "PROBLEM", 174, 201], ["parasite clearance", "OBSERVATION", 126, 144], ["haplotype diversity", "OBSERVATION", 182, 201]]], ["This leads the authors to conclude that western Cambodia harbours at least three distinct populations of artemisinin-resistant P. falciparum.", [["artemisinin", "CHEMICAL", 105, 116], ["P. falciparum", "DISEASE", 127, 140], ["artemisinin", "CHEMICAL", 105, 116], ["artemisinin", "SIMPLE_CHEMICAL", 105, 116], ["P. falciparum", "ORGANISM", 127, 140], ["P. falciparum", "SPECIES", 127, 140], ["P. falciparum", "SPECIES", 127, 140], ["artemisinin", "TREATMENT", 105, 116], ["resistant P. falciparum", "PROBLEM", 117, 140], ["falciparum", "OBSERVATION", 130, 140]]], ["In particular, one of the subpopulations with resistant strains of P. falciparum showed a single haplotype extending across half of chromosome 13, corroborating the evidence from Cheeseman et al. (2012) and Takala-Harrison et al. (2013) that this locus is implicated in resistance to artemisinin.IntroductionExperimental confirmation of the kelch gene as a likely target of adaptation While Cheeseman et al. (2012) , Takala-Harrison et al. (2013) and Miotto et al. (2013) were all able to localize a putative locus on chromosome 13 strongly associated with the slow parasite clearance phenotype, it was only recently that Ariey et al. (2014) were able to identify causative mutations with high confidence.", [["chromosome 13", "ANATOMY", 132, 145], ["chromosome 13", "ANATOMY", 518, 531], ["P. falciparum", "DISEASE", 67, 80], ["artemisinin", "CHEMICAL", 284, 295], ["artemisinin", "CHEMICAL", 284, 295], ["P. falciparum", "ORGANISM", 67, 80], ["chromosome 13", "CELLULAR_COMPONENT", 132, 145], ["locus", "CELLULAR_COMPONENT", 247, 252], ["artemisinin", "SIMPLE_CHEMICAL", 284, 295], ["kelch", "GENE_OR_GENE_PRODUCT", 341, 346], ["locus", "CELLULAR_COMPONENT", 509, 514], ["chromosome 13", "CELLULAR_COMPONENT", 518, 531], ["chromosome 13", "DNA", 132, 145], ["kelch gene", "DNA", 341, 351], ["chromosome 13", "DNA", 518, 531], ["P. falciparum", "SPECIES", 67, 80], ["P. falciparum", "SPECIES", 67, 80], ["resistant strains", "PROBLEM", 46, 63], ["P. falciparum", "PROBLEM", 67, 80], ["a single haplotype", "PROBLEM", 88, 106], ["the slow parasite clearance phenotype", "PROBLEM", 557, 594]]], ["Ariey et al. (2014) used an in vitro drug selection technique to subject a parasite line to high doses of artemisinin for 5 years.", [["artemisinin", "CHEMICAL", 106, 117], ["artemisinin", "CHEMICAL", 106, 117], ["artemisinin", "SIMPLE_CHEMICAL", 106, 117], ["an in vitro drug selection technique", "TREATMENT", 25, 61], ["a parasite line", "TREATMENT", 73, 88], ["artemisinin", "TREATMENT", 106, 117]]], ["Comparing the sequenced data from the selected line with that of a clonal population not experiencing any selection, the authors identified eight mutations in seven genes that were present in the artemisinin treatment group but absent from the control group.", [["artemisinin", "CHEMICAL", 196, 207], ["artemisinin", "CHEMICAL", 196, 207], ["artemisinin", "SIMPLE_CHEMICAL", 196, 207], ["a clonal population", "PROBLEM", 65, 84], ["the artemisinin treatment group", "TREATMENT", 192, 223]]], ["Ariey et al. (2014) narrowed their list of candidates and concluded that only the mutation appearing in the kelch gene on chromosome 13 appeared at the same time as when artemisinin resistance developed in their treatment group.", [["chromosome 13", "ANATOMY", 122, 135], ["artemisinin", "CHEMICAL", 170, 181], ["artemisinin", "CHEMICAL", 170, 181], ["kelch", "GENE_OR_GENE_PRODUCT", 108, 113], ["chromosome 13", "CELLULAR_COMPONENT", 122, 135], ["artemisinin", "SIMPLE_CHEMICAL", 170, 181], ["kelch gene", "DNA", 108, 118], ["chromosome 13", "DNA", 122, 135], ["the mutation", "PROBLEM", 78, 90], ["artemisinin resistance", "PROBLEM", 170, 192]]], ["To determine whether there was concordance between the presence of this mutation in the kelch gene and artemisinin-resistant parasites from Cambodia, Ariey et al. (2014) sequenced the locus at which these mutations were present in parasite samples from patients showing the drug-resistant phenotype and from patients who did not in different geographical locations in Cambodia.", [["samples", "ANATOMY", 240, 247], ["artemisinin", "CHEMICAL", 103, 114], ["artemisinin", "CHEMICAL", 103, 114], ["kelch", "GENE_OR_GENE_PRODUCT", 88, 93], ["artemisinin", "SIMPLE_CHEMICAL", 103, 114], ["locus", "CELLULAR_COMPONENT", 184, 189], ["patients", "ORGANISM", 253, 261], ["patients", "ORGANISM", 308, 316], ["kelch gene", "DNA", 88, 98], ["patients", "SPECIES", 253, 261], ["patients", "SPECIES", 308, 316], ["this mutation", "PROBLEM", 67, 80], ["resistant parasites", "PROBLEM", 115, 134], ["these mutations", "PROBLEM", 199, 214], ["parasite samples", "TEST", 231, 247]]], ["They found that mutations in the kelch gene were strongly associated with the slow clearance phenotype observed in the locations where malaria is prevalent.", [["malaria", "DISEASE", 135, 142], ["kelch", "GENE_OR_GENE_PRODUCT", 33, 38], ["kelch gene", "DNA", 33, 43], ["mutations in the kelch gene", "PROBLEM", 16, 43], ["the slow clearance phenotype", "PROBLEM", 74, 102], ["malaria", "PROBLEM", 135, 142], ["mutations", "OBSERVATION", 16, 25], ["malaria", "OBSERVATION", 135, 142]]], ["In this extended analysis, Ariey et al. (2014) identified 17 mutations in the kelch gene, and all were significantly associated with artemisinin resistance.IntroductionSeveral follow-up studies confirmed the findings of Ariey et al. (2014) .", [["artemisinin", "CHEMICAL", 133, 144], ["artemisinin", "CHEMICAL", 133, 144], ["kelch", "GENE_OR_GENE_PRODUCT", 78, 83], ["artemisinin", "SIMPLE_CHEMICAL", 133, 144], ["kelch gene", "DNA", 78, 88], ["17 mutations in the kelch gene", "PROBLEM", 58, 88], ["artemisinin resistance", "PROBLEM", 133, 155], ["IntroductionSeveral follow-up studies", "TEST", 156, 193], ["artemisinin resistance", "OBSERVATION", 133, 155]]], ["Ashley et al. (2014) examined the geographical extent of resistance by tracking the prevalence of mutations in the kelch gene (see Fig. 1 ).", [["kelch", "GENE_OR_GENE_PRODUCT", 115, 120], ["kelch gene", "DNA", 115, 125], ["mutations in the kelch gene", "PROBLEM", 98, 125], ["resistance", "OBSERVATION", 57, 67]]], ["The authors found several single point mutations in kelch significantly associated with slow parasite clearance rates.", [["several single point mutations in kelch", "PROBLEM", 18, 57], ["slow parasite clearance rates", "PROBLEM", 88, 117]]], ["Recent work (Cheeseman et al. 2015; Miotto et al. 2015; Takala-Harrison et al. 2015; Tun et al. 2015) has also precisely mapped the origins and extent of muta-tions associated with artemisinin resistance (see Fig. 1 ).", [["artemisinin", "CHEMICAL", 181, 192], ["artemisinin", "CHEMICAL", 181, 192], ["artemisinin", "SIMPLE_CHEMICAL", 181, 192], ["muta-tions", "PROBLEM", 154, 164], ["artemisinin resistance", "PROBLEM", 181, 203], ["muta", "ANATOMY", 154, 158], ["artemisinin resistance", "OBSERVATION", 181, 203]]], ["Ghorbal et al. (2014) used the CRISPR-Cas9 system to introduce a mutation (C580Y) implicated in artemisinin resistance (Ariey et al. 2014) into kelch, which produced the slow parasite clearance phenotype and demonstrated the first direct link between a mutant kelch and the characteristic phenotype.", [["artemisinin", "CHEMICAL", 96, 107], ["artemisinin", "CHEMICAL", 96, 107], ["artemisinin", "SIMPLE_CHEMICAL", 96, 107], ["kelch", "GENE_OR_GENE_PRODUCT", 144, 149], ["CRISPR", "DNA", 31, 37], ["mutant kelch", "PROTEIN", 253, 265], ["the CRISPR-Cas9 system", "TREATMENT", 27, 49], ["a mutation", "PROBLEM", 63, 73], ["the slow parasite clearance phenotype", "PROBLEM", 166, 203], ["a mutant kelch", "PROBLEM", 251, 265]]], ["This work was expanded upon by Straimer et al. (2015) to confirm the role of multiple mutations and additional genetic factors in conferring artemisinin resistance.IntroductionOf the five examples reviewed in this study, this example of using classic statistical methods to find the association between the kelch gene and artimisinin resistance in P. falciparum is perhaps the most familiar to population geneticists.", [["artemisinin", "CHEMICAL", 141, 152], ["artimisinin", "CHEMICAL", 322, 333], ["P. falciparum", "DISEASE", 348, 361], ["artemisinin", "CHEMICAL", 141, 152], ["artemisinin", "SIMPLE_CHEMICAL", 141, 152], ["kelch", "GENE_OR_GENE_PRODUCT", 307, 312], ["artimisinin", "GENE_OR_GENE_PRODUCT", 322, 333], ["P. falciparum", "ORGANISM", 348, 361], ["kelch gene", "DNA", 307, 317], ["P. falciparum", "SPECIES", 348, 361], ["P. falciparum", "SPECIES", 348, 361], ["multiple mutations", "PROBLEM", 77, 95], ["this study", "TEST", 209, 219], ["P. falciparum", "PROBLEM", 348, 361]]], ["As a eukaryotic pathogen with a high rate of recombination, sequence analysis of the P. falciparum genome was amenable to traditional genome scan approaches.", [["P. falciparum", "ORGANISM", 85, 98], ["P. falciparum genome", "DNA", 85, 105], ["P. falciparum", "SPECIES", 85, 98], ["P. falciparum", "SPECIES", 85, 98], ["a eukaryotic pathogen", "PROBLEM", 3, 24], ["a high rate of recombination", "TREATMENT", 30, 58], ["sequence analysis", "TEST", 60, 77], ["the P. falciparum genome", "TREATMENT", 81, 105], ["traditional genome scan approaches", "TEST", 122, 156]]], ["Clever stratification of the samples gave additional power to the genomic scans, and in combination with novel experimental methods, researchers were able to find a locus under recent strong selection that was responsible for the evolution of resistance to artimisinin.", [["samples", "ANATOMY", 29, 36], ["artimisinin", "CHEMICAL", 257, 268], ["artimisinin", "CHEMICAL", 257, 268], ["samples", "CANCER", 29, 36], ["artimisinin", "SIMPLE_CHEMICAL", 257, 268], ["the genomic scans", "TEST", 62, 79], ["resistance to artimisinin", "PROBLEM", 243, 268]]], ["The identification of the kelch gene by population genetics methods offers a clear example where standard methodologies to identify selective sweeps are powerful in identifying a causal locus.", [["kelch", "GENE_OR_GENE_PRODUCT", 26, 31], ["kelch gene", "DNA", 26, 36]]], ["Given that P. falciparum can be manipulated experimentally to confirm computational predictions, this organism is an attractive choice for future studies of drug resistance, especially since malaria continues to be a costly disease and new drug-resistant loci may be unknown.Evolution of oseltamivir resistance in influenza virusAnnual influenza epidemics are estimated to result in 3-5 million cases of severe illness and 250 000-500 000 deaths worldwide (WHO 2014b).", [["P. falciparum", "DISEASE", 11, 24], ["malaria", "DISEASE", 191, 198], ["oseltamivir", "CHEMICAL", 288, 299], ["influenza virusAnnual influenza epidemics", "DISEASE", 314, 355], ["illness", "DISEASE", 411, 418], ["deaths", "DISEASE", 439, 445], ["oseltamivir", "CHEMICAL", 288, 299], ["P. falciparum", "ORGANISM", 11, 24], ["oseltamivir", "ORGANISM", 288, 299], ["influenza virusAnnual influenza", "ORGANISM", 314, 345], ["P. falciparum", "SPECIES", 11, 24], ["influenza virusAnnual influenza", "SPECIES", 314, 345], ["P. falciparum", "SPECIES", 11, 24], ["P. falciparum", "PROBLEM", 11, 24], ["this organism", "PROBLEM", 97, 110], ["drug resistance", "PROBLEM", 157, 172], ["malaria", "PROBLEM", 191, 198], ["a costly disease", "PROBLEM", 215, 231], ["new drug-resistant loci", "PROBLEM", 236, 259], ["oseltamivir resistance", "PROBLEM", 288, 310], ["influenza virusAnnual influenza epidemics", "PROBLEM", 314, 355], ["severe illness", "PROBLEM", 404, 418], ["resistant loci", "OBSERVATION", 245, 259], ["oseltamivir resistance", "OBSERVATION", 288, 310], ["severe", "OBSERVATION_MODIFIER", 404, 410], ["illness", "OBSERVATION", 411, 418]]], ["Subtypes of the influenza type A virus are named according to the two surface proteins that allow influenza virus to bind and release from host cells, hemagglutinin (HA) and neuraminidase (NA).", [["surface", "ANATOMY", 70, 77], ["cells", "ANATOMY", 144, 149], ["influenza type A", "DISEASE", 16, 32], ["influenza type A virus", "ORGANISM", 16, 38], ["influenza virus", "ORGANISM", 98, 113], ["host cells", "CELL", 139, 149], ["hemagglutinin (HA)", "GENE_OR_GENE_PRODUCT", 151, 169], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 174, 187], ["surface proteins", "PROTEIN", 70, 86], ["host cells", "CELL_TYPE", 139, 149], ["hemagglutinin", "PROTEIN", 151, 164], ["HA", "PROTEIN", 166, 168], ["neuraminidase", "PROTEIN", 174, 187], ["influenza type A virus", "SPECIES", 16, 38], ["influenza virus", "SPECIES", 98, 113], ["influenza type A virus", "SPECIES", 16, 38], ["influenza virus", "SPECIES", 98, 113], ["the influenza type A virus", "PROBLEM", 12, 38], ["influenza virus", "PROBLEM", 98, 113], ["hemagglutinin (HA)", "TREATMENT", 151, 169], ["neuraminidase (NA)", "TREATMENT", 174, 192], ["influenza", "OBSERVATION", 16, 25]]], ["For example, H1N1 designates the particular subtype of influenza that was responsible for the 2009 swine flu epidemic.", [["influenza", "DISEASE", 55, 64], ["swine flu", "DISEASE", 99, 108], ["influenza", "ORGANISM", 55, 64], ["swine", "SPECIES", 99, 104], ["H1N1", "PROBLEM", 13, 17], ["influenza", "PROBLEM", 55, 64], ["H1N1", "OBSERVATION", 13, 17], ["influenza", "OBSERVATION", 55, 64]]], ["These two surface proteins, hemagglutinin and neuraminidase, are primary antigenic targets for the immune system and are also potential targets for pharmaceutical intervention.", [["surface", "ANATOMY", 10, 17], ["immune system", "ANATOMY", 99, 112], ["hemagglutinin", "GENE_OR_GENE_PRODUCT", 28, 41], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 46, 59], ["surface proteins", "PROTEIN", 10, 26], ["hemagglutinin", "PROTEIN", 28, 41], ["neuraminidase", "PROTEIN", 46, 59], ["These two surface proteins", "TEST", 0, 26], ["hemagglutinin", "TREATMENT", 28, 41], ["neuraminidase", "TREATMENT", 46, 59], ["primary antigenic targets", "PROBLEM", 65, 90], ["pharmaceutical intervention", "TREATMENT", 148, 175]]], ["One common influenza drug is oseltamivir, which is marketed under the trade name Tamiflu.", [["oseltamivir", "CHEMICAL", 29, 40], ["oseltamivir", "CHEMICAL", 29, 40], ["oseltamivir", "SIMPLE_CHEMICAL", 29, 40], ["oseltamivir", "TREATMENT", 29, 40], ["Tamiflu", "TREATMENT", 81, 88], ["common", "OBSERVATION_MODIFIER", 4, 10], ["influenza", "OBSERVATION", 11, 20]]], ["Oseltamivir works by inhibiting the influenza neuraminidase surface protein, the protein that cleaves sialic acid from the receptor of the host cell and allows replicated virus to spread to other uninfected cells (Moscona 2005) .", [["cell", "ANATOMY", 144, 148], ["cells", "ANATOMY", 207, 212], ["Oseltamivir", "CHEMICAL", 0, 11], ["sialic acid", "CHEMICAL", 102, 113], ["Oseltamivir", "CHEMICAL", 0, 11], ["sialic acid", "CHEMICAL", 102, 113], ["Oseltamivir", "SIMPLE_CHEMICAL", 0, 11], ["neuraminidase surface protein", "GENE_OR_GENE_PRODUCT", 46, 75], ["sialic acid", "SIMPLE_CHEMICAL", 102, 113], ["host cell", "CELL", 139, 148], ["cells", "CELL", 207, 212], ["influenza neuraminidase surface protein", "PROTEIN", 36, 75], ["host cell", "CELL_TYPE", 139, 148], ["uninfected cells", "CELL_TYPE", 196, 212], ["Oseltamivir", "TREATMENT", 0, 11], ["the influenza neuraminidase surface protein", "PROBLEM", 32, 75], ["the protein", "TEST", 77, 88], ["sialic acid", "TEST", 102, 113], ["replicated virus", "PROBLEM", 160, 176], ["host cell", "OBSERVATION", 139, 148]]], ["Resistance to oseltamivir in N1-containing influenza is conferred by a single histidine-to-tyrosine amino acid change at the 275th amino acid position in the neuraminidase protein.", [["oseltamivir", "CHEMICAL", 14, 25], ["influenza", "DISEASE", 43, 52], ["histidine", "CHEMICAL", 78, 87], ["tyrosine", "CHEMICAL", 91, 99], ["amino acid", "CHEMICAL", 100, 110], ["amino acid", "CHEMICAL", 131, 141], ["oseltamivir", "CHEMICAL", 14, 25], ["histidine", "CHEMICAL", 78, 87], ["tyrosine", "CHEMICAL", 91, 99], ["amino acid", "CHEMICAL", 100, 110], ["amino acid", "CHEMICAL", 131, 141], ["oseltamivir", "SIMPLE_CHEMICAL", 14, 25], ["influenza", "ORGANISM", 43, 52], ["tyrosine", "AMINO_ACID", 91, 99], ["amino acid", "AMINO_ACID", 100, 110], ["amino acid", "AMINO_ACID", 131, 141], ["neuraminidase protein", "GENE_OR_GENE_PRODUCT", 158, 179], ["275th amino acid position", "PROTEIN", 125, 150], ["neuraminidase protein", "PROTEIN", 158, 179], ["oseltamivir", "TREATMENT", 14, 25], ["influenza", "PROBLEM", 43, 52], ["a single histidine", "TREATMENT", 69, 87], ["tyrosine amino acid change", "TREATMENT", 91, 117], ["the 275th amino acid position", "TREATMENT", 121, 150], ["the neuraminidase protein", "TREATMENT", 154, 179], ["oseltamivir", "OBSERVATION", 14, 25]]], ["Note that this amino acid is often referred to as amino acid 274, which is its position in N2, a convention which we will follow here.", [["amino acid", "CHEMICAL", 15, 25], ["amino acid 274", "CHEMICAL", 50, 64], ["amino acid", "CHEMICAL", 15, 25], ["amino acid", "CHEMICAL", 50, 60], ["N2", "CHEMICAL", 91, 93], ["amino acid", "AMINO_ACID", 15, 25], ["amino acid 274", "AMINO_ACID", 50, 64], ["this amino acid", "TEST", 10, 25], ["amino acid", "TEST", 50, 60]]], ["The H274Y mutation was known from laboratory studies, but researchers predicted that fitness costs would prevent H274Y from spreading widely.", [["H274Y", "CHEMICAL", 113, 118], ["H274Y", "GENE_OR_GENE_PRODUCT", 4, 9], ["The H274Y mutation", "PROBLEM", 0, 18], ["laboratory studies", "TEST", 34, 52]]], ["However, oseltamivir resistance due to the H274Y mutation has been documented extensively following the 2007-2008 flu season when global surveillance indicated the increasing prevalence of H1N1 influenza viruses with acquired resistance (Moscona 2009) .", [["oseltamivir", "CHEMICAL", 9, 20], ["influenza viruses", "DISEASE", 194, 211], ["oseltamivir", "CHEMICAL", 9, 20], ["oseltamivir", "SIMPLE_CHEMICAL", 9, 20], ["H274Y", "GENE_OR_GENE_PRODUCT", 43, 48], ["H1N1 influenza viruses", "ORGANISM", 189, 211], ["H274Y", "DNA", 43, 48], ["H1N1 influenza viruses", "SPECIES", 189, 211], ["H1N1 influenza viruses", "SPECIES", 189, 211], ["oseltamivir resistance", "TREATMENT", 9, 31], ["the H274Y mutation", "PROBLEM", 39, 57], ["global surveillance", "TEST", 130, 149], ["H1N1 influenza viruses", "PROBLEM", 189, 211], ["oseltamivir resistance", "OBSERVATION", 9, 31], ["H1N1 influenza viruses", "OBSERVATION", 189, 211]]], ["A combination of phylogenetics and elegant laboratory studies led to the discovery of two permissive mutations that mitigated the cost of the H274Y mutation, thus showing the importance of epistasis for influenza evolution.", [["influenza", "DISEASE", 203, 212], ["H274Y", "GENE_OR_GENE_PRODUCT", 142, 147], ["elegant laboratory studies", "TEST", 35, 61], ["two permissive mutations", "PROBLEM", 86, 110], ["the H274Y mutation", "PROBLEM", 138, 156], ["epistasis", "PROBLEM", 189, 198], ["influenza evolution", "PROBLEM", 203, 222], ["epistasis", "OBSERVATION", 189, 198], ["influenza", "OBSERVATION", 203, 212]]], ["The study of the evolution of oseltamivir resistance has relied heavily on phylogenetic methods and taught us about the importance of epistasis, which, in turn, is of crucial importance for making predictions on influenza evolution.Epistasis as a determining factor in the evolution of oseltamivir resistanceThe interactions among sites in the genome can give rise to a phenomenon called epistasis where the effects of one mutation at a site are dependent on the presence or absence of mutations at other sites.", [["oseltamivir", "CHEMICAL", 30, 41], ["influenza", "DISEASE", 212, 221], ["oseltamivir", "CHEMICAL", 286, 297], ["oseltamivir", "CHEMICAL", 30, 41], ["oseltamivir", "CHEMICAL", 286, 297], ["oseltamivir", "SIMPLE_CHEMICAL", 30, 41], ["oseltamivir", "SIMPLE_CHEMICAL", 286, 297], ["genome", "CELLULAR_COMPONENT", 344, 350], ["The study", "TEST", 0, 9], ["oseltamivir resistance", "TREATMENT", 30, 52], ["epistasis", "PROBLEM", 134, 143], ["influenza evolution", "PROBLEM", 212, 231], ["Epistasis", "PROBLEM", 232, 241], ["oseltamivir resistance", "TREATMENT", 286, 308], ["epistasis", "PROBLEM", 388, 397], ["one mutation", "PROBLEM", 419, 431], ["mutations at other sites", "PROBLEM", 486, 510], ["oseltamivir resistance", "OBSERVATION", 30, 52], ["epistasis", "OBSERVATION", 134, 143], ["influenza", "OBSERVATION", 212, 221], ["oseltamivir resistance", "OBSERVATION", 286, 308]]], ["Epistatic interactions, when they exist, ensure that the fitness effects of a drug resistance mutation are dependent on the genetic background on which it emerges.", [["Epistatic interactions", "PROBLEM", 0, 22], ["a drug resistance mutation", "PROBLEM", 76, 102]]], ["Epistasis in drug resistance evolution has been characterized by several in vitro studies, including the case of the five interacting mutations involved in cefotaxime resistance in Escherichia coli that produce predictable mutation orders (Weinreich et al. 2006 ) and the hundreds of interacting mutations that determine viral fitness in antiretroviral resistance in HIV (Hinkley et al. 2011) .Epistasis as a determining factor in the evolution of oseltamivir resistanceIn the case of oseltamivir resistance, the H274Y mutation was shown to have detrimental effects on viral fitness after it was first identified in the laboratory (Ives et al. 2002; Abed et al. 2004; Herlocher et al. 2004 ).", [["cefotaxime", "CHEMICAL", 156, 166], ["oseltamivir", "CHEMICAL", 448, 459], ["oseltamivir", "CHEMICAL", 485, 496], ["cefotaxime", "CHEMICAL", 156, 166], ["oseltamivir", "CHEMICAL", 448, 459], ["oseltamivir", "CHEMICAL", 485, 496], ["cefotaxime", "SIMPLE_CHEMICAL", 156, 166], ["Escherichia coli", "ORGANISM", 181, 197], ["HIV", "ORGANISM", 367, 370], ["oseltamivir", "SIMPLE_CHEMICAL", 448, 459], ["oseltamivir", "SIMPLE_CHEMICAL", 485, 496], ["H274Y", "GENE_OR_GENE_PRODUCT", 513, 518], ["H274Y", "DNA", 513, 518], ["Escherichia coli", "SPECIES", 181, 197], ["HIV", "SPECIES", 367, 370], ["Escherichia coli", "SPECIES", 181, 197], ["HIV", "SPECIES", 367, 370], ["Epistasis in drug resistance evolution", "PROBLEM", 0, 38], ["vitro studies", "TEST", 76, 89], ["the five interacting mutations", "PROBLEM", 113, 143], ["cefotaxime resistance", "TREATMENT", 156, 177], ["Escherichia coli", "PROBLEM", 181, 197], ["interacting mutations", "PROBLEM", 284, 305], ["viral fitness in antiretroviral resistance", "PROBLEM", 321, 363], ["HIV", "PROBLEM", 367, 370], ["Epistasis", "PROBLEM", 394, 403], ["oseltamivir resistance", "TREATMENT", 448, 470], ["oseltamivir resistance", "TREATMENT", 485, 507], ["the H274Y mutation", "PROBLEM", 509, 527], ["viral fitness", "PROBLEM", 569, 582], ["drug resistance", "OBSERVATION", 13, 28], ["Escherichia coli", "OBSERVATION", 181, 197], ["antiretroviral resistance", "OBSERVATION", 338, 363], ["oseltamivir resistance", "OBSERVATION", 448, 470], ["oseltamivir resistance", "OBSERVATION", 485, 507]]], ["This led researchers to believe that viruses carrying H274Y were 'unlikely to be of clinical consequence' (Ives et al. 2002) .", [["H274Y", "GENE_OR_GENE_PRODUCT", 54, 59], ["viruses", "PROBLEM", 37, 44]]], ["Why then did the resistant H1N1 strains subsequently reach a global frequency of nearly 95% (WHO 2009) during the 2008-2009 flu season?", [["the resistant H1N1 strains", "PROBLEM", 13, 39]]], ["Bloom and others showed that the H274Y mutation reduces the amount of folded neuramindase that reaches the host cell surface and thereby reduces the virus' fitness.", [["cell surface", "ANATOMY", 112, 124], ["H274Y", "GENE_OR_GENE_PRODUCT", 33, 38], ["neuramindase", "GENE_OR_GENE_PRODUCT", 77, 89], ["cell surface", "CELLULAR_COMPONENT", 112, 124], ["neuramindase", "PROTEIN", 77, 89], ["the H274Y mutation", "PROBLEM", 29, 47], ["folded neuramindase", "PROBLEM", 70, 89], ["the virus' fitness", "PROBLEM", 145, 163], ["amount", "OBSERVATION_MODIFIER", 60, 66], ["folded neuramindase", "OBSERVATION", 70, 89], ["host cell", "OBSERVATION", 107, 116], ["surface", "OBSERVATION_MODIFIER", 117, 124], ["virus", "OBSERVATION", 149, 154]]], ["They hypothesized that secondary mutations at other sites in the influenza genome may have acted to ameliorate deleterious effects of the H274Y mutation, permitting it to reach high global frequency (Bloom et al. 2010 ).Epistasis as a determining factor in the evolution of oseltamivir resistanceBloom and colleagues took sequences from before and after 2007 and created a phylogenetic tree.", [["influenza", "DISEASE", 65, 74], ["oseltamivir", "CHEMICAL", 274, 285], ["oseltamivir", "CHEMICAL", 274, 285], ["H274Y", "GENE_OR_GENE_PRODUCT", 138, 143], ["oseltamivir", "SIMPLE_CHEMICAL", 274, 285], ["influenza genome", "DNA", 65, 81], ["secondary mutations at other sites", "PROBLEM", 23, 57], ["the influenza genome", "PROBLEM", 61, 81], ["the H274Y mutation", "PROBLEM", 134, 152], ["Epistasis", "PROBLEM", 220, 229], ["oseltamivir resistance", "TREATMENT", 274, 296], ["secondary mutations", "OBSERVATION", 23, 42], ["oseltamivir resistance", "OBSERVATION", 274, 296]]], ["They found five nonsynonymous mutations that separated the 2008 strains in which H274Y was common from the 1999 strains in which H274Y was found to have a strongly negative fitness effect.", [["five nonsynonymous mutations", "PROBLEM", 11, 39], ["nonsynonymous mutations", "OBSERVATION", 16, 39]]], ["They then added the mutations one by one to the 1999 strain and found that two of the five mutations (R222Q, V234M) had a strong effect on the amount of neuraminidase at the cell surface.", [["cell surface", "ANATOMY", 174, 186], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 153, 166], ["cell surface", "CELLULAR_COMPONENT", 174, 186], ["neuraminidase", "PROTEIN", 153, 166], ["amount", "OBSERVATION_MODIFIER", 143, 149], ["neuraminidase", "OBSERVATION", 153, 166], ["cell surface", "OBSERVATION", 174, 186]]], ["In viruses that had these two mutations, H274Y no longer reduced the fitness of the virus.", [["the virus", "PROBLEM", 80, 89], ["viruses", "OBSERVATION", 3, 10]]], ["In the absence of oseltamivir, the created triple-mutant virus (with H274Y, R222Q, V234M mutations) had a fitness comparable to wild type.", [["oseltamivir", "CHEMICAL", 18, 29], ["oseltamivir", "CHEMICAL", 18, 29], ["oseltamivir", "SIMPLE_CHEMICAL", 18, 29], ["triple-mutant virus", "ORGANISM", 43, 62], ["oseltamivir", "TREATMENT", 18, 29], ["the created triple-mutant virus", "PROBLEM", 31, 62]]], ["In the presence of oseltamivir, the triple-mutant virus had much higher fitness than wild type (Bloom et al. 2010) .", [["oseltamivir", "CHEMICAL", 19, 30], ["oseltamivir", "CHEMICAL", 19, 30], ["oseltamivir", "SIMPLE_CHEMICAL", 19, 30], ["triple-mutant virus", "ORGANISM", 36, 55], ["oseltamivir", "TREATMENT", 19, 30], ["the triple-mutant virus", "PROBLEM", 32, 55], ["oseltamivir", "OBSERVATION", 19, 30]]], ["A phylogeny with the status of these three mutations (H274Y, R222Q and V234M) is shown in Fig. 2 .Epistasis as a determining factor in the evolution of oseltamivir resistanceSubsequent studies also identified potential epistatic interactions between mutations in hemagglutinin and neuraminidase that impacted viral fitness and may have influenced the spread of oseltamivir resistance (Hensley et al. 2011; Ginting et al. 2012; Behera et al. 2015) .", [["oseltamivir", "CHEMICAL", 152, 163], ["oseltamivir", "CHEMICAL", 361, 372], ["oseltamivir", "CHEMICAL", 152, 163], ["oseltamivir", "CHEMICAL", 361, 372], ["oseltamivir", "SIMPLE_CHEMICAL", 152, 163], ["hemagglutinin", "GENE_OR_GENE_PRODUCT", 263, 276], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 281, 294], ["oseltamivir", "SIMPLE_CHEMICAL", 361, 372], ["hemagglutinin", "PROTEIN", 263, 276], ["neuraminidase", "PROTEIN", 281, 294], ["Epistasis", "PROBLEM", 98, 107], ["oseltamivir resistance", "TREATMENT", 152, 174], ["Subsequent studies", "TEST", 174, 192], ["potential epistatic interactions", "PROBLEM", 209, 241], ["mutations in hemagglutinin", "TREATMENT", 250, 276], ["neuraminidase", "TREATMENT", 281, 294], ["impacted viral fitness", "PROBLEM", 300, 322], ["oseltamivir resistance", "TREATMENT", 361, 383], ["oseltamivir resistance", "OBSERVATION", 152, 174], ["viral fitness", "OBSERVATION", 309, 322], ["oseltamivir resistance", "OBSERVATION", 361, 383]]], ["Taken together these results suggest that epistasis had a profound impact on the evolution of resistance to oseltamivir and allowed the H274Y resistance mutation to spread through the global population.", [["oseltamivir", "CHEMICAL", 108, 119], ["H274Y", "CHEMICAL", 136, 141], ["oseltamivir", "CHEMICAL", 108, 119], ["oseltamivir", "SIMPLE_CHEMICAL", 108, 119], ["epistasis", "PROBLEM", 42, 51], ["oseltamivir", "TREATMENT", 108, 119], ["the H274Y resistance mutation", "PROBLEM", 132, 161], ["epistasis", "OBSERVATION", 42, 51], ["profound", "OBSERVATION_MODIFIER", 58, 66]]], ["This work also provides cautionary evidence for the clinical assessment of drug resistance mutations.", [["the clinical assessment", "TEST", 48, 71], ["drug resistance mutations", "PROBLEM", 75, 100]]], ["Secondary mutations that interact epistatically with drug resistance mutations are important factors that need to be incorporated when making predictions about the epidemiological consequences of drug resistance mutations.", [["Secondary mutations", "PROBLEM", 0, 19], ["drug resistance mutations", "PROBLEM", 53, 78], ["drug resistance mutations", "PROBLEM", 196, 221]]], ["Knowing that even deleterious drug resistance mutations can spread when they emerge on permissive backgrounds tells us that we should pay close attention to identifying and monitoring potential epistatic interactions during virological surveillance.Epistasis and the predictability of adaptive evolutionTo what extent is epistasis a general feature of adaptive evolution?", [["deleterious drug resistance mutations", "PROBLEM", 18, 55], ["epistatic interactions", "PROBLEM", 194, 216], ["virological surveillance", "TEST", 224, 248], ["Epistasis", "PROBLEM", 249, 258], ["adaptive evolution", "PROBLEM", 285, 303], ["epistasis", "PROBLEM", 321, 330], ["epistasis", "OBSERVATION", 321, 330]]], ["Both theoretical and empirical work predict that adaptation itself may enrich for epistatic interactions (Draghi et al. 2011; Draghi & Plotkin 2013; Gong et al. 2013; Rajon & Masel 2013; Szendro et al. 2013; Gong & Bloom 2014) .", [["epistatic interactions", "PROBLEM", 82, 104]]], ["This means that epistasis is likely to play a more general role in adaptive evolution and is not limited to specific case studies.", [["epistasis", "PROBLEM", 16, 25], ["specific case studies", "TEST", 108, 129], ["epistasis", "OBSERVATION", 16, 25], ["is likely to", "UNCERTAINTY", 26, 38]]], ["It also means that researchers interested in adaptation need model systems in which to test theory regarding epistasis.", [["model systems", "TREATMENT", 61, 74], ["epistasis", "PROBLEM", 109, 118], ["epistasis", "OBSERVATION", 109, 118]]], ["Influenza resistance evolution has been a formative model for testing population genetic predictions regarding the role of epistasis in adaptive evolution.Epistasis and the predictability of adaptive evolutionOseltamivir resistance evolution provided some of the first evaluations for methodologies that can potentially predict the sites within proteins that interact with one another based on sequence data and phylogenetic trees.", [["Influenza", "DISEASE", 0, 9], ["Oseltamivir", "CHEMICAL", 209, 220], ["Oseltamivir", "CHEMICAL", 209, 220], ["Influenza resistance evolution", "PROBLEM", 0, 30], ["epistasis", "PROBLEM", 123, 132], ["Epistasis", "PROBLEM", 155, 164], ["adaptive evolutionOseltamivir resistance", "TREATMENT", 191, 231], ["the first evaluations", "TEST", 259, 280], ["methodologies", "TREATMENT", 285, 298], ["sequence data", "TEST", 394, 407], ["epistasis", "OBSERVATION", 123, 132], ["Oseltamivir resistance", "OBSERVATION", 209, 231]]], ["Bloom and colleagues initially predicted the R194G mutation as a potential candidate for a positive epistatic interaction with H274Y using a phylogenetic method (Bloom & Glassman 2009 ) to infer stabilizing effects of mutations.", [["R194G", "GENE_OR_GENE_PRODUCT", 45, 50], ["R194G", "DNA", 45, 50], ["H274Y", "PROTEIN", 127, 132], ["a positive epistatic interaction", "PROBLEM", 89, 121], ["a phylogenetic method", "TREATMENT", 139, 160], ["mutations", "PROBLEM", 218, 227]]], ["They showed that R194G did indeed restore H274Y-mutant surface expression to wild type levels in the absence of oseltamivir (Bloom et al. 2010) .", [["surface", "ANATOMY", 55, 62], ["oseltamivir", "CHEMICAL", 112, 123], ["oseltamivir", "CHEMICAL", 112, 123], ["H274Y", "GENE_OR_GENE_PRODUCT", 42, 47], ["oseltamivir", "SIMPLE_CHEMICAL", 112, 123], ["H274Y", "PROTEIN", 42, 47], ["oseltamivir", "TREATMENT", 112, 123]]], ["Meanwhile Kryazhimskiy et al. (2011) examined hemagglutinin and neuraminidase sequences of multiple influenza strains and successfully predicted a known epistatic interaction (Collins et al. 2009 ) between H274Y and another mutation (D344N, see Fig. 3 ) in addition to the V234M and R222Q mutations identified by Bloom et al. (2010) .", [["hemagglutinin and neuraminidase sequences", "DNA", 46, 87], ["hemagglutinin", "TREATMENT", 46, 59], ["neuraminidase sequences", "TEST", 64, 87], ["multiple influenza strains", "PROBLEM", 91, 117]]], ["Their methodology was based on a statistical ranking of the co-occurrence of specific amino acid substitutions within a phylogeny.Epistasis and the predictability of adaptive evolutionPredicting the evolution of influenza is an intriguing prospect for evolutionary geneticists, which we will briefly discuss in the Discussion.", [["amino acid", "CHEMICAL", 86, 96], ["influenza", "DISEASE", 212, 221], ["amino acid", "CHEMICAL", 86, 96], ["amino acid", "AMINO_ACID", 86, 96], ["specific amino acid substitutions", "PROBLEM", 77, 110], ["Epistasis", "PROBLEM", 130, 139], ["influenza", "PROBLEM", 212, 221], ["acid substitutions", "OBSERVATION", 92, 110], ["influenza", "OBSERVATION", 212, 221]]], ["These studies have shown that phylogenetic methods can not only affirm theoretical predictions regarding the patterns of epistasis but can also predict epistatic interactions that may be of clinical importance.", [["These studies", "TEST", 0, 13], ["phylogenetic methods", "PROBLEM", 30, 50], ["epistasis", "PROBLEM", 121, 130], ["epistatic interactions", "PROBLEM", 152, 174], ["epistasis", "OBSERVATION", 121, 130]]], ["They also establish a connection between protein phylogenies and fitness that may prove to be useful for future work in both population genetics and infectious disease.Epistasis and the predictability of adaptive evolutionand plotted using ggtree (Yu & Lam 2015) .", [["infectious disease", "DISEASE", 149, 167], ["a connection between protein phylogenies", "PROBLEM", 20, 60], ["infectious disease", "PROBLEM", 149, 167], ["Epistasis", "PROBLEM", 168, 177], ["infectious", "OBSERVATION", 149, 159]]], ["The phylogeny suggests an epistatic interaction between mutations R222Q, V234M and H274Y.", [["an epistatic interaction between mutations", "PROBLEM", 23, 65], ["epistatic", "OBSERVATION_MODIFIER", 26, 35], ["interaction", "OBSERVATION", 36, 47]]], ["Based on a maximum-likelihood reconstruction, branches with the H274Y resistance mutation are coloured red, whereas those without are coloured grey.", [["a maximum-likelihood reconstruction", "TREATMENT", 9, 44], ["the H274Y resistance mutation", "PROBLEM", 60, 89], ["red", "PROBLEM", 103, 106], ["branches", "OBSERVATION_MODIFIER", 46, 54]]], ["Nonresistant branches with only the V234M mutation are coloured in light blue while nonresistant branches with both V234M and R222Q mutations are coloured in dark blue.", [["V234M", "GENE_OR_GENE_PRODUCT", 116, 121], ["Nonresistant branches", "PROBLEM", 0, 21], ["the V234M mutation", "PROBLEM", 32, 50], ["branches", "OBSERVATION_MODIFIER", 13, 21], ["branches", "OBSERVATION_MODIFIER", 97, 105], ["dark blue", "OBSERVATION", 158, 167]]], ["The clade in which mutations, R222Q and V234M, are nearly fixed is shaded in blue.", [["fixed", "OBSERVATION", 58, 63], ["shaded", "OBSERVATION_MODIFIER", 67, 73], ["blue", "OBSERVATION", 77, 81]]], ["The phylogeny is consistent with the idea that the substitutions at site 222 and 234 act as 'permissive' mutations, ameliorating the fitness costs of H274Y on the previous background and allowing it to spread.", [["H274Y", "CHEMICAL", 150, 155], ["the substitutions at site", "PROBLEM", 47, 72], ["'permissive' mutations", "PROBLEM", 92, 114], ["consistent with", "UNCERTAINTY", 17, 32]]], ["The branch length scale is given in units of substitutions per site.The role of SGV for drug resistance evolution in HIVHIV drug resistance has been a challenge since the introduction of HIV treatment because HIV adapts rapidly due to its high mutation rate, fast generation time and large population size (Coffin 1995) .", [["SGV", "CHEMICAL", 80, 83], ["HIVHIV", "CHEMICAL", 117, 123], ["SGV", "GENE_OR_GENE_PRODUCT", 80, 83], ["HIVHIV", "ORGANISM", 117, 123], ["HIV", "ORGANISM", 187, 190], ["HIV", "ORGANISM", 209, 212], ["HIVHIV", "SPECIES", 117, 123], ["HIV", "SPECIES", 187, 190], ["HIV", "SPECIES", 209, 212], ["The branch length scale", "TREATMENT", 0, 23], ["substitutions per site", "TREATMENT", 45, 67], ["SGV", "TREATMENT", 80, 83], ["drug resistance evolution", "PROBLEM", 88, 113], ["HIVHIV drug resistance", "TREATMENT", 117, 139], ["HIV treatment", "TREATMENT", 187, 200], ["HIV adapts", "PROBLEM", 209, 219], ["its high mutation rate", "PROBLEM", 235, 257], ["branch", "OBSERVATION_MODIFIER", 4, 10], ["length", "OBSERVATION_MODIFIER", 11, 17], ["drug resistance", "OBSERVATION", 124, 139], ["large", "OBSERVATION_MODIFIER", 284, 289], ["population", "OBSERVATION_MODIFIER", 290, 300], ["size", "OBSERVATION_MODIFIER", 301, 305]]], ["Although drug resistance in HIV has become less prevalent as treatments have improved (Lee et al. 2014; Feder et al. 2015) , a fundamental question both for both clinicians and population geneticists remains: when exactly do drug-resistant mutations (DRMs) originate?", [["HIV", "ORGANISM", 28, 31], ["HIV", "SPECIES", 28, 31], ["HIV", "SPECIES", 28, 31], ["drug resistance", "PROBLEM", 9, 24], ["HIV", "PROBLEM", 28, 31], ["resistant mutations (DRMs)", "PROBLEM", 230, 256], ["drug resistance", "OBSERVATION", 9, 24], ["less prevalent", "OBSERVATION_MODIFIER", 43, 57]]], ["Some patients may have pre-existing drug resistance mutations prior to receiving any drug therapy.", [["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["pre-existing drug resistance mutations", "PROBLEM", 23, 61], ["any drug therapy", "TREATMENT", 81, 97], ["drug resistance", "OBSERVATION", 36, 51]]], ["Although these pre-existing mutations, also known as SGV, may offer no selective advantage (and could in fact be deleterious) before the onset of treatment when therapy begins, they quickly rise to high frequency in the HIV population and cause treatment failure (Pennings 2012) .", [["HIV", "SPECIES", 220, 223], ["these pre-existing mutations", "PROBLEM", 9, 37], ["treatment", "TREATMENT", 146, 155], ["therapy", "TREATMENT", 161, 168], ["the HIV population", "PROBLEM", 216, 234], ["treatment failure", "PROBLEM", 245, 262], ["mutations", "OBSERVATION", 28, 37], ["high frequency", "OBSERVATION_MODIFIER", 198, 212]]], ["However, HIV can also acquire drug resistance mutations de novo after the onset of therapy.", [["HIV", "ORGANISM", 9, 12], ["HIV", "SPECIES", 9, 12], ["HIV", "SPECIES", 9, 12], ["HIV", "PROBLEM", 9, 12], ["drug resistance mutations", "PROBLEM", 30, 55], ["therapy", "TREATMENT", 83, 90]]], ["Clinically, the extent to which drug resistance mutations arise from SGV or de novo mutation should inform treatment approaches.", [["SGV", "GENE_OR_GENE_PRODUCT", 69, 72], ["drug resistance mutations", "PROBLEM", 32, 57], ["de novo mutation", "PROBLEM", 76, 92], ["treatment approaches", "TREATMENT", 107, 127]]], ["If SGV is critically important in the establishment of drug resistance, efforts should be focused on identifying any potential drug resistance mutations in the pretreatment HIV population to determine an appropriate regimen.", [["HIV", "SPECIES", 173, 176], ["drug resistance mutations", "PROBLEM", 127, 152], ["the pretreatment HIV population", "TREATMENT", 156, 187], ["an appropriate regimen", "TREATMENT", 201, 223]]], ["However, if resistance occurs de novo after the start of treatment, patient adherence, drug penetrance and dosage should be the clinical focus.", [["patient", "ORGANISM", 68, 75], ["patient", "SPECIES", 68, 75], ["treatment", "TREATMENT", 57, 66], ["drug penetrance", "PROBLEM", 87, 102]]], ["To this end, it is important to understand whether drug resistance mutations present before treatment onset can be identified in patient samples, and to assess the ultimate contribution of SGV to treatment failure.The role of SGV for drug resistance evolution in HIVFrom a population genetics perspective, drug resistance evolution in HIV allows us to understand the role of SGV in adaptation more generally.", [["samples", "ANATOMY", 137, 144], ["patient", "ORGANISM", 129, 136], ["SGV", "CANCER", 189, 192], ["SGV", "GENE_OR_GENE_PRODUCT", 226, 229], ["SGV", "GENE_OR_GENE_PRODUCT", 375, 378], ["SGV", "PROTEIN", 375, 378], ["patient", "SPECIES", 129, 136], ["HIV", "SPECIES", 335, 338], ["HIV", "SPECIES", 335, 338], ["drug resistance mutations", "PROBLEM", 51, 76], ["treatment", "TREATMENT", 92, 101], ["treatment failure", "PROBLEM", 196, 213], ["drug resistance evolution", "PROBLEM", 234, 259], ["drug resistance evolution", "PROBLEM", 306, 331], ["HIV", "PROBLEM", 335, 338]]], ["First, every infected person is an independent evolutionary replicate, and transmitted drug resistance is relatively rare.", [["person", "ORGANISM", 22, 28], ["person", "SPECIES", 22, 28], ["transmitted drug resistance", "PROBLEM", 75, 102], ["infected", "OBSERVATION", 13, 21], ["drug resistance", "OBSERVATION", 87, 102]]], ["Around 2.8-11.5% of untreated patients have transmitted drug resistance mutations depending on the region of the world , although these numbers are lower when considering drug resistance to any specific treatment.", [["patients", "ORGANISM", 30, 38], ["patients", "SPECIES", 30, 38], ["transmitted drug resistance mutations", "PROBLEM", 44, 81], ["drug resistance", "PROBLEM", 171, 186], ["any specific treatment", "TREATMENT", 190, 212], ["drug resistance", "OBSERVATION", 56, 71]]], ["Therefore, most drug resistance emerges independently within a patient, and it is sufficient to follow a single patient over time to chart the evolution of an HIV population, in contrast to monitoring the acquisition of drug resistance mutations across multiple patients in a transmission chain.", [["patient", "ORGANISM", 63, 70], ["patient", "ORGANISM", 112, 119], ["patients", "ORGANISM", 262, 270], ["patient", "SPECIES", 63, 70], ["patient", "SPECIES", 112, 119], ["patients", "SPECIES", 262, 270], ["HIV", "SPECIES", 159, 162], ["an HIV population", "PROBLEM", 156, 173], ["drug resistance mutations", "PROBLEM", 220, 245], ["drug resistance", "OBSERVATION", 16, 31]]], ["Second, the mutations conferring drug resistance are well catalogued (Bennett et al. 2009; Wensing et al. 2014) , allowing us to quantify their frequency prior to treatment using allele-specific PCR (asPCR).", [["allele", "DNA", 179, 185], ["the mutations", "PROBLEM", 8, 21], ["treatment", "TREATMENT", 163, 172], ["allele-specific PCR", "TEST", 179, 198]]], ["Finally, adaptation can be rapid, allowing us to observe the evolution of drug resistance as it happens.SGV contributes to treatment failure in HIVBefore an HIV-infected person starts treatment, a blood sample is taken to sequence the virus (see Schutten 2006 for an overview of genotyping assays).", [["blood sample", "ANATOMY", 197, 209], ["SGV", "DISEASE", 104, 107], ["HIV-infected", "DISEASE", 157, 169], ["person", "ORGANISM", 170, 176], ["blood", "ORGANISM_SUBSTANCE", 197, 202], ["HIV", "SPECIES", 157, 160], ["person", "SPECIES", 170, 176], ["HIV", "SPECIES", 157, 160], ["drug resistance", "PROBLEM", 74, 89], ["treatment failure", "PROBLEM", 123, 140], ["treatment", "TREATMENT", 184, 193], ["a blood sample", "TEST", 195, 209], ["genotyping assays", "TEST", 279, 296], ["drug resistance", "OBSERVATION", 74, 89], ["treatment", "OBSERVATION_MODIFIER", 123, 132], ["failure", "OBSERVATION", 133, 140], ["infected", "OBSERVATION", 161, 169]]], ["Sanger sequencing of HIV before the start of treatment is standard in clinical practice, but next-generation sequencing where the H274Y substitution at site 275 (site 274 in N2 numbering scheme) appears multiple times immediately following the D344N substitution at site 344 (shaded in blue).", [["HIV", "ORGANISM", 21, 24], ["site 275", "DNA", 152, 160], ["site 274", "DNA", 162, 170], ["site 344", "DNA", 266, 274], ["HIV", "SPECIES", 21, 24], ["HIV", "SPECIES", 21, 24], ["HIV", "PROBLEM", 21, 24], ["treatment", "TREATMENT", 45, 54], ["the H274Y substitution at site", "TREATMENT", 126, 156], ["the D344N substitution", "TREATMENT", 240, 262]]], ["This cooccurrence is consistent with the idea that the substitution at site 344 acts as a 'permissive' mutation and that these mutations interact in a positively epistatic manner.SGV contributes to treatment failure in HIVis not (Simen et al. 2009; Codo\u00f1er et al. 2011) .", [["SGV", "CHEMICAL", 179, 182], ["HIVis", "DISEASE", 219, 224], ["the substitution at site", "PROBLEM", 51, 75], ["a 'permissive' mutation", "PROBLEM", 88, 111], ["these mutations", "PROBLEM", 121, 136], ["treatment failure", "PROBLEM", 198, 215], ["consistent with", "UNCERTAINTY", 21, 36], ["treatment", "OBSERVATION_MODIFIER", 198, 207], ["failure", "OBSERVATION", 208, 215]]], ["A sequence of the protease, reverse transcriptase, and integrase genes are used to determine whether any drug resistance mutations are present at high frequencies, and if so, these results help the clinician and patient choose a combination of drugs with which to start treatment (Hirsch et al. 2008) .", [["patient", "ORGANISM", 212, 219], ["protease", "PROTEIN", 18, 26], ["reverse transcriptase", "PROTEIN", 28, 49], ["integrase genes", "DNA", 55, 70], ["patient", "SPECIES", 212, 219], ["the protease", "TREATMENT", 14, 26], ["reverse transcriptase", "TREATMENT", 28, 49], ["any drug resistance mutations", "PROBLEM", 101, 130], ["drugs", "TREATMENT", 244, 249], ["treatment", "TREATMENT", 270, 279]]], ["If the majority of the viral population in a patient carries a resistance mutation, then this information will be used to choose a drug regimen that will work for the specific virus.", [["patient", "ORGANISM", 45, 52], ["patient", "SPECIES", 45, 52], ["the viral population", "PROBLEM", 19, 39], ["a resistance mutation", "PROBLEM", 61, 82], ["a drug regimen", "TREATMENT", 129, 143], ["the specific virus", "PROBLEM", 163, 181]]], ["However, drug resistance mutations at low population frequencies (at 20% or less) are not detected by standard sequencing protocols (Simen et al. 2009 ).", [["drug resistance mutations at low population frequencies", "PROBLEM", 9, 64]]], ["An important question therefore is whether this low-frequency SGV is present in most patients, and if so, whether it allows the viral population to adapt and evolve drug resistance.", [["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93], ["the viral population", "PROBLEM", 124, 144], ["drug resistance", "PROBLEM", 165, 180], ["drug resistance", "OBSERVATION", 165, 180]]], ["An important study by Paredes et al. (2010) used asPCR to determine whether drug resistance mutations were already present as minority variants in the viral population of 183 patients.", [["patients", "ORGANISM", 175, 183], ["patients", "SPECIES", 175, 183], ["An important study", "TEST", 0, 18], ["asPCR", "TREATMENT", 49, 54], ["drug resistance mutations", "PROBLEM", 76, 101], ["viral", "OBSERVATION_MODIFIER", 151, 156]]], ["These patients originally took part in a clinical trial, so blood samples from before the start of treatment and at treatment failure (if applicable) were stored for them.", [["blood samples", "ANATOMY", 60, 73], ["patients", "ORGANISM", 6, 14], ["blood samples", "ORGANISM_SUBSTANCE", 60, 73], ["patients", "SPECIES", 6, 14], ["blood samples", "TEST", 60, 73], ["treatment", "TREATMENT", 99, 108], ["treatment failure", "PROBLEM", 116, 133]]], ["Treatment failure is defined as having virus detectable in the blood at levels higher than should be expected given that the patient is on treatment.", [["blood", "ANATOMY", 63, 68], ["blood", "ORGANISM_SUBSTANCE", 63, 68], ["patient", "ORGANISM", 125, 132], ["patient", "SPECIES", 125, 132], ["Treatment failure", "PROBLEM", 0, 17], ["virus", "PROBLEM", 39, 44], ["the blood at levels", "TEST", 59, 78], ["treatment", "TREATMENT", 139, 148], ["failure", "OBSERVATION", 10, 17]]], ["The authors focused on two important resistance mutations in the reverse transcriptase gene, K103N and Y181C, because the patients were treated with a combination of reverse transcriptase inhibitors.", [["patients", "ORGANISM", 122, 130], ["reverse transcriptase gene", "DNA", 65, 91], ["reverse transcriptase", "PROTEIN", 166, 187], ["patients", "SPECIES", 122, 130], ["K103N", "TEST", 93, 98], ["Y181C", "TREATMENT", 103, 108], ["reverse transcriptase inhibitors", "TREATMENT", 166, 198]]], ["In 73 of the 183 patients, they found that either K103N or Y181C was already present as a minority variant (mostly around 1% frequency), but they could not detect the mutation in the other 110 patients.", [["patients", "ORGANISM", 17, 25], ["patients", "ORGANISM", 193, 201], ["patients", "SPECIES", 17, 25], ["patients", "SPECIES", 193, 201], ["K103N", "PROBLEM", 50, 55], ["Y181C", "PROBLEM", 59, 64], ["a minority variant", "PROBLEM", 88, 106]]], ["Of the patients with the minority variant, treatment failed in 26 but was successful in 47.", [["patients", "ORGANISM", 7, 15], ["patients", "SPECIES", 7, 15]]], ["Out of the patients without the minority variants, treatment failed in only 16 but was successful in 94.", [["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19], ["treatment", "TREATMENT", 51, 60]]], ["Altogether, treatment failed in 23% of the 183 patients.", [["patients", "ORGANISM", 47, 55], ["patients", "SPECIES", 47, 55], ["treatment", "TREATMENT", 12, 21]]], ["When only considering the patients without detectable SGV, treatment failed in 15% of the patients.", [["patients", "ORGANISM", 26, 34], ["patients", "ORGANISM", 90, 98], ["patients", "SPECIES", 26, 34], ["patients", "SPECIES", 90, 98], ["treatment", "TREATMENT", 59, 68]]], ["This means that in 8% of the patients, failure can be attributed to the presence of a minority variant (see Fig. 4 ).SGV contributes to treatment failure in HIVThe estimate from Paredes et al. (2010) that 8% of treatment failures come from SGV may be an underestimate because the authors only looked at the presence of two drug resistance mutations, and they may not have detected the variants in all cases.", [["SGV", "CHEMICAL", 117, 120], ["SGV", "DISEASE", 240, 243], ["patients", "ORGANISM", 29, 37], ["patients", "SPECIES", 29, 37], ["failure", "PROBLEM", 39, 46], ["a minority variant", "PROBLEM", 84, 102], ["treatment failure", "PROBLEM", 136, 153], ["treatment failures", "PROBLEM", 211, 229], ["two drug resistance mutations", "PROBLEM", 319, 348], ["failure", "OBSERVATION", 39, 46], ["minority variant", "OBSERVATION", 86, 102], ["treatment", "OBSERVATION_MODIFIER", 136, 145], ["failure", "OBSERVATION", 146, 153]]], ["However, the two mutations are the most important for the treatment they looked at, and the result is fairly similar to a different estimate which we will describe below.SGV contributes to treatment failure in HIVA less direct method to study the role of SGV for the evolution of HIV drug resistance was developed by one of us (Pennings 2012) .", [["SGV", "CHEMICAL", 170, 173], ["HIV drug resistance", "DISEASE", 280, 299], ["SGV", "SIMPLE_CHEMICAL", 170, 173], ["SGV", "GENE_OR_GENE_PRODUCT", 255, 258], ["HIV", "ORGANISM", 280, 283], ["HIV", "SPECIES", 280, 283], ["the two mutations", "PROBLEM", 9, 26], ["the treatment", "TREATMENT", 54, 67], ["treatment failure", "PROBLEM", 189, 206], ["HIV drug resistance", "PROBLEM", 280, 299], ["treatment", "OBSERVATION_MODIFIER", 189, 198], ["failure", "OBSERVATION", 199, 206]]], ["We re-analysed data from a previous study (Margot et al. 2006) and looked for excess adaptation early during treatment.", [["a previous study", "TEST", 25, 41], ["treatment", "TREATMENT", 109, 118]]], ["We found that in the study of interest, resistance evolution happened at a constant rate in the second and third year of treatment.", [["resistance evolution", "PROBLEM", 40, 60], ["treatment", "TREATMENT", 121, 130]]], ["In both of those years, the virus acquired resistance in 3.5% of the patients who previously had a virus without drug resistance.", [["patients", "ORGANISM", 69, 77], ["patients", "SPECIES", 69, 77], ["the virus acquired resistance", "PROBLEM", 24, 53], ["a virus", "PROBLEM", 97, 104], ["drug resistance", "PROBLEM", 113, 128]]], ["Such a constant rate of Fig. 4 Determining the amount of drug resistance from standing genetic variation (SGV) in HIV-1 using two studies.", [["HIV-1", "ORGANISM", 114, 119], ["HIV-1", "SPECIES", 114, 119], ["HIV-1", "SPECIES", 114, 119], ["a constant rate of Fig", "TREATMENT", 5, 27], ["drug resistance", "PROBLEM", 57, 72], ["standing genetic variation", "PROBLEM", 78, 104], ["two studies", "TEST", 126, 137], ["amount", "OBSERVATION_MODIFIER", 47, 53], ["drug resistance", "OBSERVATION", 57, 72]]], ["In two different studies, the percentage of patients acquiring drug resistance is partitioned into those whose HIV populations acquired drug resistance from SGV (light blue) and those whose populations acquired drug resistance via de novo mutation (dark blue).", [["patients", "ORGANISM", 44, 52], ["HIV", "ORGANISM", 111, 114], ["patients", "SPECIES", 44, 52], ["HIV", "SPECIES", 111, 114], ["HIV", "SPECIES", 111, 114], ["SGV (light blue)", "PROBLEM", 157, 173], ["de novo mutation", "PROBLEM", 231, 247], ["percentage", "OBSERVATION_MODIFIER", 30, 40], ["drug resistance", "OBSERVATION", 63, 78]]], ["The total rate of failure is higher in the Paredes study than in the Margot study, but the percentage that is attributable to SGV is similar in the two studies.", [["SGV", "DISEASE", 126, 129], ["failure", "PROBLEM", 18, 25], ["the Margot study", "TEST", 65, 81], ["total", "OBSERVATION_MODIFIER", 4, 9], ["failure", "OBSERVATION", 18, 25], ["higher", "OBSERVATION_MODIFIER", 29, 35], ["similar", "OBSERVATION_MODIFIER", 133, 140]]], ["The calculation of the percentage of patients failing from SGV from the Paredes et al. (2010) study is shown in the inset.", [["patients", "ORGANISM", 37, 45], ["patients", "SPECIES", 37, 45], ["study", "TEST", 94, 99], ["percentage", "OBSERVATION_MODIFIER", 23, 33]]], ["Patients are partitioned into those starting without drug-resistant SGV (left) and those with drug-resistant SGV (right).", [["SGV", "ANATOMY", 68, 71], ["left", "ANATOMY", 73, 77], ["SGV", "ANATOMY", 109, 112], ["SGV", "DISEASE", 68, 71], ["SGV", "DISEASE", 109, 112], ["Patients", "ORGANISM", 0, 8], ["SGV", "CANCER", 68, 71], ["SGV", "CANCER", 109, 112], ["Patients", "SPECIES", 0, 8], ["drug-resistant SGV (left)", "PROBLEM", 53, 78], ["left", "ANATOMY_MODIFIER", 73, 77], ["right", "ANATOMY_MODIFIER", 114, 119]]], ["Eleven patients are expected to have failed due to de novo mutations based on the sample size ( 15% of 73 patients), and the remaining 15 failures are attributed to failure due to drug resistance from SGV.SGV contributes to treatment failure in HIV\u00a9 2015 John Wiley & Sons Ltd evolution of drug resistance was also observed in several other trials (e.g. UK Collaborative Group on HIV Drug Resistance and UK CHIC Study Group and Others 2010).", [["SGV", "CHEMICAL", 205, 208], ["HIV Drug Resistance", "DISEASE", 380, 399], ["patients", "ORGANISM", 7, 15], ["patients", "ORGANISM", 106, 114], ["SGV", "CANCER", 201, 204], ["patients", "SPECIES", 7, 15], ["patients", "SPECIES", 106, 114], ["HIV", "SPECIES", 245, 248], ["HIV", "SPECIES", 380, 383], ["de novo mutations", "PROBLEM", 51, 68], ["the sample size", "TEST", 78, 93], ["the remaining 15 failures", "PROBLEM", 121, 146], ["failure", "PROBLEM", 165, 172], ["drug resistance from SGV", "PROBLEM", 180, 204], ["treatment failure", "PROBLEM", 224, 241], ["drug resistance", "PROBLEM", 290, 305], ["size", "OBSERVATION_MODIFIER", 89, 93], ["failure", "OBSERVATION", 165, 172], ["drug resistance", "OBSERVATION", 180, 195], ["treatment", "OBSERVATION_MODIFIER", 224, 233], ["failure", "OBSERVATION", 234, 241], ["drug resistance", "OBSERVATION", 290, 305]]], ["In years 2 and 3 of treatment, SGV that was present before treatment probably plays no role, so the 3.5% likely reflects evolution of resistance from de novo mutations.", [["SGV", "CANCER", 31, 34], ["SGV", "SPECIES", 31, 34], ["treatment", "TREATMENT", 20, 29], ["treatment", "TREATMENT", 59, 68], ["resistance from de novo mutations", "PROBLEM", 134, 167], ["no", "UNCERTAINTY", 84, 86]]], ["In the first year of treatment, it is expected that both new mutations and SGV contribute to the evolution of resistance, so if resistance evolved in more than 3.5% of the patients' viral populations, this suggests that SGV played a role.SGV contributes to treatment failure in HIVIn Margot et al. (2006) , there were 600 patients in total in the first year of treatment.", [["SGV", "CHEMICAL", 220, 223], ["SGV", "DISEASE", 238, 241], ["SGV", "GENE_OR_GENE_PRODUCT", 75, 78], ["patients", "ORGANISM", 172, 180], ["SGV", "GENE_OR_GENE_PRODUCT", 220, 223], ["patients", "ORGANISM", 322, 330], ["SGV", "PROTEIN", 220, 223], ["patients", "SPECIES", 172, 180], ["patients", "SPECIES", 322, 330], ["SGV", "SPECIES", 220, 223], ["treatment", "TREATMENT", 21, 30], ["both new mutations and SGV", "PROBLEM", 52, 78], ["resistance", "PROBLEM", 110, 120], ["resistance", "PROBLEM", 128, 138], ["the patients' viral populations", "PROBLEM", 168, 199], ["treatment failure", "PROBLEM", 257, 274], ["treatment", "TREATMENT", 361, 370], ["new", "OBSERVATION_MODIFIER", 57, 60], ["mutations", "OBSERVATION", 61, 70], ["viral populations", "OBSERVATION", 182, 199], ["treatment", "OBSERVATION_MODIFIER", 257, 266], ["failure", "OBSERVATION", 267, 274]]], ["The expected number of people with resistance after 1 year was 21 (this is 3.5%, the rate that is seen in year 2 and year 3).", [["people", "ORGANISM", 23, 29], ["people", "SPECIES", 23, 29], ["number", "OBSERVATION_MODIFIER", 13, 19]]], ["In reality, there were 57 people with resistance, so 36 more than expected.", [["people", "ORGANISM", 26, 32], ["people", "SPECIES", 26, 32]]], ["Thirty-six of 600 is 6% (see Fig. 4 ), so it was estimated that SGV leads to resistance in 6% of the patients.SGV contributes to treatment failure in HIVOne may note that the total number of failing patients is much higher in Paredes et al. (2010) .", [["SGV", "DISEASE", 110, 113], ["patients", "ORGANISM", 101, 109], ["patients", "ORGANISM", 199, 207], ["patients", "SPECIES", 101, 109], ["patients", "SPECIES", 199, 207], ["treatment failure", "PROBLEM", 129, 146], ["treatment", "OBSERVATION_MODIFIER", 129, 138], ["failure", "OBSERVATION", 139, 146]]], ["This may be because they have a stricter criterion for treatment success [<200 copies for Paredes et al. (2010) vs. <400 copies for Margot et al. (2006) ].", [["treatment success", "TREATMENT", 55, 72]]], ["Also, the patients were on similar but not the same treatments (3TC/AZT/EFV or ABC/3TC/AZT/EFV in the Paredes study and 3TC/ TDF/EFV or 3TC/d4T/EFV in the Margot study).Quantifying the importance of SGV in drug resistance evolutionIn the light of different overall rates of evolution in the two studies, it is perhaps surprising to see that the estimated rate of evolution from SGV is similar (8% and 6%).", [["3TC", "CHEMICAL", 64, 67], ["AZT", "CHEMICAL", 68, 71], ["EFV", "CHEMICAL", 72, 75], ["3TC", "CHEMICAL", 83, 86], ["AZT", "CHEMICAL", 87, 90], ["EFV", "CHEMICAL", 91, 94], ["3TC", "CHEMICAL", 120, 123], ["TDF", "CHEMICAL", 125, 128], ["EFV", "CHEMICAL", 129, 132], ["3TC", "CHEMICAL", 136, 139], ["d4T", "CHEMICAL", 140, 143], ["EFV", "CHEMICAL", 144, 147], ["3TC", "CHEMICAL", 64, 67], ["AZT", "CHEMICAL", 68, 71], ["EFV", "CHEMICAL", 72, 75], ["3TC", "CHEMICAL", 83, 86], ["AZT", "CHEMICAL", 87, 90], ["EFV", "CHEMICAL", 91, 94], ["3TC", "CHEMICAL", 120, 123], ["TDF", "CHEMICAL", 125, 128], ["EFV", "CHEMICAL", 129, 132], ["3TC", "CHEMICAL", 136, 139], ["d4T", "CHEMICAL", 140, 143], ["EFV", "CHEMICAL", 144, 147], ["patients", "ORGANISM", 10, 18], ["EFV", "SIMPLE_CHEMICAL", 72, 75], ["AZT", "SIMPLE_CHEMICAL", 87, 90], ["EFV", "SIMPLE_CHEMICAL", 91, 94], ["3TC", "SIMPLE_CHEMICAL", 120, 123], ["EFV", "SIMPLE_CHEMICAL", 129, 132], ["3TC", "SIMPLE_CHEMICAL", 136, 139], ["SGV", "GENE_OR_GENE_PRODUCT", 199, 202], ["patients", "SPECIES", 10, 18], ["3TC/AZT", "TREATMENT", 64, 71], ["EFV", "TREATMENT", 72, 75], ["ABC", "TEST", 79, 82], ["3TC", "TREATMENT", 83, 86], ["AZT", "TREATMENT", 87, 90], ["EFV", "TREATMENT", 91, 94], ["the Paredes study", "TEST", 98, 115], ["3TC/ TDF", "TREATMENT", 120, 128], ["EFV", "TREATMENT", 129, 132], ["3TC", "TREATMENT", 136, 139], ["d4T", "TREATMENT", 140, 143], ["EFV", "TREATMENT", 144, 147], ["the Margot study", "TEST", 151, 167], ["SGV", "TEST", 378, 381], ["drug resistance", "OBSERVATION", 206, 221], ["different", "OBSERVATION_MODIFIER", 247, 256], ["overall", "OBSERVATION_MODIFIER", 257, 264], ["rates", "OBSERVATION_MODIFIER", 265, 270], ["similar", "OBSERVATION_MODIFIER", 385, 392]]], ["When Pennings used a third data set to estimate the rate of evolution of resistance due to SGV-based on a trial of long treatment interruptions with 435 patients (Danel et al. 2009 )-her estimate was again 6%, which suggests that these estimates are fairly robust (Pennings 2012) .Quantifying the importance of SGV in drug resistance evolutionAdaptation from SGV has been discussed extensively in the literature; however, there are relatively few studies that have attempted to quantify its relative importance as a mode of adaptation.", [["patients", "ORGANISM", 153, 161], ["SGV", "GENE_OR_GENE_PRODUCT", 311, 314], ["SGV", "CANCER", 359, 362], ["SGV", "PROTEIN", 91, 94], ["patients", "SPECIES", 153, 161], ["a third data", "TEST", 19, 31], ["resistance", "PROBLEM", 73, 83], ["SGV", "PROBLEM", 91, 94], ["long treatment interruptions", "TREATMENT", 115, 143], ["her estimate", "TEST", 183, 195], ["drug resistance", "OBSERVATION", 318, 333]]], ["Altogether, the results from studying HIV suggest that SGV plays an important and quantitatively predictable role in treatment failures for this particular disease.", [["HIV", "ORGANISM", 38, 41], ["SGV", "GENE_OR_GENE_PRODUCT", 55, 58], ["HIV", "SPECIES", 38, 41], ["HIV", "SPECIES", 38, 41], ["SGV", "SPECIES", 55, 58], ["studying HIV", "TEST", 29, 41], ["treatment failures", "TREATMENT", 117, 135], ["this particular disease", "PROBLEM", 140, 163]]], ["SGV may also play a large role in treatment outcomes for other diseases, both those caused by pathogens and others such as cancer (Bozic et al. 2013 ).", [["cancer", "ANATOMY", 123, 129], ["cancer", "DISEASE", 123, 129], ["SGV", "GENE_OR_GENE_PRODUCT", 0, 3], ["cancer", "CANCER", 123, 129], ["SGV", "SPECIES", 0, 3], ["treatment outcomes", "TREATMENT", 34, 52], ["other diseases", "PROBLEM", 57, 71], ["pathogens", "PROBLEM", 94, 103], ["large", "OBSERVATION_MODIFIER", 20, 25]]], ["Next-generation sequencing can be used to determine whether drug-resistant SGV exists in patients prior to treatment, thus informing clinical decisions for individual patients.", [["SGV", "CANCER", 75, 78], ["patients", "ORGANISM", 89, 97], ["patients", "ORGANISM", 167, 175], ["patients", "SPECIES", 89, 97], ["patients", "SPECIES", 167, 175], ["SGV", "SPECIES", 75, 78], ["Next-generation sequencing", "TREATMENT", 0, 26], ["treatment", "TREATMENT", 107, 116]]], ["Apart from its clinical relevance, the particular example of HIV drug resistance evolution is also well-suited for validating evolutionary theory regarding adaptation from SGV (Orr &Clonal interference among nonrecombining populations of Mycobacterium tuberculosisMycobacterium tuberculosis, the causative agent of tuberculosis (TB), is a nonrecombining bacterium that is believed to reproduce entirely clonally (although see Namouchi et al. 2012) .", [["Mycobacterium tuberculosis", "DISEASE", 238, 264], ["Mycobacterium tuberculosis", "DISEASE", 264, 290], ["tuberculosis", "DISEASE", 315, 327], ["TB", "DISEASE", 329, 331], ["HIV", "ORGANISM", 61, 64], ["SGV", "GENE_OR_GENE_PRODUCT", 172, 175], ["Orr &Clonal", "ORGANISM", 177, 188], ["Mycobacterium tuberculosisMycobacterium tuberculosis", "ORGANISM", 238, 290], ["Mycobacterium tuberculosis", "SPECIES", 238, 264], ["Mycobacterium tuberculosis", "SPECIES", 264, 290], ["HIV", "SPECIES", 61, 64], ["SGV", "SPECIES", 172, 175], ["Mycobacterium tuberculosis", "SPECIES", 238, 264], ["Mycobacterium tuberculosis", "SPECIES", 264, 290], ["HIV drug resistance evolution", "PROBLEM", 61, 90], ["SGV (Orr &Clonal interference", "TREATMENT", 172, 201], ["Mycobacterium tuberculosisMycobacterium tuberculosis", "PROBLEM", 238, 290], ["tuberculosis (TB)", "PROBLEM", 315, 332], ["a nonrecombining bacterium", "PROBLEM", 337, 363], ["Mycobacterium tuberculosis", "OBSERVATION", 238, 264], ["Mycobacterium tuberculosis", "OBSERVATION", 264, 290], ["tuberculosis", "OBSERVATION", 315, 327]]], ["Mycobacterium tuberculosis latently infects approximately one-third of the world's population, and tuberculosis caused $ 1.5 million deaths in 2014.", [["Mycobacterium tuberculosis", "DISEASE", 0, 26], ["tuberculosis", "DISEASE", 99, 111], ["deaths", "DISEASE", 133, 139], ["Mycobacterium tuberculosis", "ORGANISM", 0, 26], ["Mycobacterium tuberculosis", "SPECIES", 0, 26], ["Mycobacterium tuberculosis", "SPECIES", 0, 26], ["Mycobacterium tuberculosis", "PROBLEM", 0, 26], ["tuberculosis", "PROBLEM", 99, 111], ["infects", "OBSERVATION_MODIFIER", 36, 43], ["approximately", "OBSERVATION_MODIFIER", 44, 57], ["one-third", "OBSERVATION_MODIFIER", 58, 67], ["tuberculosis", "OBSERVATION", 99, 111]]], ["The vast majority of these deaths occurred in low-or middle-wealth countries (WHO 2014a).", [["deaths", "DISEASE", 27, 33], ["these deaths", "PROBLEM", 21, 33], ["vast", "OBSERVATION_MODIFIER", 4, 8], ["majority", "OBSERVATION_MODIFIER", 9, 17]]], ["Although tuberculosis is often effectively treated with combination therapies of antibiotics, drug resistance is common to nearly all known drugs.", [["tuberculosis", "DISEASE", 9, 21], ["tuberculosis", "PROBLEM", 9, 21], ["combination therapies", "TREATMENT", 56, 77], ["antibiotics", "TREATMENT", 81, 92], ["drug resistance", "TREATMENT", 94, 109], ["tuberculosis", "OBSERVATION", 9, 21]]], ["Multiply drug-resistant and extensively drug-resistant strains can be particularly difficult to treat, requiring longer courses of more expensive medications.", [["Multiply drug-resistant and extensively drug-resistant strains", "PROBLEM", 0, 62], ["more expensive medications", "TREATMENT", 131, 157], ["drug-resistant", "OBSERVATION_MODIFIER", 9, 23], ["resistant strains", "OBSERVATION", 45, 62]]], ["Therefore, much work has been done in categorizing the genomic locations and probable mechanisms of these drug resistance mutations.Clonal interference among nonrecombining populations of Mycobacterium tuberculosisMany mutations have been identified that confer a large degree of drug resistance within patients.", [["Mycobacterium tuberculosis", "DISEASE", 188, 214], ["Mycobacterium tuberculosis", "ORGANISM", 188, 214], ["patients", "ORGANISM", 303, 311], ["Mycobacterium tuberculosis", "SPECIES", 188, 214], ["patients", "SPECIES", 303, 311], ["Mycobacterium tuberculosis", "SPECIES", 188, 214], ["these drug resistance mutations", "PROBLEM", 100, 131], ["Clonal interference", "PROBLEM", 132, 151], ["Mycobacterium tuberculosis", "PROBLEM", 188, 214], ["Many mutations", "PROBLEM", 214, 228], ["drug resistance", "PROBLEM", 280, 295], ["drug resistance", "OBSERVATION", 106, 121], ["Mycobacterium tuberculosis", "OBSERVATION", 188, 214], ["large", "OBSERVATION_MODIFIER", 264, 269], ["drug resistance", "OBSERVATION", 280, 295]]], ["These drug resistance mutations have been found by collecting M. tuberculosis samples, assaying their growth in media containing different antibiotics and identifying associations between mutations and resistance profiles.", [["samples", "ANATOMY", 78, 85], ["tuberculosis", "DISEASE", 65, 77], ["M. tuberculosis", "SPECIES", 62, 77], ["M. tuberculosis", "SPECIES", 62, 77], ["These drug resistance mutations", "PROBLEM", 0, 31], ["collecting M. tuberculosis samples", "PROBLEM", 51, 85], ["different antibiotics", "TREATMENT", 129, 150], ["mutations and resistance profiles", "PROBLEM", 188, 221], ["tuberculosis", "OBSERVATION", 65, 77]]], ["A comprehensive list of drug resistance mutations can be found in the Tuberculosis Drug Resistance Database (Sandgren et al. 2009 ) where 1178 drug resistance mutations of various effect sizes to nine drugs are recorded within more than 30 different genes.Clonal interference among nonrecombining populations of Mycobacterium tuberculosisDespite the apparent adaptability of M. tuberculosis, diversity in intrapatient populations has historically been considered to be very low (Sreevatsan et al. 1997; Musser et al. 2000) .", [["Tuberculosis", "DISEASE", 70, 82], ["Mycobacterium tuberculosis", "DISEASE", 312, 338], ["tuberculosis", "DISEASE", 378, 390], ["Mycobacterium tuberculosis", "ORGANISM", 312, 338], ["M. tuberculosis", "ORGANISM", 375, 390], ["Mycobacterium tuberculosis", "SPECIES", 312, 338], ["M. tuberculosis", "SPECIES", 375, 390], ["Mycobacterium tuberculosis", "SPECIES", 312, 338], ["M. tuberculosis", "SPECIES", 375, 390], ["drug resistance mutations", "PROBLEM", 24, 49], ["drug resistance mutations", "PROBLEM", 143, 168], ["various effect sizes", "PROBLEM", 172, 192], ["nine drugs", "TREATMENT", 196, 206], ["Clonal interference", "PROBLEM", 256, 275], ["Mycobacterium tuberculosis", "PROBLEM", 312, 338], ["M. tuberculosis", "PROBLEM", 375, 390], ["diversity in intrapatient populations", "PROBLEM", 392, 429], ["Tuberculosis", "OBSERVATION", 70, 82], ["Mycobacterium tuberculosis", "OBSERVATION", 312, 338], ["tuberculosis", "OBSERVATION", 378, 390], ["diversity", "OBSERVATION_MODIFIER", 392, 401]]], ["It is only recently that studies have found that considerable diversity exists within M. tuberculosis populations (Al-Hajoj et al. 2010; Navarro et al. 2011; Sun et al. 2012; Eldholm et al. 2014) .", [["tuberculosis", "DISEASE", 89, 101], ["M. tuberculosis", "ORGANISM", 86, 101], ["M. tuberculosis", "SPECIES", 86, 101], ["M. tuberculosis", "SPECIES", 86, 101], ["tuberculosis", "OBSERVATION_MODIFIER", 89, 101]]], ["By combining new sequencing data with the knowledge of well-documented drug resistance mutations in M. tuberculosis, we can test our theoretical understanding of how clonal evolution proceeds and arrive at a more complete picture of how M. tuberculosis drug resistance emerges within a patient.The dynamics of clonal interference in TBRecombination is thought to be evolutionarily adaptive because it allows different adaptive mutations that reside on different genetic backgrounds in a population to appear together (Fisher 1930; Muller 1932; Felsenstein 1974 ).", [["M. tuberculosis", "DISEASE", 100, 115], ["tuberculosis", "DISEASE", 240, 252], ["M. tuberculosis", "ORGANISM", 100, 115], ["clonal", "CELL", 166, 172], ["M. tuberculosis", "ORGANISM", 237, 252], ["patient", "ORGANISM", 286, 293], ["clonal", "CELL", 310, 316], ["M. tuberculosis", "SPECIES", 100, 115], ["M. tuberculosis", "SPECIES", 237, 252], ["patient", "SPECIES", 286, 293], ["M. tuberculosis", "SPECIES", 100, 115], ["M. tuberculosis", "SPECIES", 237, 252], ["drug resistance mutations", "PROBLEM", 71, 96], ["M. tuberculosis", "PROBLEM", 100, 115], ["clonal interference in TBRecombination", "PROBLEM", 310, 348], ["different adaptive mutations", "PROBLEM", 408, 436], ["tuberculosis", "OBSERVATION", 103, 115], ["tuberculosis", "OBSERVATION", 240, 252], ["clonal interference", "OBSERVATION", 310, 329], ["thought to be", "UNCERTAINTY", 352, 365]]], ["In addition, it can unlink positively selected traits from deleterious passenger mutations and mitigate the effects of linked selection (Hill & Robertson 1966; Birky & Walsh 1988; Good & Desai 2014) .", [["deleterious passenger mutations", "PROBLEM", 59, 90]]], ["In populations with no recombination, each mutation remains on the genetic background on which it originally occurred.", [["each mutation", "PROBLEM", 38, 51], ["no", "UNCERTAINTY", 20, 22], ["recombination", "OBSERVATION", 23, 36]]], ["Therefore, if multiple positively selective traits enter the population simultaneously on different backgrounds, these traits cannot be recombined to augment each other.", [["multiple positively selective traits", "PROBLEM", 14, 50]]], ["Instead, they must compete against each other as they both rise in frequency in the population (Muller 1932) .", [["rise", "OBSERVATION_MODIFIER", 59, 63]]], ["This process is known as clonal interference (Gerrish & Lenski 1998).The dynamics of clonal interference in TBWhile clonal interference has been extensively modelled (Rouzine et al. 2003; Desai & Fisher 2007; Park & Krug 2007; Martens & Hallatschek 2011; Neher 2013) and investigated in laboratory experiments (Miralles et al. 1999; Pepin & Wichman 2008; Kvitek & Sherlock 2013; Lang et al. 2013) , few systems exist that allow us to test these predictions in natural populations.", [["clonal", "CELL", 85, 91], ["TBWhile clonal", "CELL", 108, 122], ["clonal interference in TBWhile clonal interference", "PROBLEM", 85, 135], ["Kvitek", "TEST", 355, 361], ["clonal interference", "OBSERVATION", 85, 104], ["clonal interference", "OBSERVATION", 116, 135]]], ["Globally, influenza seems to evolve clonally across years (Strelkowa & L\u20ac assig 2012) , but intrahost populations of nonrecombining bacteria allow for many semi-independent evolutionary trajectories to be compared over much shorter time scales.", [["influenza", "DISEASE", 10, 19], ["influenza", "PROBLEM", 10, 19], ["nonrecombining bacteria", "PROBLEM", 117, 140], ["many semi-independent evolutionary trajectories", "PROBLEM", 151, 198], ["influenza", "OBSERVATION", 10, 19]]], ["Although there is evidence that HIV experiences clonal interference within patients, recombination complicates its study (Pandit & de Boer 2014) .", [["HIV", "ORGANISM", 32, 35], ["clonal", "CELL", 48, 54], ["patients", "ORGANISM", 75, 83], ["HIV", "SPECIES", 32, 35], ["patients", "SPECIES", 75, 83], ["HIV", "SPECIES", 32, 35], ["HIV experiences clonal interference", "PROBLEM", 32, 67], ["its study", "TEST", 111, 120]]], ["There is also a strong interest in clonal evolution in cancer, but sampling at different time points is often much harder for cancer than for M. tuberculosis or HIV, which makes cancer as a study system more difficult Walter et al. 2012) .The dynamics of clonal interference in TBIntrahost evolution of M. tuberculosis provides a fairly straightforward way to examine clonal interference in vivo and to understand the extent to which it can slow the evolutionary process.", [["cancer", "ANATOMY", 55, 61], ["cancer", "ANATOMY", 126, 132], ["cancer", "ANATOMY", 178, 184], ["cancer", "DISEASE", 55, 61], ["cancer", "DISEASE", 126, 132], ["tuberculosis", "DISEASE", 145, 157], ["cancer", "DISEASE", 178, 184], ["tuberculosis", "DISEASE", 306, 318], ["clonal", "CELL", 35, 41], ["cancer", "CANCER", 55, 61], ["cancer", "CANCER", 126, 132], ["M. tuberculosis", "ORGANISM", 142, 157], ["HIV", "ORGANISM", 161, 164], ["cancer", "CANCER", 178, 184], ["clonal", "CELL", 255, 261], ["M. tuberculosis", "ORGANISM", 303, 318], ["M. tuberculosis", "SPECIES", 142, 157], ["HIV", "SPECIES", 161, 164], ["M. tuberculosis", "SPECIES", 303, 318], ["M. tuberculosis", "SPECIES", 142, 157], ["HIV", "SPECIES", 161, 164], ["M. tuberculosis", "SPECIES", 303, 318], ["cancer", "PROBLEM", 55, 61], ["cancer", "PROBLEM", 126, 132], ["M. tuberculosis", "PROBLEM", 142, 157], ["HIV", "PROBLEM", 161, 164], ["cancer", "PROBLEM", 178, 184], ["a study system", "TEST", 188, 202], ["clonal interference", "PROBLEM", 255, 274], ["M. tuberculosis", "PROBLEM", 303, 318], ["clonal interference in vivo", "PROBLEM", 368, 395], ["strong", "OBSERVATION_MODIFIER", 16, 22], ["interest", "OBSERVATION_MODIFIER", 23, 31], ["clonal", "OBSERVATION_MODIFIER", 35, 41], ["evolution", "OBSERVATION_MODIFIER", 42, 51], ["cancer", "OBSERVATION", 55, 61], ["tuberculosis", "OBSERVATION", 145, 157], ["clonal interference", "OBSERVATION", 255, 274], ["M. tuberculosis", "OBSERVATION", 303, 318]]], ["Because there is no recombination, allele frequencies from pooled resequencing can, in some cases, be reconstructed into Box 3.", [["Box 3", "GENE_OR_GENE_PRODUCT", 121, 126], ["Box 3", "DNA", 121, 126], ["recombination", "PROBLEM", 20, 33], ["allele frequencies", "PROBLEM", 35, 53], ["no", "UNCERTAINTY", 17, 19]]], ["Horizontal gene transfer and the bacterial core and accessory genomes Bacteria have a circular chromosome (typically 1-10 Mb in size and in 1-2 copies per cell) that generally contains the 'core' or 'essential' genome and typically codes for fundamental functions like DNA repair and replication, cell structures and shapes, and metabolic functions.", [["chromosome", "ANATOMY", 95, 105], ["cell", "ANATOMY", 155, 159], ["cell structures", "ANATOMY", 297, 312], ["chromosome", "CELLULAR_COMPONENT", 95, 105], ["cell", "CELL", 155, 159], ["' genome", "CELLULAR_COMPONENT", 209, 217], ["DNA", "CELLULAR_COMPONENT", 269, 272], ["cell", "CELL", 297, 301], ["bacterial core and accessory genomes Bacteria", "DNA", 33, 78], ["circular chromosome", "DNA", 86, 105], ["essential' genome", "DNA", 200, 217], ["Horizontal gene transfer", "PROBLEM", 0, 24], ["the bacterial core", "PROBLEM", 29, 47], ["accessory genomes Bacteria", "PROBLEM", 52, 78], ["a circular chromosome", "TEST", 84, 105], ["fundamental functions", "TREATMENT", 242, 263], ["DNA repair", "TREATMENT", 269, 279], ["size", "OBSERVATION_MODIFIER", 128, 132], ["' genome", "OBSERVATION", 209, 217], ["DNA repair", "OBSERVATION", 269, 279], ["shapes", "OBSERVATION_MODIFIER", 317, 323], ["metabolic functions", "OBSERVATION", 329, 348]]], ["Many species of bacteria have an additional 'accessory' or 'satellite' genome that is typically 0.1-10% of the size of the core genome and can be present on the main circular chromosome or on extrachromosomal elements, such as plasmids.", [["chromosome", "ANATOMY", 175, 185], ["plasmids", "ANATOMY", 227, 235], ["satellite' genome", "CELLULAR_COMPONENT", 60, 77], ["chromosome", "CELLULAR_COMPONENT", 175, 185], ["satellite' genome", "DNA", 60, 77], ["core genome", "DNA", 123, 134], ["circular chromosome", "DNA", 166, 185], ["extrachromosomal elements", "DNA", 192, 217], ["plasmids", "DNA", 227, 235], ["Many species of bacteria", "PROBLEM", 0, 24], ["'satellite' genome", "PROBLEM", 59, 77], ["plasmids", "TREATMENT", 227, 235], ["satellite' genome", "OBSERVATION", 60, 77], ["typically 0.1-10", "OBSERVATION_MODIFIER", 86, 102], ["size", "OBSERVATION_MODIFIER", 111, 115], ["core genome", "OBSERVATION", 123, 134], ["main", "OBSERVATION_MODIFIER", 161, 165], ["circular chromosome", "OBSERVATION", 166, 185], ["extrachromosomal elements", "OBSERVATION", 192, 217]]], ["The core genome is usually defined as the set of genetic regions that are present within all members of the species, and the accessory genome is that which can vary between individual strains or cells.", [["cells", "ANATOMY", 195, 200], ["cells", "CELL", 195, 200], ["core genome", "DNA", 4, 15], ["accessory genome", "DNA", 125, 141], ["core", "OBSERVATION_MODIFIER", 4, 8], ["genome", "OBSERVATION", 9, 15], ["accessory genome", "OBSERVATION", 125, 141]]], ["The accessory genome, whether on the main chromosome or not, can include chromosomal cassettes, bacteriophages, pathogenicity islands, genomic islands and transposons (Lindsay & Holden 2004) .", [["chromosome", "ANATOMY", 42, 52], ["chromosomal", "ANATOMY", 73, 84], ["chromosome", "CELLULAR_COMPONENT", 42, 52], ["chromosomal", "CELLULAR_COMPONENT", 73, 84], ["accessory genome", "DNA", 4, 20], ["chromosomal cassettes", "DNA", 73, 94], ["bacteriophages", "DNA", 96, 110], ["pathogenicity islands", "DNA", 112, 133], ["genomic islands", "DNA", 135, 150], ["transposons", "DNA", 155, 166], ["chromosomal cassettes", "PROBLEM", 73, 94], ["bacteriophages", "PROBLEM", 96, 110], ["pathogenicity islands", "PROBLEM", 112, 133], ["accessory genome", "OBSERVATION", 4, 20], ["pathogenicity", "OBSERVATION_MODIFIER", 112, 125], ["islands", "OBSERVATION_MODIFIER", 126, 133], ["genomic islands", "OBSERVATION", 135, 150]]], ["The accessory genome is sometimes called 'dispensable' because it is not required for survival in an optimal environment; however, not only can the accessory genome encode information essential to a bacterium's survival in some environments, but bacteria have evolved elaborate and fascinating methods of sharing accessory genes between cells (Amabile-Cuevas 1993; Stokes & Gillings 2011) .The dynamics of clonal interference in TBThe sharing of genetic information between cells is called horizontal gene transfer (HGT).", [["cells", "ANATOMY", 337, 342], ["cells", "ANATOMY", 474, 479], ["cells", "CELL", 337, 342], ["clonal", "CELL", 406, 412], ["cells", "CELL", 474, 479], ["accessory genome", "DNA", 4, 20], ["accessory genome", "DNA", 148, 164], ["accessory genes", "DNA", 313, 328], ["a bacterium's survival", "PROBLEM", 197, 219], ["bacteria", "PROBLEM", 246, 254], ["accessory genome", "OBSERVATION", 4, 20], ["clonal interference", "OBSERVATION", 406, 425]]], ["While bacteria are asexual and typically defined as 'clonal', both HGT (distinct from sex because it alters the genome of the recipient) and new mutations can generate novel genetic variation within a population of bacteria.", [["bacteria", "PROBLEM", 6, 14], ["asexual", "PROBLEM", 19, 26], ["new mutations", "PROBLEM", 141, 154], ["novel genetic variation", "PROBLEM", 168, 191], ["bacteria", "PROBLEM", 215, 223]]], ["The actual methods of transferring DNA through the cell membrane include transformation, transduction, and conjugation.", [["cell membrane", "ANATOMY", 51, 64], ["DNA", "CELLULAR_COMPONENT", 35, 38], ["cell membrane", "CELLULAR_COMPONENT", 51, 64], ["transferring DNA", "TREATMENT", 22, 38], ["the cell membrane", "TREATMENT", 47, 64], ["cell membrane", "OBSERVATION", 51, 64]]], ["Transformation is the uptake of naked DNA into the cell, generally mediated by membrane proteins with some DNA specificity.", [["cell", "ANATOMY", 51, 55], ["membrane", "ANATOMY", 79, 87], ["DNA", "CELLULAR_COMPONENT", 38, 41], ["cell", "CELL", 51, 55], ["membrane", "CELLULAR_COMPONENT", 79, 87], ["DNA", "CELLULAR_COMPONENT", 107, 110], ["naked DNA", "DNA", 32, 41], ["membrane proteins", "PROTEIN", 79, 96], ["naked DNA into the cell", "PROBLEM", 32, 55], ["some DNA specificity", "PROBLEM", 102, 122], ["cell", "ANATOMY", 51, 55]]], ["It is a method restricted to species that have evolved to uptake DNA.", [["DNA", "CELLULAR_COMPONENT", 65, 68], ["uptake DNA", "PROBLEM", 58, 68], ["uptake DNA", "OBSERVATION", 58, 68]]], ["Transduction is transfer of DNA that is mediated by phages (or bacteriophages, viruses that infect and replicate within a bacterium), thus it is restricted by which hosts a phage is capable of infecting.", [["DNA", "CELLULAR_COMPONENT", 28, 31], ["DNA", "PROBLEM", 28, 31], ["bacteriophages", "PROBLEM", 63, 77], ["viruses", "PROBLEM", 79, 86], ["infecting", "PROBLEM", 193, 202], ["infecting", "OBSERVATION", 193, 202]]], ["There are two types: generalized transduction, where random bacterial DNA is incorporated into phage DNA, and specialized transduction, where the incorporation is limited to a specific set of bacterial genes.", [["DNA", "CELLULAR_COMPONENT", 70, 73], ["DNA", "CELLULAR_COMPONENT", 101, 104], ["random bacterial DNA", "DNA", 53, 73], ["phage DNA", "DNA", 95, 104], ["bacterial genes", "DNA", 192, 207], ["generalized transduction", "PROBLEM", 21, 45], ["random bacterial DNA", "PROBLEM", 53, 73], ["bacterial genes", "PROBLEM", 192, 207], ["two", "OBSERVATION_MODIFIER", 10, 13], ["types", "OBSERVATION_MODIFIER", 14, 19], ["generalized", "OBSERVATION_MODIFIER", 21, 32], ["transduction", "OBSERVATION", 33, 45], ["bacterial DNA", "OBSERVATION", 60, 73], ["phage DNA", "OBSERVATION_MODIFIER", 95, 104], ["bacterial genes", "OBSERVATION", 192, 207]]], ["Perhaps the most common method of HGT is conjugation, which requires cell-to-cell contact.", [["cell", "ANATOMY", 69, 73], ["cell", "ANATOMY", 77, 81], ["cell", "CELL", 69, 73], ["cell", "CELL", 77, 81], ["most common", "OBSERVATION_MODIFIER", 12, 23]]], ["One famous method of conjugation is the E. coli F conjugative plasmids, which code for cellular structures that bring the cells into contact (called 'pili') as well as for machinery to inject the DNA into the recipient cell.", [["plasmids", "ANATOMY", 62, 70], ["cellular structures", "ANATOMY", 87, 106], ["cells", "ANATOMY", 122, 127], ["cell", "ANATOMY", 219, 223], ["cellular", "CELL", 87, 95], ["cells", "CELL", 122, 127], ["DNA", "CELLULAR_COMPONENT", 196, 199], ["cell", "CELL", 219, 223], ["E. coli F conjugative plasmids", "DNA", 40, 70], ["recipient cell", "CELL_TYPE", 209, 223], ["E. coli", "SPECIES", 40, 47], ["E. coli", "SPECIES", 40, 47], ["the E. coli F conjugative plasmids", "TREATMENT", 36, 70], ["recipient cell", "OBSERVATION", 209, 223]]], ["The genetic material transferred via HGT can be recombined onto the main bacterial chromosome or onto extrachromosomal elements.", [["chromosome", "ANATOMY", 83, 93], ["bacterial chromosome", "CELLULAR_COMPONENT", 73, 93], ["HGT", "DNA", 37, 40], ["bacterial chromosome", "DNA", 73, 93], ["extrachromosomal elements", "DNA", 102, 127], ["main", "OBSERVATION_MODIFIER", 68, 72], ["bacterial chromosome", "OBSERVATION", 73, 93], ["extrachromosomal elements", "OBSERVATION", 102, 127]]], ["Often 'cassettes' of genes evolve together and can spread through a bacterial population, including in many cases of drug resistance (Amabile-Cuevas 1993; Stokes & Gillings 2011) .The dynamics of clonal interference in TBhaplotypes (see below).", [["clonal", "CELL", 196, 202], ["a bacterial population", "PROBLEM", 66, 88], ["clonal interference in TBhaplotypes", "PROBLEM", 196, 231], ["clonal interference", "OBSERVATION", 196, 215]]], ["Its large genome size ( $ 4.5 Mb), well-documented drug resistance mutations, and long time course of infection mean that patterns of diversity can be tracked over time.", [["infection", "DISEASE", 102, 111], ["Its large genome size", "PROBLEM", 0, 21], ["drug resistance mutations", "PROBLEM", 51, 76], ["infection", "PROBLEM", 102, 111], ["large", "OBSERVATION_MODIFIER", 4, 9], ["genome", "OBSERVATION_MODIFIER", 10, 16], ["size", "OBSERVATION_MODIFIER", 17, 21], ["drug resistance", "OBSERVATION", 51, 66], ["long time", "OBSERVATION_MODIFIER", 82, 91], ["infection", "OBSERVATION", 102, 111]]], ["Although previous studies have shown the presence of competing clonal lineages in M. tuberculosis populations in a patient using neutral markers (Al-Hajoj et al. 2010; Navarro et al. 2011 ), we can further use our understanding of drug resistance mutations to better understand the evolutionary dynamics of within-host populations.", [["tuberculosis", "DISEASE", 85, 97], ["clonal", "CELL", 63, 69], ["M. tuberculosis populations", "ORGANISM", 82, 109], ["patient", "ORGANISM", 115, 122], ["M. tuberculosis", "SPECIES", 82, 97], ["patient", "SPECIES", 115, 122], ["M. tuberculosis", "SPECIES", 82, 97], ["previous studies", "TEST", 9, 25], ["competing clonal lineages in M. tuberculosis populations", "PROBLEM", 53, 109], ["neutral markers", "TREATMENT", 129, 144], ["drug resistance mutations", "PROBLEM", 231, 256], ["clonal lineages", "OBSERVATION", 63, 78], ["M.", "OBSERVATION_MODIFIER", 82, 84], ["tuberculosis", "OBSERVATION", 85, 97]]], ["Among patients who are infected with drug-sensitive strains of M. tuberculosis, drug resistance can evolve within a patient during treatment.", [["M. tuberculosis", "DISEASE", 63, 78], ["patients", "ORGANISM", 6, 14], ["M. tuberculosis", "ORGANISM", 63, 78], ["patient", "ORGANISM", 116, 123], ["patients", "SPECIES", 6, 14], ["M. tuberculosis", "SPECIES", 63, 78], ["patient", "SPECIES", 116, 123], ["M. tuberculosis", "SPECIES", 63, 78], ["M. tuberculosis", "PROBLEM", 63, 78], ["drug resistance", "PROBLEM", 80, 95], ["treatment", "TREATMENT", 131, 140], ["tuberculosis", "OBSERVATION", 66, 78]]], ["By tracking the frequencies of drug resistance mutations over time in a single patient, we can observe clonal interference between lineages that each carry beneficial mutations in real time.", [["patient", "ORGANISM", 79, 86], ["patient", "SPECIES", 79, 86], ["drug resistance mutations", "PROBLEM", 31, 56]]], ["Sun et al. (2012) conducted the first analysis of this kind by tracking drug resistance allele frequencies in three patients across at least two time points.", [["patients", "ORGANISM", 116, 124], ["patients", "SPECIES", 116, 124], ["tracking drug resistance allele frequencies", "TREATMENT", 63, 106]]], ["The first patient was entirely free of drug resistance mutations at the onset of treatment, but by the second time point of sampling had four segregating drug resistance mutations.", [["patient", "ORGANISM", 10, 17], ["patient", "SPECIES", 10, 17], ["drug resistance mutations", "PROBLEM", 39, 64], ["treatment", "TREATMENT", 81, 90], ["four segregating drug resistance mutations", "PROBLEM", 137, 179], ["drug resistance", "OBSERVATION", 154, 169]]], ["At the final time point, 94% of the sample had a single drug resistance mutation, and 6% was divided among other drug-resistant strains, including those containing drug resistance mutations not present at the second time point.", [["strains", "ANATOMY", 128, 135], ["the sample", "TEST", 32, 42], ["a single drug resistance mutation", "PROBLEM", 47, 80], ["resistant strains", "PROBLEM", 118, 135], ["drug resistance mutations", "PROBLEM", 164, 189], ["resistant strains", "OBSERVATION", 118, 135]]], ["This suggests that while M. tuberculosis rapidly acquires resistance mutations, different drugresistant strains compete against each other due to lack of recombination.", [["tuberculosis", "DISEASE", 28, 40], ["M. tuberculosis", "ORGANISM", 25, 40], ["M. tuberculosis", "SPECIES", 25, 40], ["M. tuberculosis", "SPECIES", 25, 40], ["M. tuberculosis", "PROBLEM", 25, 40], ["resistance mutations", "PROBLEM", 58, 78], ["different drugresistant strains", "PROBLEM", 80, 111], ["tuberculosis", "OBSERVATION", 28, 40]]], ["The second patient entered the study with an M. tuberculosis population fixed for a certain drug resistance mutation (rpoB L533P) but remained sensitive to the antibiotic rifampicin.", [["tuberculosis", "DISEASE", 48, 60], ["rifampicin", "CHEMICAL", 171, 181], ["rifampicin", "CHEMICAL", 171, 181], ["patient", "ORGANISM", 11, 18], ["rifampicin", "SIMPLE_CHEMICAL", 171, 181], ["rpoB L533P", "DNA", 118, 128], ["patient", "SPECIES", 11, 18], ["M. tuberculosis", "SPECIES", 45, 60], ["M. tuberculosis", "SPECIES", 45, 60], ["the study", "TEST", 27, 36], ["an M. tuberculosis population", "TREATMENT", 42, 71], ["a certain drug resistance mutation", "PROBLEM", 82, 116], ["rpoB L533P", "TEST", 118, 128], ["the antibiotic rifampicin", "TREATMENT", 156, 181], ["tuberculosis", "OBSERVATION", 48, 60]]], ["Eighteen months later, this patient had a population whose genetic composition was dominated by a different drug resistance mutation (rpoB H526Y) and was now resistant to rifampicin, suggesting that successive sweeps of alternative drug resistance mutations can lead to multidrugresistant strains.", [["rifampicin", "CHEMICAL", 171, 181], ["rifampicin", "CHEMICAL", 171, 181], ["patient", "ORGANISM", 28, 35], ["rifampicin", "SIMPLE_CHEMICAL", 171, 181], ["rpoB H526Y", "DNA", 134, 144], ["patient", "SPECIES", 28, 35], ["a different drug resistance mutation", "PROBLEM", 96, 132], ["rifampicin", "TREATMENT", 171, 181], ["alternative drug resistance mutations", "TREATMENT", 220, 257], ["multidrugresistant strains", "PROBLEM", 270, 296]]], ["Eldholm et al. (2014) performed a similar study, but with much greater sequencing depth, in a single patient who was followed over 42 months as extensive drug resistance was acquired by the pathogen.", [["patient", "ORGANISM", 101, 108], ["patient", "SPECIES", 101, 108], ["a similar study", "TEST", 32, 47], ["extensive drug resistance", "PROBLEM", 144, 169], ["the pathogen", "PROBLEM", 186, 198]]], ["The patient, who was started on a standard antibiotic regimen (pyrazinamide, rifampicin and isoniazid), was given increasingly uncommon drugs as their tuberculosis population acquired more drug resistance mutations.", [["pyrazinamide", "CHEMICAL", 63, 75], ["rifampicin", "CHEMICAL", 77, 87], ["isoniazid", "CHEMICAL", 92, 101], ["tuberculosis", "DISEASE", 151, 163], ["pyrazinamide", "CHEMICAL", 63, 75], ["rifampicin", "CHEMICAL", 77, 87], ["isoniazid", "CHEMICAL", 92, 101], ["patient", "ORGANISM", 4, 11], ["pyrazinamide", "SIMPLE_CHEMICAL", 63, 75], ["rifampicin", "SIMPLE_CHEMICAL", 77, 87], ["isoniazid", "SIMPLE_CHEMICAL", 92, 101], ["patient", "SPECIES", 4, 11], ["a standard antibiotic regimen", "TREATMENT", 32, 61], ["pyrazinamide", "TREATMENT", 63, 75], ["rifampicin", "TREATMENT", 77, 87], ["isoniazid", "TREATMENT", 92, 101], ["increasingly uncommon drugs", "TREATMENT", 114, 141], ["their tuberculosis population", "PROBLEM", 145, 174], ["drug resistance mutations", "PROBLEM", 189, 214], ["tuberculosis", "OBSERVATION", 151, 163], ["drug resistance", "OBSERVATION", 189, 204]]], ["The dynamics of clonal interference are shown in Fig. 5 , based on data from Eldholm et al. (2014) .", [["clonal", "CELL", 16, 22], ["clonal interference", "OBSERVATION", 16, 35]]], ["Allele frequencies were measured at several time points, so alleles with similar frequency trajectories can be assumed to be on the same background or in the same clone.", [["clone", "CELL", 163, 168], ["Allele frequencies", "PROBLEM", 0, 18]]], ["Therefore, the clonal frequency changes can be inferred across time.", [["the clonal frequency changes", "PROBLEM", 11, 39]]], ["Eldholm et al. (2014) identified 12 drug resistance mutations reaching frequency >25%, of which only seven ultimately fixed (shown in green), suggesting that clonal interference may purge over 40% of strongly selected drug resistance mutations even after reaching high frequencies (shown in blue).The dynamics of clonal interference in TBThe knowledge of these positively selected drug resistance mutations can also allow us to understand the dynamics of co-occurring hitchhiking mutations that were already on the background on which the drug resistance mutation arose.", [["clonal", "CELL", 313, 319], ["12 drug resistance mutations", "PROBLEM", 33, 61], ["frequency", "TEST", 71, 80], ["clonal interference", "PROBLEM", 158, 177], ["selected drug resistance mutations", "PROBLEM", 209, 243], ["these positively selected drug resistance mutations", "PROBLEM", 355, 406], ["co-occurring hitchhiking mutations", "PROBLEM", 455, 489], ["the drug resistance mutation", "PROBLEM", 535, 563], ["clonal interference", "OBSERVATION", 313, 332]]], ["Eldholm et al. (2014) found that 23 mutations not directly associated with drug resistance also fixed in the population over the 42 weeks of sampling.", [["23 mutations", "PROBLEM", 33, 45], ["drug resistance", "PROBLEM", 75, 90]]], ["While these mutations may have been neutral, compensatory, or positively selected through adaptation unrelated to drugs, it is also possible that some or all of them are slightly deleterious but rose in frequency due to their linkage to beneficial mutations.The dynamics of clonal interference in TBFrom Eldholm et al. (2014) it may be noted that, in most cases, the drug resistance mutations were added to haplotypes one by one, which suggests that each individual mutation leads to an increase in fitness.", [["clonal", "CELL", 274, 280], ["drugs", "TREATMENT", 114, 119], ["slightly deleterious", "PROBLEM", 170, 190], ["beneficial mutations", "PROBLEM", 237, 257], ["the drug resistance mutations", "PROBLEM", 363, 392], ["each individual mutation", "PROBLEM", 450, 474], ["slightly", "OBSERVATION_MODIFIER", 170, 178], ["deleterious", "OBSERVATION", 179, 190], ["clonal interference", "OBSERVATION", 274, 293], ["increase", "OBSERVATION_MODIFIER", 487, 495]]], ["This is troubling, because part of the rationale behind using multiple drugs at the same time is that it should make it much harder for the pathogen to evolve resistance, as it needs to acquire multiple mutations at the same time.", [["multiple drugs", "TREATMENT", 62, 76], ["the pathogen", "PROBLEM", 136, 148], ["multiple mutations", "PROBLEM", 194, 212]]], ["It has been suggested that imperfect drug penetration may explain the evolution of resistance in tuberculosis despite multidrug therapy (Lipsitch & Levin 1998; Moreno-Gamez et al. 2015) .The dynamics of clonal interference in TBThe study of clonal interference, thus far largely investigated within experimental and theoretical models, has a unique application in the study of clonal dynamics of natural populations of the human pathogen M. tuberculosis.", [["tuberculosis", "DISEASE", 97, 109], ["M. tuberculosis", "DISEASE", 438, 453], ["clonal", "CELL", 203, 209], ["clonal", "CELL", 377, 383], ["human", "ORGANISM", 423, 428], ["M. tuberculosis", "ORGANISM", 438, 453], ["human", "SPECIES", 423, 428], ["M. tuberculosis", "SPECIES", 438, 453], ["human", "SPECIES", 423, 428], ["M. tuberculosis", "SPECIES", 438, 453], ["imperfect drug penetration", "PROBLEM", 27, 53], ["resistance in tuberculosis", "PROBLEM", 83, 109], ["multidrug therapy", "TREATMENT", 118, 135], ["TBThe study", "TEST", 226, 237], ["clonal interference", "PROBLEM", 241, 260], ["the study", "TEST", 364, 373], ["tuberculosis", "PROBLEM", 441, 453], ["resistance", "OBSERVATION_MODIFIER", 83, 93], ["tuberculosis", "OBSERVATION", 97, 109], ["multidrug therapy", "OBSERVATION", 118, 135], ["clonal interference", "OBSERVATION", 203, 222], ["clonal interference", "OBSERVATION", 241, 260], ["tuberculosis", "OBSERVATION", 441, 453]]], ["Using the presence of drug resistance mutations as a positive control for strong directional selection, we are able to better understand the evolutionary dynamics of clonally evolving pathogen populations such as M. tuberculosis.", [["tuberculosis", "DISEASE", 216, 228], ["M. tuberculosis", "ORGANISM", 213, 228], ["M. tuberculosis", "SPECIES", 213, 228], ["M. tuberculosis", "SPECIES", 213, 228], ["drug resistance mutations", "TREATMENT", 22, 47], ["a positive control", "TREATMENT", 51, 69], ["clonally evolving pathogen populations", "PROBLEM", 166, 204], ["M. tuberculosis", "PROBLEM", 213, 228], ["drug resistance", "OBSERVATION", 22, 37], ["tuberculosis", "OBSERVATION", 216, 228]]], ["Although we currently only have detailed data for a few well-studied patients that include deep coverage of the entire genome across multiple time points, it appears to be the case that clonal interference in M. tuberculosis populations occurs in a way that is similar to what is seen in laboratory experiments.", [["tuberculosis", "DISEASE", 212, 224], ["patients", "ORGANISM", 69, 77], ["clonal", "CELL", 186, 192], ["M. tuberculosis populations", "ORGANISM", 209, 236], ["patients", "SPECIES", 69, 77], ["M. tuberculosis", "SPECIES", 209, 224], ["M. tuberculosis", "SPECIES", 209, 224], ["clonal interference in M. tuberculosis populations", "PROBLEM", 186, 236], ["tuberculosis", "OBSERVATION", 212, 224]]], ["With the knowledge of hundreds of drug resistance mutations and the availability of affordable whole-genome sequencing, we expect to see many more studies of within-host dynamics of tuberculosis in the near future.", [["tuberculosis", "DISEASE", 182, 194], ["drug resistance mutations", "PROBLEM", 34, 59], ["tuberculosis", "PROBLEM", 182, 194], ["tuberculosis", "OBSERVATION", 182, 194]]], ["We especially look forward to studies where population's genetics can be used to understand genetic patterns associated with diverse treatment outcomes.Evolution of drug resistance within populations of Staphylococcus aureus bacteria via horizontal gene transferThere is a growing need to address drug resistance within bacterial species that exhibit horizontal gene transfer (HGT, see Box 3), which is the sharing of genetic material between cells.", [["cells", "ANATOMY", 443, 448], ["Staphylococcus aureus bacteria", "ORGANISM", 203, 233], ["cells", "CELL", 443, 448], ["Staphylococcus aureus", "SPECIES", 203, 224], ["Staphylococcus aureus", "SPECIES", 203, 224], ["studies", "TEST", 30, 37], ["diverse treatment outcomes", "TREATMENT", 125, 151], ["drug resistance", "PROBLEM", 165, 180], ["Staphylococcus aureus bacteria", "PROBLEM", 203, 233], ["horizontal gene transfer", "TREATMENT", 238, 262], ["drug resistance", "PROBLEM", 297, 312], ["bacterial species", "PROBLEM", 320, 337], ["drug resistance", "OBSERVATION", 165, 180], ["Staphylococcus aureus", "OBSERVATION", 203, 224], ["bacterial species", "OBSERVATION", 320, 337]]], ["Resistance to antibiotics has been increasingly reported for many bacterial spe-cies with HGT, including S. aureus, Helicobacter pylori, Salmonella enterica, E. coli and many others.", [["S. aureus", "ORGANISM", 105, 114], ["Helicobacter pylori", "ORGANISM", 116, 135], ["Salmonella enterica", "ORGANISM", 137, 156], ["E. coli", "ORGANISM", 158, 165], ["S. aureus", "SPECIES", 105, 114], ["Helicobacter pylori", "SPECIES", 116, 135], ["Salmonella enterica", "SPECIES", 137, 156], ["E. coli", "SPECIES", 158, 165], ["S. aureus", "SPECIES", 105, 114], ["Helicobacter pylori", "SPECIES", 116, 135], ["Salmonella enterica", "SPECIES", 137, 156], ["E. coli", "SPECIES", 158, 165], ["antibiotics", "TREATMENT", 14, 25], ["many bacterial spe-cies", "PROBLEM", 61, 84], ["HGT", "PROBLEM", 90, 93], ["S. aureus", "PROBLEM", 105, 114], ["Helicobacter pylori", "PROBLEM", 116, 135], ["Salmonella enterica", "PROBLEM", 137, 156], ["E. coli", "PROBLEM", 158, 165], ["bacterial spe-cies", "OBSERVATION", 66, 84], ["aureus", "OBSERVATION", 108, 114], ["Helicobacter pylori", "OBSERVATION", 116, 135], ["E. coli", "OBSERVATION", 158, 165]]], ["Most bacterial species primarily reproduce clonally, passing their current genomes vertically to the next generation.", [["Most bacterial species", "PROBLEM", 0, 22]]], ["HGT can move genes, sets of genes or even chromosomes between cells of even distantly related species (Nelson et al. 1999; Keeling & Palmer 2008; Syvanen 2012; Meric et al. 2015) .", [["chromosomes", "ANATOMY", 42, 53], ["cells", "ANATOMY", 62, 67], ["chromosomes", "CELLULAR_COMPONENT", 42, 53], ["cells", "CELL", 62, 67], ["HGT", "DNA", 0, 3], ["chromosomes", "DNA", 42, 53]]], ["This makes defining a bacterial species difficult, let alone tracking the spread of drug resistance.Evolution of drug resistance within populations of Staphylococcus aureus bacteria via horizontal gene transferOne useful framework for understanding the spread of drug resistance in species with HGT is the concept of a selective sweep.", [["Staphylococcus aureus bacteria", "ORGANISM", 151, 181], ["Staphylococcus aureus", "SPECIES", 151, 172], ["Staphylococcus aureus", "SPECIES", 151, 172], ["a bacterial species", "PROBLEM", 20, 39], ["drug resistance", "PROBLEM", 84, 99], ["drug resistance", "PROBLEM", 113, 128], ["Staphylococcus aureus bacteria", "PROBLEM", 151, 181], ["horizontal gene transfer", "TREATMENT", 186, 210], ["drug resistance in species", "PROBLEM", 263, 289], ["a selective sweep", "TREATMENT", 317, 334], ["bacterial species", "OBSERVATION", 22, 39], ["drug resistance", "OBSERVATION", 84, 99], ["drug resistance", "OBSERVATION", 113, 128], ["Staphylococcus aureus", "OBSERVATION", 151, 172], ["drug resistance", "OBSERVATION", 263, 278]]], ["In general, in a selective sweep, a new adaptive mutation arises and spreads through a population, causing a corresponding reduction in genetic diversity around the adaptive site (Maynard Smith & Haigh 1974) .", [["a new adaptive mutation", "PROBLEM", 34, 57], ["a corresponding reduction in genetic diversity", "PROBLEM", 107, 153], ["reduction", "OBSERVATION_MODIFIER", 123, 132], ["genetic diversity", "OBSERVATION", 136, 153]]], ["In clonal populations (e.g. populations of M. tuberculosis), a selective sweep can lead to the removal of entire lineages and a strong genomewide reduction in diversity.", [["tuberculosis", "DISEASE", 46, 58], ["clonal populations", "CELL", 3, 21], ["M. tuberculosis", "ORGANISM", 43, 58], ["M. tuberculosis", "SPECIES", 43, 58], ["M. tuberculosis", "SPECIES", 43, 58], ["M. tuberculosis", "PROBLEM", 43, 58], ["a selective sweep", "TREATMENT", 61, 78], ["the removal of entire lineages", "TREATMENT", 91, 121], ["a strong genomewide reduction", "TREATMENT", 126, 155], ["clonal populations", "OBSERVATION", 3, 21], ["tuberculosis", "OBSERVATION", 46, 58], ["strong", "OBSERVATION_MODIFIER", 128, 134], ["genomewide", "OBSERVATION_MODIFIER", 135, 145], ["reduction", "OBSERVATION_MODIFIER", 146, 155], ["diversity", "OBSERVATION_MODIFIER", 159, 168]]], ["By contrast, in recombining populations (e.g. populations of P. falciparum) the extent of the reduction in diversity is inversely proportional to the ratio of recombination and selection, r/s [such that the greatest reduction in diversity occurs when recombination (r) is weak and selection (s) is strong] (Kaplan et al. 1989) .", [["P. falciparum", "DISEASE", 61, 74], ["P. falciparum", "ORGANISM", 61, 74], ["P. falciparum", "SPECIES", 61, 74], ["P. falciparum", "SPECIES", 61, 74], ["P. falciparum", "PROBLEM", 61, 74], ["reduction", "OBSERVATION_MODIFIER", 94, 103], ["greatest", "OBSERVATION_MODIFIER", 207, 215], ["reduction", "OBSERVATION_MODIFIER", 216, 225]]], ["Selective sweeps in organisms that exhibit HGT can be best understood by distinguishing between gene-specific and genomewide selective sweeps (Shapiro & Polz 2014).", [["Selective sweeps in organisms", "PROBLEM", 0, 29]]], ["Gene-specific selective sweeps occur when an adaptive mutation or gene can be transmitted across a population faster via HGT than by clonal expansion, which means that the adaptive mutation spreads independent of the rest of the genome.", [["specific selective sweeps", "TREATMENT", 5, 30], ["an adaptive mutation", "PROBLEM", 42, 62], ["clonal expansion", "TEST", 133, 149], ["the adaptive mutation", "PROBLEM", 168, 189]]], ["Perhaps more familiarly, a genomewide selective sweep occurs when an adaptive mutation spreads via clonal expansion of the genome that first acquired the adaptive mutation.", [["genome", "CELLULAR_COMPONENT", 123, 129], ["a genomewide selective sweep", "PROBLEM", 25, 53], ["an adaptive mutation", "PROBLEM", 66, 86], ["the adaptive mutation", "PROBLEM", 150, 171]]], ["When r/s ( 1 genomewide selective sweeps are more likely, and genomic diversity can be strongly reduced.", [["r/s", "PROBLEM", 5, 8], ["1 genomewide selective sweeps", "PROBLEM", 11, 40], ["more likely", "UNCERTAINTY", 45, 56]]], ["Thus far, it appears that many adaptive events in microbial species with HGT may fall into the r/s \u226b 1 regime which leads to gene-specific sweeps (Shapiro & Polz 2014) , although more data are needed.", [["many adaptive events", "PROBLEM", 26, 46], ["microbial species", "PROBLEM", 50, 67]]], ["For example, what looks to be a high r/s ratio may be partially be explained by the slowing of genomewide sweeps due to clonal interference and perhaps selection for low-frequency genotypes (Shapiro & Polz 2014) .", [["a high r/s ratio", "PROBLEM", 30, 46], ["the slowing of genomewide sweeps", "PROBLEM", 80, 112], ["clonal interference", "PROBLEM", 120, 139], ["low-frequency genotypes", "PROBLEM", 166, 189], ["may be partially be explained", "UNCERTAINTY", 47, 76], ["slowing", "OBSERVATION_MODIFIER", 84, 91]]], ["Nevertheless, it is useful to frame the evolution of bacterial species with HGT in the context of both genomewide and gene-specific sweeps.Evolution of drug resistance within populations of Staphylococcus aureus bacteria via horizontal gene transferA more traditional framework for studying the evolution of bacterial genomes with HGT has been to study evolution within the 'core' genome, defined as the gene regions that are shared by all isolates within a species, vs. the 'accessory' genome, which is the genetic material that is not shared by all isolates of a species (see Box 3).", [["Staphylococcus aureus bacteria", "ORGANISM", 190, 220], ["core' genome", "CELLULAR_COMPONENT", 375, 387], ["bacterial genomes", "DNA", 308, 325], ["'core' genome", "DNA", 374, 387], ["gene regions", "DNA", 404, 416], ["accessory' genome", "DNA", 476, 493], ["Staphylococcus aureus", "SPECIES", 190, 211], ["Staphylococcus aureus", "SPECIES", 190, 211], ["bacterial species", "PROBLEM", 53, 70], ["drug resistance", "PROBLEM", 152, 167], ["Staphylococcus aureus bacteria", "PROBLEM", 190, 220], ["bacterial genomes", "PROBLEM", 308, 325], ["the 'accessory' genome", "PROBLEM", 471, 493], ["bacterial species", "OBSERVATION", 53, 70], ["drug resistance", "OBSERVATION", 152, 167], ["Staphylococcus aureus", "OBSERVATION", 190, 211], ["bacterial genomes", "OBSERVATION", 308, 325], ["accessory' genome", "OBSERVATION", 476, 493]]], ["We will use the example of S aureus and the accessory element SCCmec to explore the evolution of drug resistance within a bacterial species capable of horizontal gene transfer (note that SCCmec recombines onto the circular chromosome as a gene cassette, see Boxes 1 and 3).", [["chromosome", "ANATOMY", 223, 233], ["S aureus", "ORGANISM", 27, 35], ["chromosome", "CELLULAR_COMPONENT", 223, 233], ["Boxes 1", "GENE_OR_GENE_PRODUCT", 258, 265], ["accessory element SCCmec", "DNA", 44, 68], ["SCCmec", "DNA", 187, 193], ["circular chromosome", "DNA", 214, 233], ["gene cassette", "DNA", 239, 252], ["Boxes 1 and 3", "DNA", 258, 271], ["S aureus", "SPECIES", 27, 35], ["S aureus", "SPECIES", 27, 35], ["S aureus", "PROBLEM", 27, 35], ["the accessory element SCCmec", "PROBLEM", 40, 68], ["drug resistance", "PROBLEM", 97, 112], ["a bacterial species", "PROBLEM", 120, 139], ["SCCmec", "PROBLEM", 187, 193], ["drug resistance", "OBSERVATION", 97, 112]]], ["We have chosen to consider MRSA not only because it is a major emerging health threat but also because it is an instructive example in how the phylogenetic relationships between global isolates reveal different evolutionary histories depending on whether the core genome or an accessory genetic element is considered.Clinical background and historical analysis of the Staphylococcus aureus genomeStaphylococcus aureus is a human commensal that is known for causing dangerous skin, blood stream and other hospital-associated infections as well as having the ability to become resistant to the majority of antibiotics (Lowy 2003; Stryjewski & Corey 2014) .", [["skin", "ANATOMY", 475, 479], ["blood stream", "ANATOMY", 481, 493], ["Staphylococcus aureus", "DISEASE", 368, 389], ["infections", "DISEASE", 524, 534], ["Staphylococcus aureus genomeStaphylococcus aureus", "ORGANISM", 368, 417], ["human", "ORGANISM", 423, 428], ["skin", "ORGAN", 475, 479], ["blood", "ORGANISM_SUBSTANCE", 481, 486], ["core genome", "DNA", 259, 270], ["accessory genetic element", "DNA", 277, 302], ["MRSA", "SPECIES", 27, 31], ["Staphylococcus aureus genomeStaphylococcus aureus", "SPECIES", 368, 417], ["human", "SPECIES", 423, 428], ["Staphylococcus aureus genomeStaphylococcus aureus", "SPECIES", 368, 417], ["human", "SPECIES", 423, 428], ["MRSA", "PROBLEM", 27, 31], ["the core genome", "PROBLEM", 255, 270], ["an accessory genetic element", "PROBLEM", 274, 302], ["Clinical background", "TEST", 317, 336], ["historical analysis", "TEST", 341, 360], ["the Staphylococcus aureus genomeStaphylococcus aureus", "PROBLEM", 364, 417], ["dangerous skin, blood stream", "PROBLEM", 465, 493], ["other hospital-associated infections", "PROBLEM", 498, 534], ["antibiotics", "TREATMENT", 604, 615], ["Staphylococcus aureus", "OBSERVATION", 368, 389], ["infections", "OBSERVATION", 524, 534]]], ["In addition to methicillin resistance, which first emerged in the 1960s, there is also a growing number of cases of resistance to other antibiotics, including vancomycin, quinolones, aminoglycosides, streptogramins, oxazolidinones and rifamycins (Lowy 2003; Stryjewski & Corey 2014) .", [["methicillin", "CHEMICAL", 15, 26], ["vancomycin", "CHEMICAL", 159, 169], ["quinolones", "CHEMICAL", 171, 181], ["aminoglycosides", "CHEMICAL", 183, 198], ["streptogramins", "CHEMICAL", 200, 214], ["oxazolidinones", "CHEMICAL", 216, 230], ["rifamycins", "CHEMICAL", 235, 245], ["methicillin", "CHEMICAL", 15, 26], ["vancomycin", "CHEMICAL", 159, 169], ["quinolones", "CHEMICAL", 171, 181], ["aminoglycosides", "CHEMICAL", 183, 198], ["streptogramins", "CHEMICAL", 200, 214], ["oxazolidinones", "CHEMICAL", 216, 230], ["rifamycins", "CHEMICAL", 235, 245], ["methicillin", "SIMPLE_CHEMICAL", 15, 26], ["vancomycin", "SIMPLE_CHEMICAL", 159, 169], ["quinolones", "SIMPLE_CHEMICAL", 171, 181], ["aminoglycosides", "SIMPLE_CHEMICAL", 183, 198], ["streptogramins", "SIMPLE_CHEMICAL", 200, 214], ["oxazolidinones", "SIMPLE_CHEMICAL", 216, 230], ["rifamycins", "SIMPLE_CHEMICAL", 235, 245], ["methicillin resistance", "PROBLEM", 15, 37], ["other antibiotics", "TREATMENT", 130, 147], ["vancomycin", "TREATMENT", 159, 169], ["quinolones", "TREATMENT", 171, 181], ["aminoglycosides", "TREATMENT", 183, 198], ["streptogramins", "TREATMENT", 200, 214], ["oxazolidinones", "TREATMENT", 216, 230], ["rifamycins", "TREATMENT", 235, 245], ["methicillin resistance", "OBSERVATION", 15, 37], ["growing", "OBSERVATION_MODIFIER", 89, 96]]], ["MRSA can be particularly deadly.", [["MRSA", "DISEASE", 0, 4], ["MRSA", "SPECIES", 0, 4], ["MRSA", "SPECIES", 0, 4], ["MRSA", "PROBLEM", 0, 4]]], ["For example, mortality rates for patients with MRSA bloodstream infections has been reported to be $ 30% (De Kraker et al. 2011 ).", [["bloodstream", "ANATOMY", 52, 63], ["MRSA bloodstream infections", "DISEASE", 47, 74], ["patients", "ORGANISM", 33, 41], ["patients", "SPECIES", 33, 41], ["MRSA", "SPECIES", 47, 51], ["MRSA", "SPECIES", 47, 51], ["mortality rates", "TEST", 13, 28], ["MRSA bloodstream infections", "PROBLEM", 47, 74]]], ["In the USA $ 94 000 infections and $ 19 000 deaths per year are caused by MRSA (Stockman 2009 ).", [["infections", "DISEASE", 20, 30], ["deaths", "DISEASE", 44, 50], ["MRSA", "SPECIES", 74, 78], ["MRSA", "SPECIES", 74, 78], ["MRSA", "PROBLEM", 74, 78], ["MRSA", "OBSERVATION", 74, 78]]], ["Drug resistance can arise via new mutations within the genome of a single clone (Strahilevitz & Hooper 2005; Howden et al. 2008) , via horizontal gene transfer between clones (Coombs et al. 2011 ) and even via horizontal gene transfer from another bacterial species (Hanssen & Ericson Sollid 2006; Bloemendaal et al. 2010; Malachowa & Deleo 2010; Smyth et al. 2012) .", [["Drug resistance", "PROBLEM", 0, 15], ["new mutations", "PROBLEM", 30, 43], ["new", "OBSERVATION_MODIFIER", 30, 33], ["mutations", "OBSERVATION", 34, 43]]], ["Staphylococcus aureus strains acquire methicillin resistance via the mobile genetic element SCCmec [most likely via transduction (defined in Box 3) (Maslanova et al. 2013 )], which integrates as a cassette of genes into the bacterium's chromosome.Clinical background and historical analysis of the Staphylococcus aureus genomeThe genome of S. aureus is $ 2.8 Mbp total, where $ 2.3 Mbp compose the core genome and $ 0.5 Mbp compose the accessory genome.", [["chromosome", "ANATOMY", 236, 246], ["methicillin", "CHEMICAL", 38, 49], ["Staphylococcus aureus", "DISEASE", 298, 319], ["methicillin", "CHEMICAL", 38, 49], ["Staphylococcus aureus strains", "ORGANISM", 0, 29], ["methicillin", "SIMPLE_CHEMICAL", 38, 49], ["chromosome", "CELLULAR_COMPONENT", 236, 246], ["Staphylococcus aureus", "ORGANISM", 298, 319], ["S. aureus", "ORGANISM", 340, 349], ["mobile genetic element SCCmec", "DNA", 69, 98], ["bacterium's chromosome", "DNA", 224, 246], ["core genome", "DNA", 398, 409], ["accessory genome", "DNA", 436, 452], ["Staphylococcus aureus", "SPECIES", 0, 21], ["Staphylococcus aureus", "SPECIES", 298, 319], ["S. aureus", "SPECIES", 340, 349], ["Staphylococcus aureus", "SPECIES", 0, 21], ["Staphylococcus aureus", "SPECIES", 298, 319], ["S. aureus", "SPECIES", 340, 349], ["Staphylococcus aureus strains", "PROBLEM", 0, 29], ["methicillin resistance", "PROBLEM", 38, 60], ["the mobile genetic element SCCmec", "PROBLEM", 65, 98], ["Clinical background", "TEST", 247, 266], ["historical analysis", "TEST", 271, 290], ["the Staphylococcus aureus genome", "PROBLEM", 294, 326], ["S. aureus", "PROBLEM", 340, 349], ["Mbp", "TEST", 382, 385], ["aureus", "OBSERVATION", 15, 21], ["methicillin resistance", "OBSERVATION", 38, 60], ["most likely", "UNCERTAINTY", 100, 111], ["Staphylococcus aureus genome", "OBSERVATION", 298, 326], ["aureus", "OBSERVATION", 343, 349], ["accessory genome", "OBSERVATION", 436, 452]]], ["The most common method for analysing the genomes of S. aureus isolates has been multilocus sequence typing (MLST), in which a standardized set of housekeeping genes from the core genome are sequenced and categorized into allelic types, allowing placement of each isolate into a defined 'clonal complex' (Enright & Day 2000; Enright et al. 2002; Maiden et al. 2014) .", [["S. aureus", "ORGANISM", 52, 61], ["housekeeping genes", "DNA", 146, 164], ["core genome", "DNA", 174, 185], ["S. aureus", "SPECIES", 52, 61], ["S. aureus", "SPECIES", 52, 61], ["S. aureus isolates", "PROBLEM", 52, 70], ["multilocus sequence typing", "TEST", 80, 106], ["placement of each isolate", "TREATMENT", 245, 270], ["aureus", "OBSERVATION", 55, 61]]], ["MLST has historically been applied to the core genome, revealing that S. aureus is a highly clonal species with relatively few recombination events in the core genome (Robinson & Enright 2004 ).", [["S. aureus", "ORGANISM", 70, 79], ["core genome", "DNA", 42, 53], ["core genome", "DNA", 155, 166], ["S. aureus", "SPECIES", 70, 79], ["S. aureus", "SPECIES", 70, 79], ["S. aureus", "PROBLEM", 70, 79], ["a highly clonal species", "PROBLEM", 83, 106], ["aureus", "OBSERVATION", 73, 79], ["highly", "OBSERVATION_MODIFIER", 85, 91], ["clonal species", "OBSERVATION", 92, 106]]], ["When MLST is applied to international collections of isolates, it appears that a small number of clonal lineages are responsible for most infections.", [["infections", "DISEASE", 138, 148], ["clonal lineages", "CELL", 97, 112], ["clonal lineages", "CELL_TYPE", 97, 112], ["isolates", "TREATMENT", 53, 61], ["a small number of clonal lineages", "PROBLEM", 79, 112], ["most infections", "PROBLEM", 133, 148], ["small", "OBSERVATION_MODIFIER", 81, 86], ["number", "OBSERVATION_MODIFIER", 87, 93], ["clonal lineages", "OBSERVATION", 97, 112], ["responsible for", "UNCERTAINTY", 117, 132]]], ["For example, Oliveira et al. (2002) applied MLST to over 3000 MRSA isolates from hospitals across Europe, South America, and the USA, and found that just five clones caused 70% of the infections (Oliveira et al. 2002) .", [["infections", "DISEASE", 184, 194], ["MRSA", "SPECIES", 62, 66], ["MLST", "PROBLEM", 44, 48], ["the infections", "PROBLEM", 180, 194], ["infections", "OBSERVATION", 184, 194]]], ["As findings such as these emerged, it was thought that methicillin resistance was likely to have spread across the population of S. aureus when relatively few clones acquired SCCmec and then clonally expanded (i.e. genomewide sweeps) (Kreiswirth et al. 1993; Cris ostomo et al. 2001; Feil & Enright 2004) .", [["methicillin", "CHEMICAL", 55, 66], ["methicillin", "CHEMICAL", 55, 66], ["methicillin", "SIMPLE_CHEMICAL", 55, 66], ["S. aureus", "ORGANISM", 129, 138], ["clones", "CELL", 159, 165], ["SCCmec", "DNA", 175, 181], ["S. aureus", "SPECIES", 129, 138], ["S. aureus", "SPECIES", 129, 138], ["methicillin resistance", "PROBLEM", 55, 77], ["S. aureus", "PROBLEM", 129, 138], ["SCCmec", "PROBLEM", 175, 181], ["methicillin resistance", "OBSERVATION", 55, 77], ["aureus", "OBSERVATION", 132, 138]]], ["However, closer analysis of the population structure of the S. aureus accessory genome reveals a different story.The mobile element SCCmec as a clinical indicator of hospital-and community-associated infectionsIn the first few decades of MRSA outbreaks, it was found that the strains causing hospital-associated (HA-MRSA) vs. community-associated (CA-MRSA) infections displayed distinct clinical and genetic differences (these differences may be eroding, as will be addressed later).", [["infections", "DISEASE", 200, 210], ["HA-MRSA) vs. community-associated (CA-MRSA) infections", "DISEASE", 313, 367], ["S. aureus", "ORGANISM", 60, 69], ["CA-MRSA", "ORGANISM", 348, 355], ["S. aureus accessory genome", "DNA", 60, 86], ["mobile element SCCmec", "DNA", 117, 138], ["S. aureus", "SPECIES", 60, 69], ["MRSA", "SPECIES", 238, 242], ["MRSA", "SPECIES", 316, 320], ["MRSA", "SPECIES", 351, 355], ["S. aureus", "SPECIES", 60, 69], ["MRSA", "SPECIES", 238, 242], ["MRSA", "SPECIES", 351, 355], ["closer analysis", "TEST", 9, 24], ["the S. aureus accessory genome", "PROBLEM", 56, 86], ["The mobile element SCCmec", "PROBLEM", 113, 138], ["associated infections", "PROBLEM", 189, 210], ["MRSA outbreaks", "PROBLEM", 238, 252], ["the strains", "PROBLEM", 272, 283], ["HA", "PROBLEM", 313, 315], ["MRSA", "PROBLEM", 316, 320], ["community-associated (CA-MRSA) infections", "PROBLEM", 326, 367], ["mobile element SCCmec", "OBSERVATION", 117, 138], ["infections", "OBSERVATION", 200, 210], ["few", "OBSERVATION_MODIFIER", 223, 226], ["MRSA outbreaks", "OBSERVATION", 238, 252], ["MRSA", "OBSERVATION", 316, 320]]], ["HA-MRSA tends to be resistant to a wider array of antibiotics and often causes blood stream and other hospital-related infections in individuals with additional medical conditions.", [["blood stream", "ANATOMY", 79, 91], ["HA-MRSA", "CHEMICAL", 0, 7], ["infections", "DISEASE", 119, 129], ["blood", "ORGANISM_SUBSTANCE", 79, 84], ["MRSA", "SPECIES", 3, 7], ["HA", "PROBLEM", 0, 2], ["MRSA", "PROBLEM", 3, 7], ["a wider array of antibiotics", "TREATMENT", 33, 61], ["blood stream", "PROBLEM", 79, 91], ["related infections", "PROBLEM", 111, 129], ["MRSA", "OBSERVATION", 3, 7], ["infections", "OBSERVATION", 119, 129]]], ["CA-MRSA tends to be more virulent (caused by virulence genes also transmitted via HGT) and often causes skin infections in otherwise healthy individuals (David & Daum 2010; Chua et al. 2014) .", [["skin", "ANATOMY", 104, 108], ["skin infections", "DISEASE", 104, 119], ["CA", "GENE_OR_GENE_PRODUCT", 0, 2], ["skin", "ORGAN", 104, 108], ["virulence genes", "DNA", 45, 60], ["MRSA", "SPECIES", 3, 7], ["CA", "TEST", 0, 2], ["MRSA", "PROBLEM", 3, 7], ["virulent", "PROBLEM", 25, 33], ["skin infections", "PROBLEM", 104, 119], ["MRSA", "OBSERVATION", 3, 7], ["skin", "ANATOMY", 104, 108], ["infections", "OBSERVATION", 109, 119]]], ["These clinical differences are partly mediated by the mobile genetic element called SCCmec, a chromosomal gene cassette that confers resistance to methicillin and can also confer resistance to other antibiotics (Katayama et al. 2000; Hanssen & Ericson Sollid 2006) .", [["chromosomal", "ANATOMY", 94, 105], ["methicillin", "CHEMICAL", 147, 158], ["methicillin", "CHEMICAL", 147, 158], ["SCCmec", "GENE_OR_GENE_PRODUCT", 84, 90], ["chromosomal", "CELLULAR_COMPONENT", 94, 105], ["methicillin", "SIMPLE_CHEMICAL", 147, 158], ["mobile genetic element", "DNA", 54, 76], ["SCCmec", "DNA", 84, 90], ["chromosomal gene cassette", "DNA", 94, 119], ["a chromosomal gene cassette", "TREATMENT", 92, 119], ["methicillin", "TREATMENT", 147, 158], ["other antibiotics", "TREATMENT", 193, 210]]], ["Interestingly, genetic changes within this gene cassette track successive epidemic waves of MRSA (Katayama et al. 2000; Chambers & DeLeo 2009) , and extensive work has been done to investigate the source and spread of this mobile element, both as a phylogenetically informative sequence and as an adaptive factor in its own right.", [["MRSA", "DISEASE", 92, 96], ["gene cassette", "DNA", 43, 56], ["MRSA", "SPECIES", 92, 96], ["genetic changes", "PROBLEM", 15, 30], ["MRSA", "PROBLEM", 92, 96], ["MRSA", "OBSERVATION", 92, 96], ["right", "ANATOMY_MODIFIER", 324, 329]]], ["SCCmec is currently classified into 11 types (with more subtypes) using mutations and the orientation of segments within the cassette (Milheiric \u00dfo et al. 2007; IWG-SCC 2015) .The mobile element SCCmec as a clinical indicator of hospital-and community-associated infectionsThere have been a number of studies showing that the population structure of S. aureus is different between HA-MRSA and CA-MRSA strains (David & Daum 2010; Mediavilla et al. 2012; Stryjewski & Corey 2014) .", [["infections", "DISEASE", 263, 273], ["SCCmec", "GENE_OR_GENE_PRODUCT", 0, 6], ["S. aureus", "ORGANISM", 350, 359], ["HA-MRSA", "ORGANISM", 381, 388], ["CA-MRSA strains", "ORGANISM", 393, 408], ["SCCmec", "DNA", 0, 6], ["mobile element SCCmec", "DNA", 180, 201], ["S. aureus", "SPECIES", 350, 359], ["MRSA", "SPECIES", 384, 388], ["MRSA", "SPECIES", 396, 400], ["S. aureus", "SPECIES", 350, 359], ["SCCmec", "PROBLEM", 0, 6], ["mutations", "TREATMENT", 72, 81], ["The mobile element SCCmec", "PROBLEM", 176, 201], ["associated infections", "PROBLEM", 252, 273], ["studies", "TEST", 301, 308], ["S. aureus", "PROBLEM", 350, 359], ["HA", "PROBLEM", 381, 383], ["MRSA", "PROBLEM", 384, 388], ["CA", "PROBLEM", 393, 395], ["MRSA strains", "PROBLEM", 396, 408], ["11 types", "OBSERVATION_MODIFIER", 36, 44], ["mobile element SCCmec", "OBSERVATION", 180, 201], ["infections", "OBSERVATION", 263, 273], ["aureus", "OBSERVATION", 353, 359], ["MRSA", "OBSERVATION", 384, 388]]], ["Both HA-MRSA and CA-MRSA strains are thought to arise when methicillin-sensitive clones newly acquire a SCCmec cassette from a source population, most likely the staphylococcus species S. epidermidis (Wu et al. 1996; Hanssen et al. 2004 Hanssen et al. , 2005 Meric et al. 2015) .", [["methicillin", "CHEMICAL", 59, 70], ["methicillin", "CHEMICAL", 59, 70], ["HA-MRSA", "ORGANISM", 5, 12], ["CA-MRSA strains", "ORGANISM", 17, 32], ["clones", "CELL", 81, 87], ["staphylococcus species", "ORGANISM", 162, 184], ["S. epidermidis", "ORGANISM", 185, 199], ["methicillin-sensitive clones", "CELL_LINE", 59, 87], ["SCCmec cassette", "DNA", 104, 119], ["MRSA", "SPECIES", 8, 12], ["MRSA", "SPECIES", 20, 24], ["S. epidermidis", "SPECIES", 185, 199], ["S. epidermidis", "SPECIES", 185, 199], ["Both HA", "PROBLEM", 0, 7], ["MRSA", "PROBLEM", 8, 12], ["CA", "PROBLEM", 17, 19], ["MRSA strains", "PROBLEM", 20, 32], ["methicillin", "PROBLEM", 59, 70], ["a SCCmec cassette", "TREATMENT", 102, 119], ["a source population", "PROBLEM", 125, 144], ["the staphylococcus species S. epidermidis", "PROBLEM", 158, 199], ["MRSA", "OBSERVATION", 8, 12], ["most likely", "UNCERTAINTY", 146, 157], ["epidermidis", "OBSERVATION_MODIFIER", 188, 199]]], ["It has been found that HA-MRSA strains tend to carry the longer SCCmec types I, II, and III elements in just a few clonal backgrounds, whereas CA-MRSA strains tends to carry the shorter SCCmec types IV and V elements in diverse clonal backgrounds (Enright et al. 2002; Robinson & Enright 2003; David & Daum 2010; Coombs et al. 2011) .", [["HA-MRSA strains", "ORGANISM", 23, 38], ["CA-MRSA strains", "ORGANISM", 143, 158], ["SCCmec types IV", "GENE_OR_GENE_PRODUCT", 186, 201], ["SCCmec types I, II, and III elements", "DNA", 64, 100], ["SCCmec types IV and V elements", "DNA", 186, 216], ["MRSA", "SPECIES", 26, 30], ["MRSA", "SPECIES", 146, 150], ["HA", "PROBLEM", 23, 25], ["MRSA strains", "PROBLEM", 26, 38], ["MRSA strains", "PROBLEM", 146, 158], ["MRSA", "OBSERVATION", 26, 30]]], ["For example, the early HA-MRSA pandemic could be relatively neatly classified into just five clonal complexes (Musser & Kapur 1992; Fitzgerald et al. 2001; Enright et al. 2002; Robinson & Enright 2003) .", [["MRSA", "SPECIES", 26, 30], ["the early HA", "PROBLEM", 13, 25], ["MRSA pandemic", "PROBLEM", 26, 39], ["early", "OBSERVATION_MODIFIER", 17, 22], ["HA", "OBSERVATION_MODIFIER", 23, 25], ["MRSA", "OBSERVATION", 26, 30]]], ["In contrast, as researchers began analysing the strains responsible for the emerging CA-MRSA health threat, they found these strains to display more diversity and a stronger association between clonal type and geographic location (Chua et al. 2010; David & Daum 2010; Coombs et al. 2011) .", [["CA", "GENE_OR_GENE_PRODUCT", 85, 87], ["MRSA", "SPECIES", 88, 92], ["the strains", "PROBLEM", 44, 55], ["the emerging CA-MRSA health threat", "PROBLEM", 72, 106], ["these strains", "PROBLEM", 119, 132]]], ["As of 2006 the SCCmec type IV element alone was found to have entered at least nine different clonal complexes of S. aureus (Lina et al. 2006) .The mobile element SCCmec as a clinical indicator of hospital-and community-associated infectionsThe clinical and genetic differences between hospitalassociated (HA-) and community-associated (CA-) MRSA are eroding in the modern pandemic, mainly due to the emergence of CA-MRSA strains that seed an increasing number of hospital outbreaks (Chambers & DeLeo 2009; David & Daum 2010; Mediavilla et al. 2012; Hsu et al. 2015) .", [["infections", "DISEASE", 231, 241], ["MRSA", "DISEASE", 342, 346], ["S. aureus", "ORGANISM", 114, 123], ["CA-MRSA strains", "ORGANISM", 414, 429], ["SCCmec type IV element", "DNA", 15, 37], ["mobile element SCCmec", "DNA", 148, 169], ["S. aureus", "SPECIES", 114, 123], ["MRSA", "SPECIES", 342, 346], ["MRSA", "SPECIES", 417, 421], ["S. aureus", "SPECIES", 114, 123], ["the SCCmec type IV element", "TREATMENT", 11, 37], ["S. aureus", "PROBLEM", 114, 123], ["The mobile element SCCmec", "PROBLEM", 144, 169], ["associated infections", "PROBLEM", 220, 241], ["The clinical and genetic differences between hospitalassociated (HA-) and community-associated (CA", "PROBLEM", 241, 339], ["MRSA", "PROBLEM", 342, 346], ["CA", "PROBLEM", 414, 416], ["MRSA strains", "PROBLEM", 417, 429], ["clonal complexes", "OBSERVATION", 94, 110], ["aureus", "OBSERVATION", 117, 123], ["mobile element SCCmec", "OBSERVATION", 148, 169], ["infections", "OBSERVATION", 231, 241], ["increasing", "OBSERVATION_MODIFIER", 443, 453], ["number", "OBSERVATION_MODIFIER", 454, 460]]], ["A study of MRSA infections in 2004 MRSA infections in -2005 in the city of San Francisco, California, found that $ 90% of MRSA infections were acquired in the community (Liu et al. 2008) .", [["MRSA infections", "DISEASE", 11, 26], ["MRSA infections", "DISEASE", 35, 50], ["infections", "DISEASE", 127, 137], ["MRSA", "SPECIES", 11, 15], ["MRSA", "SPECIES", 35, 39], ["MRSA", "SPECIES", 122, 126], ["MRSA", "SPECIES", 11, 15], ["MRSA", "SPECIES", 122, 126], ["A study", "TEST", 0, 7], ["MRSA infections", "PROBLEM", 11, 26], ["MRSA infections", "PROBLEM", 35, 50], ["MRSA infections", "PROBLEM", 122, 137], ["MRSA", "OBSERVATION_MODIFIER", 11, 15], ["infections", "OBSERVATION", 16, 26], ["MRSA infections", "OBSERVATION", 122, 137]]], ["In the United States, there is currently a predominant CA-MRSA clone, called USA300 (typically containing SCCmec Type IV), that is responsible for the vast majority of community-associated infections in addition to causing hospital outbreaks (Seybold et al. 2006; Chambers & DeLeo 2009 ).", [["infections", "DISEASE", 189, 199], ["CA", "GENE_OR_GENE_PRODUCT", 55, 57], ["MRSA clone", "CELL", 58, 68], ["SCCmec Type IV", "GENE_OR_GENE_PRODUCT", 106, 120], ["MRSA", "SPECIES", 58, 62], ["USA300", "SPECIES", 77, 83], ["a predominant CA", "PROBLEM", 41, 57], ["MRSA clone", "PROBLEM", 58, 68], ["USA300", "PROBLEM", 77, 83], ["SCCmec Type IV", "TREATMENT", 106, 120], ["associated infections", "PROBLEM", 178, 199], ["predominant", "OBSERVATION_MODIFIER", 43, 54], ["CA", "OBSERVATION", 55, 57], ["MRSA clone", "OBSERVATION", 58, 68], ["infections", "OBSERVATION", 189, 199]]], ["Mathematical models predict that these CA-MRSA strains will eventually replace the strains traditionally categorized as HA-MRSA, rendering the communityassociated and hospital-associated categories far less useful (D'Agata et al. 2009 ).", [["CA", "GENE_OR_GENE_PRODUCT", 39, 41], ["HA-MRSA", "ORGANISM", 120, 127], ["MRSA", "SPECIES", 42, 46], ["MRSA", "SPECIES", 123, 127], ["these CA", "PROBLEM", 33, 41], ["MRSA strains", "PROBLEM", 42, 54], ["the strains", "PROBLEM", 79, 90], ["HA", "PROBLEM", 120, 122], ["MRSA", "PROBLEM", 123, 127], ["MRSA", "OBSERVATION", 123, 127]]], ["The success of these CA-MRSA strains is potentially mediated by the arrival of the SCCmec Type IV cassette, which may be particularly suited to recurrent horizontal transfer because it confers faster growth rates at little or no fitness cost (Okuma et al. 2002; Diep et al. 2008; Chambers & DeLeo 2009; Mediavilla et al. 2012 ).The mobile element SCCmec as a clinical indicator of hospital-and community-associated infectionsHigh-resolution population structure analysis of Staphylococcus aureus using the mobile element SCCmecThe mobile element SCCmec as a clinical indicator of hospital-and community-associated infectionsAs the clinical and genetic differences between CA-and HA-MRSA strains have eroded in the modern pandemic, so too has the emphasis on their differences within recent literature.", [["infections", "DISEASE", 415, 425], ["Staphylococcus aureus", "DISEASE", 474, 495], ["infections", "DISEASE", 614, 624], ["CA-MRSA", "GENE_OR_GENE_PRODUCT", 21, 28], ["Staphylococcus aureus", "ORGANISM", 474, 495], ["CA", "GENE_OR_GENE_PRODUCT", 672, 674], ["HA-MRSA strains", "ORGANISM", 679, 694], ["SCCmec Type IV cassette", "DNA", 83, 106], ["mobile element SCCmec", "DNA", 332, 353], ["mobile element SCCmec", "DNA", 506, 527], ["mobile element SCCmec", "DNA", 531, 552], ["MRSA", "SPECIES", 24, 28], ["Staphylococcus aureus", "SPECIES", 474, 495], ["MRSA", "SPECIES", 682, 686], ["Staphylococcus aureus", "SPECIES", 474, 495], ["these CA-MRSA strains", "PROBLEM", 15, 36], ["the SCCmec Type IV cassette", "TREATMENT", 79, 106], ["The mobile element SCCmec", "PROBLEM", 328, 353], ["associated infections", "PROBLEM", 404, 425], ["Staphylococcus aureus", "PROBLEM", 474, 495], ["associated infections", "PROBLEM", 603, 624], ["CA", "TEST", 672, 674], ["HA", "PROBLEM", 679, 681], ["MRSA strains", "PROBLEM", 682, 694], ["CA", "OBSERVATION", 21, 23], ["mobile element", "OBSERVATION_MODIFIER", 332, 346], ["SCCmec", "OBSERVATION", 347, 353], ["infections", "OBSERVATION", 415, 425], ["Staphylococcus aureus", "OBSERVATION", 474, 495], ["infections", "OBSERVATION", 614, 624], ["MRSA", "OBSERVATION", 682, 686], ["eroded", "OBSERVATION_MODIFIER", 700, 706]]], ["Instead, attention is moving towards leveraging new sequencing technologies (Maiden et al. 2014 ) to achieve higher resolution into the global patterns of methicillin resistance acquisition.", [["methicillin", "CHEMICAL", 155, 166], ["methicillin", "CHEMICAL", 155, 166], ["methicillin", "SIMPLE_CHEMICAL", 155, 166], ["methicillin resistance acquisition", "TREATMENT", 155, 189], ["methicillin resistance", "OBSERVATION", 155, 177]]], ["Overall, analyses of the core genome of MRSA strains suggest that relatively few methicillin-resistant clones have dispersed widely across the globe (Robinson & Enright 2003) , while analyses of the accessory genome of MRSA suggest that new strains emerge locally via frequent de novo transfers of the SCCmec element.", [["clones", "ANATOMY", 103, 109], ["methicillin", "CHEMICAL", 81, 92], ["methicillin", "CHEMICAL", 81, 92], ["MRSA strains", "ORGANISM", 40, 52], ["clones", "CELL", 103, 109], ["MRSA", "CANCER", 219, 223], ["core genome", "DNA", 25, 36], ["methicillin-resistant clones", "CELL_LINE", 81, 109], ["accessory genome", "DNA", 199, 215], ["SCCmec element", "DNA", 302, 316], ["MRSA", "SPECIES", 40, 44], ["MRSA", "SPECIES", 219, 223], ["MRSA strains", "PROBLEM", 40, 52], ["relatively few methicillin-resistant clones", "PROBLEM", 66, 109], ["MRSA", "PROBLEM", 219, 223], ["new strains", "PROBLEM", 237, 248], ["the SCCmec element", "PROBLEM", 298, 316], ["MRSA", "OBSERVATION", 40, 44], ["globe", "ANATOMY", 143, 148]]], ["In other words, it appears that there has been clonal expansion of relatively few core genomes, while the accessory genome frequently goes through gene-specific sweeps.", [["core genomes", "DNA", 82, 94], ["accessory genome", "DNA", 106, 122], ["clonal expansion", "PROBLEM", 47, 63], ["clonal", "OBSERVATION_MODIFIER", 47, 53], ["expansion", "OBSERVATION_MODIFIER", 54, 63], ["relatively", "OBSERVATION_MODIFIER", 67, 77], ["few", "OBSERVATION_MODIFIER", 78, 81]]], ["To illustrate this, Lina et al. (2006) applied MLST to both the core genome and the SCCmec element and found no association between clonal complex background and SCCmec element sequence type.", [["core genome", "DNA", 64, 75], ["SCCmec element", "DNA", 84, 98], ["SCCmec element sequence type", "DNA", 162, 190], ["MLST", "TREATMENT", 47, 51], ["the SCCmec element", "TEST", 80, 98], ["clonal complex background and SCCmec element sequence type", "PROBLEM", 132, 190], ["no association", "UNCERTAINTY", 109, 123]]], ["The authors therefore concluded that SCCmec appears to transfer both repeatedly across distinct clonal complexes (particularly in the case of SCCmec IV) and repeatedly within a clonal complex, which suggests that SCCmec spreads through gene-specific sweeps.", [["SCCmec IV", "GENE_OR_GENE_PRODUCT", 142, 151], ["SCCmec", "DNA", 37, 43], ["SCCmec IV", "PROTEIN", 142, 151], ["SCCmec", "DNA", 213, 219], ["SCCmec", "PROBLEM", 37, 43], ["SCCmec IV", "TREATMENT", 142, 151], ["SCCmec", "PROBLEM", 213, 219], ["clonal complexes", "OBSERVATION", 96, 112], ["SCCmec", "OBSERVATION", 213, 219]]], ["Chua et al. showed in another study that MRSA from geographically and genetically distant isolates (i.e. distantly related core genomes) can nevertheless have relatively conserved accessory elements, including SCCmec type IV (Chua et al. 2011) , which again suggests that transfer happens often and sweeps are gene-specific.", [["SCCmec type IV", "GENE_OR_GENE_PRODUCT", 210, 224], ["accessory elements", "DNA", 180, 198], ["MRSA", "SPECIES", 41, 45], ["another study", "TEST", 22, 35], ["MRSA", "PROBLEM", 41, 45], ["MRSA", "OBSERVATION", 41, 45], ["accessory elements", "OBSERVATION", 180, 198]]], ["Another example is a study by N\u20ac ubel et al. (2008) where the authors used an improved sequence typing method of the core and accessory genome to investigate the genetic relationships within a single clonal lineage (ST5, belonging to clonal complex CC5) using 135 isolates from across 22 countries and six continents.", [["clonal lineage", "ANATOMY", 200, 214], ["clonal lineage", "CELL", 200, 214], ["ST5", "CANCER", 216, 219], ["clonal lineage", "CELL_TYPE", 200, 214], ["ST5", "PROTEIN", 216, 219], ["clonal complex CC5", "PROTEIN", 234, 252], ["a study", "TEST", 19, 26]]], ["In contrast to lower resolution studies that came before, their analyses of the core genome sequences found geographicallyassociated phylogenetic clades within the ST5 clonal lineage.", [["clonal lineage", "ANATOMY", 168, 182], ["ST5 clonal lineage", "CELL", 164, 182], ["core genome sequences", "DNA", 80, 101], ["ST5 clonal lineage", "CELL_TYPE", 164, 182], ["lower resolution studies", "TEST", 15, 39], ["the core genome sequences", "TEST", 76, 101], ["geographicallyassociated phylogenetic clades", "PROBLEM", 108, 152], ["lower resolution", "OBSERVATION_MODIFIER", 15, 31], ["phylogenetic clades", "OBSERVATION", 133, 152], ["ST5 clonal lineage", "OBSERVATION", 164, 182]]], ["Additionally, their analyses of the SCCmec sequence revealed that at least 23 independent transfers of SCCmec occurred into this clonal group alone, with acquisitions appearing to occur locally (rather than a single acquisition then disseminating globally; Fig. 6 ).", [["SCCmec sequence", "DNA", 36, 51], ["SCCmec", "DNA", 103, 109], ["the SCCmec sequence", "TEST", 32, 51], ["SCCmec", "PROBLEM", 103, 109]]], ["We could refer to this case of multiple origins of the adaptive SCCmec element as a soft, gene-specific sweep (Pennings & Hermisson 2006) .", [["adaptive SCCmec element", "DNA", 55, 78]]], ["The authors estimate that previous calculations for the rate of SCCmec acquisitions were at least an order of magnitude too low.The mobile element SCCmec as a clinical indicator of hospital-and community-associated infectionsTaken together, we now know that genetically diverse core genomes can nevertheless contain closely related resistance alleles and that frequent transfers can occur even within a clonal lineage.", [["clonal lineage", "ANATOMY", 403, 417], ["infections", "DISEASE", 215, 225], ["clonal lineage", "CELL", 403, 417], ["SCCmec", "DNA", 64, 70], ["mobile element SCCmec", "DNA", 132, 153], ["resistance alleles", "DNA", 332, 350], ["clonal lineage", "CELL_TYPE", 403, 417], ["previous calculations", "TEST", 26, 47], ["SCCmec acquisitions", "TEST", 64, 83], ["The mobile element SCCmec", "PROBLEM", 128, 153], ["associated infections", "PROBLEM", 204, 225], ["genetically diverse core genomes", "PROBLEM", 258, 290], ["closely related resistance alleles", "PROBLEM", 316, 350], ["mobile element SCCmec", "OBSERVATION", 132, 153], ["infections", "OBSERVATION", 215, 225]]], ["This makes understanding the evolutionary history of these alleles complicated, because alleles can be transmitted independently of the clonal expansion of core genome lineages.", [["alleles", "DNA", 59, 66], ["core genome lineages", "CELL_TYPE", 156, 176]]], ["Nevertheless, these studies of drug resistance in S. aureus illustrate that researchers can achieve fine resolution into the demographic and adaptive history of S. aureus using improved sequencing technologies, in this case facilitated by the exploration of both the core and accessory genomes.The mobile element SCCmec as a clinical indicator of hospital-and community-associated infectionsAs researchers begin to use whole-genome sequencing in S. aureus, an even finer resolution into the evolutionary history of MRSA outbreaks is possible.", [["infections", "DISEASE", 381, 391], ["MRSA", "DISEASE", 515, 519], ["S. aureus", "ORGANISM", 50, 59], ["S. aureus", "ORGANISM", 161, 170], ["S. aureus", "ORGANISM", 446, 455], ["MRSA", "CANCER", 515, 519], ["core and accessory genomes", "DNA", 267, 293], ["mobile element SCCmec", "DNA", 298, 319], ["S. aureus", "SPECIES", 50, 59], ["S. aureus", "SPECIES", 161, 170], ["S. aureus", "SPECIES", 446, 455], ["MRSA", "SPECIES", 515, 519], ["S. aureus", "SPECIES", 50, 59], ["S. aureus", "SPECIES", 161, 170], ["S. aureus", "SPECIES", 446, 455], ["MRSA", "SPECIES", 515, 519], ["these studies", "TEST", 14, 27], ["drug resistance", "PROBLEM", 31, 46], ["S. aureus", "PROBLEM", 50, 59], ["S. aureus", "PROBLEM", 161, 170], ["the exploration", "TEST", 239, 254], ["The mobile element SCCmec", "PROBLEM", 294, 319], ["associated infections", "PROBLEM", 370, 391], ["whole-genome sequencing", "TREATMENT", 419, 442], ["S. aureus", "PROBLEM", 446, 455], ["MRSA outbreaks", "PROBLEM", 515, 529], ["aureus", "OBSERVATION", 164, 170], ["accessory genomes", "OBSERVATION", 276, 293], ["mobile element SCCmec", "OBSERVATION", 298, 319], ["infections", "OBSERVATION", 381, 391], ["aureus", "OBSERVATION", 449, 455], ["MRSA", "OBSERVATION", 515, 519]]], ["For example, Holden et al. (2013) were able to pinpoint both the population size changes and geographic origin of a specific clone (EMRSA-15/ST22), and Harris et al. (2013) were able to construct the transmission pathway of a hospital outbreak between staff and patients.", [["clone", "CELL", 125, 130], ["patients", "ORGANISM", 262, 270], ["patients", "SPECIES", 262, 270], ["EMRSA", "TEST", 132, 137], ["population", "OBSERVATION_MODIFIER", 65, 75], ["size", "OBSERVATION_MODIFIER", 76, 80], ["geographic", "OBSERVATION_MODIFIER", 93, 103], ["origin", "OBSERVATION_MODIFIER", 104, 110]]], ["Thus, the growing availability of sequence data and whole-genome sequencing technologies has provided the ability to determine that resistance may generally be unconstrained by global transmission dynamics and instead can be tracked on local spatial scales.", [["sequence data", "TEST", 34, 47]]], ["This presents researchers with the opportunity to use sequencing as a tool to monitor transmission networks within hospitals to limit the numbers of hospital-acquired drug-resistant infections.", [["infections", "DISEASE", 182, 192], ["resistant infections", "PROBLEM", 172, 192], ["infections", "OBSERVATION", 182, 192]]], ["Overall, the transmission and repeated evolution of drug resistance in bacterial populations capable of HGT presents important and interesting problems for reconstructing population structure and spatial distributions of resistance.DiscussionThe costs that drug-resistant pathogens impose on human health are enormously high, making any tool that can lead to increased understanding of the evolution and spread of drug resistance of great potential value.", [["human", "ORGANISM", 292, 297], ["human", "SPECIES", 292, 297], ["human", "SPECIES", 292, 297], ["drug resistance", "PROBLEM", 52, 67], ["bacterial populations", "PROBLEM", 71, 92], ["reconstructing population structure", "PROBLEM", 156, 191], ["resistance", "PROBLEM", 221, 231], ["resistant pathogens", "PROBLEM", 262, 281], ["drug resistance", "OBSERVATION", 52, 67], ["bacterial populations", "OBSERVATION", 71, 92], ["spatial", "OBSERVATION_MODIFIER", 196, 203], ["distributions", "OBSERVATION_MODIFIER", 204, 217], ["resistance", "OBSERVATION_MODIFIER", 221, 231]]], ["It is therefore important that tools from the field of evolutionary genetics, including population genetic and phylogenetic ones, are applied to pathogen populations where these tools could provide meaningful insights.", [["pathogen populations", "PROBLEM", 145, 165]]], ["In addition to the possibility of helping to prevent the evolution and spread of drug resistance, valuable lessons can be learned to deepen our understanding of evolutionary biology, making pathogens attractive study organisms.", [["pathogens attractive study organisms", "PROBLEM", 190, 226]]], ["In this review we highlighted five evolutionary genetic studies in pathogens haplotypes are painted with colours in proportion to the country of origin that isolates with this haplotype were found.", [["pathogens haplotypes", "PROBLEM", 67, 87], ["this haplotype", "PROBLEM", 171, 185]]], ["Fourteen lineages (labelled 'A' through 'N') tend to cluster with geographical origin emerge, suggesting that specific haplotypes of the core genome of the S. aureus ST5 clone are largely endemic to a geographical area.", [["S. aureus", "ORGANISM", 156, 165], ["ST5 clone", "ORGANISM", 166, 175], ["core genome", "DNA", 137, 148], ["S. aureus ST5", "SPECIES", 156, 169], ["S. aureus", "SPECIES", 156, 165], ["Fourteen lineages", "TREATMENT", 0, 17], ["A' through 'N')", "TREATMENT", 29, 44], ["the S. aureus ST5 clone", "PROBLEM", 152, 175], ["aureus", "OBSERVATION", 159, 165], ["endemic", "OBSERVATION_MODIFIER", 188, 195]]], ["In panel (B) the same minimum-spanning tree is used, but now haplotypes are painted with colours in proportion to the SCCmec element type co-occurring in the isolate.", [["SCCmec element type", "DNA", 118, 137]]], ["Some SCCmec elements are nontypeable ('nt'), likely due to being novel variants.", [["SCCmec elements", "DNA", 5, 20], ["Some SCCmec elements", "PROBLEM", 0, 20], ["nontypeable", "PROBLEM", 25, 36], ["novel variants", "PROBLEM", 65, 79], ["SCCmec elements", "OBSERVATION", 5, 20], ["nontypeable", "OBSERVATION_MODIFIER", 25, 36], ["likely due to", "UNCERTAINTY", 45, 58]]], ["The most parsimonious distribution of acquisition events of SCCmec is indicated with roman numerals placed along the branches of the tree (where the roman numeral corresponds to the SCCmec type), although the actual number of SCCmec acquisitions may be higher.", [["SCCmec", "DNA", 60, 66], ["SCCmec", "DNA", 226, 232], ["SCCmec", "PROBLEM", 60, 66], ["most", "OBSERVATION_MODIFIER", 4, 8], ["parsimonious", "OBSERVATION_MODIFIER", 9, 21], ["distribution", "OBSERVATION_MODIFIER", 22, 34], ["branches", "ANATOMY_MODIFIER", 117, 125], ["tree", "ANATOMY_MODIFIER", 133, 137], ["may be", "UNCERTAINTY", 246, 252], ["higher", "OBSERVATION_MODIFIER", 253, 259]]], ["Note that while the different SCCmec types are present across the globe, the acquisition events tend to occur at the tips of the tree, suggesting that methicillin resistance tends to evolve within a local S. aureus strain as opposed to occurring once and then disseminating globally.Discussionthat we hope give a sampling of the range of biological lessons that can be learned from the study of drug resistance in pathogens.", [["methicillin", "CHEMICAL", 151, 162], ["methicillin", "CHEMICAL", 151, 162], ["methicillin", "SIMPLE_CHEMICAL", 151, 162], ["S. aureus", "ORGANISM", 205, 214], ["S. aureus", "SPECIES", 205, 214], ["S. aureus", "SPECIES", 205, 214], ["methicillin resistance", "PROBLEM", 151, 173], ["a local S. aureus strain", "PROBLEM", 197, 221], ["the study", "TEST", 382, 391], ["drug resistance in pathogens", "PROBLEM", 395, 423], ["SCCmec", "OBSERVATION", 30, 36], ["globe", "ANATOMY", 66, 71], ["tips", "ANATOMY_MODIFIER", 117, 121], ["tree", "ANATOMY_MODIFIER", 129, 133], ["methicillin resistance", "OBSERVATION", 151, 173], ["aureus", "OBSERVATION", 208, 214]]], ["First, we showed how classic population genetic methods for finding selective sweeps were used to successfully identify the region involved with resistance to artemisinin in the malaria parasite Plasmodium falciparum.", [["artemisinin", "CHEMICAL", 159, 170], ["malaria parasite", "DISEASE", 178, 194], ["Plasmodium falciparum", "DISEASE", 195, 216], ["artemisinin", "CHEMICAL", 159, 170], ["artemisinin", "SIMPLE_CHEMICAL", 159, 170], ["malaria parasite", "ORGANISM", 178, 194], ["Plasmodium falciparum", "ORGANISM", 195, 216], ["Plasmodium falciparum", "SPECIES", 195, 216], ["Plasmodium falciparum", "SPECIES", 195, 216], ["selective sweeps", "TREATMENT", 68, 84], ["artemisinin", "TREATMENT", 159, 170], ["the malaria parasite Plasmodium falciparum", "PROBLEM", 174, 216], ["malaria", "OBSERVATION", 178, 185], ["Plasmodium falciparum", "OBSERVATION", 195, 216]]], ["Next, we described how phylogenetic methods helped uncover the role of epistasis in the evolution of influenza surface proteins in general and in the evolution of oseltamivir resistance in particular.", [["surface", "ANATOMY", 111, 118], ["oseltamivir", "CHEMICAL", 163, 174], ["oseltamivir", "CHEMICAL", 163, 174], ["influenza surface proteins", "GENE_OR_GENE_PRODUCT", 101, 127], ["oseltamivir", "SIMPLE_CHEMICAL", 163, 174], ["influenza surface proteins", "PROTEIN", 101, 127], ["epistasis", "PROBLEM", 71, 80], ["influenza surface proteins", "PROBLEM", 101, 127], ["oseltamivir resistance", "TREATMENT", 163, 185], ["epistasis", "OBSERVATION", 71, 80], ["influenza", "OBSERVATION", 101, 110], ["oseltamivir resistance", "OBSERVATION", 163, 185]]], ["In our third example, we highlighted the importance of SGV in the evolution of resistance to antiretrovirals in patients with HIV.", [["HIV", "DISEASE", 126, 129], ["SGV", "GENE_OR_GENE_PRODUCT", 55, 58], ["patients", "ORGANISM", 112, 120], ["patients", "SPECIES", 112, 120], ["HIV", "SPECIES", 126, 129], ["HIV", "SPECIES", 126, 129], ["antiretrovirals", "TREATMENT", 93, 108], ["HIV", "PROBLEM", 126, 129]]], ["Fourth, we showed that drug resistance mutations can be used to explore the dynamics of clonal interference within a patient infected with Mycobacterium tuberculosis.", [["Mycobacterium tuberculosis", "DISEASE", 139, 165], ["clonal", "CELL", 88, 94], ["patient", "ORGANISM", 117, 124], ["Mycobacterium tuberculosis", "ORGANISM", 139, 165], ["patient", "SPECIES", 117, 124], ["Mycobacterium tuberculosis", "SPECIES", 139, 165], ["Mycobacterium tuberculosis", "SPECIES", 139, 165], ["drug resistance mutations", "PROBLEM", 23, 48], ["clonal interference", "PROBLEM", 88, 107], ["Mycobacterium tuberculosis", "PROBLEM", 139, 165], ["Mycobacterium tuberculosis", "OBSERVATION", 139, 165]]], ["Finally, we discussed the complications involved in studying bacterial populations and how horizontal gene transfer of genetic elements contributes to the spread of antibiotic resistance in Staphylococcus aureus.", [["Staphylococcus aureus", "DISEASE", 190, 211], ["Staphylococcus aureus", "ORGANISM", 190, 211], ["Staphylococcus aureus", "SPECIES", 190, 211], ["Staphylococcus aureus", "SPECIES", 190, 211], ["the complications", "PROBLEM", 22, 39], ["studying bacterial populations", "PROBLEM", 52, 82], ["genetic elements", "PROBLEM", 119, 135], ["antibiotic resistance", "TREATMENT", 165, 186], ["Staphylococcus aureus", "PROBLEM", 190, 211], ["antibiotic resistance", "OBSERVATION", 165, 186], ["Staphylococcus aureus", "OBSERVATION", 190, 211]]], ["These five examples are not meant to be exhaustive, but rather to show the wealth of possible study organisms and evolutionary questions that can be addressed.", [["study organisms", "TEST", 94, 109]]], ["We hope that these five examples convince the reader that the evolutionary genetics of drug resistance is an appealing field.", [["drug resistance", "PROBLEM", 87, 102], ["drug resistance", "OBSERVATION", 87, 102]]], ["In each of the cases we highlighted, the study of drug resistance has been useful in expanding our understanding of basic evolutionary processes.", [["the study", "TEST", 37, 46], ["drug resistance", "PROBLEM", 50, 65]]], ["The insights gained from these examples are not limited to the organisms mentioned in this review, but the discoveries that can be made do, in some ways, depend on the organism, its biology, and the availability of data.", [["the organisms", "PROBLEM", 59, 72]]], ["For example, the work on epistasis in influenza was only possible because of the extensive sequence collection that is continuously happening around the world.", [["influenza", "DISEASE", 38, 47], ["epistasis", "PROBLEM", 25, 34], ["influenza", "PROBLEM", 38, 47], ["the extensive sequence collection", "PROBLEM", 77, 110], ["collection", "OBSERVATION", 100, 110]]], ["The work on mapping a resistance allele in the malaria parasite P. falciparum also depended on the availability of data but additionally was possible because P. falciparum has a high recombination rate that facilitates linkagebased analyses.", [["malaria", "DISEASE", 47, 54], ["P. falciparum", "DISEASE", 64, 77], ["P. falciparum", "DISEASE", 158, 171], ["malaria parasite", "ORGANISM", 47, 63], ["P. falciparum", "ORGANISM", 64, 77], ["P. falciparum", "ORGANISM", 158, 171], ["resistance allele", "DNA", 22, 39], ["P. falciparum", "SPECIES", 64, 77], ["P. falciparum", "SPECIES", 158, 171], ["P. falciparum", "SPECIES", 64, 77], ["P. falciparum", "SPECIES", 158, 171], ["a resistance allele", "PROBLEM", 20, 39], ["the malaria parasite", "PROBLEM", 43, 63], ["falciparum", "PROBLEM", 67, 77], ["P. falciparum", "PROBLEM", 158, 171], ["a high recombination rate", "TREATMENT", 176, 201], ["malaria", "OBSERVATION", 47, 54]]], ["The described studies on SGV in HIV were possible because the relevant mutations were known and because evolution of resistance can happen independently in every patient, giving researchers the ability to work with replicate evolutionary histories.", [["SGV", "CANCER", 25, 28], ["HIV", "ORGANISM", 32, 35], ["patient", "ORGANISM", 162, 169], ["HIV", "SPECIES", 32, 35], ["patient", "SPECIES", 162, 169], ["SGV", "SPECIES", 25, 28], ["HIV", "SPECIES", 32, 35], ["The described studies", "TEST", 0, 21], ["HIV", "PROBLEM", 32, 35], ["the relevant mutations", "PROBLEM", 58, 80]]], ["The work in M. tuberculosis was possible, once again, because the resistance mutations are well known and because haplotypes could be reconstructed from allele frequencies due to a lack of recombination.", [["tuberculosis", "DISEASE", 15, 27], ["M. tuberculosis", "ORGANISM", 12, 27], ["M. tuberculosis", "SPECIES", 12, 27], ["M. tuberculosis", "SPECIES", 12, 27], ["the resistance mutations", "PROBLEM", 62, 86], ["haplotypes", "PROBLEM", 114, 124], ["allele frequencies", "PROBLEM", 153, 171], ["tuberculosis", "OBSERVATION", 15, 27]]], ["Finally, the example of drug resistance evolution in MRSA shows how horizontal gene transfer can be studied when extensive multilocus genotyping data are available from isolates collected across the globe.DiscussionSimilar analyses can and are being performed in other pathogens.", [["MRSA", "DISEASE", 53, 57], ["MRSA", "CANCER", 53, 57], ["MRSA", "SPECIES", 53, 57], ["drug resistance evolution", "PROBLEM", 24, 49], ["MRSA", "PROBLEM", 53, 57], ["extensive multilocus genotyping data", "TEST", 113, 149], ["DiscussionSimilar analyses", "TEST", 205, 231], ["drug resistance", "OBSERVATION", 24, 39], ["MRSA", "OBSERVATION", 53, 57], ["globe", "ANATOMY", 199, 204]]], ["For example, we highlighted work on selective sweeps in P. falciparum, but selective sweeps and hitchhiking are also being studied in HIV (Zanini & Neher 2013; Pennings et al. 2014; Feder et al. 2015) , in hepatitis C virus (Bull et al. 2011) , and in influenza (Koelle et al. 2006; Strelkowa & L\u20ac assig 2012) .", [["P. falciparum", "DISEASE", 56, 69], ["hepatitis C", "DISEASE", 206, 217], ["influenza", "DISEASE", 252, 261], ["P. falciparum", "ORGANISM", 56, 69], ["HIV", "ORGANISM", 134, 137], ["hepatitis C virus", "ORGANISM", 206, 223], ["P. falciparum", "SPECIES", 56, 69], ["HIV", "SPECIES", 134, 137], ["hepatitis C virus", "SPECIES", 206, 223], ["P. falciparum", "SPECIES", 56, 69], ["HIV", "SPECIES", 134, 137], ["hepatitis C virus", "SPECIES", 206, 223], ["selective sweeps", "TREATMENT", 36, 52], ["P. falciparum", "PROBLEM", 56, 69], ["hepatitis C virus", "PROBLEM", 206, 223], ["influenza", "PROBLEM", 252, 261]]], ["We used MRSA as an example for the importance of horizontal gene transfer, but there are many other such examples.", [["MRSA", "SPECIES", 8, 12], ["MRSA", "PROBLEM", 8, 12], ["horizontal gene transfer", "TREATMENT", 49, 73], ["MRSA", "OBSERVATION", 8, 12]]], ["For example, a recent study on pneumococcus describes horizontal gene transfer and soft selective sweeps related to drug resistance and vaccine escape (Croucher et al. 2014) .", [["a recent study", "TEST", 13, 27], ["pneumococcus", "PROBLEM", 31, 43], ["horizontal gene transfer", "TREATMENT", 54, 78], ["soft selective sweeps", "TREATMENT", 83, 104], ["drug resistance", "TREATMENT", 116, 131], ["drug resistance", "OBSERVATION", 116, 131]]], ["Another example of a group of pathogens in which the evolution of drug resistance can be studied are the herpes viruses.", [["herpes viruses", "DISEASE", 105, 119], ["herpes viruses", "ORGANISM", 105, 119], ["pathogens", "PROBLEM", 30, 39], ["drug resistance", "PROBLEM", 66, 81], ["the herpes viruses", "PROBLEM", 101, 119], ["pathogens", "OBSERVATION", 30, 39], ["drug resistance", "OBSERVATION", 66, 81], ["herpes viruses", "OBSERVATION", 105, 119]]], ["Cytomegalovirus (CMV) is the herpes virus for which drug resistance is best studied and for which many resistance mutations are known (Hakki & Chou 2011) , and population geneticists have recently started to analyse CMV sequences (Renzette et al. 2015) .", [["Cytomegalovirus (CMV) is the herpes virus", "DISEASE", 0, 41], ["Cytomegalovirus", "ORGANISM", 0, 15], ["CMV", "ORGANISM", 17, 20], ["herpes virus", "ORGANISM", 29, 41], ["CMV", "ORGANISM", 216, 219], ["CMV sequences", "DNA", 216, 229], ["CMV", "SPECIES", 17, 20], ["CMV", "SPECIES", 216, 219], ["Cytomegalovirus (CMV)", "PROBLEM", 0, 21], ["the herpes virus", "PROBLEM", 25, 41], ["drug resistance", "PROBLEM", 52, 67], ["many resistance mutations", "PROBLEM", 98, 123], ["CMV sequences", "TEST", 216, 229], ["herpes virus", "OBSERVATION", 29, 41]]], ["Drug resistance also evolves in other herpes viruses, such as varicella-zoster virus and herpes simplex virus (Piret & Boivin 2014; Brunnemann et al. 2015) , but these viruses have not been extensively analysed using population genetic or evolutionary genetic methods.DiscussionIn all these cases, the role of evolutionary genetics is to connect information contained in genomic sequences to the processes underlying pathogen evolution, and this will require careful attention to the diverse biological properties of pathogens as we have discussed in this review (see Box 1).", [["herpes viruses", "DISEASE", 38, 52], ["varicella-zoster virus", "DISEASE", 62, 84], ["herpes simplex virus", "DISEASE", 89, 109], ["herpes viruses", "ORGANISM", 38, 52], ["varicella-zoster virus", "ORGANISM", 62, 84], ["herpes simplex virus", "ORGANISM", 89, 109], ["varicella-zoster virus", "SPECIES", 62, 84], ["herpes simplex virus", "SPECIES", 89, 109], ["varicella-zoster virus", "SPECIES", 62, 84], ["herpes simplex virus", "SPECIES", 89, 109], ["Drug resistance", "PROBLEM", 0, 15], ["other herpes viruses", "PROBLEM", 32, 52], ["varicella-zoster virus", "PROBLEM", 62, 84], ["herpes simplex virus", "PROBLEM", 89, 109], ["these viruses", "PROBLEM", 162, 175], ["pathogens", "PROBLEM", 517, 526], ["herpes viruses", "OBSERVATION", 38, 52], ["varicella", "ANATOMY", 62, 71], ["zoster virus", "OBSERVATION", 72, 84], ["pathogen", "OBSERVATION", 417, 425]]], ["Pathogen evolution represents an enormous opportunity for population geneticists to study major questions in evolutionary biology and also contributes to our understanding of some of the most important issues in public health.", [["enormous", "OBSERVATION_MODIFIER", 33, 41]]], ["By combining innovative population genetics approaches with appropriate data collection, we hope that future studies will make beneficial contributions to the fields of evolutionary biology and public health.The advantages of pathogens as evolutionary model systemsThe field of population genetics traditionally leans heavily on the use of fruit flies, yeast, Escherichia coli, and humans as model organisms.", [["fruit flies", "ORGANISM", 340, 351], ["Escherichia coli", "ORGANISM", 360, 376], ["humans", "ORGANISM", 382, 388], ["yeast", "SPECIES", 353, 358], ["Escherichia coli", "SPECIES", 360, 376], ["humans", "SPECIES", 382, 388], ["yeast", "SPECIES", 353, 358], ["Escherichia coli", "SPECIES", 360, 376], ["humans", "SPECIES", 382, 388], ["future studies", "TEST", 102, 116], ["pathogens", "PROBLEM", 226, 235], ["fruit flies", "PROBLEM", 340, 351], ["yeast", "PROBLEM", 353, 358], ["Escherichia coli", "PROBLEM", 360, 376], ["pathogens", "OBSERVATION", 226, 235], ["Escherichia coli", "OBSERVATION", 360, 376]]], ["However, it is becoming clear that many pathogens can also be excellent model systems.", [["many pathogens", "PROBLEM", 35, 49], ["pathogens", "OBSERVATION", 40, 49]]], ["Some pathogens already function as model organisms in the lab [e.g., influenza (Foll et al. 2014) , HIV (van Opijnen & Berkhout 2005) , polio (Acevedo et al. 2014 ) and E. coli (Toprak et al. 2012) ], which allows researchers to assess characteristics of population genetic and epidemiological relevance from laboratory populations, for example the cell surface expression assays that were performed in the previously mentioned study of oseltamivir resistance in influenza.", [["cell surface", "ANATOMY", 349, 361], ["influenza", "DISEASE", 69, 78], ["oseltamivir", "CHEMICAL", 437, 448], ["influenza", "DISEASE", 463, 472], ["oseltamivir", "CHEMICAL", 437, 448], ["E. coli", "ORGANISM", 169, 176], ["cell", "CELL", 349, 353], ["oseltamivir", "SIMPLE_CHEMICAL", 437, 448], ["HIV", "SPECIES", 100, 103], ["E. coli", "SPECIES", 169, 176], ["E. coli", "SPECIES", 169, 176], ["Some pathogens", "PROBLEM", 0, 14], ["influenza", "PROBLEM", 69, 78], ["HIV (van Opijnen & Berkhout", "TREATMENT", 100, 127], ["polio", "PROBLEM", 136, 141], ["E. coli", "PROBLEM", 169, 176], ["the cell surface expression assays", "TEST", 345, 379], ["oseltamivir resistance", "PROBLEM", 437, 459], ["influenza", "PROBLEM", 463, 472], ["influenza", "OBSERVATION", 463, 472]]], ["In some pathogen systems, researchers can also apply known selective pressures with precision in a laboratory environment, thus allowing high-resolution measurements of an organism's response to selection.", [["selective", "OBSERVATION_MODIFIER", 59, 68], ["pressures", "OBSERVATION_MODIFIER", 69, 78]]], ["Additionally, because some pathogens evolve drug resistance quickly and repeatedly within patients, there are cases where many replicate evolutionary histories can be studied (HIV, HCV, TB, etc.) .The advantages of pathogens as evolutionary model systemsPathogens are also among the organisms for which the most genetic sequence data are available for population genetics analysis: In 2014, over 270 000 S. aureus sequences, 50 000 influenza sequences, 40 000 HIV sequences, and 5000 malaria sequences were released in GenBank alone (Benson et al. 2013; accessed 26 May 2015) .", [["HIV, HCV, TB", "DISEASE", 176, 188], ["malaria", "DISEASE", 484, 491], ["patients", "ORGANISM", 90, 98], ["HIV", "ORGANISM", 176, 179], ["HCV", "ORGANISM", 181, 184], ["S. aureus", "ORGANISM", 404, 413], ["HIV sequences", "DNA", 460, 473], ["patients", "SPECIES", 90, 98], ["S. aureus", "SPECIES", 404, 413], ["HIV", "SPECIES", 460, 463], ["HIV", "SPECIES", 176, 179], ["HCV", "SPECIES", 181, 184], ["S. aureus", "SPECIES", 404, 413], ["HIV", "SPECIES", 460, 463], ["some pathogens", "PROBLEM", 22, 36], ["HIV", "PROBLEM", 176, 179], ["HCV", "PROBLEM", 181, 184], ["TB", "PROBLEM", 186, 188], ["pathogens", "PROBLEM", 215, 224], ["Pathogens", "PROBLEM", 254, 263], ["the organisms", "PROBLEM", 279, 292], ["the most genetic sequence data", "TEST", 303, 333], ["population genetics analysis", "TEST", 352, 380], ["S. aureus sequences", "TEST", 404, 423], ["influenza sequences", "TEST", 432, 451], ["HIV sequences", "TEST", 460, 473], ["malaria sequences", "TEST", 484, 501], ["drug resistance", "OBSERVATION", 44, 59], ["pathogens", "OBSERVATION", 215, 224]]], ["Moreover, decreased costs of next-generation sequencing will make the amount of new data for pathogens increase exponentially.", [["next-generation sequencing", "TREATMENT", 29, 55], ["pathogens", "PROBLEM", 93, 102], ["decreased", "OBSERVATION_MODIFIER", 10, 19]]], ["Throughout this review, we highlight uses of sequence data and population genetics theory in studying pathogens as evolutionary model systems.", [["sequence data", "TEST", 45, 58]]], ["We believe that pathogen evolution will continue to be a fruitful area of research for evolutionary biologists where fundamental insights can lead to beneficial public health consequences.The advantages of pathogens as evolutionary model systemsFrontiers in the study of pathogen evolution and drug resistance As more sequencing data emerge in the foreseeable future, there are some specific questions that we would like to see addressed at the intersection of population genetics and drug resistance in pathogens.", [["pathogen", "PROBLEM", 16, 24], ["pathogens", "PROBLEM", 206, 215], ["the study", "TEST", 258, 267], ["drug resistance", "PROBLEM", 294, 309], ["drug resistance in pathogens", "PROBLEM", 485, 513], ["pathogens", "OBSERVATION", 206, 215], ["pathogen", "OBSERVATION", 271, 279], ["drug resistance", "OBSERVATION", 294, 309]]], ["This is important because considerable genetic variation is created and selected for within the host; however, the within-host processes of short-lived infections have not yet received sufficient attention.", [["infections", "DISEASE", 152, 162], ["short-lived infections", "PROBLEM", 140, 162]]], ["We are expecting more within-host work, including time series and deep samples for pathogens that are traditionally studied at the between-host level.", [["samples", "ANATOMY", 71, 78], ["deep samples", "TEST", 66, 78], ["pathogens", "PROBLEM", 83, 92]]], ["The M. tuberculosis work described in this review is a good example, but new withinpatient work on influenza is also being done (Rogers et al. 2015) .", [["influenza", "DISEASE", 99, 108], ["M. tuberculosis", "ORGANISM", 4, 19], ["M. tuberculosis", "SPECIES", 4, 19], ["M. tuberculosis", "SPECIES", 4, 19], ["influenza", "PROBLEM", 99, 108], ["tuberculosis", "OBSERVATION", 7, 19]]], ["Second, with deeper samples and more time series, it should become increasingly possible to estimate selection pressures on pathogens and to estimate epistatic interactions between mutations.", [["samples", "ANATOMY", 20, 27], ["deeper samples", "TEST", 13, 27], ["pathogens", "PROBLEM", 124, 133], ["epistatic interactions between mutations", "PROBLEM", 150, 190]]], ["For some of this work, methods that are currently used for identifying mutations and evaluating selection in viruses grown in cell culture (Lou et al. 2013; Foll et al. 2014 ) will hopefully find use in clinical samples taken from infected patients.", [["cell culture", "ANATOMY", 126, 138], ["samples", "ANATOMY", 212, 219], ["cell culture", "CELL", 126, 138], ["patients", "ORGANISM", 240, 248], ["patients", "SPECIES", 240, 248], ["methods", "TREATMENT", 23, 30], ["mutations", "PROBLEM", 71, 80], ["viruses", "PROBLEM", 109, 116], ["cell culture", "TEST", 126, 138], ["clinical samples", "TEST", 203, 219]]], ["Extending these methods to patient data can potentially give researchers the ability to study the evolutionary dynamics of pathogens within patients over the entire course of an infection.The advantages of pathogens as evolutionary model systemsAnother important goal for these evolutionary studies of pathogens was to increase our predictive power of pathogen evolution.", [["infection", "DISEASE", 178, 187], ["patient", "ORGANISM", 27, 34], ["patients", "ORGANISM", 140, 148], ["patient", "SPECIES", 27, 34], ["patients", "SPECIES", 140, 148], ["pathogens", "PROBLEM", 123, 132], ["an infection", "PROBLEM", 175, 187], ["pathogens", "PROBLEM", 206, 215], ["these evolutionary studies", "TEST", 272, 298], ["pathogens", "PROBLEM", 302, 311], ["infection", "OBSERVATION", 178, 187], ["pathogens", "OBSERVATION", 206, 215], ["pathogen", "OBSERVATION", 352, 360]]], ["In addition to the predictive phylogenetic methodologies mentioned in our discussion of epistasis in influenza, a method that uses the shapes of protein phylogenies to predict evolutionary trajectories was evaluated using influenza data (Neher et al. 2014) .", [["influenza", "DISEASE", 101, 110], ["the predictive phylogenetic methodologies", "PROBLEM", 15, 56], ["epistasis", "PROBLEM", 88, 97], ["influenza", "PROBLEM", 101, 110], ["a method", "TREATMENT", 112, 120], ["protein phylogenies", "PROBLEM", 145, 164], ["influenza data", "TEST", 222, 236], ["epistasis", "OBSERVATION", 88, 97], ["influenza", "OBSERVATION", 101, 110]]], ["The work shows that predictability is low when evolution occurs by big steps, but much higher when evolution proceeds by small steps (Neher et al. 2014 ).", [["low", "OBSERVATION_MODIFIER", 38, 41]]], ["Although we tend to fix our attention on large adaptive events, such as drug resistance or immune escape, evolution by small steps may be more common than previously expected (Bhatt et al. 2011; Strelkowa & L\u20ac assig 2012; Gong et al. 2013) .The advantages of pathogens as evolutionary model systemsIn an organism like influenza where new vaccines are manufactured every year, the application of these and other new predictive methodologies that use population genetics theory (Luksza & L\u20ac assig 2014) are potentially groundbreaking.The advantages of pathogens as evolutionary model systemsWe hope that the works on drug resistance reviewed here offer a glimpse into a growing field at the intersection of studies in pathogen evolution and evolutionary genetics.", [["influenza", "DISEASE", 318, 327], ["large adaptive events", "PROBLEM", 41, 62], ["immune escape", "PROBLEM", 91, 104], ["pathogens", "PROBLEM", 259, 268], ["influenza", "PROBLEM", 318, 327], ["new vaccines", "TREATMENT", 334, 346], ["pathogens", "PROBLEM", 550, 559], ["large", "OBSERVATION_MODIFIER", 41, 46], ["immune escape", "OBSERVATION", 91, 104], ["small steps", "OBSERVATION_MODIFIER", 119, 130], ["pathogens", "OBSERVATION", 259, 268], ["organism", "OBSERVATION", 304, 312], ["influenza", "OBSERVATION", 318, 327], ["pathogens", "OBSERVATION", 550, 559]]]]}